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ABSTRACT 
Peptidomimetics have found wide application as biostable, bioavailable, and often potent 
mimics of natural peptides. Examples of peptidomimetics have been isolated as natural 
products, synthesized as libraries from novel subunits, and designed on the basis of X-ray 
crystallographic studies and through an intricate knowledge of the biological mode of action 
of natural peptides. They offer challenging synthetic targets and are increasingly important 
medicinal agents and biological probes. 
Chapter One introduces the fields of peptidomimetics and peptidomimetic design, with 
relevant examples taken from biochemistry, synthesis, and medicinal chemistry used to 
illustrate important concepts. The sources of peptidomimetics, along with common tools used 
for the conformational restriction of peptides, is then reviewed. Ring-closing metathesis 
(RCM), an important new method for the formation of carbocyclic rings is then reviewed, and 
discussed in terms of its application towards the synthesis of confonnationally restricted 
peptidomimetics. This section emphasises the importance ofRCM as a new and versatile tool 
for use in peptidomimetic synthesis. 
Chapter Two describes the enantioselective synthesis of the conformationally constrained, a-
substituted tetrahydropyridine, and piperidine peptide mimics, 2.9 and 2.12 respectively, via 
RCM. The solid-state conformations of 2.9 and 2.12 are examined and their application as 
potential cis-amide bond mimics discussed. Further derivatisation of 2.9 gave dihydroxy 
analogues 3.13, and dibromo analogues 2.14. A novel bicyclic lactone 2.16 was also formed 
upon crystallisation of the major isomer of 2.14. The enantiomeric purity of a key 
intermediate 2.7 was analysed, and determined to be >95%, confirming the stereoselectivity of 
a key alkylation step. 
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Chapter Three describes the enantioselective synthesis of the conformationally constrained, a-
substituted dehydroproline, and proline peptide mimics, 3.17 and 3.28, by RCM, in a manner 
similar to that detailed in Chapter Two. Use of the ruthenium methyl-butylidene catalyst 1.41 
was required for RCM to proceed. Comparison of the solid-state conformation of 3.17 to that 
of 2.9, reveals the two molecules adopt a positive torsion angle about the amide bond in the 
solid state, despite possessing opposite stereochemistry. 
Chapter Four describes the first enantioselective synthesis of the phenylalanine-based 
tetrahydropyridazinone 4.13, and its conversion to the 2-oxo-l, 6-diazobicyclo[4,3,OJnonane-
9~carboxylate dipeptide-mimetic scaffold 4.14, an important component of extended ~-strand 
mimetics. Conformationally constrained bicyclic templates of this type have been designed as 
key components in inhibitors of serine proteases such as thrombin. 
Chapter Five describes a versatile ring-closing metathesis (RCM) approach to the synthesis of 
the unsubstituted trans-cyclohexenyl ~-amino acids 5.27 and 5.28, comp·ounds that serve as 
key intermediates in the synthesis of ~-peptides that adopt stable helical conformations in 
solution. Optically active (-)-5.27 and (-)-5.28 were prepared using Evans chiral auxiliary 
chemistry. The solid-state structure of (+)-5.40a was used to determine the absolute 
stereochemistry of a key intermediate (+)-5.25, used in the preparation of (-)-5.27 and (-)-5.28. 
Cis- and trans-cyclohexenyl ~-amino acids 5.34 and 5.36 respectively, compounds containing 
an a-substituent, are synthesised by an allylationlalkylation sequence, the order of which 
defines the absolute stereochemistry of the product. This second class of cyclic ~-amino acids 
represents a new and important addition to the family of compounds. Optically active 
allylglycine hydrochloride (-)-5.53 was synthesised via the stereospecific alkylation of the 
Ni(II)-BPB-glycine complex 5.50, with allyl bromide. 
Abstract vii 
Chapter Six describes a convenient and versatile ring-closing metathesis approach to the 
synthesis of trans-aminocyclopentenylcarboxylic acids (+)-6.19 and (+)-6.20, from L-
methionine. Compounds of this type are key intermediates in the synthesis of ~-peptides that 
adopt stable helical conformations in solution. The trans-cyclopentenyl ~-amino acid 6.27 was 
prepared by an allylation/alkylation sequence similar to that described in Chapter Five, the 
order of which defines the absolute stereochemistry of the product. 
Chapter Seven describes a ring-closing metathesis approach towards the synthesis of six- and 
seven-membered cyclic lactams derived from functionalised a- or ~-amino acids. RCM of the 
allyl glycine-derived diene 7.24 at 850 C resulted in exclusive formation of the 7-membered 
lactam 7.25, while RCM of 7.24 at lOO°C, gave a 1:1 mixture by IH NMR of 7.25 and the 6-
membered lactam analogue 7.26. Preparation of a,a-disubstituted amino acid-derived lactams 
required a substituent on the allyl amide nitrogen for RCM to proceed. Dienes of type 7.37 
and 7.43, that are either unsubstituted or substituted at the a-position, are prepared by an 
alkylation/allylation sequence similar to that described in Chapter Five. RCM of 7.37 and 
7.43 gave the 7-membered lactam 7.38 and the 6-membered lactam 7.45 respectively. 
Alkylation on the lactam nitrogen of 7.38 gave dipeptide 7.39, illustrating the ability of these 
compounds to be incorporated into peptide sequences 
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CHAPTER ONE 
INTRODUCTION 
Chapter One 2 
1.1. Pep tides 
Peptides are highly flexible molecules that are capable of adopting multiple confonnations, 
many of which are biologically unimportant. The conformation of a peptide is, therefore, 
critical to its biological activity and function. A simple example is that of angiotensin, a 
biologically active octapeptide that plays an important role in the regulation of blood 
pressure. Angiotensin affects blood pressure directly by inducing constriction of blood 
vessels, and indirectly by the affecting the release of aldosterone to induce sodium ion and 
water retention. Instances of cardiovascular diseases such as hypertension and heart failure 
have been attributed to an imbalance in this system. Cleavage of the N-terminal aspartate 
residue of angiotensin leads to a decrease in activity indicating that this residue is 
important to the overall binding properties of the parent peptide. 
Asp-Arg-Val-Tyr-IIe-His-Pro-Phe 
Insulin 
Angiotensin 
A more complex example is that of insulin, a molecule consisting of two polypeptide 
chains linked by disulphide bonds, and the primary peptide involved in the regulation of 
glucose metabolism. Released in the pancreas, insulin acts on nearby liver cell receptors to 
regulate the breakdown of glycogen to glucose. A deficiency of insulin can lead to an 
increase in blood glucose levels and the onset of diabetes mellitus, a disease rated as one of 
the most widespread and serious health concerns in the world today. While these two 
peptides differ in structure, they each possess the ability to modulate a biological process 
by binding to their associated receptors in a unique way. The binding, and hence function, 
of these molecules is therefore directly related to their unique bioactive confonnation. The 
diverse nature of the amino acid residues that make up peptides allows for an almost 
unlimited exploration of confonnational space within any given molecule. As such, a wide 
range of structurally diverse biologically active peptides and proteins have been identified 
and characterised in recent decades. These peptides have been found to act as pivotal 
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components in the regulation of a myriad of physiological processes. Through interacting 
with a specific receptor, these peptides control a series of vital functions such as 
metabolism, cell-cell communication, digestion, immune response, respiration, pain, 
reproduction, and behaviour. Disease states associated with these processes are often 
linked to a disruption in the function of the biologically active peptides and the receptors or 
enzymes on which they act. It is therefore of no surprise that biologically active peptides 
are of enormous interest to medicine in the treatment of disease. 
1.2. Peptidomimetics 
Peptides and their analogues have long been used in medicinal chemistry as therapeutic 
agents against a range of pathological conditions generally characterised by a disruption of 
the interactions between an enzyme substrate or messenger and their targets, enzymes or 
receptors. However the presence of hydrolysable amide bonds means that peptide drugs 
possess the inherent disadvantages of a short half-life, poor oral availability, and poor 
pharmacokinetics. As such, considerable effort has been expended on finding modified or 
non-peptide surrogates for biologically active peptides. Surrogates of this typ ere more 
commonly designated a peptidomimetic. 
"A peptidomimetic is defined as a substance having a secondary structure, as well as other 
structural features, analogous to that of the parent peptide that allows it to displace the 
original peptide from its receptor or enzyme. As a result, the effects of the original peptide 
are either inhibited (antagonist), or duplicated (agonist)."l 
A successful peptidomimetic, while possessing all these characteristics, must also be 
sufficiently non-peptidic to overcome the problems of degradation and bioavailability 
associated with peptides, whilst exhibiting minimal side effects. This enhanced therapeutic 
profile has made peptidomimetics attractive targets in the search for more effective 
treatments of disease. As such, peptidomimetics offer challenging synthetic targets and 
have embraced much of what is modern medicinal and organic chemistry. 
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There are two common sources of peptidomimetics, natural sources, and rational drug 
design. Natural products have long served as a significant source of important 
peptidomimetics, with mass screening of animal, plant, microbial, and fungal extracts 
providing an invaluable guide to the identification and isolation of biologically active 
compounds. In some cases the parent peptide itself can be used to treat disease e.g. insulin 
in the treatment of diabetes, while in others, natural products derived from alternate 
sources serve to promote .or inhibit key biological functions. Examples of natural product 
peptidomimetics include cyclosporin A (CsA), FK-506, and ro-conotoxin MVIIA (Figure 
1.1). Cyclosporin A and FK-506 are generally viewed as immunosupressants, with the 
macro cyclic peptide CsA having emerged as the principal immunosuppressive agent for 
solid organ transplants.2 The marine natural product co-conotoxin MviiA is currently in 
clinical trials as a powerful agent against intractable pain, and with its non-addictive 
characteristics is touted as a future alternative to morphine.3 
MeO 
_,d 
6 
tacrolimus (FK-506) cyclosporin A 
I Ii I 
CKGKGACSRLMYCCTGSCRSGC 
I I 
CD-conotoxin MviiA 
Figure 1.1. 
In recent decades, rational design has corne to the fore in the development of 
peptidomimetics as biological probes and medicinal agents. Advances in the area of 
combinatorial chemistry has allowed for the generation of vast libraries of organic 
compounds, which range from purely peptidic to non-peptidic in nature, from which mass 
screening can, and has, identified new lead compounds. Solid phase chemistry and mass 
screening technology have been critical to the preparation and identification of these new 
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lead compounds. The activity of these lead compounds can be further optimised through 
the identification and variation of key structural and functional elements of the original 
peptidomimetic platform. In the same way, natural products can also be screened and their 
activity refined through structure-activity relationship studies. Technological advances in 
modern nuclear magnetic resonance (NMR) spectroscopy, computer modelling and x-ray 
structure analysis of peptides has allowed researchers to understand and visualise the 
topochemical, conformational, and electronic properties of a peptide ligand and its 
corresponding receptor. As such, a rational-based approach can be taken to the 
identification of potential pharmacophores, compounds that map all the structural and 
electronic elements of the bioactive ligand, which are then used as a basis for 
peptidomimetic design. Many peptidomimetic compounds have been developed as 
successful therapeutic agents by means of this process. 
1.3. Peptidomimetic Design 
The design and synthesis of peptidomimetics is a complex process. What follows is a 
overview of techniques used in peptidomimetics design. 
1.3.1. Conformational Restriction 
An extended or randomly orientated peptide or protein is generally devoid of biological 
activity. The biological function of a given peptide or protein is achieved through the 
spatial arrangement of the peptide backbone, which is in turn defined by the primary amino 
acid sequence. This highlights a key concept in peptidomimetics research, that is 
conformation defines biological activity. Enhanced activity can be achieved through the 
mimicking of the bioactive conformation of a native substrate, with the incorporation of 
additional structural elements designed to stabilise and make rigid this desired bioactive 
conformation. These rigid structural features are designed to ensure the correct positioning 
of key functional groups in order to optimise hydrogen bonding, electrostatic, and 
hydrophobic interactions between the peptidomimetic ligand and the receptor. As such, 
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peptidomimetics can essentially be preorganised into a bioactive conformation by the 
incorporation of rigid structural elements. These are designed to lower the entropy cost 
exhibited by a peptidomimetic upon binding to the receptor, thereby increasing its affinity 
and enhancing its overall biological activity What follows is a summary of the strategies 
used to introduce conformational restriction into peptidomimetic design. 
1.3.2. Introduction of Substituents 
The synthesis of a peptidomimetic is not always an easy process as the requirements 
mentioned above mean that the chiral pool of natural amino acids can no longer serve as 
the sole source of starting materials. Consequently, new chiral building blocks are 
required for use in peptidomimetic design and synthesis. 
Side chain modification 
An established method for the preparation of conformationally restricted chiral building 
blocks involves the modification of naturally occurring amino acid side chains. The 
incorporation of unnatural or modified amino acids, or the replacement of a residue with its 
optical isomer, provides useful information regarding possible turn sites, while 
modification of a side chain gives clues as to its role in the bioactive conformation. The 
introduction of sterically demanding substituents limits the free rotation of the amino acid 
residue (Figure 1.2). An example is the modification of tyrosine by the introduction of 
methyl groups at the 2', 6' and ~-positions (1.1).4 This has been shown to favour bioactive 
conformations and has been used to study the effects of restricted rotation of aromatic side 
chains in the interior of proteins (e.g. bovine pancreatic trypsin inhibitor),5 and peptide-
protein complexes (e.g. oxytocin and neurophysin),6 as well as other bioactive peptides 
such as methionine-enkaphilin.4 Compound 1.2, a constrained analogue of phenylalanine 
has been incorporated into potent peptidomimetic ligands of the angiotensin II receptor.7 
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1.1 1.2 
Figure 1.2. 
ex, cx-Disubstituted Amino Acidv and the Self-Regeneration of Stereocentres. 
Another powerful method in the synthesis of modified peptides has been the use of 5-
oxazolidinones to prepare a range of novel chiral building blocks for use in this regard. 
Although reported as eady as 1904, it was not until the 1950' s that this class of compound 
began to be explored in the area of synthesis. In particular, work done by Ben-Ishai 
demonstrated that 5-oxazolidinones could be prepared from the reaction of acyl amino 
acids with paraformaldehyde (Scheme 1.1).8 
Scheme 1.1 
In this case the reactivity of an oxazolidinone towards an amine was used as a method for 
amide bond formation. Ben Ishai's procedure for the synthesis of 5-oxazolidinones was 
later used by several groups to affect selectivity of peptide couplings and modify amino 
acid side chains. 5-0xazolidinones were used in peptide synthesis to selectively protect 
either the a-carbonyl, or the side-chain carboxylic acid groups, of aspartic and glutamic 
acids. This allowed for modification of either of the carboxyl groups to be carried out 
selectively. Bartlett's differential protection strategy for the manipulations of aspartic and 
glutamic acids (Scheme 1.2)/ and Hoh's synthesis of glutathione (Scheme 1.3),10 illustrate 
this principle welL Bartlett used an oxazolidinone to selectively protect the a-carbonyl 
groups of aspartic and glutamic acids to allow manipulation of the side chain carboxylic 
acid. 
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Scheme 1.2. 
Hoh's synthesis demonstrated that 5-oxazolidinones could be used to selectively react an 
amino acid with either the a-carbonyl or side-chain carboxyl group of aspartic acid. This 
methodology was used to prepare pure samples of glutathione, an important thiol-
containing tripeptide found in almost all aerobic biological species. 
( C02H 
Z, ~ 
N C02H H 
N-Z-Aspartic Acid 
Scheme 1.3. 
HCHO 
--
Glutathione 
I Gly-OEt DCC 
The use of oxazolidinones has thus become an important tool in the modification of amino 
acid side chains, with the functionality itself playing no role in subsequent reactions. In 
more recent years 5-oxazolidinones have found a more general role in the area of 
peptidomimetics. In the 1980's Karady et al.,ll and Seebach et al.,12,13 first described the 
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enantioselective synthesis of a,a-disubstituted amino acids through the stereospecific 
alkylation of amino acids. Conformational studies revealed that the presence of a methyl 
substituent at the a-position of a given amino acid residue imposed a significant restriction 
on the available confOlmational space adopted by that residue. Increased resistance to 
proteolytic cleavage has also made a,a-disubstituted amino acids useful in this regard. 
Seebach et al. subsequently pioneered a general methodology for producing enolates of a-
amino or a-:-hydroxy acids such that subsequent alkylation yielded non-racemic products. 
This simple, yet broadly applicable synthetic principle is known as the "Self Regeneration 
of Stereocentres" (SRS) and is outlined in Figure 1.3. 14 The general principle utilises a 
chiral starting material possessing two functional groups, where only one stereogenic 
centre is allowed to react with an aldehyde to form an acetal, with preference for one 
isomer. Annihilation of the original stereogenic centre and concomitant formation of a 
trigonal centre yields an intermediate, which due to the stereo genic centre of the acetal, is 
chiral. Subsequent reaction at the trigonal centre proceeds diastereoselectively under the 
influence of this temporary stereogenic centre, with cleavage of the acetal unit leading to a 
product where one of the substituents of the starting material has been replaced by a new 
one. The reaction proceeds by dissociative, enantioselective substitution at a centre of 
chirality and without the need for a chiral auxiliary - hence the name "self-regeneration', 
with hydrolysis of the acetal leading to the regeneration of the aldehyde. 
~~ 
i Y ~ 
R 
R~~ --- --- ......... 
Y 
Self-Regeneration of 
Stereocentres 
Trigonal Rl 
centre ~ 
/l.,--y 
R 
~RCHO 
Figure 1.3. The principle of the Self Regeneration of a Stereogenic centre. 
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Application of the principle of SRS to the chiral pool of proteinogenic amino acids 
subsequently allows for the preparation of a wide range of a,a-disubstituted amino acids 
for use as building blocks in peptidomimetics design (Figure 1.4). 
Substitution of an 
a~hydrogen atom 
With inversion With retention 
of configuration of configuration 
Figure 1.4. 
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Protection of an amino acid in the form of an oxazolidinone (Y=O), or imidazolidine 
(Y=NMe), results from a thermodynamically controlled reaction of the carboxylic acid 
derivative with an aldehyde. The occurrence of either the cis or trans form of the resulting 
heterocycle strongly depends on the nature of the N-acyl group and the aldehyde. For 
example, N-benzoyl oxazolidinones derived from benzaldehyde give predominantly trans 
heterocycles, while those derived from pivaldehyde give predominantly cis heterocycles. 
Hence, acetals derived from (S)-amino acids can be produced with either an (R) or (S) 
configuration at the acetal centre. Subsequent deprotonation results in the formation of a 
heterochiral enolate that can undergo diastereoselective alkylation, at the a-carbon, to form 
enantiomerically pure prodUCts. Hydrolysis of the acetal results in a wide variety of chiral 
a,a-disubstituted amino acid building blocks for use in the synthesis of peptidomimetics. 
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The principle of SRS and its extensive applications in synthesis has since been expertly 
reviewed. 14 
As an example, N-Z-phenylalanine is condensed with an aryl aldehyde to give a 9:1 
mixture of 2-aryl-4-benzyl-oxazolidinones 1.3 and 1.4, where the cis isomer 1.3 is the 
major product (Scheme 1.5). Separation of the isomers and subsequent deprotonation of 
each in the presence of Mel, followed by hydrolysis, gave enantiomerically pure samples 
of Rand S a -methyl phenylalanine. Significantly, 5-oxazolidinones of this type, 
substituted at the 2 position, direct alkylation of the subsequent enolate at the face opposite 
this substituent. 
Ph ArCHO I p-TSA 
Z'Nfc02H 
CH]CCI3 1 f:,. 
H 
PhOC" :de: E+ 
H N "~~) 4 O'L'+ o Q 1 
Ph 
Z-NJ;O + )-0 9 Ar 
1.3 cis trans 
Ph 
Z-NJ;O 
}-O 
Ai' 
1.4 
t 
/Ph 
H3C>( --
Z'N r O 
,~O 
Ai 
1. 1 M NaOH I MeOH, rt I 
2. MeOH, 10% Pd/C t 
S-a-methyl phenylalanine R-a-methyl phenylalanine 
Scheme 1.4. The enantioselective synthesis of a-methyl phenylalanine,ll 
5-0xazolidillones have been used in this manner during the synthesis of selective 
neurokinin receptor ligands of type 1.5, and bombesin receptor ligands of type 1.6, where 
the a-methyl substituent imparts conformational stability in vivo (Figure 1.5).15 
Additionally, a,a-disubstituted amino acids themselves have been found to be biologically 
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active, with one example being (S)-a-methyldopa 1.7, a compound that exhibits 
hypotensive activity and inhibits the decarboxylation of (S)-dopa by mammalian 
decarboxylase. 12 
1.7 
Figure 1.5. 
Conversely, natural product peptidomimetics can also be synthesised usmg this 
methodology. An example is (-)-mirabazole C, a tetrathiazone/thiazol alkaloid isolated 
from the blue/green alga Scytonema mirabile, that has shown selective cytotoxicity against 
solid tumours and inhibitory activity against HIV -1 protease. Akaji et al. utilised chiral 
oxazolidinone chemistry to prepare chiral methylcysteine subunits for use in the synthesis 
of the target natural product (Scheme 1.5).16 
.. 
Bnsl"Me Bns~Me 
--.... " ZN~O --...... ZHN 'C02H 
~O P:~S SBn II 
,J-N~~'(>y~~sBn 1 HoI) H 0 
BnS 
(-)-mirabazole C 
Scheme 1.5. Reagents and Conditions: i. PhCH(OMe)z, BF3.Et20, -150 C, ii. LiN(Et)2l 
BnSCH2Br, iii.LiOH. 
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a,a-Disubstituted ammo acids have subsequently emerged as very important chiral 
building blocks in peptidomimetic synthesis, and are used to induce a defined 
conformational restriction in a range of peptide and peptide-like compounds .. 
1.3.3. Peptide Backbone Modification 
Modification of a peptide backbone generally involves the exchange of units within a 
peptide chain with electronically andlor sterically equivalent units, as well as the 
incorporation of additional units. These modifications lower the peptide character of the 
mimic, thereby increasing proteolytic stability, while retaining key steric or electronic 
properties of the parent peptide. Some common examples of peptide backbone 
modification are outlined in Figure 1.6. 
Figure 1.6. 
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A key aim here is to modify the parent peptide so that it adopts a preferred bioactive 
conformation. Often this involves constraining a peptide bond to adopt either a cis- or 
trans-amide geometry. Pauling and Corey's pioneering work on the structure of peptides 
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and proteins revealed that the peptide bond is planar and rigid, such that the hydrogen of 
the substituted nitrogen is nearly always trans to the carbonyl oxygen, due to the partial 
double character of the amide bond. Delocalisation of the nitrogen electrons limits free 
rotation about the amide bond thereby limiting the rate of interconversion between the cis-
and trans-coplanar forms (Figure 1.7). 
slow 
trans- CIS-
Figure 1.7. 
The conformation of an amide bond is therefore crucial to the binding of an extended 
peptide-based ligand to a receptor. In a typical amide bond the trans-conformation is 
favoured over the cis-conformation by approximately 10 kcallmol, due to less steric 
interaction between adjacent amino acid side chains, with extended peptide ligands often 
seen binding to a receptor with a preference for one or other of the conformations. In 
many cases, biologically active peptides bind with a cis conformation despite this being 
energetically disfavoured. 
An example is the Phe-Pro cleavage site in substrates of HIV protease, a site unique to 
retroviral proteases. Initial studies of HIV protease suggested that a cis-conformation was 
preferred at this position in substrates that bind in the active site of the enzyme. This led to 
the development of the potent HIV protease inhibitor JG-365, a compound in which the 
peptide backbone has been modified to include a hydroxyethylamine isostere in place of 
the key phenylalanine residue (Figure 1.8). X-ray crystal studies of JG-365 bound to HIV 
protease revealed that the inhibitor binds to the active site in a pseudo-cis conformation 
about the C-C bond adjacent to the proline residue. The torsion angle about this bond is 
11°, indicating the conformation to be essentially planar. However, while JG-365 is a 
potent inhibitor in vitro it fails to inhibit HIV protease in cellular assays, due to its largely 
peptidic character. Studies done in this laboratory have shown that further modification of 
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the peptide backbone of JG-365, to incorporate a tetrazole moiety as a cis-amide bond 
isostere, constrains the peptide mimic to adopt a similar conformation to that of JG-365. 
The tetrazole moiety constrains the peptide such that the torsion angle about the C-
tetrazole bond is approximately 13°, a value in close agreement with that found in the 
equivalent C-C bond in the bioactive confotmation of JG-365. Consequently, compounds 
of type 1.8, that contain a modified tetrazole backbone, have been shown to be good 
inhibitors of HI V protease. 17,18 
. ~~ 
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Another prominent example can be found in the use of 1,2-disubstituted and 2,5-
disubstituted pyrroles of type 1.9 and 1.10, as cis and trans amide mimics respectively. 
(Figure 1.9) 
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Figure 1.9. 
Latent reactivity can be incorporated into compounds of this type in the form of a 
hydroxymethyl moiety that can undergo reaction to form a highly electrophilic azafulvene 
intermediate. Peptidomimetics of this type were developed in this laboratory as 
mechanism-based inhibitors of a-chymotrypsin, with reaction of the azafulvene 
intermediate with an enzyme active site nucleophile resulting in a covalently bound 
enzyme-inhibitor adduct (Figure 1.10). 
---. E Enz-xJ) 
H 
hydroxymethylpyrrole 
Figure 1.10. 
Peptidomimetics of type 1.11, and 1.12, incorporate electron-withdrawing group at the C-2 
and N-positions respectively, and are designed to deactivate the pyrrole ring system and 
suppress the formation of an azafulvene intermediate. Upon cleavage during enzyme 
hydrolysis these compounds release these electron-withdrawing groups are cleaved leading 
to azafulvene formation and the release of latent reactivity. 
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Other examples of cis and trans modified peptide isosteres are shown in Figure 1.11. N-
Alkylated amides such as 1.13 are well known for adopting a cis-amide conformation with 
N-methylated amino acids found in many naturally occurring bioactive peptidomimetics. 
The ortho-substituted benzene mimic 1.14 has been incorporated into potent inhibitors of 
HIV protease,I9 as has another popular cis-amide mimic, the cis-epoxide 1.1S,z° The 
trans-alkene isostere 1.16 has been utilised in a number of peptidomimetics, with 
derivative 1.17 having been incorporated into a potent neurotensen binder,21 while the 
fluorinated analogue 1.18 has been identified as an inhibitor of dipeptidyl protease IV. 22 
cis-amide 
bond mimics 
trans-amide 
bond mimics 
Figure 1.11. 
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In recent times, a significant method of backbone modification has been the incorporation 
of ~-amino acids into peptide chains. Oligomers composed of ~-amino acids have since 
been shown to adopt stable and distinct helical structures in solution, a phenomenon 
previously thought to be unique to a-amino acids (Figure 1.12). An additional property of 
~-peptides is their enhanced biological stability towards proteolytic enzymes, making them 
ideal for use as peptidomimetics. The development of ~-peptides as peptidomimetic 
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therapeutics has since become the focus of intense research. Recent examples include a 
range of a-helical ~-peptides that possess potent cell-lytic activity, and the tetra ~-peptide 
1.19, a powerful binding ligand of somatostatin (see Chapters Five and Six for a more 
detailed discussion). 
,,<Helix 
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Figure 1.12.23 
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1.3.4. Ring ~Formation 
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The most common, and perhaps the most important, tool in peptidomimetics design is the 
use of cyclization to restrict conformational mobility. The introduction of rigid bridges of 
varying lengths between different parts of a peptide, can improve potency by locking the 
ligand into a preferred bio~active conformation thereby increasing its affinity for its 
associated receptor or enzyme active site. The exclusion of conformations that are capable 
of inhibiting other enzymes also enhances the specificity of the ligand for its target. 
Commonly, two adjacent amino acid residues are involved in bridging, however there are 
many other sites where this is possible (Figure 1.13). 
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Figure 1.13. Bridging sites for the introduction of conformational stabilising rings. 
Two naturally occurring examples of conformationally restricted cyclic amino acids are 
proline and pipe colic acid. These residues contain a carbon bridge linking the amine 
nitrogen to the a-carbon, thereby restricting rotation about the N-aC bond. The result is a 
unique kink or bend in a peptide wherever these residues are incorporated with many 
important structural proteins and bioactive peptides containing key proline or pipecolic 
acid subunits (see Chapters Two and Three for a more detailed discussion). 
L-proline L-pipecolic acid 
Cyclic Peptidomimetics 
Well-known examples of peptidomimetics that incorporate bridging rings are Freidinger 
lactams, compounds that contain a bridge between the amide nitrogen of one residue and 
the a-carbon of an adjacent residue. Lactams of this type are commonly used to restrict 
the rotation about a key amide bond in order to stabilise a preferred bioactive 
conformation. Compounds of type 1.20 have been used to stabilise a trans amide bond 
geometry in the development of inhibitors of the renin-angiotensin system, a key 
component in the regulation of blood pressure (Figure 1.14).24 a-Substituted derivatives of 
this type have found use as versatile dipeptide isosteres.25 with similar compounds, 
incorporating varying ring sizes, having also been developed as inhibitors of Hepatitis C 
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Virus NS3 protease (see Chapter 7 for a more detailed discussion). Conversely, 
compounds of type 1.21 represent examples where bridging between adjacent amino acid 
residues leads to the stabilisation of a cis-amide bond geometry.26 Toniolo et ai. recently 
described the application of these compounds towards the construction of new helices, 
large-ring cycle correlates and nanotubes?7 Compounds of type 1.22, developed by the 
author in this laboratory, have similarly been designed as cis-amide bond mimics in this 
regard?8 
H/R;Q)n 0 ~ N~ N -H :: 
o R2 
1.20 
~~~o 
o 
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Figure 1.14 .. Conformational stabilising rings used in peptidomimetics design. 
The introduction of cyclization to restrict conformational mobility also amends itself to the 
incorporation of latent reactivity. An example is the cyclic enamino ester dipeptide 
analogue 1.26 (Scheme 1.6), developed in this laboratory as a new class of inhibitor of 
serine proteases,z9 The synthesis of these compounds involves the bromine mediated 
lactonisation of a key keto-acid phosphorane 1.24, derived from a chiral oxazolidinone 
1.23 (refer to Section 1.3.2 Introduction of Substituents), to form the bromo enol lactone 
1.25. Compounds of this type are known to be mechanism-based inhibitors of serine 
proteases, with subsequent treatment of 1.25 with an amino acid affording the dipeptide 
analogue 1.26. Enzyme mediated cleavage of the lactam ring of 1.26 results in the release 
of latent reactivity and the covalent binding of the illhibitor to the enzyme active, thereby 
inhibiting its mode of action. 
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Scheme 1.6. 
Another impressive example of the use of rings to constrain conformation can be seen in 
the computer aided de novo design of cyclic urea inhibitors of HIV protease?O The first 
high resolution X-ray crystal structures of this aspartyl protease, bound to the 
hydroxyethylamine inhibitor JG-365, confirmed that the enzyme was C2 symmetric in 
nature and contained a tetra~coordinated structural water molecule that linked the bound 
inhibitor to the flexible 'flaps' of the HIV protease dimer (Figure] .15).31 The presence of 
this water molecule is a unique feature of the retrovirus protease. As such, inhibitors of 
type 1.27 (Figure 15b), containing a C2-axis of symmetry and using a diol as the transition-
state mimetic, were developed and found to be potent inhibitors of HIV protease. 
However, diols of this type proved to be highly insoluble and possessed very poor 
bioavailabilty. Consequently, Lam et at. utilised 3-D computer techniques to develop a 
novel scaffold possessing the key diol moiety and the necessary structural motifs to bind 
the active site residues and the structural water molecule. The result was the introduction 
of cyclic ureas of type 1.28 (Figure 15c), as new and potent and selective inhibitors of HIV 
protease that exhibit high bioavailability and good human pharmacokinetics.30 Figure 15c 
shows the enhanced interactions brought about by the cyclic nature of the mimic in 
constraining key functional groups to adopt a key bioactive conformation. 
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Figure 1.15.30 a) Hydrogen-bonding observed in the crystat structure of .10-365 complexed 
to HIV protease. b) Distance geometry model of 1.27 docked to HIV protease showing the 
extended binding conformation and hydrogen bonding interactions . c) X-ray crystal 
structure of 1.28-HIV protease showin enhanced hydrogen bonding interaction. 
Other examples of peptidomimetics iw orporating rigid ring structure designed to stabilise 
bioactive conformations are shown in Figure 1.16. These include mimics that bridge 
within a single amino acid residue (1.29]2 and 1.3033), between two adjacent side chains 
(1.31 34 and 1.3235 ) or adjacent backb()nes (1.33J 6), between a backbone and a side-chain 
(1.3437), or incorporate both the backbone and the side-chain units through the introduction 
of multicyclic systems, as in the case of the potent ACE inhibitor 1.35.38 
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Many biologically active macrocyclic peptides are found in nature. Their biological 
activity, in contrast to their acyclic counterparts, is due in part to the inherent 
conformational restriction provided by the cyclic system. The restricted conformation of 
macro cyclic peptides offers enhanced binding selectivity with receptors as the bioactive 
conformation is obtained from a smaller population of conformers. This is true of all 
constrained peptidomimetics and offers a distinct entropic advantage over analogous 
acyclic peptides. Compounds 1.36 and 1.37 are examples of synthetic macrocyclic 
peptidomimetics where the non-adjacent residues are linked to bring them close in space 
and induce biological activity (Figure 1.17). Both 1.36 and 1.37 are potent inhibitors of 
HIV protease and display enhanced metabolic stability relative to acyclic inhibitors.39 
Rational design of simplified analogues of somatostatin, a macro cyclic peptide hormone 
that regulates the release of growth hormone, has led to compounds showing similar 
potency to the parent peptide, including 1.38 where a key recognition loop is constrained to 
induce receptor recognition.4o 
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Figure 1.17. 
What follows is a discussion of a general method for the introduction of rings into both 
peptide and non-peptide compounds. 
1.4. Ring-Closing Metathesis as a Method of Ring Formation 
In recent years olefin metathesis has emerged as a powerful new tool in organic synthesis 
and has seen widespread use in the preparation of modified peptides and peptidomimetics. 
The power of this reaction lies in its ability to transform a carbon-carbon double bond, a 
functional group that is relatively unreactive towards many reagents. Olefin metathesis 
involves the bringing together of two carbon-carbon double bonds (or olefins), in the 
presence of a transition metal catalyst, to form a new carbon-carbon double bond. This can 
be carried out at or near room temperature, in a variety of media (organic or aqueous), 
from starting materials that bear a variety of functional groups. Ring-closing metathesis 
(RCM) is an example of this reaction in which the initial olefins are contained within the 
same acyclic starting molecule (Figure LI8.). As such, RCM has emerged as a powerful 
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new method for the synthesis of carbocyclic rings and has since been applied extensively 
towards the synthesis of a wide range of conformationally constrained and cyclic 
peptidomimetics. 
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Many of the advances in olefin metathesis can be directly attributed to the improvements 
made in metal-carbene catalysts and the development of well-defined catalyst systems. In 
particular, work by Schrock, and Grubbs, has resulted in the molybdenum catalyst 1.39,41-
43 and ruthenium catalyst 1.40,44-47 seeing widespread use in organic chemistry in recent 
years (Figure 1.19). 
1.40 Grubbs' catalyst 
Figure 1.19. 
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A significant benefit of these catalysts is their functional group tolerance, with cyclisation 
occurring in the presence of free alcohols, carbonyl groups and other potentially reactive 
functionalities. Functional groups of this type are often incompatible with traditional 
methods of ring-closure and require extensive protection. Applications of 1.39 and 1.40, 
and related catalysts, in organic chemistry and peptidomimetic synthesis have been the 
subject of a number of reviews,48-51 with Grubbs' catalyst 1.40 being named chemical of 
the year in 1998. 
RCM is most easily understood when considering the cyclisation of a simple diene by 
means of a metathesis an exchange of groups between the two arms of the molecule. A 
schematic mechanism for the RCM reaction involving 1..40 is shown in Figure 1.20. 
lJJ 
II 
Figure 1.20. 
First, carbene 1.40 adds to one of the alkenes of an acyclic diene by means of a [2+2] 
cycloaddition, to give a metallocyclobutane. The same reaction then happens in reverse to 
give either the starting materials or, by cleavage of the other two bonds, a new carbene 
complex with styrene (R=Ph) as a byproduct. Next, an intramolecular [2+2] cycloaddition 
occurs to linle the two arms of the molecule and produce a second metallocyclobutane. 
This decomposes in the same way as the first to give a third carbene complex and the 
newly cyclised product. This new carbene complex then attacks another molecule of 
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starting material and the cycle is repeated, with the exception that ethylene is now lost 
instead of styrene in all remaining cycles. 
Since the introduction of Schrock's catalyst 1.39, and Grubbs' catalyst 1.40, many other 
catalysts have been developed with the aim of improving both reactivity and selectivity. 
For example, 1.39 has the major disadvantage of being air- and moisture sensitive, while 
the excellent profile of 1.40 is hampered by its thermal instability and low reactivity 
towards substituted double bonds. As such, ruthenium based catalysts have received the 
greatest attention due to their high selectivity, and ability to be used under less stringent 
conditions. Incorporation of large electron-donating ligands and small electron 
withdrawing halogens was found to lead to more active catalysts. The subsequent 
exchange of one PCY3 unit of 1.40 with N-heterocyclic carbene ligands led to "second 
generation" metathesis catalysts with superior reactivity and increased stability (Figure 
1.21).52-54 The highly reactive alley lidene complexes 1.42 and 1.43 are over a thousand 
times more reactive than lAO and efficiently catalyse reactions of substrates which do not 
react with catalyst 1.40, including a-~-unsaturated olefins. In addition, it was noted that, 
in many cases, catalysts with extended carbene tethers (i.e. 1041) effected RCM of more 
hindered substrates by exhibiting increased co-ordination during formation of the 
intermediate metallocyclobutane.47,48 It was also observed that addition of Ti(i-PrO)4 to 
reactions where difficulties were encountered cyclising substrates with potential metal 
coordinating functionalities adjacent to the alkene, led to an increase in the rate and yield. 55 
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Hoveyda recently established catalysts of type 1.44, as remarkably robust complexes that 
promote olefin metathesis by a "release-return" mechanism.56,57 This non-phosphine 
catalyst possesses a greater reactivity towards electron-deficient olefins than does 1.42. 
The fact that the ruthenium carbene 1.44 is air stable, can be easily purified by standard 
silica gel chromatography and can be recycled after the reaction are particularly appealing 
facets of this chemistry. Blechert and Wakamatsu have also very recently shown that 
replacement of the isopropoxybenzylidene ligand of 1.44 with BINOL,ss or biphenyl-based 
benzylidene,59 results in a large improvement in activity. As a result complex 1.45 is not 
only much more reactive than 1.44, but also the second generation Grubbs catalyst 1.42. 
Grela et al. have shown that the Hoveyda-type catalyst can be significantly improved by 
changing not only the steric, but also the electronic environment of the Ru-chelating 
isopropoxy fragment. The introduction of the strongly electron-withdrawing N02 group 
onto the 2-isopropoxybenzylidene ring of 1.44 leads to complex 1.46 which is just as stable 
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as 1.44 but dramatically more reactive.60 This observation suggests that decreasing the 
electron density on the oxygen atom of the isopropoxy fragment of 1.44 results in an 
increase in catalytic activity. Catalysts that allow RCM in methanol and water (1.47 and 
1.48) have also recently been developed. The phosphine ligands of these catalysts contain 
quaternary ammonium salts that give enhanced solubility, and activity, in protic solvents. 
Asymmetric RCM using catalysts 1.49 and 1.50 has also been described but has yet to see 
widespread use.61 
The use of ring-closing metathesis in organic chemistry has resulted in over 2500 examples 
being reported in the literature over the past 8 years. RCM of nitrogen-containing 
compounds, with applications towards the synthesis of heterocycles, alkaloids and 
peptidomimetics, has subsequently been the focus of much research and has been expertly 
reviewed.48 What follows are some recent examples of the use of RCM in peptide and 
peptidomimetic synthesis, followed by some general applications of olefin metathesis in 
organic synthesis. 
Research in this laboratory utilized 1.40 in the preparation of 5-hydroxypiperidinones of 
type 1.51 (Scheme 1.7). These compounds are based on the well-studied C2-symmetirc 
cyclic ureas such as DMP 450 (1.28), and known to be potent inhibitors of HIV protease.62 
Scheme 1.7. 
Thorstensson et aI, used 1.42 to prepare proline isosteres of type 1.52, for incorporation 
into potential inhibitors ofthrombin (Scheme 1.8).63 
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Enyne metathesis, a process by which an alkene and an alkyne are reacted to form a diene, 
has also seen development in recent years.64 An example is the use of 1.40 by Kotha in the 
preparation of 1.53 and 1.54, compounds utilised in the synthesis of highly constrained, 
and unusual, a-amino acid building blocks and peptides (Scheme 1.9).65 
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Scheme 1.9. 
Crimmins and Emmitte demonstrated the use of RCM in the synthesis of a,a-cis and trans 
disubstituted medium ring ethers, a common structural feature of many ladder ether marine 
toxins such as brevetoxins and ciguatoxins (Scheme 1.10).66 This same methodology was 
used in the synthesis of 9-membered ring ether (+)-obtusenyne. Hirama et al. later used 
RCM as a key step in the total synthesis of ciguatoxin itself,67 
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Scheme 1.10. 
Iqbal et al. utilised ReM in the synthesis of type VI f)-turn mimics, a unique member of f)-
turn family containing an s-cis peptide bond (Scheme 1.11). The understanding of the 
conformation of the type VI-f)-tum is crucial to the development of inhibitors of HIV 
protease.68 
1.40 
.. R Ph, CH(CH3h 
40-45% 
Scheme 1.11. 
Wagner et al. used ReM for the critical macrocyclisation step in the synthesis of macrolide 
analogues of the potent immunosuppresent sanglifehrin (Scheme 1.12).69 Significantly, 
this is one of the first examples of a macrocyc1e containing a conjugated diene, being 
prepared by ReM. 
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Scheme 1.12. 1.40, R=H, 57%, R=OTBDMS, 47%. 
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Grubbs and Blackwell illustrated the ability to covalently cross link short peptide 
sequences in order to initiate helix formation in short chain peptides (Scheme 1.13).70 The 
extraordinary functional group tolerance of olefin metathesis is of particular use in this 
regard. 
Boc-Val~Ser-Leu-Aib-Val-Ser-Leu-OMe (n=l) 
or Boc-Val-Hse-Leu-Aib-Val-Hse-Leu-OMe (n:=2) 
Scheme 1.13. 20mol% 1.40, n=l 85%, n=2 90% 
Similarly, general use of RCM throughout organic synthesis has led to a number of 
interesting and innovative applications being reported. 
Microwave technology has been applied to a number RCM reactions leading to shorter 
reaction times and lower catalyst loading. Grigg et al. showed that ReM of 1.55, to give 
1.56, could be achieved in one minute with 100% conversion (Scheme 1.14). 
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1.55 1.56 
Scheme 1.14. 
Grubbs et al. have recently used RCM in the preparation of rotaxanes, compounds 
composed of a dumbbell-shaped component around which one or more macrocycles are 
trapped (Scheme 1.15).71 Compounds of this type have applications as molecular switches 
in the emerging field of molecular computing. 
Scheme 1.15. 
Novel uses of RCM in the field of dendrimer chemistry have led to a number of interesting 
applications. Zimmerman et al. used 1.40 in the controlled synthesis of discrete nanotubes 
(Scheme 1.16).72 
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Scheme 1.16.72 
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Peng et al. 73 used 1.42 to ring-close G3 surface dendrons during the preparation of 
luminescent semiconducting nanocrystals with enhanced chemical, photochemical, and 
thermal properties (Scheme 1.17). 
Scheme 1.17.73 
(1) 
MeOH, CHCls 
pH"'10.3 
(3) 
Hel 
cHgestiol"l 
Chapter One 35 
Currently, applications of olefin metathesis in the petrochemical industry include its use in 
the Phillips triolefin process to procluc<:! polymerisation-grade propene by cross-metathesis 
of ethane and 2-butene. This process has also been used in the production of oeohcxene, 
an intermediate in the synthesis of musk perfume. A large ~calc industrial process 
incorporating olefin metathesis is the Shell Higher Olefins Process (SHOP), in which 
ethene is converted to detergent range al kenes (C 12-C J4 ). 
Olefin metathesis has also been applied to the synthesis of high tcnsik polymers. Grubbs 
ruthenium catalyst allows polymerisat lOn to occur in the presence of fillers. additives, 
stabilizers and other ingredients in a polymer formulation, leading to stronger, more easily 
moldable polymer formulations An i pressive example is the preparation of a 1.5 inch-
thick polycyclopentadiene resin, prepand with ruthenium technology , that is impenetrable 
to 9mm bullets (Figure 1.22). 
. 74 FIgure 1.22. 
In an age where the availability of fOSS il fuelsis gradually decreasing and the demand for 
new sources of renewable feedstocks is increasing, olefin metathesis has seen application 
in the area of oleochemicals. Oleochcmicals , incorporating natural fats and oils, have 
emerged as a distinctly viable and cost-effective source of raw materials and energy in thi5 
regard. Unlike petrochemicals, oleochemicals are derived from renewable resources, have 
good biostability, and no net CO2 roduction . Natural oils and fats (composed 
predominantly of glyccryt esters of fatly acids) are used as starting materials in a "vide 
range of chemical products. The most important are the long-chain vegetable oil s such as 
soybean and rapeseed oil (unsaturated C 18 fats) , ancl palm oil (unsaturated C)6 and C IS 
Chapter One 36 
fats), and the short and medium length vegetable oils such as coconut and palm kernel oil 
(C12-CI4) that serve as important sources for the production of cosmetics, detergents, soaps 
and emulsifiers. One example in this area is the highly efficient conversion of oleon 1.57, 
by RCM to a cis-trans mixture of 1.58 and 9-octadecene 1.59, and (Scheme 1.18). The cis 
isomer of 1.58, civetine, is an attractive ingredient in musk perfumes and is ordinarily 
prepared synthetically in poor yields over many steps. 
o 
1.57 
t ReM 
o~+~ 
1.58 1.59 
Scheme 1.18. 
Another example is the metathesis of fatty oils that contain triglycerides of unsaturated 
long-chain fatty acids, to form both intramolecular and intermolecular products. This is of 
particular interest in the printing industry. Thus, olive oil, consisting mainly of glycerol 
trioleate (triolien), yields 9-octadecene and polymeric triglycerides (Figure 1.19). 
intra inter 
Figure 1.19. 
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Drying and semidrying oils such as linseed oil and soybean oil are valuable raw materials 
for the manufacture of oil-based paint, printing ink and synthetic resins. Metathesis of 
these oils, results in high molecular-weight oils (stand oils) that retain the integrity of their 
unsaturated double bonds. Such oils have more pronounced drying properties than 
thermally polymerised oils, where the polymerisation process considerably reduces the 
number of double bonds available for cross-linking during the drying process. Thus 
metathesized soybean oil has been used as an additive in low concentrations to benefit the 
printing process by dramatically reducing the drying time of soybean oiL 
Other products that can be produced from RCM of oleochemicals include I-triacontanol, a 
plant growth stimulant, insect pheromones, three of which are commercially available by 
means of olefin-metathesis-based syntheses, and various polymers. Reactions of this type 
offer increased efficiency over current processes due to low energy requirements, low 
accident potential due to mild reaction conditions, and the fact that all the metathesis 
products are usefuL Many other commercial applications of olefin metathesis are currently 
being explored. 
The future of ring-closing metathesis, and olefin metathesis in general, remains bright as 
new catalysts and applications are continually discovered. 
1.5. Research Described in this Thesis 
Peptidomimetics have found widespread application as biostable, bioavailable, and often 
potent mimetics of naturalpeptides. This thesis describes the application of ring-closing 
metathesis (RCM) to the synthesis of conformationally constrained peptide mimics derived 
from (X,- and ~-amino acids. The ability to introduce substituents stereoselectively at the a-
position of these mimics will also be discussed. 
Chapter Two of this thesis describes the enantioselective synthesis of a class of 
conformationally constrained, a-substituted tetrahydropyridine and piperidine peptide 
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mimics, via RCM. The solid-state conformation of these mimics was examined and their 
application as potential cis-amide bond mimics discussed. The enantiomeric purity of a 
key intermediate was also analysed to determine the stereoselectivity of a key alkylation 
step, and assess the overall enantiomeric integrity of the synthesis. 
Chapter Three describes the enantioselective synthesis of a class of conformationally 
constrained, a-substituted dehydroproline and proline peptide mimics, by RCM, in a 
manner similar to that detailed in Chapter Two. The solid-state conformation of a 
dehydroproline mimic was determined by X-ray crystal analysis and discussed in 
comparison with the conformations observed for the tetrahydropyridine and piperidine 
mimics described in Chapter Two. 
Chapter Four describes the first enantioselective synthesis of the tetrahydropyridazinone 
core of a 2-oxo-l, 6-diazobicyclo(4,3,O)nonane-9-carboxylate ~-strand template. 
Conformationally constrained bicyclic templates of this type have been designed as key 
components in inhibitors of serine proteases such as thrombin. 
Chapter Five describes a versatile ring-closing metathesis (RCM) approach to the 
synthesis of aminocyclohexenylcarboxylic acids (ACHC's) that allows the preparation of 
derivatives that are either unsubstituted, or substituted at the a-position. This second class 
represents an important addition to this family of compounds. 
Chapter Six describes a convenient and versatile ring-closing metathesis approach to the 
synthesis of aminocyclopenteny1carboxylic acids (ACPC's) from L-methionine. This 
approach allows for the preparation of derivatives that are either unsubstituted, or 
substituted, at the a-position in a manner similar to that detailed in Chapter Five. 
Chapter Seven describes the a ring-closing metathesis approach towards the synthesis of 
six- and seven-membered cyclic lactams derived from functionalised a- or ~-amino acids. 
This approach allows the preparation of derivatives that are either unsubstituted or 
substituted at the a-position. 
Chapter One 39 
1.6 References for Chapter One 
1. Gante, 1 Angew. Chem. Int. Ed. Engl. 1994,33, 1699. 
2. Belshaw, P. J.; Meyer, S. D.; Johnson, D. D.; Romo, D.; Ikeda, Y.; Andrus, M.; 
Alberg, D. G.; Schultz, 1. W.; Clardy, 1; Schreiber, S. 1. Synlett 1994, 381-392. 
3. Myers, R A.; Cmz, 1. J.; Rivier, 1; Olivera, B. M. Chem. Rev. 1993,93. 
4. Jiao, D.; Russell, K. c.; Hmby, V. l Tetrahedron 1993, 49, 3511. 
5. Snyder, G. H.; Rowan III, R.; Karplus, S.; Sykes, B. D. Biochemistry 1975, 14, 
3765. 
6. Colnago,1. A.; Valentine, KG.; Opella, S. J. Biochemistly 1987, 26, 847. 
7. Hsieh, K-H.; La Hann, T. R; Speth, R C. J Med. Chem. 1989,32,898. 
8. Ben-Ishai, D. JAm. Chem. Soc. 1957, 79,5736-5738. 
9. Scholtz, l M.; Bartlett, P. A Synthesis 1989, 542-544. 
10. Itoh, M. Chem. Pharm. Bull. 1969,17, 1679-1686. 
11. Karady, S.; Amato, l S.; Weinstock, 1. M. Tetrahedron Lett. 1984,25,4337-4340. 
12. Seebach, D.; Aebi, 1 D.; Naef, R.; Weber, T. Helv. Chim. Acta 1985, 68, 144-154. 
13. Seebach, D.; Fadel, A. Helv. Chim. Acta 1985, 68, 1243-1250. 
14. Seebach, D.; Sting, A R; Hoffmann, M. Angew. Chem. Int. Ed. Engl. 1996,35, 
2708-2748. 
15. Horwell, D. C.; Pritchard, M. C.; Raphy, 1 In Advances in Amino Acid Mimetic and 
Peptidomimetics; Abell, A D., Ed.; JAI Press: Stamford, 1999; Vol. 2, p 165-190. 
16. Akaji, K; Kuriyama, N.; Kiso, Y. J Org. Chern. 1996,61,3350-3357. 
17. May, B. C. H.; Abell, A D. Tetrahedron Lett. 2001,42,5641-5644. 
18. May, B. C. H.; Abell, AD. J Arn. Chem. Soc., Perkin Trans. 12002, 172-176. 
19. van der Elst, P.; van den Berg, . Pepermans, H.; van der Auwera, 1.; Zeews, R.; 
Tourwe, D.; van Binst, G. Int. J Peptide Protein Res. 1987,318. 
20. Abell, A. D.; Boult, D. A.; Bergman, D. A; Fairlie, D. P. Bioorg. Med. Chern. Lett. 
1997, 7, 2853. 
21. Christos, T. E.; Arvanitis, A; Cain, G. A.; Johnson, A 1.; Pottorf, R S.; Tam, S. 
W.; Schmidt, W. K Bioorg. Med. Chem. Lett. 1993,3, 1035. 
22. Welsh, 1 T.; Lin, 1 Tetrahedron 1996, 52, 291. 
23. Cheng, R P.; Gellman, S. H.; DeGrado, W. F. Chern. Rev. 2001,101,3219. 
24. de Laszlo, S. E.; Bush, B. 1.; Doyle, 1 J.; Greenlee, W. 1; Hangauer, D. G.; 
Halgren, T. A.; Lynch, R l; Schorn, W.; Seigl, P. K. S. J Med. Chern. 1992,35, 
833. 
25. Zydowsky, T. M.; Dellaria, J. F.; Nellans, B. N. J Org. Chern. 1988, 53, 5607-
5616. 
26. Goswami, R.; Moloney, M. Chem. Cornmun. 1999,2333-2334. 
27. Crisma, M.; Moretto, A; Toniolo, C.; Kaczmarek, K; Zabrocld, 1 Macromolecules 
2001,34,5048-5052. 
28. Abell, A. D.; Gardiner, 1 J Org. Chem. 1999,64,9668-9672. 
29. Abell, A. D.; Taylor, l M. J Org. Chern. 1993,58, 14. 
30. Eyermann, C. J.; Jadhav, P. K.; Hodge, C. N.; Chang, C.-H.; Rodgers, l D.; Lam, 
P. Y. S. In Advances in Amino Acid Mirnetics and Peptidomimetics; Abell, A D., 
Ed.; JAI Press: Greenwich, 1997; Vol. 1, p 1-40. 
Chapter One 40 
31. Miller, M.; Schmeider, J.; Sathyanarayana, B. K.; Toth, M. V.; Marshall, G. R.; 
Clawson, L.; Selk, L.; Kent, S. B. H.; Wlodawer, A Science 1989,246, 1149. 
32. Cativiela, C. C.; Diaz de Villegas, M. D.; Avenoza, A.; Peregrina, J. M. 
Tetrahedron 1993, 49, 10987. 
33. Kazmierski, W.; Hruby, V. J. Tetrahedron 1988, 44,697. 
34. Suumaran, D. K; Prorok, M.; Lawrence, D. S. J. Am. Chem. Soc. 1991,113,706. 
35. Rone, R.; Manesis, N.; Hassan, M.; Goodman, M.; Hagler, D. H.; Kitsen, D. H.; 
Roberts, V. A. Tetrahedron 1988,44,3853. 
36. Di Maio, J.; Bellau, B. J. Chem. Soc. Perkin Trans 11989, 1687. 
37. Gante, J.; Weitzel, R Tetrahedron Lett. 1988,29,3853. 
38. Flynn, G. A.; Giroux, E. L.; Dage, R C. J. Am. Chem. Soc. 1987,109,7914. 
39. Reid, R C.; Fairlie, D. P. In Advances in Amino Acid Mimics and Peptidomimetic; 
Abell, A. D., Ed.; JAI Press: Stamford, 1997; Vol. 1, p 77. 
40. Veber, D. F.; Freidinger, R. M.; Perlow, D. S.; Palevada, W. J.; Holly, F.; Strachan, 
R. G.; Nutt, R.; Arison, B. H.; Homnic, C.; Randall, W. C.; Glitzer, M. 
S.;Saperstein, R.; Hirschmann, R. Nature 1981,292,55. 
41. Schrock, R R; Murdzek, J. S.; Bazan, G. C.; Robbins, J.; DiMare, M.; O!Regan, 
M. J. Am. Chem. Soc. 1990,112,3875. 
42. Bazan, G. C.; Khosvari, E.; Schrock, R R.; Feast, W. J.; Gibson, V. C.; O'Regan, 
M. B.; Thomas, J. K.; Davis,W. M. J. Am. Chem. Soc. 1990, 112, 8378. 
43. Bazan, G. C.; Oskam, J. H.; Cho, H.-N.; Park, L. Y.; Schankat, J. J. Am. Chem. 
Soc. 1991,113,6899. 
44. Nguyen, S. T.; Johnson, L. K; Grubbs, R. H.; Ziller, J. W. J. Am. Chem. Soc. 1992, 
114,3974. 
45. Nguyen, S. T.; Grubbs, R H.; Ziller, J. W. J. Am. Chem. Soc. 1993,115,9858. 
46. Schwab, P.; France, M. B.; Ziller, J. W.; Grubbs, R. H. Angew. Chem. Int. Ed. 
1995,34,2039. 
47. Schwab, P.; Grubbs, R. H.; Ziller, J. W. J. Am. Chem. Soc. 1996,118, 100. 
48. Phillips, A. J.; Abell, A D. Aldrichim. Acta 1999, 32, 75-89. 
49. Schuster, M.; Blechert, S. Angew. Chem. Int. Ed. Engl. 1997,37,2036. 
50. Armstrong, S. K J. Chem. Soc. Perkin Trans 11998,371. 
51. Grubbs, R. H.; Chang, S. Tetrahedron 1998,54,4413. 
52. Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999,1,953-956. 
53. Sanford, M. S.; Love, J. A.; Grubbs, R H. J. Am. Chem. Soc. 2001, 123, 6543-
6554. 
54. Herrman, W. A; Speigler, M.; Schattenmann, W. C.; Westcamp, T. Angew. Chem. 
1998,110,2631-2633. 
55. Ffustner, A.; Langemann, K J. Am. Chem. Soc. 1997, 119,9130. 
56. Kingsbury, J. S.; Harrity, J. P. A.; Bonitatebus, P. J. J.; Hoveyda, A. H. J. Am. 
Chem. Soc. 1999,121,791. 
57. Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A H. J. Am. Chem. Soc. 
2000,122,8168-8179. 
58. Wakamatsu, H.; Blechert, S. Angew. Chem. Int. Ed. 2002,41, 794-796. 
59. Wakamatsu, H.; Blechert, S. Angew. Chem.Int. Ed. 2002,41,2403-2405. 
60. Grela, K.; Harutyunyan, S.; Michrowska, A. Angew. Chem. Int. Ed. 2002,41, 
4038-4040. 
Chapter One 41 
61. Tsang, W. C. P.; Hultzsch, K. C.; Kai, C.; Alexander, 1. B.; Bonitatebus, P. J. J.; 
Schrock, R R; Hoveyda, A. H. J. Arn. Chern. Soc. 2003,125,2652-2666. 
62. Humphries, M. E.; Murphy, 1.; Phillips, A. 1.; Abell, A. D. J. Org. Chern. 2003, 68, 
2432-2436. 
63. Thorstensson, F.; Kvamstrom, I.; Musil, D.; Nilsson, 1.; Samueisson, B. J. Med. 
Chern. 2003,46, 1165-1179. 
64. Kitamura, T.; Sato, Y.; Mori, M. Adv. Synth. Catal. 2002,344,678-693. 
65. Kotha, S. Acc. Chern. Res. 2003,36,342-351. 
66. Crimmins, M. T.; Ernrnitte, K. A Synthesis 2000, 6, 899-903. 
67. Hirama, M. Science 2001, 294,1904-1907. 
68. Prabhakaran, E. N.; Rajesh, V.; Dubey, S.; Iqbal, J. Tetrahedron Lett. 2001,42, 
339-342. 
69. Cabrejas, L. M. M.; Rohrbach, S.; Wagner, D.; Kallen, 1.; Zenke, G.; Wagner, J. 
Angew. Chern. Int. Ed. 1999, 38, 2443-2446. 
70. Blackwell, H. E.; Grubbs, R. H. Angew. Chern. Int. Ed. 1998,37,3281-3284. 
71. Kilbinger, A. F. M.; Cantrill, S. 1.; Waltman, A W.; Day, M. W.; Grubbs, R H. 
Angew. Chern. Int. Ed. Engl. 2003,42,3281-3285. 
72. Kim, Y.; Mayer, M. F.; Zimmermann, S. C. Angew. Chern. Int. Ed. Engl. 2003, 42, 
1121-1126. 
73. Guo, W.; Li, 1. 1.; Wang, A; Peng, X. J. Arn. Chern. Soc. 2003, 125,3901-3909. 
74. Rouhi, A. M. In Chemical and Engineering News 2002; Vol. 80, p 29-33. 

CHAPTER Two 
SYNTHESIS OF 
(X-SUBSTITUTED TETRAHYDROPYRIDINE AND 
PIPERIDINE-BASED PEPTIDE MIMICS 
VIA 
RING-CLOSING METATHESIS 
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2.1 Introduction 
In recent decades, the design and synthesis of peptidomimetics has become increasingly 
important, as researchers seek to understand a myriad of biological processes and search 
for new and more effective treatments of disease. Here we present the design, synthesis, 
and derivatisation of a new class of a-substituted tetrapiperidine-based peptide mimics, for 
use in this process 
Piperidine and tetrahydropyridine ring systems are found widely in nature as components 
of biologically active natural products. Some simple examples are (+ )-coniine, the major 
alkaloid component of poison hemlock, and lobeline, a component of lobelia, used by 
North American Indians as a substitute for tobacco. More complex multicyclic examples 
include (+ )-cytisine and (+ )-lupanine, the toxic quinolizidine-based lupin alkaloids found 
in species of lupinus (Leguminosae) (Figure 2.1). 
Q",,~ 
H 
(+ )-coniine 
q (l 9H 
Ph)~N~Ph 
Me 
lobeline (+ )-cytisine 
Figure 2.1. Examples of piperidine based natural products 
o 
(+ )-lupanine 
An important derivative of piperidine, and a key intermediate in the biosynthesis of many 
important natural products, is L-pipecolic acid. This cyclic amino acid is produced via the 
lysine biosynthetic pathway. Here, the £-amino group of L-lysine undergoes oxidative 
deamination, followed by Schiff base formation, to give il1,6-piperideine carboxylic acid, a 
key precursor to L-pipecolic acid (Figure 2.2). Critical to this pathway is the retention of 
the carboxylic acid group at Ca. 
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L-Iysine aminoadipic 
semialdehyde 
6,1,6 -piperideine 
carboxylic acid 
Figure 2.2. L-Iysine derived biosynthesis of L-pipecolic acid 
- (:lC02H 
H 
L-pipecolic acid 
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Many important classes of natural product are derived from this proline homologue e.g. 
swainsonine and castanospermine, members of a class of polyhydroxylated indolizidines 
isolated from the Moreton Bay chestnut Castanospermum australe (Leguminosae) (Figure 
2.3). These compounds are active against the HIV retrovirus due to their ability to inhibit 
glycosidase enzymes involved in glycoprotein biosynthesis. 
N~H 'f)~"OH 
bH 
swainsonine 
OH 
HO", 
castanospermine 
Figure 2.3. Examples ofhydroxylated piperidine containing natural products. 
L-Pipecolic acid is also the precursor to quinolinic and nicotinic acids, important 
components of many vitamins and coenzymes, including NAD+ and NADP+. Nicotine, 
anabasine and anatabine, the alkaloids found in tobacco (Nicotiana tabacum (Solanaceae» 
are derived from these acids, as is the tetrahydro-derivative arecoline (Figure 2.4). 
quinolinic acid R=H 
nicotinic acid R=C02H 
(Vitamin B3) 
nicotine n=O, R=Me 
anabasine n= 1, R=H 
I 
~~(j: (Jfif 
N 
anatabine 
()C02Me 
N 
Me 
arecoline 
Figure 2.4. Many alkaloids and important vitamins and coenzymes are derived from L-
pipecolic acid. 
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L-pipecolic acid can be found in a variety of biologically active natural peptides. Like 
proline, L-pipecolic brings a high degree of constraint about the amide bond acid when 
acylated at nitrogen. For proline, this results in important biological scaffolds such as cis 
amides and ~-turns. Since proline is found in a wide range of structural and biologically 
active natural products it is not surprising to find compounds in which L-pipecolic acid 
serves a similar role. Some prominent examples of this are the macrolides FK-506 and 
rapamycin, and the cyclic depsipeptides papuamides A and B (Figure 2.5). FK-506 
(tacrolimus), isolated from Streptomyces tsukubaensis, and rapamycin, isolated from 
Streptomyces hygroscopius, are immunosuppressants that are universally used in organ 
transplant surgery. Papuamides A and B,l isolated from the marine sponge Theonella 
collected in Papua New Guinea, are known to strongly inhibit HIV -1 RF infection of human 
T-Iymphoblastanoid cells, and also exhibit potent cytotoxicity against a nunlber of human 
cancer cell lines. This novel class of compound contains a pipecolate residue adjacent to a 
key, ~-OMeTyr residue that is required for activity. 
rapamycin tacrolimus (FK-506) Papuamide A R=Me 
BR=H 
Figure 2.5. Examples of natural products containing an L-pipecolic acid subunit. 
Given the occurrence of pipecolic acids in nature, it is not surprising that they have also 
been incorporated into a wide range of pharmaceuticals. Several synthetic 
peptidomimetics contain pipecolic acid subunits. For example, the potent ACE inhibitor 
quinapril, and the prominent HIV protease inhibitor Nelfinavir, used in AIDS therapies, 
both have constituent pipecolic acids that serve to stabilise the bioactive conformation of a 
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key amide bond. Palinavir, another highly potent inhibitor of HIV, incorporates a 4-
hydroxy-pipecolic acid subunit as part of its structure (Figure 2.6)? 
~ H, ~ I (1 H QH "H H0T!rN~N o 's 0 NH-tBu 
6 
Quinapril Nelfinavir Palinavir 
Figure 2.6. Substituted pipicolic acids are found in many important pharmaceuticals. 
Substituted pipecolic acids have thus become the subject of intensive synthetic efforts in 
recent years. In addition to several racemic preparations of compounds of this type,3,4,5 a 
number of asymmetric syntheses, from chiral building blocks, have also been reported 
(carbohydrates,6,7 amino acids8C12). 
Another important compound related to pipecolic acid is the dehydro analog, i.e. 4,5-
dehydropiperidine carboxylic acid 2.1 (baikiain). This olefin-containing cyclic amino was 
first isolated in 1950 from Baikiaea plurijuga (Rhodesian teak)Y However, there have 
been surprisingly few syntheses described up till now. 14,15 One recent report describes the 
ring-closing metathesis cyclisation of an allyl glycine derivative, to give N-Boc baikiain 
methyl ester 2.1, in excellent yield (Scheme 2.1).16 Several asymmetric syntheses have 
subsequently been developed utilising this methodolgy .17, 18 
Boc, ~ 
N C02Me H 
i. ii. 
2.1 
Scheme 2.1. Grubbs' synthesis of N-Boc-(+I-)-tetrahydropipecolic acid methyl ester. 
Reagents and conditions: i. NaH, allyl bromide, DMF, 0° C for 1.5 h then rt for 30 min, 
55%; ii. RuCh(PCY3h=CHPh (1.40), benzene, rt, 2 h, 91 %. 
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However, there' are few reported examples of these compounds that contain an a-
substituent. As such, we set out to develop a methodology whereby a substituent could be 
introduced stereos electively at the a-carbon. This would allow access to conformationally 
restricted amino acid analogues of type 2.2. 
UR 
N COzMe 
I p 
2.2 
The introduction of a substituent at the a-carbon would allow interactions usually 
associated with amino acid side-chains, i.e hydrogen bonding, 1t-1t-stacking, 
hydrophobicity, hydrophilicity etc, to be incorporated into themimic, to give a compound 
with a unique conformational constraint and potential binding specificity. A general 
synthetic methodology would. allow the incorporation of a range of R groups at the a-
carbon, with stereochemical control being maintained throughout the synthesis. In this 
way a library of compounds of this type could be built up for use in peptidomimetic 
design. 
We chose to use oxazolidinone chemistry pioneered by Seebach et aZI9,ZO to introduce 
various substituents into a suitable precursor for ring-closing metathesis. 16 The inclusion 
of an olefinic moiety allows for subsequent functionalisation at this position. 
2.2 Synthesis of the Tetrahydropyridine Mimic 
In the first instance we chose to introduce a benzyl group stereoselectively at the a-
position of the proposed mimic (see 2.2 R=CHzPh), to give a phenylalanine analogue. 
This was chosen, as a model, for the introduction of an aromatic group to explore its effect 
on the properties of the mimic i.e 1t-1t-stacking, hydrophobicity, should it be incorporated 
into a peptide. lne proposed synthesis of this tetrahydropyridine mimic 2.9 is outlined in 
Scheme 2.2. 
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2.9 2.8 vi 2.6 R=OH c: 2.7R=OMe 
Scheme 2.2. Reagents and Conditions: i. NaOH; ii. PhCHO, CH2Cb, reflux; iii. PhCOCl, 
CH2Ch, 00 C for 4 h then rt for 16 h; iv. LiHMDS, THF, _78 0 C then allyl bromide; v. 
NaOH, MeOH, reflux; vi. CH2N2; vii. NaH, DMF, 00 C then allyl bromide; viii. Grubbs' 
ruthenium catalyst 1.40, CH2Ch. 
Here, L-phenylalanine is protected as the diastereomerically pure trans-5-oxazolidinone 
2.4. This is then subjected to a stereoselective alkylation, with allyl bromide, to give 2.5, 
which is subsequently hydrolysed, and alkylated on nitrogen, to give diene 2.8. Ring-
closing metathesis is then used to obtain the desired phenylalanine-derived 
tetrahydropyridine 2.9. 
The synthesis began with the preparation, from L-phenylalanine, of the key trans (or anti) 
oxazolidinone 2.4 (Scheme 2.3), a compound that has previously been reported.20-22 
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Scheme 2.3. Reagents and Conditions: i. NaOH; ii. PhCHO, CH2Ch, reflux; iii. PhCOCI, 
CH2Ch, 00 C for 4 h then rt for 16 h. 
Using the method of Seebach and Fadel,23 the sodium salt of I-phenylalanine was 
condensed, with azeotropic removal of water, with benzaldehyde in dichloromethane to 
give the corresponding Schiff base 2.3. Acylation with benzoyl chloride, at ODC for 4 h, 
followed by stirring at room temperature for 16 h, led to a 4:1 trans / cis diastereomeric 
mixture of oxazolidinones 2.4 and 2.10. The diastereomers were separated by 
crystallisation from methanol to give the desired trans isomer 2.4 in 59% overall yield.a,b 
The assignment of a trans (or anti) configuration to the major isomer 2.4 was confirmed by 
comparison with literature NMR data and further supported by the observation of a nuclear 
Overhauser enhancement (NOE) between H2 and CH2Ph. 22 In addition, a 1 H NMR 
spectrum of the trans-5-oxazolidinone 2.4, at 23°C, revealed broadening of the resonances 
for the H2 proton, the benzyl CH2 protons and a number of aromatic protons. It was 
suggested this might be due to conformational mobility of the molecule in solution. This 
conformational mobility could result from the partial double bond character exhibited by 
the amide bond ofthe ring nitrogen, thereby leading to restricted rotation (Figure 2.7). 
a Crystallisation from ethyl acetate/petroleum ether gave 2.4 in comparable yield 
b It is worth noting that literature methods for the synthesis of 5-oxazolidinones are 
consistently performed on a large scale, typically 20 - 40g. Research in this laboratory has 
found that synthesis on a smaller scale, 500mg - 5g, often gives yields somewhat lower 
than that reported for larger scales. 
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Figure 2.7. Broad IH NMR resonances for 2.4 may be due to conformational mobility in 
solution. 
Figure 2.8 shows the IH NMR spectrum collected for the trans oxazolidinone 2.4, 111 
CDCh, at both 23° C and 50° C. 
Ph PhCON~O 
~o 
p{ 
H4 
in CDCl3 at 23 deg 
ii' j I • I • r , j I I i I I I Ii! j I j i , 1 I I , I • I j I I I I I I I • I I I • I I iii 'i' iii I 
4,0 3.5 3.0 2.5 ppm 7.5 7.0 6.5 6.0 5.5 5,0 4.5 
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Figure 2.8. IH NMR spectra for the trans 5~oxazolidinone 2.4, in CDCh, at 23° C and 50° 
C. 
An increase in temperature resulted in a noticeable sharpening of the resonances for H2, 
H4, and some aromatic protons. This suggested that a coalescence of different 
conformations had occurred, a phenomenon that has been observed in numerous other 5~ 
oxazolidinones, as well as other heterocyc1es?4>26 
The introduction of the allyl substituent at C4 of 2.4 (refer Scheme 2.2), was next 
attempted. Oxazolidinone 2.4 was treated with LiHMDS, for 7 minutes at ~78°C, in THF, 
to form an enolate. Allyl bromide was then added, and the mixture stirred at ~78°C for 1 h, 
followed by warming to 20°C over 16 h. Pleasingly, this gave the desired alkylated 5~ 
oxazolidinone 2.5, in 93% yield after purification, as a single diastereoisomer by IH NMR 
(Scheme 2.4). A second compound, subsequently identified as the self-addition product 
2.11 was also observed and isolated in 6% yield. It was found that short mixing times (5-7 
minutes) between the addition of the base, and the addition of the electrophile, were 
needed to obtain high yields of 2.5. Longer mixing times (20min~lh) resulted 
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predominantly in an excess of the self-addition products being isolated (see Section 2.5 
Self Addition Products During Alkylation of 5-oxazolidinones). 
to o 
allyl bromide 
2.4 2.5 
+ 
2.11 
Scheme 2.4. Alkylation of 2.4, to give 2.5, proceeds via a chiral enolate 
The resulting configuration at C4 is defined by the absolute configuration at C2 of the 
starting oxazolidinone 2.4, which is in turn governed by that of the starting amino acid. 
The substituent at C2 effectively blocks one face of the enolate derived from 2.4, such that 
the electrophile approaches from the opposite side. It has been proposed that the enolate 
adopts a conformation in which the C2 phenyl group is pseudoequatorial, where the 
nitrogen and oxygen are pyramidal with the lone pairs pseudoaxial (Figure 2.9).27 The 
combined steric effect of the phenyl group, and the anti-stereo electronic effect of the 
'oxonium' moiety, favours electrophilic attack anti to the phenyl group. This results in 
inversion of configuration at C4 of the alkylated product. 
PhOC", R /' E+ 
H N---..( O"~o~~~~+ 
Figure 2.9. Alkylation of trans-5-oxazolidinones leads to an inversion of configuration at 
C4. 
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The configuration. depicted in Scheme 2.4 was further supported by x-ray crystallographic 
analysis, with a perspective drawing of the solid-state structure of 2.5, with atom labelling 
shown in Figure 2.10. 
C16 
C19 
Figure 2.10. Solid-state structure of 2.5 with atom labelling. 
Analysis of the solid-state structure of 2.5 allowed assignment of the relative 
stereochemistry as trans. The absolute configuration was assigned on the basis of the 
configuration of the starting amino acid, which determined the absolute stereochemistry at 
C2. In addition 2.5 was crystallised in the space group P212121 with 4 super-imposable 
molecules in the unit cell, indicating that a chiral compound had been obtained. 
Measurement ofthe optical rotation for 2.5 gave an [aJD -2.9° (c=l.O, CHCl3). 
Hydrolysis of (-)-2.5 with N aOH in methanol, followed by acidification, then gave the free 
acid 2.6. Subsequent esterification, with diazomethane, gave the a,a-disubstituted amino 
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acid methyl ester 2.7, in 91 % overall yield over these two steps (Scheme 2.5, also refer 
Scheme 2.2). 
~ NaOH )t ~Ph PhCON ,) 0 MeOH/6. PhCOHN "'~02H CH2N2 PhCOHN "'~02Me .. }-O 
Pl1' 2.5 2.6 2.7 
Scheme 2.5. Reagents and Conditions: i. NaOH, MeOH, reflux, 1 h; Ii. CH2N2, 0° C to r.t., 
91 %. Refer to Scheme 2.2. 
Methy lester 2.7 represents a key intermediate in this synthesis and has subsequently found 
use in other syntheses described later in this thesis (see Chapter 4 and 7). 
The synthesis of the proposed tetrahydropyridine mimic 2.9 was then completed by first 
ally lating the nitrogen of methyl ester 2.7. Deprotonation of 2.7, with sodium hydride in 
DMF, followed by treatment with allyl bromide, gave the dienic derivative 2.8, which was 
isolated by silica chromatography in 30% yield.c Compound 2.8 was then cyclised at room 
temperature, with 1.40 using Grubbs' ruthenium alkylidine conditions,16 to provide, after 
purification by flash chromatography, the doubly protected, phenylalanine-derived, 
1,2,3,6-tetrahydropiperideine mimic 2.9 in 94% yield (Scheme 2.6). 
~? 1. l~? ii. ClJh 
.. 
fIN C02Me N C02Me N C02Me 
PhAO PhAO PhAO 
2.7 2.8 2.9 
Scheme 2.6. Reagents and Conditions: i. NaH, allyl bromide, DMF, 0° C to rt, 30 %; ii. 
Grubbs' ruthenium catalyst A, CH2Cb, rt, 94%. 
c 23% of starting material was also recovered during purification and this was cycled back 
through the reaction to obtain more diene. 
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The factors that govern the ease of RCM reactions of peptide-based dienes are only now 
beginning to be explored.28,29 Cyclisation of 2.8 occurred quicldy and efficiently at room 
temperature, indicating that conditions were favourable for ring-closing metathesis. a,a-
Disubstitution of an amino-acId-based diene substrate would also seem to favour the ease 
of RCM cyclisations, and is consistent with the Thorpe-Ingold, or gem-dimethyl effect. 
The present study, whereby 2.8 was readily cyclised to 2.9, would appear to support this. 
Measurement of the optical rotation of a recrystallised sample of 2.9 gave an [a]D 
+38.2°, c=1.0 CHCh. 
2.3 Solid State Conformation of the Tetrahydropyridine Mimic 
Next, we desired to explore, and define, the conformational properties of the 
tetrahydropyridine peptide mimic 2.9. Pleasingly, suitable crystals were obtained, from 
which the solid-state structure was determined, by X-ray crystallography, and satisfactorily 
refined. The asymmetric unit for compound 2.9 contained two independent molecules, 
which differed slightly in conformation, principally about the benzyl group. A perspective 
drawing of one of these molecules, with atom labelling, is presented in Figure 2.11. 
C20 
C19 
C12 
Cll 
a) 
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C6 
C61 C5 
b) c) 
Figure 2.11. a) Solid-state x-ray crystal structure of one conformer of the 1,2,3,6-
tetrahydropyridine mimic 2.9. b) View showing approximate planarity of the 
tetrahydropyridine ring (C4 - C7) with Nand C3 deviating from the least squares plane. c) 
View along N-C3 axis indicating torsion angles about C8-N-C3-C2 peptide backbone are 
significantly shorter than that for proline. 
A proline-like N toCa cyc1ization, as in 2.9, results in significant restriction about the C8-
N-C3-C2 peptide backbone torsion. This also narrows the conformational space 
explorable by the adjacent torsion angles. In the displayed crystal structure of 2.9 this 
peptide backbone torsion angle (torsion angles are given for both molecules in the 
asymmetric unit) is 38.7 (2)0/40.2 (2)°, a value significantly shorter than that reported for 
proline.3D The adjacent N-C3-C2-01, C8-N-C3-CI5 and C9-C8-N-C3 torsion angles are 
53.24 (18t / 50.60 (18)°, 155.51 (15)° / 157.20 (15)° and 175.97 (l5t / 177.90 (15)°, 
respectively. The magnitude of the C9-C8-N-C3 and C8-N-C3-C15 torsion angles are 
consistent with a Z amide bond and an anti relationship between the benzoyl and benzyl 
groups respectively. The C4, C5, C6 and C7 ring atoms are approximately in tlle same 
plane with Nand C3 deviating from the least squares plane defined by the other four ring 
atoms by -0.2970 / -0.2739 A and 0.4698/0.4904 A, respectively. Some pyramidalisation 
of the amide nitrogen is evident with the angles at N summing to 351.14° /350.17°. 
In summary, solid-state x-ray analysis indicates that compound 2.9 adopts a cis-amide 
bond geometry, with significant conformational restriction occurring about the amide 
bond. This indicates that 2.9 possesses potential for use as both a proline mimic, as well as 
a ~-turn mimic. Furthermore, 'fine tuning' of the conformation could be carried out via 
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the incorporation of various other substituents at the ex-carbon. This could be used to 
explore, enhance, and maximise receptor site interactions should these compounds be 
incorporated into peptides for biological study 
2.4 Derivatisation of the 1,2,3,6-Tetrahydropyridine Mimic 
With the targeted cyclic mimic 2.9 in hand, and its conformational properties explored, we 
undertook a series of derivatisations. Efforts focussed on the functionalisation of the ring-
bound olefin and the deprotection of the methyl ester to allow potential chain extension in 
the C direction. Scheme 2.7 depicts the derivatives synthesised from compound 2.9. 
CkPh Cl? ClPh J iv. .I ", L N "'C02H N C02Me - N C02Me --Ph~O Ph~O Ph~O 
2.12 2.9 2.15 
ii./ 
2.13 2.14 
Scheme 2.7. Reagents and Conditions: i. H2, 10% Pd-ol1-C, EtOAc; ii. K20s04, NMO, 
H20/acetone; iii. Br2, CH2Ch; iv. NaOH, MeOH then H+. 
2.4.1 Preparation and Solid State Structure of an a-Substituted Piperidine Mimic 
First, the saturated pipecolic acid analogue 2.12 was prepared via reduction of the ring-
bound olefin. A sample of olefin 2.9 was dissolved in deoxygenated methanol, in the 
presence of palladium-on-carbon, and stirred for 16 h under a hydrogen atmosphere. 
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Filtration through Celite™ and purification via radial silica chromatography gave 
compound 2.12, in 92% yield, crystals of which gave an [a]D=+163.0, .OCHCh. 
Fortunately, recrystallisation of 2.12 yielded crystals suitable for X-ray crystallographic 
analysis. This was significant as it allowed us to explore and define the conformation of 
2.12, and make direct comparisons to its olefin containing precursor 2.9. X-Ray analysis 
of 2.12 revealed it to have crystallised in the space group P2,212!, with 4 super-imposable 
molecules in the unit cell. Perspective drawings of 2.12, with atom labelling, are shown in 
Figure 2.12. 
a) 
l\O' .. '" Ci5 \, CJ '; 
C7 
Cl 
01 
b) c) 
Figure 2.12. Solid-state X-ray crystal structure of the piperidine mimic 2.12. b) View 
showing boat shaped conformation adopted by the piperidine ring. c) View along N-C3 
axis indicating torsion angles about C8-N-C3-C2 peptide backbone. 
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In the current structure of 2.12, the N to Ca cyclization was again seen to impose 
significant restriction about the C8-N-C3-C2 peptide backbone. The torsion angle in this 
case was -47.7 (3t compared with 38.7 (2)0/40.2 (2)° for compound 2.9. This amounts to 
a significant change in conformation, and corresponds to an almost 90 0 clockwise rotation 
about the amide bond when compared to 2.9. The adjacent N-C3-C2-01, C8-N-C3-C15 
and C9-C8-N-C3 torsion angles are 40.0(3)°, 71.4 (3)0 and 179.5 (2)°, respectively with the 
magnitude of the C9-C8-N-C3 and C8-N-C3-C15 torsion angles again consistent with a Z 
amide bond. As expected, the anti relationship between the benzoyl and benzyl groups 
was still evident, despite the change in conformation. The ring atoms N, C3-C7 adopt a 
distinct boat conformation with no significant pyramidalisation of the amide nitrogen 
evident (angles at N sum to 359.5 0). 
In summary, solid-state x-ray analysis of compound 2.12 revealed significant 
conformational restriction about the amide bond, in a manner similar to that of2.9. It was 
also observed that the reduction of the olefin resulted in an inversion of torsion angle, i.e. a 
'conformational flip', about the amide bond compared with that of compound 2.9. As with 
2.9, 2.12 offers potential for use as both a proline mimic, and a: ~-turn mimic, with the 
difference in conformation between the two compounds providing a key contrast. Peptides 
incorporating these two motifs would adopt significantly different conformations. This 
highlights that the ability to control the conformation about an amide bond is critical in the 
design and synthesis of peptidomimetics .. 
Efforts were next directed toward derivatisation of the double bond VIa a syn-
dihydroxylation, and a trans-dibromination. Dihydroxylation was chosen to give a 
compound analogous to the biologically important hydroxyproline, with the incorporation 
of polyhydroxylated subunits into peptides also known to lead to more water-soluble 
compounds. Dibromination, via the addition of bromine, was chosen for its classical use 
amongst olefin chemistry for giving anti-addition across a double bond. This was 
envisaged to allow a comparison between cis- and trans-substituted derivatives 
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2.4.2 Preparation of a Dihydroxypiperidine Analogue 
There are many reagents that add OH groups to a double bondY Osmium tetroxide 
(Os04i2 was used as the reagent of choice in the dihydroxylation of 2.9, for its known 
ability to give syn addition from the less hindered side of a double bond. Potassium 
osmate and N-methylmorpholine-N-oxide were therefore added to a solution of 2.9 in 
H20:acetone and stirred at room temperature for 24 h (Scheme 2.8). 
2.9 2.13a ma,jor 3: I 2.13b minor 
Scheme 2.8. Reagents and Conditions: K20S04, NMO, H20:acetone (8:3), rt 24 h, 81 %. 
The reaction yielded a mixture of dihydroxy compounds 2.13a and 2.13b in a ratio of 3:1, 
based upon integration of the lH NMR resonances for the corresponding methyl ester 
peaks. Silica chromatography allowed for the separation of a fraction containing the major 
isomer, which was isolated in 55% overall yield. Separation of the minor isomer proved 
more difficult, with chromatography leading to the isolation of a fraction containing a 1:2 
mixture of the major and minor isomers, in a combined yield of 26%. Compound 2.13a 
was tentatively assigned as the major isomer based on grounds that the tetroxide dianion 
(see Scheme 2.8) is favoured in its approach of the olefin, from the face opposite that of 
the benzyl group. 
2.4.3 Preparation of a Dibromopiperidine Analogue 
Dibromination was carried out by addition of bromine to a solution of 2.9, in 
dichloromethane, until a permanent light brown colour was observed. The crude product 
was isolated in 68% yield, with IH NMR spectrum analysis revealing the presence of two 
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isomers, in a ratio of 4: 1, based on a comparison of integrals for equivalent methyl ester 
resonances at 8H 3.87 and 3.77ppm respectively. Purification by chromatography allowed 
isolation of the major isomer in 51 % yield (Scheme 2.9). Analysis by NMR spectroscopy 
and mass spectrometry confirmed the presence of a single compound, with the 1 H NMR 
spectrum displaying a distinct methyl ester resonance at 8H=3.87ppm. 
Br 
0 Ph B""6l BrOPh J 5 I " ", " " 
N C02Me .. N C02Me + N C02Me 
PhAO PhAO PhAO 
2.9 2.14a major 4:1 2.14b minor 
Scheme 2.9. Reagents and Conditions: Br2, CH2Ch, rt, 2.143 51 %. 
Compound 2.143 was assigned as the major isomer (48,5S), based on the grounds that 
addition of bromine, and formation of the bromonium ion, would predominantly occur on 
the least hindered face of the ring i.e. opposite that of the benzyl group. Subsequent attack 
with bromide could then proceed via two possible pathways. These two pathways are 
depicted in Figure 2.13. The solid-state structures of both 2.9 and 2.12 (see Figures 2.11 
and 2.12) suggest that pathway B would be the minor pathway, as attack at C5 would be 
partially hindered by the benzyl group. Pathway A is less hindered in this regard and 
favours nucleophilic attack at C6. The result is formation of the major isomer 2.143. 
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Figure 2.13. Additional of bromide to the bromonium intermediate can occur via two 
pathways. Pathway A, and formation of 2.14a, is favoured due to the absence of steric 
effects associated with the benzyl group. 
2.4.4 Solid State Structure of a Bicyclic Lactone Piperidine Analogue 
We attempted to confirm the stereochemistry of 2.14a (see Figure 2.13) by growing 
crystals of the major isomer, suitable for x-ray crystallography. This was unsuccessful in 
the short term and the sample was eventually set aside. However 6 months later a single 
crystal was discovered and found to be suitable for X-ray analysis. To our surprise, 
analysis of the crystal revealed the presence of the bicyclic compound 2.16, rather than the 
expected dibromide 2.14a. Since the lH NMR spectrum for 2.14a clearly indicated the 
presence of a methyl ester (8H=3.87ppm), the indication was that this new compound, 2.16, 
had been formed via lactonisation with displacement of bromine. 
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X-ray crystallographic analysis revealed 2.16 to have crystallised in the space group 
P2j2121, with 4 super-imposable molecules in the unit cell. Perspective drawings of 2.16, 
with atom labelling, are shown in Figure 2.14. 
CIS 
a) 
b) c) 
Figure 2.14. a) Solid-state x-ray crystal structure of 2.16, with crystallographic numbering 
scheme b) View showing boat shaped conformation adopted by the tetrahydropyridine ring 
c) View along N-C8 axis indicating a slight twist about the amide bond. 
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It is apparent that the piperidine ring atoms, of 2.16, represented by N, C3-C7 adopt a 
distinct boat conformation, with a five-membered lactone ring bridge existing between C5 
and the carboxyl group extending from C3. A distorsion of normal tetrahedral geometry 
(bond angle is 107°) is observed about C3 due to the formation of this lactone. Bond 
angles around C3, internal to the ring system, for C2-C3-C4, C2-C3-N and C4-C3-N, are 
100.3 (2)°, 106.8 (2)° and 106.7 (2t respectively. Bond angles for C3, external to the ring 
system, forN-C3-CI5, C2-C3-CIS and C4-C3-ClS are l1S.0 (3t, 110.7 (2)° and 116.0 
(2t respectively. The torsion angle about the peptide backbone of C8-N-C3-C2 is -78.9 
(3)°. A slight twisting of the amide bond is also observed, with the magnitude of the 
torsion angle about 08-C8-N-C3 being IS.1 (4t. The torsion angle about the amide bond 
represented by C9-C8-N-C3 is -IS9.9 (2t indicating a trans amide bond relationship 
exists along the peptide backbone. No significant pyrimidalisatiol1 of the amide nitrogen is 
observed with the angles at N summing to 359.2°. The absolute stereochemistry about C6 
was assigned as S, as Br and 03 adopt an anti relationship across the piperidine ring. This 
observation was significant as it confmned the assignment of the absolute stereochemistry 
of the major dibromide isomer 2.14a as (4S,58), an assignment that had previously been 
based on steric grounds (see Scheme 2.9 and Figure 2.13). Unfortunately, the crystal of 
2.16 was not recovered, and with the remaining sample having decomposed, no NMR data 
was obtained for characterisation and comparison with that of2.12a. 
A proposed mechanism of fornlation of 2.16 is outlined in Figure 2.1S. Ester hydrolysis of 
2.14a, followed by nucleophilic attack of the carboxylic acid group at CS would result in 
loss ofHBr to give lactone 2.16. The presence ofHBr would catalyse the hydrolysis of the 
ester. Lactone formation of this type is not without precedent, with halogen-mediated 
olefin functionalisation of N-protected baikiain and N-protected aminocyclohexene 
carboxylic acid having been used to access various hydroxylated derivatives.33-35 
However, lactonisation in this case occurs with retention of configuration at C4 suggesting 
an alternate mechanism may be possible. 
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Figure 2.15. Proposed mechanism of formation of the bicyclic lactone 2.16 
2.4.5 Preparation of the Tetrahydropyridine Free Acid 
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Next, we desired to prepare a derivative suitable for incorporation of compound 2.9, and its 
derivatives, into peptides via the carboxyl group. This was achieved via hydrolysis of the 
methyl ester to form the free acid 2.15 (Scheme 2.10). 
PhyN?/Ph 
° C02Me 
2.9 
PhyY/Ph 
° C02H 
2.15 
Scheme 2.10. Reagents and Conditions: NaOH, MeOH, reflux, 16 h, 92%. 
Hydrolysis of a solution of methyl ester 2.9, in methanol, with an excess of 1M aqueous 
NaOH at reflux overnight, gave the free acid 2.15 in 92% yield. 
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2.5 Self-Addition Products During the Alkylation of 5 
Oxazolidinones 
A key reaction in the overall synthesis of the tetrahydropyridine mimic 2.9 was the 
stereoselective alkylation of the benzyl-5-oxazolidinone 2.4 to give 2.5 (Figure 2.16, 
Scheme 2.2 and 2.4). 
Ph PhCON~O 
}-o 
Ph' 
2.4 
Figure 2.16. 
,I ~Ph PhCON ", 0 }-O 
Ph' 
2.5 2.9 
During the alkylation of 2.4, to give 2.5, the time between addition of the base (LiHMDS), 
and addition of the electrophile (allyl bromide), was found to be crucial. It was observed 
that a shorter mixing time (5-7 min.) was required to give the desired alkylated product 2.5, 
while a longer mixing time (> 1 h) resulted in the excess formation of the self-addition 
compound 2.11 (Scheme 11). Intermediate mixing times (20-30 min) gave a mixture of 
desired alkylated product 2.5 and self-addition product 2.11. 
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Scheme 2.11. Extended mixing times between addition of the base, and addition of the 
electrophile, resulted in the formation of self-addition products. 
To further explore the formation of this self-addition product, 2.4 was dissolved in THF at 
_78 0 C, and treated with LiHMDS in the absence of an electrophile. The reaction was 
stirred at -780 C for 2h and was then allowed to warm to rt over 16h. Compound 2.11 was 
isolated from this experiment in 55% yield, with a IH NMR spectrum ofthe crude mixture 
revealing -5% of a second diastereomer of 2.11, 2.18. This compound, which was not 
purified, was tentatively assigned as the C-1' epimer of 2.11 based on the downfield 
position of the 2-H resonance (~hI 4.92) compared with 2.11 (OH 4.72). The stereochemical 
assigmnent of compound 2.11, as depicted, has previously been deduced via X-ray crystal 
analysis.22 
A possible mechanism for the formation of 2.11 would involve base-catalysed 
fragmentation of the precursor 2.4, to give an N-acylimine of type 2.19, which would then 
react with the oxazolidinone enolate at C4 (Figure 2.16). This fragmentation is analogous 
to the heterolytic cleavage of a-substituted anlides to give N-acyliminium ions. 
Chapter Two 
H Ph 
PhCON[;O 
" 0 
PI;' ~ 
2.4 
.. PhCON=CHPh 
2.19 
.. 
N-acyliminium ion 
Figure 2.16. Proposed mechanism of formation of self-addition product 2.11. 
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A proposed transition state for the reaction between the enolate derived from 2.4 and the 
acylimine 2.19, is shown in Fig 2.17. From this it is apparent that reaction occurs from the 
side opposite the C2 phenyl group with ul-l )3-induction (Figure 2.16).22 
COPh 
. / Ph""'r-~N H Ph 
Phoc-I-I;-l= 
0-: Ph 
, 
, 
, 
Li-O 
Figure 2.17. Reaction between the enolate derived from 2.4, and the acylimine 2.19, 
occurs with ul-1, 3-induction 
This results in the stereochemistry of 2.11, depicted in Figure 2.16 and Scheme 2.11, 
occurring with >90% diastereoselectivity. Formation of other self-addition products in 
alkylations of 1,3-oxazolidinones/6 and related 1,3-oxazolanones)37 have also been 
reported. For example compounds 2.20a and 2.20b have been isolated from the alkylation 
of phenylalanine- and alanine-derived 2-(teT't-butyl)-1, 3-dioxolanones.37 
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2.6 Determination of the Enantiomeric Purity of a Key Intermediate 
Synthesis of the tetrahydropyridine mimic 2.9, outlined in Scheme 2.2, and abbreviated in 
Figure 2.18, proved successful, with the stereochemistry being established by X-ray 
crystallography. 
2.4 2.5 2.7 2.9 
. Figure 2.18. Synthesis oftetrahydropyridine mimic 2.9 from benzyl-5-oxazolidinone 2.4. 
The key to the enantioselective synthesis of 2.9 was the stereoselective alkylation of the 
benzyl 5-oxazolidinone 2.4, with allyl bromide, to give the dialkylated 5-oxazolidinone 
2.5. Crystallisation of this compound, and analysis by IH NMR, revealed the absence of 
any minor diastereoisomer. Hydrolysis of 2.5, followed by esterification, gave the key 
intermediate 2.7, which was subsequently used in the synthesis of mimic 2.9. 
During the preparation of 2.4, it was observed that, while crystallisation resulted in the 
absence of the minor diastereoisomer by IH NMR, the optical rotation ([0:]0 = +267°, 
c=1.0, CHCh) did not correspond to that reported in the literature ([0:]0 = +385.2, .0, 
CHCh). To address this issue, and to confirm the overall stereochemical integrity of the 
synthesis, the enantiomeric purity of the key derivative 2.7 was determined. This was 
achieved by conversion of 2.7 to the corresponding (R)- and (S)-Mosher esters (Scheme 
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2.12), and subsequent examination of their crude IH NMR spectra for evidence of any 
minor isomer. 
2.7 2.21 BE" 2.22R=H ~IL 2.23 R=(S)-MTPA IV. 2.24 R=(R)-MTPA 
Scheme 2.12. Reagents and Conditions: i. 03, CH2Ch / MeOH (3:1), -78° C; ii. LiBH4, 
CH2Ch; iii. DMAP, Et3N, (S)-MTPA-CI, CH2Ch, r.t., 5 min; iv. DMAP, Et3N, (R)-MTPA-
Cl, C}hCh, r.t., 5 min. (MTPA-Cl = methoxy-a-trifluorophenyl acetyl chloride) 
The alleene 2.7 was first converted to the corresponding alcohol 2.22. Ozonolysis of 2.7, in 
a 3: 1 mixture of dichloromethane / methanol at -78°C, in the presence of solid sodium 
bicarbonate, gave aldehyde 2.21 in excellent yield (96%). Reduction with lithium 
borohydride resulted in a mixture of the desired alcohol 2.22 (41 %), and the cyclic lactone 
by-product 2.23 (53%), in a ratio of 1 :1.3 (Scheme 2.13). 
~Ph 
PhCOHN "'~02Me 
2.22 
+ 
Ph 1,:,1"0 
PhCOHN~ 
o 
2.23 biproduct 
Scheme 2.13. Reagents and Conditions: i. 0 3, CH2Ch / MeOH (3:1), -78° C, 96%; ii. 
LiBHt, CH2Ch, 41 % 2.22,53%,2.23. 
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Optimisation of this reaction, to avoid the formation of 2.23, was not pursued as a 
sufficient quantity of 2.22 was obtained during the reduction. All products were isolated 
by chromatography thereby retaining any enantiomeric mix carried through the reaction 
sequence. 
Determination of the enantiomeric purity of alcohol 2.22 was then carried out by its 
subsequent reaction with firstly (5)-, and then (R)-methoxy-a-trifluoromethylphenyl acetyl 
chlorides (MTPA-CI) (Scheme 2.14)/8 to give 2.24 and 2.25 respectively. 
0 0 
Ph0 Ph0 
MoO' ~ - 0 (S)-MTPA-CI MeO: ~ 
.. 
CF3 Ph CF3 Ph 
PhCOHN "'~02Me + PhCOHN~02Me OH )!h 2.24 major = S, S minor = S,R 
PhCOHN C02Me 
2.22 0 0 
Ph0 Ph0 (R)-MTPA-CI " 0 MeO'" 0 MeO' 
CF, ~Ph CF3 .~ Ph J + PhCOHN~C02Me PhCOHN ,,' C02Me 
2.25 major = R, S minor R,R 
Scheme 2.14. Reagents and Conditions: i. DMAP, Et3N, (S)-MTPA-CI, CH2Ch, r.t., 5 
min., 100%; ii. DMAP, Et3N, (R)-MTPA-Cl, CH2Ch, r.t., 5 min., 100%. 
(S,S)-Mosher ester 2.24 was prepared by treatment of a solution of 2.22, DMAP and 
triethylamine, in dichloromethane, with a solution of (S)-MTPA-Cl in dichloromethane. 
The reaction was then repeated using (R)-MTPA-CI, to give the corresponding (R,S) 
isomer 2.25, the IH NMR spectrum of which differed from that of 2.24. In order to avoid 
kinetic resolution affecting the calculation of ee, the reactions were monitored by TLC to 
ensure complete consumption of the starting material. Note that the major isomer formed 
in the preparation of 2.24, and any minor isomer formed in the preparation of 2.25, are 
enantiomers, and therefore identical by IH NMR. The presence of any minor isomer can, 
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therefore, be observed by direct comparison of the IH NMR spectra of the respective crude 
reaction mixtures. Figure 2.19 shows representative spectra for the crude reaction mixtures 
of Mosher esters 2.24, and 2.25, derived from reaction of alcohol 2.22 with (S)-MTPA-Cl 
and (R)-MTPA-Cl respectively. 
Jl 
o 
Ph~O 
Mea, ~ 
CF, .XPh 
PhCOHN "'~02Me 
2.24 (S,S) 
CO,Mc 
I , I I ' j • , 1 I , , • I ' i , • j , 
6.5 6.0 5.5 5.0 
OMc 
, ii, i • I I , I , I • I , iii i i • I •• 
4.5 '.0 3.5 3.0 2.5 
o 
Ph. Jl 
MeO"Y '0 
CF, ~Ph 
PhCOHN "'~02M. 
Co,Me OMc 
2.25 (11,8) 
---'---'-'-
3.5 2.5 
uJ~ 
I I I I I I j I I I I \ , Ii. j , I til i I I , I iii. , i I Ii, , I • ii, I I j I j I I I • I • 
7.5 7.0 6.5 6.0 5.5 5.0 '.5 <1.0 3.5 3.0 PPII\ 
Figure 2.19. 500 MHz IH NMR spectra of the crude reaction mixtures of Mosher esters 
2.24 and 2.25 respectively. 
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Key 1 H NMR resonances used in the comparison of Mosher esters 2.24 and 2.25 included 
those for OCH2CHa, COMe, and C02Me. Chemical shifts associated with these 
resonances correspond to 0 2.60ppm, 3.50ppm and 3.67ppm respectively for 2.24, and 0 
2.50ppm, 3,46ppm and 3.60ppm respectively for 2.25. The minor isomers were not 
observed in either of the two Mosher ester reaction mixtures upon analysis of the 
respective IH NMR spectra (refer Figure 2.19). This equated to a >95% enantiomer excess 
for alcohol 2.22. This is a key finding since it also establishes the enantiomeric purity of 
the key precursors 2.7, and 2.5. These compounds have also found use elsewhere in this 
thesis, in the enantioselective preparation of a potent thrombin inhibitor described in 
Chapter 4, and also a key cyclic amide described in Chapter 7. 
2.7 Conclusion and Future Work 
An enantioselective synthesis of a 1,2,3,6-tetrahydropyridine mimic of type 2.2 has been 
described. This sequence utilised a combination of Grubbs' RCM chemistry to give the 
cycle, and Seebach oxazolidinone chemistry to establish the absolute stereochemistry. 
Initial efforts focussed on the incorporation of a benzyl substituent at the a-carbon, leading 
to the preparation of the L-phenylalanine-derived tetrahydropyridine mimic 2.9. The solid-
state conformation of this new mimetic was also determined by X-ray crystallography, 
with it displaying significant conformational restriction about the amide bond. The torsion 
angle about the amide bond was found to be 38.7 (2) / 40.2 (2t indicating that this mimic 
has potential for use as both a cis-amide bond mimic and a (3-turn mimic. 
Subsequent derivatisation of 2.9 was also undertaken. Hydrolysis of the methyl ester was 
carried out to give 2.15, a compound suitable for incorporation into peptides via the C-
terminus. Hydrogenation of the olefin of2.9 gave the saturated piperidine derivative 2.12. 
The solid-state conformation of2.12 was obtained by X-ray crystallography revealing that, 
like 2.9, significant conformational restriction existed about the amide bond. The amide 
torsion angle for 2.12 was found to be -47.7 (3t, indicating that an inversion, or 
'conformational flip', had taken place about the amide bond, with respect to 2.9, as a result 
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of reducing the olefin. This suggested that peptides incorporating 2.9 and 2.12 would 
adopt significantly different conformations due to restraints imposed by the monomer's 
differing amide torsion angles. 
Dihydroxylation and dibromination were also carried out on 2.9 to give the cis-dihydroxy-
and trans-dibromo derivatives 2.13 mid 2.14 respectively. Assigmnent of stereochemistry 
to the major isomers in these reactions was based largely on steric grounds, with approach 
of reagents predominantly occurring from the olefinic face opposite the benzyl group. 
Attempts to produce crystals suitable for x-ray crystallography proved initially 
unsuccessful, however in the case of 2.14a a crystal was obtained after a period of 6 
months. The solid-state conformation was obtained revealing that 2.14a had undergone 
lactonisation to give the bicyclic lactone 2.16. This transformation was thought to have 
occurred via hydrolysis of the methyl ester and subsequent nucleophilic attack of the 
corresponding acid group at C5. The absolute stereochemistry of 2.16 confirmed the 
assignment of the absolute stereochemistry of the major dibromide isomer 2.14a, from 
which it was derived, as (4S, 5S), an assignment that had previously been based on steric 
grounds. 
Finally, the enantiomeric purity of the key intennediate 2.7, and hence subsequent 
derivatives, was established. This was achieved by ozonolysis of 2.7, followed by 
reduction, to give alcohol 2.22, which was reacted with (S)- and (R)-MTPA-CI 
respectively. An analysis of the product MTPA esters from these two reactions revealed a 
diastereomeric excess of >95%. This was an important result as it also established the 
enantiomeric purity of 2.5 and 2.9, and confirmed the overall enantiomeric integrity of the 
synthesis. 
Future work in this area could involve the incorporation of 2.9, and its derivatives, into a 
range of peptides to explore their effect on secondary structure. Work centred on 
incorporating these procedures into solid phase protocols would provide ready access to 
peptides of this type. This sequence of reactions should also be amenable to the preparation 
of a range of tetrahydropyridine- and pyridine-based amino acid mimetics using 
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oxazolidinones derived from both natural and non-natural amino acids. Additional 
derivatisations of the olefin could lead to the establishment of a library of monomers, each 
with a unique and defined conformation, for use in the development of a range of potential 
peptidomimetics. 
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CHAPTER THREE 
SYNTHESIS OF a-SUBSTITUTED PYRROLINE 
AND PROLINE PEPTIDE MIMICS VIA 
RING-CLOSING METATHESIS 
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3.1 Introduction 
A great deal of interest exists in the design and synthesis of conformationally restricted amino 
acid mimics for use in the development of peptidomimetics. Here we present the design, 
synthesis, and derivatisation, of a new class of a-substituted pyrroline-based peptide mimics, 
for use in this process. 
Recently, attention has focused on the synthesis of simple cyclic monomeric units, for use in 
the construction of more complex peptidomimetics, biopolymers and peptide foldamers. The 
resulting compounds possess well defined, and stable, secondary structures and hence 
functions. An important natural example of this link between conformation and biological 
function, is evidenced by the ability of the pyrrolidine proline, and its derivatives, to induce 
secondary structure in peptides and proteins. While the majority of peptide sequences in 
proteins reside in helices or f3-pleated sheets, the incorporation of proline, or its analogues, 
into polypeptides chains produces a striking effect on the conformation of its associated amide 
bonds. In a normal amide bond, the trans-conformation is energetically favoured over the cis-
conformation by approximately 10 lecal/morl, due to less steric congestion between adjacent 
amino acid side chains. However, where rotation about the N-Ca bond is restricted by the 
constituent cycle of proline, this is not always the case, with the amide bond preceeding 
proline in a linear peptide sequence often adopting a cis-conformation (Figure 3.1). As a 
result, Xaaa.,cis-proline amides are seen in 10-30% of short propyl peptides, while a further 
6% of Xaa-proline amide bonds in longer peptides are known to adopt the cis-conformation. 
This element of confonnational restriction often results in a bend, or 'kink', in a linear peptide 
sequence. 
a Where Xaa is any amino acid. 
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trans- cis-
Figure 3.1. The cis-trans proline equilibrium. 
As a consequence, proline plays an important role in the structure of compounds such as 
collagen, a structurally important, fibrous protein found in bone, teeth, blood vessels, 
connective tissue, tendons, cartilage and hide (Figure 3.2). Collagen consists of intertwined 
strands of proline-, and hydroxyproline-rich amino acid chains, that combine to form a unique 
triple helix. These triple helices then associate to form strong, inelastic fibrils, with various 
activities such as running and jumping made possible by their high tensile strength. Recently, 
it has been shown that modification of the peptide backbone of collagen can lead to a change 
in conformation and stability of these triple helices.] The preparation of proline derivatives 
has subsequently become an area of interest for the development of new and important 
biomaterials. 
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Figure 3.2. Collagen is an important example of the lin1( between structure and function. 
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Hydroxyprolines,2 can be found abundantly in a diverse range of other naturally occurring 
biologically active compounds.3 trans-4-Hy droxy-L-pro line, first discovered in gelatin 
hydrolysates in 1902, has since been found in numerous proteins. For example, it has been 
identified as a component of two structurally related lipopeptides from Lyngbya majuscula: 
majuscullamide D, which is cytotoxic,4 and microcolin A, which has immunosuppressive, 
antileukemic, and protein kinase C inhibitory properties (Figure 3.3).5,6 
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Figure 3.3. Examples of naturally occurring proline analogues 
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Other examples include bulgecins A, Band C, aminoglycoside antibiotics isolated from 
Pseudomonas acidophila and Pseudomonas mesoacidophila/ and lactacystin, a derivative of 
3-hydroxypyroglutamic acid isolated from Streptomyces sp. OM_6519.8-10 Three of the four 
possible isomers of3,4-dihydroxy-L-proline have been identified in nature. The L-2,3-cis-3,4-
trans-isomer was isolated from the cell wall hydrolysates of the diatom Navicula pelliculosa 
almost 30 years ago,JI-13 while the L-2,3-trans-3,4-trans isomer was isolated from the toxic 
mushroom Amanita virosa in 1980.14•15 Finally, in 1994, the L-2,3-isomer was identified as 
the sixth residue in the repeating decapeptide sequence of Mefp 1, an adhesive protein 
produced by the marine mussel Mytilus edulis. 16- 18 
Other proline analogues of importance include 3,4-dehydro-L-proline 3.1 (Figure 3.5), a 
component of phomopsin A (Figure 3.4), the main mycotoxin isolated from the lupin 
Phomopsis leptostromiforsis. 19,20 The phomopsins inhibit polymerisation of tubulin and 
depolymerise preformed microtubules,21 causing severe liver damage in cattle and sheep. 
Noformicin,22 a potent antimicrobial and antiviral agent isolated from Nocardia formica, 
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contains a 5~iminoprolyl moiety, and exerts its biological activity through binding to the minor 
groove of DNA, 23 
3.1 3.2 
H'N~~~NH2 
ONH 
nofonnacin 
phomopsin A 
lincomycin 
H ~:rCl N~N O{i t; R 
HN~oi NH 
HOJ n Rl 
Astins A R=Cl, RI=H, R2=OH 
B R=Cl, Rl=R2=H 
C R=Cl, Rl=OH, R=H 
I R=OH, RI=R2=H 
Figure 3.4. Further examples of naturally occurring proline analogues 
Free trans-4~methyl-L-proline 3.2, is an important component of a number of antibiotics, 
including mycoplanecin A, a depsipeptide isolated from Actinoplanes awajinensis, and found 
to be active against molds, yeasts and mycobacteria, including mycobacterium tuberculosis.24 
The clinically used broad spectrum antibiotic lincomycin, isolated from Streptomyces 
lincolnensis, espinosus and variabilis, consists of N-methy l-trans-4~N-prolyl-L-proline 
attached to an aminosugar.25 Recently, astins A-C and I, cyclopeptides that contain chlorine 
substituted prolines, have been isolated from Aster tataricus,26,27 and shown to possess potent 
antitumor activity. 
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Proline analogues are also important components of a variety of synthetic peptidomimetics 
(Figure 3.5). Examples include captopril, a potent, and orally active antihypertensive agent,28 
and the potent HIV inhibitor 3.3, 29 while the fluoroproline derivative 3.4 has been used in the 
study of collagen. 1 
CaptopriI 3.3 
E, 
~Co,H 
H 
3.4 
Figure 3.5. Examples of substituted pro lines found in pharmacueticals 
However, there are relatively few reported examples of proline analogues with a substitutent at 
the a_carbon.30-32 Derivatives of the tripeptide Pro-Lys-Oly-NH2 (PLO), a modulator of 
dopamine receptors in the central nervous system, has led to the development of compounds 
such as 3.5 (Figure 3.6), an extremely potent analogue, found to have 4 orders of magnitude 
greater activity than PLO itself.33,34 
o 0 
~NH2 
~OH ~~H 
3.5 (-)-Brevianamide B 
Figure 3.6. Examples of a-substituted proline analogues 
C02Rl 
ct>~~R2 
o 
3.6 
The brevianamides, paraherquamides, and asperparalines constitute an unusual family of 
fungal metabolites that possess a unique bicyclo[2,2,2]diazaoctane core ring system that has 
been proposed to arise in nature via a biological Diels-Alder reaction.35 Bicyclic lactams of 
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type 3.6 have found use as novel XaaPro Type VI turn mimics, with various analogues 
evaluated as inhibitors of cyclophilin A, with Kd'S ranging from as low as 51lM.36 
Significantly, syntheses of the a-substituted compounds shown in Figure 3.6, utilise chemistry 
pioneered by Seebach et al., for the stereoselective alkylation of proline. 31,32 Synthesis of the 
a-substituted dehydro equivalents has also recently been reported.3o,37,38 
Given the prominent role of conformationally restricted amino acids and peptides in the design 
of peptidomimetics, and as part of a wider study towards the synthesis of a general class of a-
substituted cyclic amino acids, we present here a new and versatile method for the 
stereoselective introduction of a substituent at the a-carbon of a proline analogue of type 3.7. 
As for the analogous piperidine series described in Chapter 2, the introduction of a substituent 
at the a-carbon would allow interactions usually associated with amino acid side-chains, i.e 
hydrogen bonding, TC-TC-stacking, hydrophobicity, hydrophilicity etc, to be incorporated into 
the mimic. Oxazolidinone chemistry developed by Seebach et al. was again utilised to 
introduce a substituent at the a-carbon, with ring-closing metathesis used in the formation of 
the heterocyclic ring. Inclusion of an olefmic moiety allows for subsequent functionalisation 
at this position, the result being a range of substituted proline analogues of interest in 
peptidomimetic design. 
The key to the synthesis involves the introduction of a vinyl group by oxidative degradation of 
an alk:ylated methionine, followed by allylation on nitrogen, and finally RCM of the resulting 
diene as shown in Figure 3.7. 
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Figure 3.7. 
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As with the piperidine system (see Chapter 2), we envisaged that substitution at the a-carbon 
of the diene would further enhance ring closure in accordance with the Thorpe-Ingold effect 
The oxidative degradation of methionine analogues has also been used in the preparation of 
arninocyc1opentanecarboxylic acids described in Charter 6. 
We chose to introduce a benzyl group stereoselectively at the a-position of the proposed 
mimic, to give a phenylalanine analogue, that would allow direct conformational comparison 
with the previously prepared 6-membered series (see Chapter 2). The proposed synthesis of 
the pyrroline mimic is outlined in Scheme 3.1. 
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L-methionine 
Ph 
~ vii. N C02Me .. 
Ph~O 
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=< N C02Me 
Ph~O 
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Scheme 3.1. Reagents and Conditions: i. a) NaOH, b) PhCHO, CH2Ch, reflux, c) PhCOCI, 
CH2Ch, 00 C for 4 h then rt for 16 h; ii .. base, THF, -780 C then benzyl bromide; iii. a) H20 2, 
AcOH, b) xylene, 2000 C, sealed tube; v .. NaOH, MeOH, reflux; vi. CH2N2; vi. NaH, DMF, 
00 C then allyl bromide; vii. 1.41, benzene, reflux. 
Here, L-methionine is protected as the diastereomerically pure trans oxazolidinone 3.11, in a 
manner similar to the used during the piperidine synthesis detailed in Chapter 2 (Scheme 2.2). 
This would then be subjected to a stereoselective alkylation, with benzyl bromide, to give 
3.12. Oxidative degradation of 3.12 gives the vinyl oxazolidinone 3.13, which would 
subsequently be hydrolysed, and alkylated at nitrogen, to give diene 3.16. Ring closing 
metathesis would then give the desired pyrroline 3.17. Note that the cyclic peptidomimetic 
3.17, possesses the same relative stereochemistry as the natural amino acid phenylalanine. As 
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with the piperidine series, this synthetic method should provide a convenient and general 
synthesis of pyrroline-based, and a-substituted proline-based, amino acid mimics from 
oxazolidinones derived from natural L-, and non-natural D-methionine. 
In the proposed synthesis we were presented with either an alkylation-elimination, or an 
elimination-alkylation approach, in the preparation of 3.13 from 3.11. Seebach et al. noted 
that alkylation of the vinyl imidazolidinones oftype 3.18 (Figure 3.8) resulted in a mixture of 
diastereoisomers 3.19 being produced in moderate yield.39 
R 
~ PhOC\ 
>Y PhCO~O PhCON'Y° HN~ ,.R - ,/\"~~ 4 O'u+ -- PhCON 0 + }-NMe }-NMe }-NMe 
7\ Me 7\ 7\ 
3.18 3.19 3.20 
Electro12hile Ratio 3.19/3.20 Yield% 3.19 %de 
allyl bromide >95:5 77 79 
benzy I bromide >95:5 75 87 
Figure 3.8. Alkylation of vinyl oxazolidinones by Seebach et al .. 
Additional studies with compounds of type 3.21 (Figure 3.9), revealed that, in contrast, the 
corresponding alkylated vinyl derivatives 3.22 could be obtained with little or no 
racemisation.39 
SMe 
X R Yield% 
1. H202/HOAc (y ~ or NaI04iMeOH ,.R NMe Me 62 Ph x a • Ph~X a NMe Et 75 
2. xylene, 2100 0 H 13 (25,4R) 
26 (25,45) 
3.21 3.22 0 Me 75 
Figure 3.9. Oxidative elimination of methionine-derived a-substituted oxazolidinones. 
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It was therefore concluded, that the optimum order of transformations for the preparation of 
the alkylated vinyl oxazolidinone 3.13 from 3.11 (Scheme 3.1) would be via an alkylation-
oxidative elimination sequence. 
3.2 Synthesis of a Methionine-derived trans 5-0xazolidinone 
The synthesis began with the preparation, from L-methionine, of the trans-oxazolidinone 3.11 
(Scheme 3.2). 
L-methionine 
SMe 
_i_ii_, __ PhCO~O 
J-o 
P}{ 
3.11 major 
SMe 
+ PhCON~O 
i-o Ph 
3.23 minor 
Scheme 3.2. Reagents and Conditions: i. NaOH; ii. PhCHO, CH2Ch, reflux; iii. PhCOCl, 
CH2Cb, 0° C for 4 h then rt for 16 h. 
Using the method of Seebach and Fadel,40 the sodium salt of L-methionine was condensed 
azeotropically with benzaldehyde in dichloromethane to give the corresponding Schiff base. 
Acylation with benzoyl chloride, at O°C for 4 h, followed by stirring at room temperature for 
16 h, gave a crude mixture containing a 4:1 trans / cis diastereomeric mixture of phenyl-5-
oxazolidinones 3.11, and 3.23. The diastereomers were subsequently separated by 
crystallisation from methanol to give the major isomer 3.11, as a white solid, in 63% overall 
yield. Measurement of the optical rotation for 3.11 gave a [a]D = +222°, .0 CHCh (lit. = 
+280.4°, c=l.O CHCb). Crystals of the same sample gave a melting point of 157-159° C, 
which agreed with the literature value (157° C).41 
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The configuration of the major isomer 3.11 was assigned trans based on comparison of the III 
and BC NMR data with that reported in the literature,40,41 where the III chemical shift ofII2 
(DR 6.71), for the trans isomer, lay significantly up field compared with that of the cis isomer. 
Further comparison with the cis and trans isomers of the 2-phenyl-oxazolidonones (see 
Chapter 2) and the related 2-(t-butyl)-oxazolidinones, revealed that this was invariably the 
case.hA2 
The III NMR spectrum of the trans oxazolidinone 3.11, at 23°C, revealed broadening of the 
resonances for the II2 proton, the side-chain CII2 protons, a number of aromatic protons, as 
well as the thiomethyl group. This is presumably due to restricted rotation about the anude 
bond. This was confirmed by determining the III NMR spectrum at elevated temperature. 
Figure 3.10 shows the III NMR spectrum collected for the trans oxazolidinone 3.11, in CDCh, 
at both 23° C and 50° C (see also Chapter 2, Figure 2.7). 
b Analysis, by the researchers, of alkylation products of both 2-phenyl-oxazolidinones, and 2-
(t-butyl)-oxazolidinones, and comparison of the optical rotations of their derived amino acids, 
also confirmed the assignment of 3.11 as the major isomer. 
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Figure 3.10. IH NMR spectra for the trans 5-oxazolidinone 3.11, in CDCh, at 25° C and 50° 
C. 
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Increasing the temperature results in a noticeable sharpening of the resonances for H2, H4, the 
sidechain CH2 protons and the thiomethyl protons. 
The corresponding 2-(t-butyl)-oxazolidinone 3.24 was synthesised in a similar manner to that 
of 3.11 (Scheme 3.3), to illustrate that the cis-diastereoisomer was also accessible. 
SMe SMe SMe SMe 
1 i., ii. 1 + iii. PhCO~O PhCO~O H2N C02H ~ C02-'" • + 
;(0 )1:.-0 7\ 
L-methionine 3.24 major 3.25 minor 
Scheme 3.3. Reagents and Conditions: i. NaOH; ii. t-BuCHO, pentane, reflux; iii. PhCOCl, 
CH2Ch, 0° C, 2 days. 
Thus, the sodium salt of L -methionine was condensed azeotropically with 
trimethylacetaldehyde, in pentane, to give the corresponding Schiff base. Acylation with 
benzoyl chloride, at O°C, followed by stirring at 0° C for 2 days, gave by IH NMR, a 5:1 cis / 
trans diastereomeric mixture of 2-(tert-buty l)-oxazolidinones 3.24, and 3.25. Crystallisation 
from methanol gave the major isomer 3.24 as a white solid in 71 % yield, with the IH and l3C 
NMR data corresponding to that reported in the literature.40 Measurement of the optical 
rotation of 3.24 gave an [a]D = +58° (c=l.O, CHCh), a value in close agreement with that 
reported in the literature (lit. +62.2°, .0, CHCb). The solid-state conformation of 3.24 
was subsequently determined to allow confirmation of the relative stereochemistry. The 
absolute stereochemistry at C4 of 3.24 was assigned as S based upon the stereochemistry of 
the starting amino acid (S)-methionine. The crystal was found to possess a P2 j space group, 
with 2 super-imposable molecules in the unit cell, indicating the 3.24 to be chiral. A 
perspective drawing of 3.24, with atom labelling, is shown in Figure 3.11. 
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CI4 
CIS 
CI7 
CIO 
l;"'igure 3.n. Solid-state conformation of the cis-2-(t-butyl)-oxazolidinone 3.24. 
The preparation of trans-3.n and c is-3.24 represents an important result. Subsequent 
alkylation of these compounds allows access to either stereochemistry at C4, of the resultant 
a,a-dialkylated products. The high optical rotations of 3.n, and 3.24, together with the P21 
space group obtained for the solid-state crystal structure of 3.24, indicate that optically active 
samples of these compounds had been prepared for this purpose. 
3.3 Synthesis and Solid-State Conformation of a Key Alkylated 5-
Oxazolidinone 
The introduction of the benzyl substituent at C4 of 3.11, was next attempted. Seebach et al. 
noted that deprotonation of methionine-derived 2-phenyl-oxazolidinones and 2-(t-butyl)-
oxazolidinones, at C4, requires the use of sterically non-hindered bases such as lithium 
diisopropylamide (LDA) and lithium diethylamide (LDEA) (Figure 3.12).40,41 
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Phco>ro 
~ 
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• PhCONXYO )-0 )-0 
R R 
R Base R' Yield% ds 
tBu (3.24) LDEA Me 69 
Ph (3.11) LDA BrCH2C02Et 85-94 >95% 
Figure 3.12. Alkylation of methionine-derived 5-oxazolidinones 
Based on these results, we first used LDEA in an attempt to effect alkylation of 3.11. Thus, to 
a solution of diethylamine in THF, cooled to -78 0 C under argon, was added n-BuLi, and the 
solution was stirred at _78 0 C for 5min. A solution of 3.11, in THF, was then added and the 
mixture was stirred at -78 0 C, for 40min, during which time the solution turned bright yellow. 
Benzyl bromide was then added and the reaction was stirred at _78° C for 2h and allowed to 
warm to rt overnight. However, upon workup, IH NMR analysis revealed that alkylation had 
not occurred, with 3.11 being recovered in quantitative yield. Repeated attempts rendered the 
same result. 
LDA was then used in an attempt to effect alkylation of3.11 (Scheme 3.4). Thus a solution of 
3.11, in THF, was cooled to _78° C under argon. LDA was added, and the resulting dark 
red/orange solution was stirred at _78 0 C for 15 min. Benzyl bromide was added and the 
reaction was stirred at _78° C for 2 h, then allowed to warm to rt overnight. Upon workup, IH 
NMR analysis of the crude mixture revealed the presence of additional aromatic resonances, a 
new pair of diastereotopic methylene resonances at OH =3.37 and 3.88ppm, and the absence of 
the H4 resonance at oH=5.00ppm associated with 3.11. Subsequent purification, by silica 
chromatography, gave the dialkylated oxazolidinone 3.12 as a white solid in modest yield 
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(52%). Further elution also afforded the self addition product 3.30 (74mg, 2%) (refer Chapter 
2.5 Self-Addition Products During the Alkylation of 5-0xazolidinones) 
SMe SMe ~Me PhCO~O ~ Ph 1.LDA PhCON~O PhCOHN .. + PhCON 0 
,\Lo 2. BnBr ,~O }-O 
Pli Plt' PI}' 
(+)-3.11 (+1-)-3.12 3.302% 
Scheme 3.4. Reagents and Conditions: LDA, THF, -78° C, 15min., then BnBr, _78° C to rt, 
52% rae. 
Measurement of the optical rotation of a recrystallised sample of 3.12 gave an [a]D = 0.3°, 
.0 CHCh.c The solid state crystal structure of 3.12 was determined, and satisfactorily 
refmed, to further explore this lack of optical rotation, and establish the relative configuration. 
A perspective drawing of 3.12, with atom labelling, is shown in Figure 3.13. 
c For 3.11 [a]d +222°, c=l.O, MeOH. 
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Figure 3.13. Solid-state structure of3.12, with atom labelling. 
Analysis of 3.12 revealed one molecule in the asymmetric unit, with the oxazolidinone ring 
defined by Ol-C2-N-C4-C5 adopting an essentially planar arrangement in the solid state. No 
significant pyramidisation of nitrogen was observed, with bond angles at N summing to 
358.53°. It was observed that the C2 phenyl group, and the C4 benzyl group, existed in a 
trans relationship across the ring, revealing that alkylation had occurred at the face opposite 
the C2 phenyl group. Significantly, 3.12 was crystallised in the space group P2dc, indicating 
the compound to be racemic. This supported our previous observation arising from the 
sample's lack of optical rotation, and indicated that racemisation of the molecule had taken 
place. This suggests that scrambling at C2 must have occurred, followed by alkylation at the 
face opposite the C2 substituent, to give racemic 3.12. The mechanism of this racemisation is 
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not yet understood, however as 3.11 has been shown to be optically active ([aJD +222°, 
c=l.O, CHCh), this scrambling is clearly subsequent to its formation, and the result of fue 
reaction conditions used in the formation of 3.12. 
HaVing obtained 3.12, and established the relative stereochemical outcome of fue alkylation, 
we set about overcoming the problem of racemisation. Fortunately, a visit from Professor 
Koichi Narasaka, from the University of Tokyo, led us to try pyrrolidine as fue amine used in 
the in situ generation of the lithium base.d Pyrrolidine represents a cyclic equivalent of the 
non-hindered base diethylamine, and has been used for the generation of lifuium enolates in a 
variety of alkylation reactions (Figure 3.14).43,44 
Q 
H 
diethylamine pyrrolidine diisopropylamine 
Figure 3.14. Pyrrolidine has been used in fue generation of lithium enolates 
Subsequently, alkylation of 3.11, with benzyl bromide, in the presence of the lithium-
pyrrolidine base was attempted (Scheme 3.5). n-Butyllithium was added to a solution of 
pyrrolidine, cooled to -500 C in THF, al1d the solution was stirred for 30 min, following which 
3.11, in THF, was added. The reaction mixture was stirred for 20 minutes, whereupon benzyl 
bromide was added, and the solution stirred at -500 C for 1 h and then allowed to warm to 
room temperature overnight. 
d Prof. Narasaka also suggested that in similar alkylations, where a non-hindered amine is 
required, pyrrolidine ought to be a first choice. 
THE UBRAHY 
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Scheme 3.5. Reagents and Conditions: pyrrolidine, n-BuLi, THF, -50°, 30 min., 3.11, stir 20 
min. at -50°C then add benzyl bromide, stir -50°C 1 h then at r.t. for 16 h, 61 %. 
Analysis of the IH NMR spectrum obtained for the crude mixture indicated the presence ofthe 
dialkylated product, with purification via silica-based chromatography giving 3.12 in 53% 
overall yield. The IH NMR spectrum was consistent with the absence of any minor 
diastereoisomer, with measurement of the optical rotation giving an [a]D=+14° (c=1.0, 
CHCh). It was concluded that alkylation, using the lithium-pyrrolidine base, had occurred 
stereoselectively, with the resulting configuration at C4 of 3.12 defined by the absolute 
configuration at C2 of the starting oxazolidinone 3.11, which is in turn governed by the 
starting amino acid. The value of optical rotation obtained for 3.12, is in line with that 
obtained for phenylalanine-derived analogue 2.5 described in Chapter 2 ([aJD = _3°, c=1.0, 
CHCh), and suggested that alkylation had occurred with high stereo controL This was further 
supported when the solid-state crystal structure of the vinyl derivative 3.13 derived from it, 
was found to possess a space group indicating the molecule to be chiral (see Figure 3.15). 
Note also that the same sample of3.11 used to prepare (+)-3.12 in Scheme 3.5, was used in the 
reaction yielding (+/ -)-3.12 described in Scheme 3.4. 
Preparation of (+)-3.12 also yielded a by-product, subsequently assigned as compound 3.26, 
which was isolated from the reaction mixture in 36% yield. The proposed mechanism of 
formation for 3.26 is shown in Scheme 3.6. 
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Scheme 3.6. Alkylation of3.11 also resulted in the isolation of3.26. 
The nucleophilic nature of pyrrolidine led us to conclude that nucleophilic attack had occurred 
at the carbonyl group of the oxazolidinone ring of 3.11, resulting in ring-opening and loss of 
benzaldehyde. Suppression of this by-product was achieved by the addition of an excess of n-
BuLi during the generation of the base, to yield after purification, 3.12 and 3.26, in 61 % and 
23% respectively. Further rigorous optimisation of this reaction was not carried out as an 
ample supply of the dialkylated oxazolidinone (+)-3.12 was obtained for use in subsequent 
steps. 
3.4 Synthesis and Solid-State Conformation of a Key Vinyl-S-
Oxazolidinone 
Oxidative degradation of the methionine side~chain of 3.12 was next carried out, using 
conditions described by Seebach et al. (Scheme 3.7). Hydrogen peroxide was added to a 
solution of3.12, in acetic acid, to form the sulfoxide 3.27, which was subsequently dissolved 
in degassed xylene, and sealed in a glass tube under vacuum. The tube was then heated at 
2000 C for 16 h to give a dark brown solution, which upon purification via chromatography, 
gave the a,a-disubstituted vinyl oxazolidinone 3.13, in 86% yield over two steps. 
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SMe MeS~O 
~ Ph ~ Ph ~ Ph 
PhCON~O i. PhCON~O ii. PhCON~O .. 
}-O ~O ,~O 
PI}' PIt PI{ 
3.12 3.27 3.13 
Scheme 3.7. Reagents andConditions: i. H20 2, AcOH, 94%; ii. xylene, 2000 C, sealed tube, 
.93%. 
Crystallisation gave 3.13, as colourless crystals, from which the solid-state structure was 
determined and suitably refined. Perspective drawings of 3.13, with atom labelling, are shown 
in Figure 3.15. 
CI9 
C26 C27 
CI7 
CIO 
CI6 
a) 
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Figure 3.15. Perspective drawings of 3.13 with atom labelling: a) phenyl group at C2 and the 
introduced benzyl group at C4 adopt a trans configuration across the ring. b) the 
oxazolidinone ring depicted by 01-C2-N-C4-C5 adopts an essentially planar conformation. c) 
restriction occurs about C2-N-C4 with bond angles at N summing to 360.0°. 
The phenyl group at C2 of 3.13, and the introduced benzyl group at C4, existed in a trans 
relationship across the oxazolidinone ring, reconfirming the relative stereochemistry observed 
in the solid state structure of3.12 (see Figure 3.13). The absolute stereochemistry of3.13 was 
assigned based upon the structure of the trans oxazolidinone 3.11, the absolute configuration 
of which is known, and defined by that of the starting amino acid (see Scheme 3.2). The 
oxazolidinone ring of 3.13 is shown to adopt an essentially planar conformation with the 
torsion angle defined by C4-N-C6-06 having a magnitude of -6.9 (3)°, indicating a slight 
twist in the amide bond geometry. A distortion about nitrogen was observed, due to the 
oxazolidinone ring, with the bond angles defined by C2-N-C4, C4-N-C6 and C6-N-C2 having 
values of 112.07 (16)°, 122.9 (17)° and 125.03 (17t respectively. No pyramidilisation was 
observed however, with the bond angles at nitrogen summing to 360.0°. Significantly, 3.13 
crystallised in the space group P212121, with 4 super-imposable molecules in the unit cell, 
indicating a single enantiomer had been obtained. This was supported by measurement of the 
optical rotation of 3.13, which gave a value of [a]D = + 139°, .0 CHCh. Herein lies a key 
observation, with the chirality associated with 3.13, coupled with its high optical rotation, 
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consistent with a high enantiomeric excess being obtained during its preparation, and also that 
of its precursor, 3.12. 
3.5 Synthesis and Solid-State Conformation of the a-Substituted 
Pyrroline Mimic 
The vinyl-5-oxazolidinone 3.13, was then hydrolysed with aqueous NaOH in refluxing 
methanol, followed by acidification, to give the free acid 3.14 (Scheme 3.8). 
~ Ph PhCON~O 
}-O 
Pl-i' 
3.13 
i. 
.. 
~ Ph 
ii. X 
---,,..... PhCOHN C02Me 
3.14 3.15 
Scheme 3.8. Reagents and Conditions: i. NaOH, MeOH, reflux, 1 h; ii. CH2N2, 0° C to rt, 
99% over 2 steps. 
Subsequent esterification, with diazomethane, gave the a,a-disubstituted amino acid methyl 
ester 3.15, in 99% yield over two steps. Measurement of the optical rotation for 3.15 gave a 
[a]D +54°, (c=l.O, CHCh). 
The preparation of the vinyl glycine derivative 3.15 represents a significant result. As in 
Chapter 2, the ability to introduce functional groups stereoselectively, in the formation of 
chiral building blocks, is of great importance in the synthesis of peptidomimetics. Here, 3.15 
serves as the key precursor in the proposed synthesis of the chiral alkylated pyrrolidine and 
proline-based peptidomimetics of type 3.7 (refer introduction). 
The synthesis of the proposed pyrroline mimic 3.17 (see Scheme 3.1) was then completed by 
first allylating the nitrogen of methyl ester 3.15 (Scheme 3.9). Deprotonation of 3.15, with 
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sodium hydride in DMF, at 0°, followed by addition of allyl bromide, gave the dienic 
derivative 3.16, which was isolated by silica chromatography in 31 % yield. e Subsequent 
measurement ofthe optical rotation for 3.16 gave an [a]D -63°, (c=1.0, CHCh). 
SMe 
~ Ph 
PhCON Y 0 ~y 
.' 0 
.. 
Pl!' 
3.12 3.15 3.16 
Scheme 3.9. Reagents and Conditions: i. NaH, allyl bromide, DMF, 0° C for 1.5 h. then rt for 
30 min., 3.16 31 %,51 % recovered 3.15. 
3.5.1 ReM Studies 
Diene 3.16 was then exposed to Grubbs' ruthenium alkylidine conditions,45 at room 
temperature using Grubbs' ruthenium catalyst 1.40, in an attempt to form the pyrroline mimic 
3.17. However, the starting diene 3.16 was recovered in quantitative yield. The reaction was 
repeated using a variety of solvents (CH2Ch, toluene, benzene), and temperatures (rt, reflux), 
but again resulted in full recovery of the diene. Reaction with Grubbs' second generation 
ruthenium catalyst 1.42, a compound reported to perform RCM at a rate of over a thousand 
times that of 1.40, at both room temperature and at reflux, in CH2Ch and in benzene, was also 
unsuccessful, with the starting diene being recovered quantitatively (Figure 3.16). 
e 51 % of 3.15 was recovered during purification and this was cycled back through the reaction 
to obtain more diene. 
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Figure 3.16. Attempted RCM of3.16 using catalysts 1.40 and 1.42, proved unsuccessful 
In considering the factors affecting RCM, Grubbs et at. noted that the nature of the carbene 
ligand has a large influence on the initiation rates of RCM reactions, and even on the ability of 
catalysts to induce RCM at alL In reviewing this area Abell and Phillips noted that in many 
cases catalysts with extended carbene tethers (i.e. CHCHCR2) effected RCM of more 
demanding substrates in the event that the more frequently used benzylidene catalysts could 
not. 46 This is consistent with catalysts of this type exhibiting a greater propensity for co-
ordination of a hindered substrate olefin during formation of the intermediate 
metallocyc1obutane. The inability of diene 3.16 to undergo RCM, while the analogous 2.8 
(see Chapter 2) is high yielding, supports this concept (Figure 3.17). 
L I =:/Ph 
X2Ru I 
='\. 
R 
2.8 3.16 
Figure 3.17. Interactions influencing RCM of3.16. 
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Subsequently, the methylbutenylidene ruthenium catalyst 1.41, a carbene possessing an 
extended conjugated 'tether', was utilised in an attempt to effect RCM (Scheme 3.10). 
3.16 3.17 
Scheme 3.10. Reagents and Conditions: 5 mol% 1.41, benzene reflux, 16 h, 94%. 
Thus, diene 3.16 was heated at reflux, in dry degassed benzene, in the presence of catalyst 
1.41. The reaction was followed by TLC and showed the gradual disappearance of the starting 
material, and subsequent formation of a new, more polar, compound. After 16h at reflux, 
isolation and purification via chromatography gave a white crystalline solid in 94% yield. lH 
NMR analysis of this solid showed the absence of the multiplets (OH= 4.99, 5.34, 5.36, 5.39, 
6.22ppm), associated with the terminal olefins of 3.16, and the presence of a singlet, 
integrating to two protons, at oH=5.71ppm. This indicated, to our satisfaction, that the desired 
ring closlU'e had occurred to give the pyrroline mimic 3.17. This result supported our earlier 
statements regarding the effect of extended carbene ligands on co-ordination, and subsequent 
RCM, of hindered olefins. Measurement of the optical rotation for 3.17 gave an [a]D = -
116.6° (c=LO, CHCh). Note that the benzyl group of this cyclic peptidomimetic possesses the 
same relative stereochemistry as the natural amino acid phenylalanine. 
3.5.2 Solid-State Structure of the Pyrroline Mimic 
Recrystallisation of a racemic sample of 3.17, derived from racemic 3.12 (refer Scheme 3.4), 
from ethyl acetate / petroleum ether, allowed the solid-state crystal structure to be determined 
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and satisfactorily refined. Perspective drawings of the solid-state structure of 3.17, with atom 
labelling, are shown in Figure 3.18. 
CIS 
a) 
07 
b) c) 
Figure 3.18. a) Solid-state x-ray crystal structure of 3.17. b) View showing the approximate 
planarity of the pyrrolidine ring. c) View along N-C3 axis indicating torsion angles about C8-
N-C3-C2 peptide backbone are significantly shorter than that for proline. 
Chapter Three 109 
An analysis of the solid state structure of 3.17 reveals that the proline-like N to Ca cyclisation 
results in significant restriction about the C7-N-C3-C2 peptide backbone in a manner similar 
to that observed for 2.9 (refer Figure 2.11). The torsion angle for 3.17 is 52.86 (13t, a value 
significantly shorter than that for proline,47,f but longer than that of the tetrahydropyridine 
mimic 2.9. The adjacent N-C3-C2-01, C7-N-C3-CI4 and C8-C7-N-C3 torsion angles are 
44.99 (14t, -68.67 (15)0 and 176.79 (lIt respectively. The magnitude of the C8-C7-N-C3 
and C7-N-C3-C14 torsion angles are consistent with a Z-arnide bond with an anti relationship 
existing between the benzoyl and benzyl groups respectively. The pyrroline ring, represented 
by N, C3-C6, is essentially planar, with N deviating from the least squares plane defined by 
the other 4 atoms by 0.0365 A. Some pyrarnidalisation of nitrogen was observed, with the 
bond angles at N summing to 358.55°, and C7 (the benzoyl group) deviating away from the 
plane of the pyrrolidine ring (see Figure 3.18c). Some twisting of the amide bond was also 
observed, with the magnitude of the torsion angle about C6-N-C7-C8 found to be -17.99 
(18)°. 
In summary, solid-state X-ray analysis reveals that compound 3.17 adopts a cis-amide bond 
geometry with significant conformational restriction about the amide bond. As with the 
tetrahydropyridine mimic 2.9 described in Chapter 2 (see Figure 2.11), 3.17 has potential for 
use as both a proline mimic, and I)-turn mimic. Comparison ofthe solid-sate conformations of 
3.17 and 2.9 reveals that, while the two mimics possess opposite stereochemistry at C3, and 
have opposite rotations (-116.6° and +38.2° respectively), both give a positive torsion angle 
value about the peptide backbone (see Figure 3.19). 
f Proline angles vary depending on structure and environment ie they adopt a constrained but 
fluid system. 
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cs 
38.r 140.2° 
3.17 2.9 
Figure 3.19. Both 3.17 and 2.9 maintain a positive torsion about the peptide backbone, despite 
possessing opposite stereochemistry at C3. 
It is envisaged that the introduction of different substituents at the a-carbon of 3.17 would 
allow for 'fine tuning' of this torsion angle, and aid in maximising any receptor site 
interactions should these compounds be incorporated into peptides for biological study 
3.6 Synthesis of the a-Substituted Proline Mimic 
The olefin 3.17 was stirred, in deoxygenated methanol, in the presence of palladium-on-
carbon, for 16 h under a hydrogen atmosphere. Filtration through Celite™ and purification 
via radial silica chromatography gave the a-substituted proline mimic 3.28 in 95% yield 
(Scheme 3.11), crystals of which were used to measure the optical rotation ([aJD -106.5°, 
CHCb). 
Scheme 3.12. Reagents and Conditions: H2, Pd-C, MeOH, 16 h, 95%. 
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3.7 Attempts to Establish the Enantiomeric Purity of a Key 
Intermediate 
Synthesis of the pyrroline mimic 3.17 outlined in Scheme 3.1, and abbreviated in Figure 3.20, 
was successfully completed, with the stereochemistry and solid-state conformation being 
established by X-ray crystallography. 
SMe 
~ Ph 
PhCON~O 
}--o 
Pl{ 
3.12 
SMe 
PhCO)Yo 
}--o 
Pn' 
3.11 
~ Ph 
---------. PbCON~O 
}--o 
Pn' 
3.13 3.15 
3.17 
Figure 3.20. Synthesis ofpyrroline mimic 3.17 from benzyl-5-oxazolidinone 3.11. 
The key to the enantioselective synthesis of 3.17 was the stereoselective alkylation of the 
oxazolidinone 3.11, in a manner similar to that described in the preparation of the piperidine 
analogue 2.9 in Chapter 2. Alkylation of 3.11 with benzyl bromide, gave the dialkylated 5-
oxazolidinone 3.12, the crystallisation of which, showed no sign of any minor diastereoisomer 
by 1H NMR. Oxidative degradation of 3.12, to give 3.13, followed by hydrolysis and 
esterification, gave the key intermediate 3.15, which was used in the synthesis of mimic 3.17. 
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Repeated recrystallisation of 3.11 gave a sample that showed no sign of any minor 
diastereoisomer by IH NMR, and gave an optical rotation ([a]D = +222°, c=1.0CHCh), 
slightly lower than that reported in the literature ([a]D +280.4°, c=1.O CHCh).41 However, 
this difference was consistent with that observed for 2.5 in chapter 2 (+267°, literature 
+385.2°), a compound subsequently shown to be optically pure (see Chapter 2.6). To address 
this issue we set out to establish the enantiomeric purity of the key derivative 3.15, in a 
manner similar to that described for 2.7 (see Scheme 2.12). Ozonolysis of 3.15, followed by 
reduction of the resultant aldehyde, was envisaged to give an alcohol suitable for the 
preparation of Mosher esters (see Scheme 2.14 and Figure 2.19). However, attempts at 
preparing the aldehyde, via oxidation of 3.15 with ozone and solid NaHC03, at-78°C in THF, 
in a manner analogous to that described for 2.19 (Scheme 2.13), instead resulted in elimination 
of the vinyl group to give the N-benzoyl-phenylalanine methyl ester 3.29 (Scheme 3.11). 
Measurement of the optical rotation of 3.29 revealed a [a]D, in EtOH, essentially equal to 
zero, indicating the compound to be racemic.g,48 
~ Ph PhCOHN~02Me 
(+)-3.15 
.. 
rae 3.29 
Scheme 3.11. Reagents and Conditions: 0 3, NaHC03, CH2Ch / MeOH (3:1), _78° C then 
DMS. 
Despite this, evidence for the enantioselective synthesis of 3.15 is amply supported by 1) the 
absence of any minor isomer being detected by I H NMR during the preparation of the 
oxazolidinone 3.11, and its associated high optical rotation ([a]D = +222°, c=l.O CHCh); 2) 
the absence of any minor diastereoisomer being detected by 1 H NMR during the preparation of 
3.12, and its associated optical rotation ([a]D = +14.3°, c=1.0 CHCh); 3) the absence of any 
minor diastereoisomer being detected by IH NMR during the preparation of 3.13, the 
g N-Benzoyl-L-phenylalanine methyl ester, [a]D = -45.3°, c=l.O EtOH. 
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procurement of its solid-state structure, associated space group (P2j 2121), and optical rotation 
([a]D +139.0°, .0 CHCb); the optical rotations associated with subsequent derivatives of 
3.13, namely 3.15 itself ([a]D = -54.1°, c=1.0 CHCb), 3.16 ([a]D = -62.8°, c=1.0 CHCb), 3.17 
([a]D = -116.6°, c=1.0 CHCh), and 3.28 ([a]D -106.5°, .0, CHCh). These observations 
are consistent with those observed in Chapter 2, where the ee of analogous compounds was 
found to be >95% (Chapter 2.6). 
3.8 Conclusion and Future Work 
A synthesis of an optically active proline mimic of type 3.7 has been achieved. The sequence 
utilised a combination of Grubbs' RCM chemistry to form the cycle, and Seebach 
oxazolidinone chemistry to establish the stereochemistry. A benzyl group was successfully 
incorporated at the a-carbon, leading to the preparation of the pyrroline mimic 3.17. The 
solid-state structure was determined for 3.17, and showed a significant conformational 
restriction about the amide bond, with an amide torsion angle of +52.86 (13)°. This indicated 
that, as with the tetrahydropyridine mimic 2.9 described in Chapter 2, 3.17 has potential for 
use as both a cis-amide bond mimic and a ~-turn mimic. Further comparison between 3.17 
and 2.9, revealed that, while the two mimics possess opposite stereochemistry at C3, and 
. opposite optical rotations, both give a positive torsion angle value about the peptide backbone 
(Figure 3.19). Hydrogenation of 3.17 also yielded the a-substituted proline mimic 3.28. 
Determination of the enantiomeric purity of the key intermediate 3.15 was also attempted, 
however ozonolysis of 3.15, in a manner similar to that used for the preparation of equivalent 
Mosher esters described in Chapter 2, instead resulted in formation of racemic N-benzoyl-
phenylalanine methyl ester 3.29. The solid-state structure of 3.13, a key intermediate in the 
synthesis, its associated P212121 space group, and the observations that all compounds in the 
sequence were optically active and contained no minor isomers by IH NMR, nevertheless 
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provided ample evidence to conclude that the synthesis of 3.17 had been stereoselective in 
nature. These observations were consistent with those in Chapter 2, where the ee of analogous 
compounds was found to be >95% 
Future work could involve further derivatisation of 3.17 to obtain a library of monomeric 
compounds for incorporation into peptides, to examine their effect on secondary structure. 
The preparation of a range of mimics, derived from both natural and non-natural amino acids, 
could subsequently be used in the development of a range of potential peptidomimetics 
possessing defined conformation. 
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CHAPTER FOUR 
ENANTIOSELECTIVE SYNTHESIS OF THE 
TETRAHYDROPYRIDAZINONE CORE 
OFA 
2-oxo-l ,6-DIAZOBICYCLO( 4,3 ,O)-NONANE-9-
CARBOXYLATE ~-STRAND TEMPLATE 
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4.1 Introduction 
Over 90% of all protein structure can be found in the form of common secondary structure 
motifs, or templates, such as reverse turns, ~-strands and a-helices. These motifs provide 
the basis of a myriad of ligand-receptor, and enzyme-substrate interactions, for a multitude 
of biological processes. It has been known for some time that proteases bind their 
substrates, and inhibitors, by constraining them to adopt ~-sheets / strands within the active 
site. This conformational requirement has been exploited in the design of inhibitors of the 
aspartic acid proteases renin, 1 and of HIV -1 protease. Cascading ~-sheets have also been 
suggested as the cause of the insoluble amyloid fibrils associated with Alzheimer's 
disease.2 In addition, protein-DNA interactions can occur with the protein interface 
adopting a ~-strand conformation.3 Due to the biological importance of these processes, 
much interest has been directed towards the development of mimics for these secondary 
structure motifs. A number of combinatorial libraries have been developed in this regard, 
to explore these biological structure-function relationships. 
One such class of mimic are the 2-oxo-l,6-diazobicyclo( 4,3,0)nonane-9-carboxylate 
dipeptidomimetic scaffolds of type 4.1, that can be found in extended ~-strand mimetics 
and other bioactives.4 
4.1 X=N 
4.2X=CH 
These scaffolds, together with those of type 4.2, are designed to mimic the extended ~­
strand conformation adopted by substrates in the active site of a variety of serine 
proteases.5 Homologation studies of these proteases have revealed a conserved trypsin-like 
core, with key insertions leading to a modification of substrate specificity. Inspection of 
numerous enzyme / substrate, and enzyme / inhibitor, X-ray crystal structures has 
highlighted the extended strand motif adopted by the inhibitor / substrate in the active site.6 
Inhibition of certain enzymes of this type is envisaged to be beneficial in treating their 
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associated disease states. Preliminary reports suggest that the selectivity displayed by 
compounds of type 4.1, for one protease over another, is influenced by the nature of the 
substituents on the 2-oxo-1,6-diazobicyclo[4,3,OJnonane-9-carboxylate core.7 The recent 
screening of a library of such compounds against a range of serine proteases supports this 
observation, with the identification of a number of potent and selective inhibitors. 8 One 
such target for these inhibitors has been the serine protease thrombin, a key enzyme in the 
blood coagulation cascade. 
Thrombin is grouped among a class of enzymes referred to as 'protective' enzymes and 
plays a number of key roles in the blood coagulation cascade (See Figure 4.1 ).9,10 Along 
with fibrinogen, thrombin is involved in preventing blood loss in the event of circulatory 
system damage, by forming blood clots at the site of injury. Specifically, it catalyses the 
conversion of fibrinogen to fibrin, one of the two major components of a blood clot, or 
thrombus. This conversion is brought about by the selective cleavage of key Arg-Gly 
peptide bonds, within fibrinogen, to form fibrin. I I 
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Figure 4.1 The blood coagulation cascccle. The intrinsic and extrinsic pathways converge 
at Factor X, with the final pathway invo lving the activation of thrombin _ This converts 
fibrinogen into fibrin , which aggregates into a cross-linked filamentous array to form the 
clot. Above-left. Ribbon diagram of thrombin_ Left and belo'\.v left. Electron micrographs 
displaying the filamentous nature of a blood clot. 
Thrombin is also among one of the mo -t potent known stimulators of platelet aggregation 
and thereby leads to the activation of the second major component of a blood clot. 
Thrombin directly activates Factor XIlJ LO Factor XlIIa, resulting in covalent cross-linking 
of fibrin _ Fibrin then readily aggregates into ordered fibrous arrays, stabili sed by these 
cross-links, thereby helping to stabili'e the gro'Vving clot. F inally, thrombin is self-
regulatory. It catalyses its own synth _sis via the activation of Factor V and VIII , and 
regulates its own activity via generation of the anticoagulant Activated Protein C. 
Recently groups led by Boatman, Kl .an and Takahashi have used the diazobicyclic 
template 4.3 in the preparation of inhib tors for a range of serine proteascs. Tn particular 
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compounds such as 4.4 were designed as, and subsequently found to be, potent inhibitors 
of thrombin. 5,7,8 
trJ:;T-XX H2N~N-( 
o COR 
4.3 X=H, R=OH 0 
4.4 R=HN~ 
H2N(HN~)CHN-k)3 S~ 
The template was designed as a mimic for the extended tl-strand secondary structure 
adopted by fibrinogen in the active site of thrombin.6,12 The bicyclic ring structure serves 
to rigidify the peptide backbone of the inhibitor, while placing the functional groups in 
approximately the same orientation as an idealised peptide (Figure 4.2). 
Figure 4.2. Template 4.3 was designed to mimic the tl-strand structure adopted by 
fibrinogen, thrombin's natural substrate. 
This strategy has been used extensively in the preparation of potential ~-turn mimetics.4 tl-
Turn mimetics of this type generally encompass the i+ 1, and i+2, residues of the tum, and 
position the i, and i+3, residues for formation of a hydrogen bond between the respective 
amide NH and carbonyl. However, bicyclic structures such as 4.1 and 4.2 also orient the 
atoms encompassed by the template in positions that are approximately the same as those 
in an extended strand. These properties have led to the recent use of compounds of this 
type in the preparation of tl-strand mimetics. In the development of template 4.3, the 
researchers chose substituents to match those of the D-Phe-Pro portion of PPACK, a 
known inhibitor of thrombin, and a compound that had earlier reached phase II clinical 
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evaluation. This led to a number of compounds being identified that were not only potent, 
but very selective inhibitors of thrombin (i.e. 4.4).5,7,8 
Table 4.1 illustrates extensive in vitro assay results for a number of these inhibitors against 
a range of coagulation and anticoagulation enzymes. 
Table 4.1. Inhibition and Selectivity of Coagulation vs Anticoagulation enzymes.5 
f~J~~~H 0 H2N~ N~ 
o : y 
o : 
lNH 
MOL098 X=N, Y=CH2Cl 
M0L144 X=N, Y=2-benzothiazolyl 
MOL174 X=CH, Y=2-benzothiazolyl 
H2NANH 
Enzyme3 PPACKb 
thrombin 1.5 
trypsin ND 
Factor Xa 165 
Factor VIla 200 
Protein C 281 
plasmin 699 
urokinase 508 
t-PA 106 
MOL098b 
1.2 
ND 
385 
140 
528 
978 
927 
632 
MOL144C 
0.64 
270 
270 
3320 
415 
600 
495 
MOL174C 
0.23 
19.3 
200 
1250 
251 
325 
93 
a Inhibitor concentration (selectivity=Ki otherlKi thrombin), IC50 (nM), Ki (nM) 
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Comparison of the data for PPACK with those of the constrained ~-strand inhibitors 
indicated that the template imparted greater selectivity for thrombin than the more flexible 
peptide. MOL144 and MOL174 were further evaluated in an in vivo study revealing that 
both compounds were very effective in blocking platelet disposition. The bioavailability 
of these two compounds was also evaluated in rats and non-human primates, with 
MOL144 approximating 25% in rat and primate, while MOL174 approximated 2% in both 
species. This indicated that although MOL144 and MOL174 displayed similar 
characteristics in the in vitro assays, MOLI44, which incorporated a diazobicyclic 
template, was consistently at least lO-fold more bioavailable in vivo. 
Important precursors in the synthesis of the diazobicyclic template core of type 4.3, and the 
associated inhibitors, are the tetrahydropyridazinones of type 4.5 (Scheme 4.1). To date 
substituted compounds of this type, where R is other than H, have only been synthesised as 
racemic mixtures, a point of note when considering the synthesis of subsequent templates. 
These mixtures are then subjected to a regioselective 1 ,3-dipolar cycloaddition to give the 
racemic bicyclic template 4.3. 5 
CH20 
.. 
( 
COR' 
4.5 
R~~) 
PHN -< 
COR' o 
4.3 
--_ .. M0L144 
R=CH2Ph 
Scheme 4.1. Templates of type 4.3 are formed via ai, 3-dipolar cycloaddition reaction. 
Final extension of the peptide chain yields a mixture of diastereomeric ~-strand mimetics, 
such as MOL144, that must be separated by HPLC.5 This basic methodology has also 
recently been extended onto solid phase to provide access to small libraries of f3-strand 
mimetics as mixtures of isomers. 5,7,8 
Here lies a deficiency in the synthesis. While the generation of isomers is sometimes 
desirable to explore conformational constraints, once the necessary stereochemical 
requirements for a template are determined, only compounds with the required 
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configuration can be used in the preparation of subsequent inhibitors. For thrombin, this 
corresponds to a D-configuration for the P3 substituent being required to induce inhibitory 
activity. An opportunity therefore arose for the development of an asymmetric synthesis of 
compounds of this type, for use in peptidomimetic design. 
Subsequently, efforts were made to develop an enantioselective synthesis of a peptidic 
tetrahydropyridazinone ring system, of type 4.5, from (S)-phenylalanine (R=CH2Ph). 
Derivatives of this type could then be utilised in the preparation of bicyclic 
peptidomimetics of type 4.3, in what would be the first enantioselective synthesis of this 
important class of ~-strand mimetic. 
4.2 Synthesis of the Tetrahydropyridazinone Core 
We began by considering the existing synthesis of the racemic phenylalanine-derived 
tetrahydropyridazinone template 4.10 (Scheme 4.2). 5 
ix. rae 4.10 R=Et 
rae 4.11 R=H 
i., ii., iii. 
viii. 
4.6 
~NH , NH BocHN 
o 
4.9 
o \Jh 
BocHN C02Me 
iv., v. 
4.7 
vii 
.. 
4.8 
Scheme 4.2. Reagents and Conditions: i. PhCHO, Et3N, CH2Ch, rt; ii. LDA, _78 0 C, then 
allyl bromide, _780 C to rt; iii. 1 M aq. HCI, MeOH, rt, 1 h; iv. BOC20, NaHC03, THF / 
H20, rt, 3 days; v. 0 3, NaHC03, CH2Ch / MeOH; vi. Hydrazine, THF, reflux, 3 days; vii. 
PhO (cat.), H2, MeOH, rt, 48 h; viii. HCOH, ethyl acrylate, reflux; ix. LiOH, THF, rt, 1.5 
h. 
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Here the benzaldimine of phenylalanine methyl ester was formed and alkylated with allyl 
bromide, with the imine then being hydrolysed to give (+I-)-a-allylphenylalanine methyl 
ester 4.6. Subsequent protection as the N-Boc derivative, followed by ozonolysis of the 
olefin, gave aldehyde 4.7 which, when treated with hydrazine, gave the cyclic hydrazone 
4.8. Reduction of the cyclic hydrazone gave the tetrahydropyridazinone 4.9 as a racemate. 
This then underwent a 1,3-dipolar cycloaddition, when treated with formaldehyde in an 
excess of ethyl acrylate, to give a mixture of diastereomeric and regioisomeric products. 
The desired bicyclic template 4.10 was then isolated from this mixture, albeit in racemic 
form. Hydrolysis of 4.10, to give 4.11, allows for chain extension in the C-terminal 
direction and subsequent incorporation of the template into potential inhibitors. 
From an asymmetric standpoint, the key feature of this synthesis is the non-stereoselective 
allcylation of phenylalanine to give the racemic allylphenylalanine derivative 4.6. It was 
felt that if this key a,a-disubstituted amino acid could be obtained in an enantiomerically 
pure form, it could be taken through the sequence shown in Scheme 4.1 to give the bicyclic 
template 4.10 as a single isomer. 
The key to our synthesis was the use of chiral oxazolidinone chemistry to generate 
enantiomerically pure a,a-disubstituted amino acids of type 4.6. We had previously used 
this chemistry to develop an enantioselective synthesis of phenylalanine-derived 
tetrahydropiperidine mimetics of type 2.9. (see Chapter 2).13 There we had successfully 
alkylated (S)-phenylalanine, stereoselectively, to form compound 2.7, an enantiomerically 
pure, N-benzoyl protected equivalent of compound 4.6 (refer Schemes 2.2 and 4.1). The 
enantiomeric synthesis of this key a, a-disubstituted amino acid is outlined in Scheme 4.3, 
with the absolute stereochemistry of 2.5 having been previously determined by X-ray 
crystallography (see Chapter 2).13 
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Scheme 4.3. Reagents and Conditions: i. NaOH, then PhCHO, CH2Ch, reflux, then 
PhCOCI, CH2Ch, -20° C, then 0° C for 3 days, 62%; ii. LiHMDS, _78° C, THF, allyl 
bromide, 93%;, iii. NaOH, MeOH, reflux, quant.; iv. CH2N2, 99%. 
As the enantiomeric purity of (-)-2.7, and hence 2.5, had also previously been determined 
to be >95% (via synthesis of Mosher esters, see Chapter 2.6), we felt confident it could be 
used here for the synthesis of a single enantiomer of 4.10, albeit N-benzoylated. 
The N-benzoyl protecting group was chosen for ease of access of the starting 
oxazolidinone 2.4, and to allow synthesis of the required D-enantiomer of 2.7. It should be 
noted, however, that Cbz-protected oxazolidinones, with the ring substituents syn, can also 
be prepared,14-16 to allow synthesis of the opposite enantiomer should this be desired. The 
starting trans-phenyl-5-oxazolidinone 2.4 was prepared, in three steps, from (S)-
phenylalanine as previously described (refer chapter 2),16 in 62% overall yield. 
Deprotonation of 2.4 at C-4, with lithium hexamethyldisilaside, and alkylation of the 
resulting anion with allyl bromide, gave the alkylated oxazolidinone 2.5, as a single 
diastereoisomer by IH NMR, in excellent yield (93%). Note that the stereochemistry at C-
4 has been inverted to give the desired D-configuration. Subsequent hydrolysis of the 
oxazolidinone ring of 2.5, with NaOH in methanol, led to the isolation of the free acid 2.6, 
which, on addition of an excess of diazomethane, gave optically active 2.7, in excellent 
overall yield (91 %,2 steps). 
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We next set about preparation of the heterocyclic core of the dipeptide mimetic in a 
manner similar to that previously reported for racemic 4.10 (see Scheme 4.2). The 
synthesis of the N-benzoyl derivative 4.14 is outlined in Scheme 4.4. 
ii. 
2.7 2.2] 
iv . 
.. 
4.14 
PY;h I N 
" I 
PhCOHN" NH 
o 
4.12 
I iii 
r~,I~: PhCOHN~ 
o 
4.13 
Scheme 4.4. Reagents and Conditions: i. 0 3, NaHC03, CH2Ch / MeOH then Me2S; ii. 
hydrazine, THF, reflux, 3 days; iii. Pt20 (cat.), H2, MeOH, rt, 48 h or NaB(CN)H3, MeOH 
/ HCI, 0° C to rt, 18 h; iv. CH20, ethyl acrylate, reflux. 
Firstly, ozonolysis of 2.7 was carried out. A mixture of the olefin and solid NaHC03 
dissolved in a 3: 1 mixture of CH2Ch / methanol, was cooled to -78° C and ozone bubbled 
through the solution until a deep blue colour resulted. Decomposition of the intermediate 
ozonide with dimethylsulfide, followed by filtration, gave the previously synthesised 
aldehyde 2.21, as a colourless oil, in 96% yield (Scheme 4.5, see also Scheme 2.13). This 
compound has previously been prepared in the synthesis of the corresponding Mosher 
esters, in which the enantiomeric purity of 2.7 was established to be >95% (see Chapter 
2.6). 
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\1 
--_ .. PhCOHN'" C02Me 
(-)-2.7 ozonide (-)-2.21 
Scheme 4.5. Reagents and Conditions: 0 3, NaHC03, THF, _78° C, then Me2S, rt, 6 h, 
96%. 
Conversion to the cyclic hydrazone was then undertaken, with 2.21 refluxed with 
hydrazine, in THF, for 3 days, to give 4.12 (Scheme 4.6). 
2.21 
NH2 
f 
NH2 
Ph:q.N-NfI 
1" /H 
" Lo. 
PhCOHN ~ 
r \...OMe 
acyclic intermediate 
___ .... ~ 1", ~ -MeOH Ph:C; 
PhCOHN' (NH 
o 
4.12 
Scheme 4.6. Reagents and Conditions: hydrazine hydrate, THF, rt 10 min. then reflux 3 
days, 85%. 
Previous preparations of the N-Boc derivative 4.8, reported by Boatman et at, found that 
treatment of the aldehyde ester with hydrazine, at room temperature, gave mixtures of the 
desired cyclic hydrazone along with a number of acyclic hydrazones.5 TLC and' NMR 
evidence indicated rapid formation of the acyclic hydrazone, and slow formation of the 
heterocycle. Subsequently, it was found that heating the reaction mixture for an extended 
period gave the desired cyclic hydrazone in good yield. This was also found to be the case 
in the preparation of 4.12, with isolation, after purification, giving a white solid in 85% 
yield. Measurement of the optical rotation gave an [a]D = -128.4°, c=l.O CHCb. 
Hydrogenation of 4.12 over Adam's catalyst (Pt02), as reported for the preparation of 
racemic 4.9,5 gave variable results in our hands. However, reduction of 4.12 with sodium 
cytmoborohydride gave the desired tetrahydropyridazinone 4.13, cleanly, in 73% yield 
(Scheme 4.7). Measurement of the optical rotation gave [a]D = -25.7°, c=l.O CHCh. 
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Scheme 4.7. Reagents and Conditions: NaBH3CN, HCI, MeOH, 73%. 
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Preparation of the core compound 4.13 represents a key result, as it describes the first 
enantioselective synthesis of a phenylalanine-based tetrahydropyridazinone of this type. 
This can now be used in the enantioselective preparation of the diazobicyclic template 
4.14. 
4.3 Synthesis of the Diazobicyclic Template 
Finally, treatment of 4.13 with formaldehyde, and subsequent heating with an excess of 
ethyl acrylate, gave rise to a 1,3-dipolar cycloaddition as reported for the preparation of 
4.10.5 Purification by chromatography gave the desired diazabicyclic template 4.14 in a 
modest yield of 27% (Scheme 4.8). 
1~rNH PhCOH~~(rlm 
o 
4.13 4.14 
Scheme 4.8. Reagents and Conditions: CH20, ethyl acrylate, reflux, 4 h, 21 %. 
The absolute configuration of 4.14 was assigned, as shown, on the basis of the previously 
determined absolute configuration of oxazolidinone 2.5 (see Scheme 4.3 and Chapter 2), 
and the relative configuration of template 4.10 as reported by Takahashi and Kahn (see 
Scheme 4.2).5,7,8 X-Ray crystallography of derivative 4.15 bound to thrombin, prepared by 
these researchers from racemic 4.10, as a potential thrombin inhibitor, also confirmed these 
assignments. 
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4.15 
This assignment of relative configuration is consistent with that reported for related 
compounds.4,17 The IH and J3C chemical shift data for 4.14, along with the molecular 
connectivity information obtained from HSQC and CIGAR experiments, are shown in 
Figure 4.3.a 
2.55/3.04, 34.0 
\ 
3.04,52.1 Pt, Jj3.00/3.21,54.3 
3.57/3.68, 41.2 1", f 2.25/2.55,28.9 
" N 
7.05 HN \ 4.60,57.5 
1667-1 \ 170.2 
. ~ 0 . 0 Ph 0 0 \ /4.22,61.8 59.5 ~ 165.5 1.28, 14.1 
All data re in the format oR, Oc Key 2D NMR correlations 
Figure 4.3. Assignment of 1H asnd 13C MNR data for 4.14 based on HSQC and CIGAR 
derived information. 
The factors governing the stereochemical and regiochemical outcomes of 1,3-dipolar 
addition reactions are still less than clear. However the stereochemical outcome in the 
preparation of 4.14 can, in some respects, be rationalised when considering the 
conformation adopted by the tetrahydropyridazone precursor 4.13. X-Ray crystallography 
of a number of pyridazinones, and the related cyclic amides,18 has revealed that these 
compounds adopt a half chair conformation in the solid state. In these structures, the ring 
bound amide is essentially planar due to it exhibiting partial double bound character. It is 
a A 2D NOESY experiment gave no useful information regarding the relative 
stereochemistry. 
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thought that this planar character is accentuated upon addition of formaldehyde to form the 
intermediate imine. Therefore 1,3-dipolar addition, in the presence of ethyl acrylate, can 
take place with the electrophile approaching from either face of the imine intermediate. 
Modelling studies of this intermediate, and indeed analysis of the X-ray structures of 
template derivatives such as 4.15, indicate that the benzyl group substantially blocks one 
face of the dipole, such that the favoured approach of the electrophile is from the side 
opposite this substituent. In the formation of template 4.14, 1,3-dipolar addition proceeds 
with the regioselection shown, with the exo product being favoured (Figure 4.4). 
~O 
HN 
intermediate imine + ethyl acrylate exo product 
~O 
HN 
P:C; I" 11 
" N 
PhCOHN (:( 
o C02Et 
.. 
intermediate imine + ethyl acrylate endo product 
Figure 4.4. X-Ray crystallographic, and modelling, studies suggest that the benzyl 
substituent blocks one face of dipole intermediate, thereby favouring the formation of the 
exo-product 4.14, with stereochemistry shown. 
4.3.1 Formation of a Dimeric Byproduct 
During initial efforts at inducing 1,3-dipolar cycloaddition to form template 4.14 an 
interesting byproduct was isolated. It was found that if, on addition of formaldehyde to 
4.13 in ethyl acrylate, insufficient heat was applied to promote formation of the desired 
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template (Le. 80-90° C instead of reflux at 100-110° C), a single compound could be 
isolated cleanly as a solid in a moderate yield of 45%. Since 1,3-dipolar cycloadditions of 
azomethine imines in solution are known to suffer from many side reactions, including 
dimerisation due to their high reactivities, we were intrigued as to what this byproduct 
might be. Analyse of the IH NMR spectrum revealed a resonance pattern similar to that of 
the starting pyridazinone, but with an additional pair of diastereotopic methylene signals at 
<5 4.42 and 5.09 ppm. It was thought that we had perhaps isolated a reduced imine, or 
cyclopropyl derivative of 4.13, as a result of its reaction with formaldehyde. Further 
analysis by 13 C NMR spectroscopy seemed to support this, with the presence of an 
additional carbon signal, at <5 64.5 ppm, being observed in the spectrum. However, upon 
analysis by electrospray mass spectrometry it was revealed that the parent ion (M+) had a 
mass of 643. This indicated that a dimeric compound had been obtained, with IH NMR 
and BC NMR analysis indicating that it was symmetrical in nature. Further 2-D NMR 
analysis, in the form of COSY, HSQC and CIGAR experiments, led to the structure being 
assigned as 4.16. 
4.16 
It was concluded that insufficient heat had been applied to the reaction to promote five-
membered ring formation upon 1,3-dipolar cycloaddition with ethyl acrylate. Instead, 
dimerisation, also via 1,3-dipolar addition, had taken place, forming a more stable six-
membered ring between two formylated derivatives of 4.13. The mechanism of formation 
of 4.16 is suggested in Figure 4.5, with two molecules of the azomethine imine 
intermediate reacting together via 1,3-dipolar addition to form a central, thermally stable, 
six-membered heterocyclic ring. 
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Figure 4.5. Suggested mechanism of formation of the symmetrical dimmer 4.16 
4.4 Conclusion and Future Work 
In conclusion, we have developed the first enantioselective synthesis of the phenylalanine-
based tetrahydropyridazinone 4.13, and its conversion to the 2-oxo-l, 6-
diazobicyclo[4,3,OJnonane-9-carboxylate dipeptido-mimetic scaffold 4.14, an important 
component of extended f3-strand mimetics. The nature, and absolute configuration, of the 
starting amino acid can be varied to give a versatile and general method for the preparation 
of compounds of type 4.1. This template has shown versatility in the development of 
inhibitors for a wide range of serine proteases, in particular that of thrombin. An example 
is MOL144, a compound that exhibits potent thrombin inhibitory properties as well as 
good bioavailability. 
Key to this synthesis was the preparation of enantiomerically pure samples of the a,a-
disubstituted amino acid 2.7. Existing methodology, used in the synthesis of the racemic 
template 4.10, was then employed to allow the preparation of tetrahydropyridazone 4.13, 
as a single enantiomer. Subsequent imine formation, and 1,3-dipolar cycloaddition in the 
presence of ethyl acrylate, led to the desired diazabicyclic template 4.14 being isolated, as 
a single diastereomer, in moderate yield. The stereochemistry of this compound was 
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assigned based on the previously determined absolute configuration of 2.5, and also the 
relative configuration of 4.10 as reported in the literature. 
In addition, it was found that insufficient heating during this 1,3-dipolar cycloaddition 
reaction led to the formation of an unknown byproduct. Subsequent NMR and mass 
spectroscopy studies revealed this to be the symmetrical dimer 4.16, formed as a result of 
1,3-dipolar cycloaddition between two imine intermediates of 4.13. 
Future work could include the synthesis of a range of thrombin inhibitors incorporating the 
diazobicyclic template 4.14. Variation of Y groups alluded to in Table 4.1, could lead to 
more potent, and more selective, inhibitors of this important enzyme. In addition, the 
nature and configuration of the starting amino acid could be varied to establish a general 
preparation of compounds of type 4.1. Peptidomimetics containing these templates, and 
incorporating key residues specific to other enzyme substrates, could be used to probe for 
potentially new inhibitors of these enzymes. 
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CHAPTER FIVE 
SYNTHESIS OF a-SUBSTITUTED 
CYCLOHEXENYL-BASED 
~-AMINO ACIDS BY 
RING-CLOSING METATHESIS 
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5.1 Introduction 
Recently, there has been increasing interest in the synthesis of cyclic ~-amino acids for use in 
the preparation of ~-peptide foldamers with stable and defined conformations. Here we 
present a versatile ring-closing metathesis (ReM) approach to cyclic ~-amino acids that 
allows the preparation of examples that are either unsubstituted, or substituted, at the a-
position. 
5.1.1 ~-Amino Acids 
Although not as abundant as their a-analogues, ~-amino acids have recently emerged as an 
increasingly important class of compound in medicinal chemistry. ~-Amino acids are found in 
humans, animals, microorganisms, marine organisms, in either free form or as derivatives, and 
possess a wide range of pharmacological properties. They are also found in a number of 
peptide natural products that exhibit antibiotic, antifungal as well as cytotoxic activity. An 
example is the a-hydroxy-~-amino acid component of the medicinally important natural 
product paclitaxel (Taxol®),1-4 isolated in the mid 1960's from the stem and bark tissues of the 
Pacific yew tree (Taxus brevi/alia) (Figure 5.1),5-7 and currently used in the treatment of a 
variety of cancers. The intact paclitaxel molecule is required for optimal cytotoxicity, with the 
stereochemistry of the a-hydroxy-~-amino acid moiety of critical importance.s 
o 
[)hANH 0 
Ph~O'" 
61-1 
OAc 
Paclitaxel (Taxo\) 
Figure 5.1. ~-Amino acids are found in a variety of natural products including the potent 
anticancer agent placitaxel (Taxol®). 
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~-Amino acids are important components of ~-lactams,8,9 a class of compound that includes 
antibiotics/o (3-1actamase inhibitors, 11 human leukocyte elastase inhibitors,9 and cholesterol 
uptake inhibitors. 12 Key examples are the historically important penicillins 5.1 (Figure 
5.2),8,10 with the rapid increase in penicillin-resistant strains of bacteria in recent decades 
leading to new (3-lactam ring systems being discovered and developed. These include the 
penems 5.2,13 carbepenems 5.3 - 5.5,14,15 and the so-called third generation antibiotics such as 
the cephams 5.6,16 carbecephams 5.7,17 and oxaisocephams 5.8. 18 Much effort has gone into 
the synthesis of ~-amino acids for use in the development of new and important compounds of 
this type. 
R)=rJ( 
o --C02H 
5.1 
R X 
o)=r-tR 
C02H 
5.2 X=S . 
5.3 X=CH2 
5.4 X=CH-CH3 
OH RY~)=;(J ~J±tSYIR 0 0 N{,:R 
C02H S 5.6 X=S cephalosporins 
5.5 5.7 X=CH2 carbacephams 
5.8 X=O oxaisocephams 
Figure 5.2. ~-Amino acids have been used as important precursors to (3-lactams. 
Recently, the development of linear ~-peptides for use as therapeutics has resulted in a number 
of promising finds. Short chain ~-peptides have so far been shown to inhibit an intestinal 
membrane bound cholesterol- and lipid-transporting protein,19 while others have been shown 
to possess antimicrobial and haemolytic activities.zo-24 Examples include the peptidase 
resistant tetrapeptides 5.13 and 5.14 (Figure 5.3), both of which have exceptionally high 
affinities for a human somatostatin receptor.25 This was one of the first cases where an a-
peptide hormone was shown to be mimicked by a small ~-peptide, with 5.14 having emerged 
as one of the most tightly binding ligands known for this receptor. 
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Figure 5.3. Tetra-~-peptides 5.13 and 5.14 have been shown to have extremely high binding 
affinities for a human somatostatin receptor. 
~-Peptides also possess enhanced biological stability towards a wide range of proteolytic 
enzymes, both in vitro and in vivo, compared with that of their a-peptide equivalents, making 
them of particular interest in this regard,z6-28 
In addition to linear ~-peptides, cyclic peptides such as 5.15 and 5.16 (Figure 5.4), have been 
shown to adopt secondary structure,29 fonning cylindrical stacks stabilised by hydrogen bonds 
between adjacent levels. In the (S,S,S,S) tetramer 5.15, the amide bonds are orthogonal to the 
ring plane and all point in the same direction. The orthogonal amide bonds of the (S,R,S,R) 
tetramer 5.16 alternately point in opposite directions. 
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5.15 (S,S,S,S) 5.16 (S,R,S,R) 
~o ~::~ ~O o 
o~o __ , 
t:::~ 
"~O 
o 
Figure 5.4. Side view of the solid-state structures of the cylindrical stacks composed of the 
cyclopeptides 5.15 (left) and 5.16 (right). 
These cylindrical stacks display similar properties to the peptide nanotubes investigated by 
Ghadiri et al,30 and Sun and Lorenzi.3 ) Compounds of this type are of interest in the 
development of potential pharmaceuticals as ion pore chalmels and structural scaffolds, as 
well as in the area of pseudo-polymer materials research. Similar cyclo-~-peptides have also 
been shown to have a high affinity for a range of biological receptors,32 as well as antiprolific 
activity against the growth of a number of human cancer celllines.33 
The chemistry and pharmacology of ~-amino acids has been widely reviewed, however the 
study of cyclic ~-amino acids has received somewhat less attention. In addition to their own 
pharmacological activity, cyclic ~-amino acids are useful as building blocks for the 
preparation of a range of biologically active peptides. Insertion of cyclic ~-amino acids in 
place of a-amino acids, in a biologically active peptide, can lead to increased activity, 
associated with stabilisation of a particular bioactive conformation, or enhanced bio-stability 
brought about by the increased resistance of ~-peptides to enzymatic degradation.34,35 An 
example is the replacement of proline in GYKI 14766 (Figure 5.5), with cis-2-
aminocyclohexane carboxylic acid (ACHC), to give a series of potent and selective thrombin 
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inhibitors. Further extension of the N-terminal side-chain led to the development of the more 
active, and much more selective, inhibitor 5.9.36 
If ~ ___ N HN~ o-~ NH 
- K NV NH2 
HN 0 0 
\ 
Me OHC 
GYKI14766 
°rB-N~ Me-(D)-~-(2naphthyl)-Ala 0 ArgH 
5.9 
Figure 5.5. Replacement of a-amino acids with ~-amino acids can lead to new and important 
derivatives, i.e. the potent and selective thrombin inhibitor 5.9. 
In addition, cyclic ~-amino acids are used as starting materials for the preparation of a wide 
range of heterocycles, potential pharmaceuticals, and natural products, with enantiomerically 
pure forms also serving as effective chiral auxiliaries or additives. Heterocycles of type 5.10 
(Figure 5.6), have been shown to exhibit excellent anti-inflammatory activity,37 while more 
complex alkaloids such as clivonine, clividine, and gelsimine, make use of cyclic ~-amino 
acids as key precursors. 38,39 
X 
c(,(' 
N R] 
t 
R2 
5.10 
X=0,H2 
Y=N, 0, S 
Clivonine 
Figure 5.6. Examples of heterocyclic compounds synthesised from cyclic ~-amino acids 
Early syntheses of ~-lactam antibiotics utilised cyclic ~-amino acids to generate a ~-lactam 
core with the desired stereochemistry. An example is thienanlycin 5.11 (Figure 5.7), an early 
carbapenam, whose wide spectrum of antibacterial activity triggered intense synthetic interest 
in this area.40,41 
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thienamycin 5.11 
R 1=CH(OH)CH3, R2=H2 
R3=S(CH2)2NH2, R4=C02H 
Figure 5.7. Cyclic f)-amino acids are important precursors to f)-lactam antibiotics such as 
thienamycin 5.11. 
Synthetic examples of cyclic f)-amino acids include the a-substituted ACHC derivative 
Tilidine (Figure 5.8).42 This compound was synthesised via a 1,4 Diels-Alder cycloaddition 
reaction to give a mixture of isomers, the minor of which is currently in clinical use for the 
treatment of moderate to severe pain. 
(XNHMe 
"'r>-< 
Tilidine 5.12 
Figure 5.8. Tilidine is an example of an a-substituted ACHC, while 5.12 has been used in the 
area of asymmetric catalysis. 
This Diels-Alder strategy has also been recently utilized by Wipf et al for the preparation of 
ring-functionalised ACHe's for use as new ligand scaffolds to aid in asymmetric 
transformations. Compound 5.12, is an ACHC derivative used in catalytic asymmetric 
alkylzinc additions to aldehydes.43,44 
5.1.2 p-Peptides 
Recently, an exciting, and pioneering, new chapter has been opened in the area of f)-amino 
acid research. Early investigations of polymeric f)-peptides indicated that they were able to 
adopt stable helical structures,45-47 with later studies revealing that sheet structures and turns 
can also be adopted. Seebach et aI, along with researchers from Novartis Pharma A. G., 
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showed that a range of acyclic ~-oligopeptides adopt a distinct helical structure in solution. 
Subsequent research has revealed that variously substituted ~-peptides, where the nature and 
position of the side-chains were varied, also adopt the same type of helix and that the nature of 
the substituent influences the precise nature of the folding. It was further found that as few as 
4-6 residues are required to induce this form of secondary structure, a stark contrast to a-
peptides, where upwards of 15 to 20 amino acid residues are necessary before distinct 
secondary structure can be exhibited. Figure 5.9 illustrates the various types of helical 
conformations that can be adopted by polyamide sequences composed of C2 - and/or C3_ 
substituted ~-amino acids. 
u-Peplide 
'I·Helix 
poly·Ala 
f.t·Holix 
poIY-II:}.hAla 
Il-Peptldas 
12·H1311x 101 1 2.-Helll< 
poly-~u·hAla poIY·(lla-hAla·r~~-hAl") 
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14 
't(~~\ Y 
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Figure 5.9. Structures of the a-helix, ~-peptide-based 14-helix, 12-helix, and 10/12-helix.48 
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In addition, helices formed by B-peptides were not only stable at room temperature, but 
remarkably resistant to unfolding at higher temperature.49 While eventually being made to 
unfold, B-peptides of this type were quickly observed to recover their helical form 
spontaneously and rapidly. This type of behaviour is seen as desirable in an oligomer that is 
of interest primarily for its predictable and reproducible folding patterns and has led to the 
development of helical B-peptides as potential pharmaceuticals. Compounds of this type are 
also of interest in such areas as protein recognition research, pharmaceuticals, and the 
development of DNA-binding proteins where recurring helical structures interact directly with 
the major groove of DNA. In all these areas the nature of the secondary structural interactions 
playa key role in the biological process. 
The conformation of B-peptides can be analysed in terms of the main chain torsional angles, 
which are assigned the angles ((), cj>, e, \jf (Figure 5.10). Folded helical or tum-like 
conformations of B-peptides require a gauche conformation about the e torsion angle defined 
by the C2 _C3 bond. A trans rotamer leads to a fully extended conformation provided the 
values of cj> and \jf are appropriate. The effects of substituents on the conformation of B-amino 
acids have been the subject of extensive experimental studies, and are summarised in Figure 
5.12.50-53 
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/ CO HCi> e 1jf H o e 0 "i(f~N,/ ~N~NHRI Unsubstituted residue: 
0 0 H conformationally flexible 
0 R3 0 ~3 -Residue: H 2lleH JI 2.\'i ~N~-lNHRI VN~\ H favours gauche conformation 
JReH HJSi 0 0 0 ~NYNHR' ~2-Residue: 
r!, favours gauche conformation 
V"H~H~ H R2 c' trans (anti) R3 JlleH H 3Si 0 0 
o jS ~NVNHR' ~2,3 -Residue anti configuration strongly favours gauche conformation 
Or!- H R2 
NH 2Re 'l,~H gauche 0 R3 0 
3ReH H3Si ~N~NHRI [32,3 -Residue syn configuration H 2Si 
H =2 strongly favours trans conformation 
r!, ."" R ~~i ~ H 0 gauche [32,3 -Residue cyclic, trans configuration c' ~CONHR' 3ReH H 3Si 
H2Re RCOHN requires gauche configuration 
Figure 5.10. Effects of substituents on the torsion angle e. 
The unsubstituted f)-amino acid, f)-alanine, is highly flexible, analogous to Gly in the aramino 
acids, with alkyl substituents at positions 2 and 3 favouring a gauche conformation about the 
C2 _C3 bond. C2 , C3 - Disu bsti tuted amino acids are even more conformationally constrained 
and favour gauche conformers when the substituents are anti. Gauche-type torsion angles are 
even more strongly promoted when these atoms are included in a cycloalkane ring, such as in 
trans-2-aminocyclohexanecarboxylic acid (ACHC). Gellman et aZ demonstrated that a 
hexamer composed of a repeating unit of trans-2-aminocyclohexanecarboxylic acid (trans-
ACHC), led to extremely stable helical structures where the cyclohexyl rings adopted a step-
like arrangement along the backbone (Figure 5.11).54,55 
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(a) 
(Il) 
Figure 5.11. ~-Peptide hexamer with trans-2-aminocyclohexanecarboxylic acid (ACHC) 
repeating units adopts a helical structure (ribbon) in the solid state.54 
Gellman predicted, and sho\ved expermentally, that these helices were 14-helices, i.e. 
stabilised by 14-membered bydrogen-botlded rings, and differed from that of the ex-helix in 
many respects. The 14-helix adopted b the hexamer assumes a more compressed helical 
structure, having a slightly wider radius, 2 .7 A, and a pitch of 5.0 A, compared with for that of 
the G,-helix (2.2A and 5.4 A respectively:' It was also fOllnd that the amide carbonyl and NH 
groups project towards the N- and C-terninii, respectively , in the 14-helix, resulting in a net 
dipole opposite to that of the ex-helix (F gure 5.12a). Further, while the a-helix has a 3.6-
residue repeat , the 14-helix repeats apprc ximately every 3 residues, which positions the side 
chains of every third residue directly abc ve one another along one face of the helix. (Figure 
5.11 b, see also Figure 5.9). 
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It was noted that the trans-ACHC based hexamers developed by Gellman had the same 
backbone conformation and hydrogen-bonding pattern as the 14-helix compounds synthesised 
by Seebach (Figure 5.9). Further studies showed these cyclic ~-amino acid based oligomers 
have a much higher intrinsic propensity for helical folding than did the acyclic oligomers. 
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Figure 5.12.55 
One of the most striking properties exhibited by these ACHC hexamers was their packing 
pattern adopted in the solid state. It was observed that there are two types of three-way 
interfaces found in this packing pattern, one 'tight' and the other 'loose'. The tight three-way 
interface, involving extensive cyclohexyl-cyclohexyl contacts, is displayed by the three 
molecules in the upper left corner of Figure 5J2b. The loose three-way interface, with benzyl 
groups and solvent at the centre, is displayed by the three molecules in the lower left corner of 
Figure 5.12b. This packing pattern suggests a strategy for creating ~-peptides that adopt a 
well-defined tertiary structure due to the extensive cyclohexyl-cyclohexyl contacts between 
adjacent molecules. This has been proposed as a method for developing ~-peptides, based on 
this trimeric cyclohexane packing motif, that adopt a three-helix bundle in solution, where the 
cyclohexane-cyclohexane contacts are promoted by the hydrophobic effect. The further 
development of water-soluble ~-peptides would require incorporation of hydrophilic residues 
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to compliment the hydrophobic trans-ACHC residues. As the 14-helix has approximately 3 
residues per turn, ~-peptides that contain a trans-ACHC residue at every third position, with 
hydrophilic residues at adjacent positions, should adopt helical conformations with a 
hydrophobic 'stripe' running along one side. The nature of these hydrophilic residues, and 
their positioning, would potentially determine the properties, and stacking patterns, exhibited 
by these structures. Conceivably this could lead to the development of helical bundle motifs, 
based on ~-peptides, analogous to that displayed by many transmembrane bound proteins and 
a number of electron and proton transport proteins. Given that a small number of underivatised 
trans-ACHC residues constrain the ~-peptides to adopt a stable defined conformation, a need 
still exists to explore more highly functionalised versions of these oligomers in an attempt to 
develop medicinally useful compounds. While a host of cyclic a-amino acids are known, 
there still remains a clear need to develop a range of cyclic ~-amino acids if one is to control 
the structure, and hence function, of ~-peptides derived from them in a predictable fashion.56 
New and versatile methods for the preparation of cyclic ~-amino acids, particularly those 
bearing substituents, are needed to achieve this goal. The synthesis of such compounds 
represents the pioneering of a major new field of molecular design focussed on synthetic 
polymers, or foldamers, with protein-like folding properties and protein-like activities. 
To date, access to ACHC monomers, and their misaturated equivalents, for use in synthesis, 
has predominantly been through use of crystallisation or chemico-enzymatic methods. Nohira 
et al accessed optically active samples via preferential crystallisation of N-benzoyl salts.57 
Gellman utilised chemistry developed by Kobayashi et aI, for the enzymatic 
desymmetrization, via selective ester hydrolysis, of diester 5.18 (Scheme 5.1), and subsequent 
selective Curtius degradation, to give cis-aminocyclohexenecarboxylic acid 5.19.58 
Conversion to trans-ACHC 5.20 could easily be achieved via hydrogenation and 
epimerisation. Diamino derivatives such as 5.21 have also been prepared, with the relative, 
and absolute stereochemistry being verified by its conversion to 5.22, for which a crystal 
structure was obtained.59 
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O i. ", Me02C : 
C02Me 
5.18 
v. QNHBOC ZEIN'" . ~~ ..
VI., Vll. 
C02Me 
5.21 
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-
C02Me 
ii... ,,0 ~ "Q BocEIN' - - BocEIN' 
C02Me C02Me 
5,li iv. 
y 
5.20 
O,"OH ZEIN'" -
C02Me 
Scheme 5.1. Reagents and Conditions: i. a) PLE, 98%, 96% ee b) Curtius rearrangement; ii. a) 
H2, Pd-C, MeOH, b) Boc20, K2C03, 31% from 5.18; iii. NaOME, MeOH, reflux, 70%; iv. a) 
CF3C02H, 0° C, quant. b) KI, NaHC03/H20-CH2Clz, rt, 98% c) DBU, benzene, reflux, 94% d) 
Mel Ag20/DMF, rt, 95% e) NaOMe, 0° C, 99%; v. a) MsCl, Et3N, 0° C, b) BU4N+ N3- c) P(n-
BU)3.H20 d) Boc20, 88%; vi. H2, Pd-C then CbzCl, DIEA, 74%; vii. NaOMe, MeOH, reflux, 
60%. 
This methodology was originally developed by Kobayashi, for the preparation of 
aminocyclohexenecarboxylic acid derivatives for use in the enantioselective synthesis of 
fortamine, the aminocyclitol moiety of the antibiotic fortamicin A.60 
5.19 ___ NoH ___ 
ZEIN~ 
C02Me 
Scheme 5.2. Enantioselective synthesis of Fortamine. 
OH 
HOD,NH2 
MeEIN : OH 
OMe 
Berkessel et al used (R)-l-phenylethylamine to selectively crystallise and isolate the optically 
pure diacid 5.23. This was then utilised in a one pot-procedure, via the Hofmann degradation 
of the corresponding anhydride, to give trans-ACHC in good yields.61 Bernath et al had 
previously accomplished this with the equivalent cyclohexene compounds.62 
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" -~.~ 
'C02I-! 
5.23 
o 
~o 
o 
(XC02I-! 
"'NH HCI 2. 
Scheme 5.3. One-pot procedure for preparation of trans-ACHC from diacid 5.23. 
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Wipf et al have adopted a combination of Diels-Alder and chiral auxiliary chemistry to access 
ACHC's for use in asymmetric catalysis. 
i. ii. 
Scheme 5.4. Reagents and Conditions: i. Ti(O-iPr)2Cb (lOmol%), 4 A sieves, butadiene, 00 C, 
58 h, 97%, 85% ee; ii. a) LiOH, H202, H20/THF, 00 C, 85%, b) DPPA, Et3N, t-BuOH, 74%. 
As such, trans-aminocyclohexenecarboxylic acid represents an attractive target towards the 
development of derivatised cyclic ~-amino acids, for use in the synthesis of novel foldamers. 
To this end, we set out to develop a method whereby a range of cyclic ~-amino acids could be 
synthesised. It was proposed that we use a versatile ring-closing metathesis (RCM) approach 
to the synthesis of cyclic ~-amino acids, that allowed the preparation of compounds of type 
5.53, that were either unsubstituted, or substituted at the a-position. 
5.53 
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This second class of compound represents an important addition to the family of cyclic ~­
amino acids. The olefin of these units is able to be hydrogenated, to give the corresponding 
saturated analogue, or functionalised to give new and important derivatives. 
5.2 Synthesis of a-Free Cyclohexenyl-Based f)-Amino Acids 
We set out to develop a method whereby both the a-free and a-substituted derivatives could 
be accessed from a common precursor. The proposed synthesis involves the use of chemistry 
developed by Podlech and Seebach for the stereoselective alkylation of N-Cbz-protected ~­
amino acids.63 Here, alkylation of Cbz-protected 3-amino-4-phenylbutanoic acid methyl ester, 
with a range of electrophiles, via a dilithiated intermediate, led to the formation of the a-
substituted derivative as a single diastereoisomer (Scheme S.S). It was also found that 
subsequent alkylation of these a-substituted derivatives, in a similar manner, gave rise to the 
a,a-disubstituted derivative, also as a single diastereoisomer, with the stereochemistry shown. 
~ ~ ~ ~ 5 1.2LDA/LiCl ~ i 1.2LDA/LiCl ~ 5 ~ -.. ~ "El • ~ E2 
BnO ~ 2. electrophile 1 BnO ~ 2. electrophile 2 BnO ~ "'E\ 
o OMe 0 OMe 0 OMe 
Scheme 5.5. Stereos elective alkylation of ~-amino acids developed by Podlech and Seebach.63 
These findings led us to consider the use of 3-Cbz-aminohex-S-enoate as a cornmon precursor 
for the synthesis of cyclohexenyl-based ~-amino acids. The basic synthetic strategy involves 
the selective allylation of 3-Cbz-amino-hex-S-enoate 5.25, obtained from Cbz-protected allyl-
glycine 5.24, to give a diene that is then cyclized by RCM to give the corresponding 
unsubstituted aminocyclohexenecarboxylic acid 5.27. In addition, a-substituted cyclohexenyl 
~-amino acids can be prepared by an alkylation-allylation sequence, the order of which 
dictates the stereochemistry of the ring substituents. The synthesis of the a-free N-Cbz-
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aminocyclohexenecarboxylic acid methyl ester 5.27, along with some simple derivatives, is 
outlined in Scheme 5.6. 
CbzHN~02H 
(+1-)-5.24 
CbzHNY 
C02Me 
(+1-)-5.27 
i. 
iii. 
-..;(~ .. - .. -
!iV. ~ 
CbZHNY 
C02Me 
(+1-)-5.28 
(+1-)-5.25 
CI, ~CY3 
,Ru~ 
Cl I PI PCY3 1 
1.40 
:: vi. :: Ph Y~ 2~ CbzHN -~-l- CbzHN * * ( 
C02H 0 NA C02Me H 
(+/-)-5.29 5.30 
Scheme 5.6. Reagents and Conditions: i. a) Et3N, CIC02Et,THF, -15 0 C, 15min, then 
diazomethane, 0°; b) AgOBn, Et3N, MeOH, -25 0 C to rt; ii. LiCl, 2 equiv LDA, _78° C, THF 
then allyl bromide; iii. 1.40, benzene, reflux; iv. H2, Pd-C,MeOH then DlEA, CbzCl, DMAP, 
CH2Ch; v. NaOH, MeOH; vi. EDCl, HOBt, DIEA, L-PheOMe.HCl. 
The synthesis began with the preparation of the key 3-Cbz-aminohex-5-enoic acid methyl 
ester 5.25. Among the many methods for the synthesis of ~-amino acids, we chose to use 
Arndt-Eistert methodology for its flexibility, high yields and its use of readily available 
starting materials. Thus, (+I-)-N-Cbz-allylglycine 5.24 was reacted with triethylamine and 
ethylchlorofonnate, to form the corresponding mixed anhydride, which, upon treatment with 
diazomethane, gave the diazoketone intermediate 5.31 (Scheme 5.7). A characteristic singlet 
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at ()H 5.45ppm, corresponding to the CHN2 proton, signified the successful preparation of this 
intermediate which was isolated as a yellow solid in 98% yield. Exposure of the diazoketone 
5.31, to silver benzoate, at low temperature, in the presence of methanol, with the exclusion of 
light, resulted in a Wolff rearrangement to form the desired (+I-}3-Cbz-aminohex-5-enoate 
5.25, in 94% yield. 
CbZHN~OH 
o 
5.24 
J i 
)Q CbZHN~NtNJ 
o 
5.31 
ii. 
.. ~ ~ .. CH CbzHN ~. 
o 
L ~O ---> C CbzHN '?') ~ ... OMe 
Scheme 5.7. Reagents and Conditions: i Et3N, ClC02Et, THF, -15 0 C, 15min, then 
diazomethane, 00 C; ii) AgOBz, Et3N, MeOH, -250 C to rt, 94%. 
With this key p-amino acid in hand we set about introducing a substituent at the a-position, in 
the manner previously described by Podlech and Seebach.63 Thus, 5.25 was deprotonated with 
LDA, in THF at _78 0 C, in the presence of LiCl, and the corresponding enolate alkylated with 
allyl bromide (Scheme 5.8). It is well documented that these conditions proceed via a doubly 
lithiated intermediate to give the relative stereochemistry shown, with the addition of LiCl 
leading to higher yields and better diastereoselectivities.63-66 The mechanism for this reaction 
is shown in Scheme 5.8. 
Chapter Five 
2LDA 
--
(+/-)-5.25 
OLi 
A,,' 
BnO N 
. D 
E-=<0Me 
~~~ :. ·OLi 
Ny-0Li 
OBn 
allyl 
bromide 
lk-l,2 
Scheme 5.8. Stereos elective alkylation of 5.25 via a doubly lithiated intermediate 
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Here, the bulky benzyloxycarbamide group on the ~-carbon effectively blocks one face of the 
planar dilithiated enolate intermediate. The result is that the incoming electrophile approaches 
from the Re face of the enolate, with the alkylation occurring with relative topicity lk-l,2 (like-
1,2) as shown. Purification by silica chromatography gave (+1-)-5.26, as a single 
diastereoisomer by lH NMR, in 59% overall yield. 
Next, we demonstrated the basic methodology for the preparation of cyclic ~-amino acids of 
this type, by subjecting diene 5.26 to ring closing metathesis conditions (Scheme 5.9).67 
) ~ 
CbZHNY 
C02Me 
(+1-)-5.26 
i . 
.. __ .->- CbzHNY 
C02Me 
(+1-)-5.27 
ii. CbZHNY 
C02Me 
(+/-)-5.28 
Scheme 5.9. Reagents and Conditions: i. benzene, rt, 2h, 1.40 96%, 1.42 94%; ii. H2, Pd-C, 
MeOH then DlEA, CbzCl, DMAP, CH2Cb, 84%. 
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To this end, diene 5.26 was treated with Grubbs' ruthenium catalyst 1.40, in dry degassed 
benzene, and stirred at room temperature for 2h. Purification of the residue by silica 
chromatography gave the cyclic ~~amino acid 5.27, as a single diastereoisomer by IH NMR, in 
96% yield. Comparable results were also obtained using Grubbs' second generation catalyst 
1.42. The trans relative stereochemistry of5.27 was confirmed by its conversion to the known 
aminocyclohexane carboxylic acid 5.28. Thus, olefin 5.27 was hydrogenated in the presence 
of 10% palladium~on~carbon, followed by reprotection with benzylchloroformate, to give the 
literature compound 5.28 in 84% yield.59 Comparison of IH NMR data for 5.28, with that 
reported in the literature, confirmed the assigned relative stereochemistry of both the cyclic ~~ 
amino acids, as well as that of their dienic precursor 5.26. 
Hydrolysis of the ester of 5.27 in the presence ofNaOH, gave the corresponding free acid 5.29 
in quantitative yield, a derivative suitable for incorporation into peptides (Scheme 5.10). This 
was illustrated by the coupling of 5.29 with phenylalanine methyl ester, under standard 
conditions, to give the dipeptide diastereoisomers 5.30a and 5.30b, in a ratio of 1: 1 by IH 
NMR, in 91 % combined yield. However, the epimers could not be separated by silica~based 
chromatography. 
cburnXiPh 
o N C02Me 
H ii. i. 
.. .. 5.30a 
cburn9iPh 
o N C02Me H 
(+1-)-5.27 (+1-)-5.29 
5.30b 
Scheme 5.10. Reagents and Conditions: NaOH, MeOH, 100%; ii. EDCI, HOBt, DIEA, L~ 
PheOMe.HCI, CH2Ch, 91%. 
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5.3 Synthesis of a-Substituted Cyclohexeneyl-Based {3-Amino Acids 
With the basic methodology for the synthesis of a-free cyclohexenyl ~-amino acids in place, 
we turned our attention to the synthesis of a-substituted cyclohexenyl ~-amino acids. This 
strategy involved the preparation of suitable dienes, from the common precursor 5.25, via an 
alkylation - allylation sequence, the order of which dictated the stereochemistry of the ring. 
The synthesis of both trans-a-substituted and cis-a-substituted cyclohexenyl ~-amino acids is 
shown in Scheme 5.1 1. 
) 
-
- R CbZHN~ 
COzMe 
(+I-)-5.32a R=Me 
(+I-)-5.32b R=Et 
(+I-)-5.33a R=Me 
(+I-)-5.33b R=Et 
1 iii. 
CbzHN~R 
COzMe 
(+I-)-5.34a R=Me 
(+I-)-5.34b R=Et 
I. 
... 
) 
ii. 
(+1-)-5.25 
) ~ 
CbrlfNq 
C02Me 
(+1-)-5.26 
(+1-)-5.35 
1 iii. 
~ CbzHN~~e 
COzMe 
(+1-)-5.36 
Scheme 5.11. Reagents and Conditions: i. LiCl, 2 equiv ofLDA, THF, _78° C, Mel or EtI, 
5.32a 86%, 5.32b 63%, 5.35 68%; ii. LiCl, 2 equiv ofLDA, THF, _78° C, allyl bromide, 5.33a 
47%, 5.33b 42%, 5.26 59%; iii. 1.40, benzene, reflux, 5.34a 96%, 5.34b 94%, 5.36 91%. 
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The synthesis began with the preparation of the a-substituted trans examples 5.34a and 5.34b. 
Alkylation of 5.25 with either methyl or ethyl iodide, in the presence of LDA and LiCI at _78° 
C in THF, gave the a-methyl and a-ethyl substituted ethyl esters 5.32a and 5.32b, after 
purification by silica chromatography, in 86% and 64% yield respectively. IH NMR analysis 
indicated that a single diastereoisomer had being isolated in each case, as for the preparation 
of 5.26 (Scheme 5.8), with the stereochemistry at C2 and C3 as shown. 
Compounds 5.32a and 5.32b were then alkylated a second time, with allyl bromide, to give, 
after purification by silica chromatography, the a,a-disubstituted dienes 5.33a and 5.33b in 
47% and 42% respectively (Scheme 5.12). 
) ) ) ~ 
- 1. - ii. CbZHNq, CbzHN~C02Me CbZHN~R .. 
C02Me C02Me 
(+1-)-5.25 (+1-)-5.323 R""Me (+1-)-5.333 R""Me 
(+I-)-5.32b R=Et (+I-)-5.33b R""Et 
Scheme 5.12. Reagents and Conditions: i. LiCI, 2 equiv of LDA, THF, _78° C, Mel or Etl, 
5.32a 86%, 5.32b 63%; ii. LiCI, 2 equiv ofLDA, THF, -78° C, allyl bromide, 5.33a 47%, 
5.33b 42%. 
Note that this second alkylation leads to an inversion of stereochemistry at C2, and is the result 
of the electrophile approaching the planar enolate from the face opposite the 
benzyloxycarbonylamino group, in a manner similar to that for the preparation of 5.26 
(Scheme 5.8). On exposure of 5.33a and 5.33b to RCM conditions, this stereochemistry 
lends itself to a trans relationship being adopted by the benzyloxycarbonylamino and methyl 
ester substituents of the subsequent cyclic ~-amino acids. As for the preparation of 5.32a and 
5.32b, dienes 5.33a and 5.33b were isolated as single diastereoisomers by IH NMR. 
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Subsequent exposure of dienes 5.33a and 5.33b to Grubbs' ruthenium catalyst 1.40, in 
benzene at reflux gave, after purification by silica chromatography, the a-substituted cyclic p-
amino acids 5.34a and 5.34b, each as a single diastereoisomer by IH NMR as shown, in 96% 
and 94% yield respectively (Scheme 5.13).a 
(+1-)-5.33a R=Me 
(+I-)-5.33b R=Et 
.. 
(+1-)-5.343 R=Me 
(+I-)-5.34b R=Et 
Scheme 5.13. Reagents and Conditions: 1.40 or 1.42, benzene, reflux, 5.34a 96%, 5.34b 94% 
The indicated trans stereochemistry is based upon the results of the previous sequence 
(Schemes 5.6 and 5.9), and literature precedent, details of which were discussed earlier (see 
Scheme 5.8).63-66 
With the synthesis of the a-substituted trans isomers established, we turned our attention to the 
preparation of the cis isomer 5.36 (Scheme 5.11). This was achieved by reversing the order of 
the alkylation steps i.e. alkylation of 5.25 with allyl bromide, followed by alkylation with 
methyl iodide (Scheme 5.14). 
) ~ (( rI 1. CbzHNY ii. iii. (+1-)-5.25 .. .. CbZHN~~e .. CbzHN~~e 
C02Me C02Me C02Me 
(+1-)-5.26 (+1-)-5.35 (+1-)-5.36 
Scheme 5.14. Reagents and Conditions: i. LiCl, 2 equiv ofLDA, THF, _78° C, allyl bromide, 
59%; ii. LiCl, 2 equiv ofLDA, THF, _78° C, Mel, 68%; iii. 1.40, benzene, reflux, 91 %. 
a Comparable results were obtained using Grubbs' second generation catalyst 1.42. 
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This resulted in 5.35, an epimer of 5.33a, being isolated, as a single diastereoisomer by IH 
NMR after purification, in 59% yield. RCM of 5.35, in refluxing benzene, in the presence of 
1.40, gave the a~substituted cis cyclic ~ ~amino acid 5.36. Purification by silica 
chromatography resulted in 5.36 being isolated as a single diastereoisomer by IH NMR, in 
91 % overall yield. 
We have therefore demonstrated that it is possible to prepare either the cis or trans a-
substituted cyclic ~-amino acids using this methodology. It is interesting to note that while cis 
isomers of this type have not been used in the preparation of ~-peptides, they are of use as 
inhibitors of matrix metalloproteases.68 
Having established the synthesis of a-substituted cyclohexenyl ~-amino acids, via a double 
alkylation method, we further investigated the possibility of directly alkylating the a~free 
aminocyclohexenecarboxylic acid 5.27, to give the equivalent cis-a-substituted derivative 
5.36. To this end, deprotonation of (+1-)-5.27 was attempted, under standard conditions, in the 
presence of LDA/LiCl. Methyl iodide was then added and the reaction stirred for 1 h at _78° 
C, and then allowed to warm to room temperature overnight. Upon workup, IH NMR analysis 
of the residue showed that the a-methyl ACHC (+1-)-5.36 had not been formed. Instead, the 
presence of a sharp methyl singlet at CH 2.84ppm indicated that N-methylation had occurred, 
on the amide nitrogen of (+1-)-5.27, to give the N-methylated ACHC (+1-)-5.37 (Scheme 5.15). 
Purification of the residue, by silica chromatography, gave (+1-)-5.37 in 78% yield, 
(1 mNJI JI )< z -ZHN~~e .. 'N I 
C02Me C02Me Me C02Me 
(+1-)-5.36 (+1-)-5.27 (+1-)-5.37 
Scheme 5.15. Alkylation of 5.27 with Mel gave the N-methylated derivative 5.37. 
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It is conceivable that manipulation of the N-protecting group i.e. use of phthaloyl instead of 
carbamate, would eliminate the possibility of N-methylation and allow for alkylation to occur. 
However, further research was not carried out in this area to establish the viability of this 
method. 
5.4 Enantioselective Synthesis of Cyclohexenyl-Based ~-Amino Acids 
With the basic methodology for the preparation of cyclic ~-amino acids in place, we now 
demonstrated that it was possible to prepare a single enantiomer of the cyclic ~-amino acids, 
given that our strategy had been established using racemic 5.25. Although numerous methods 
have been reported for the synthesis of ~-amino acids, we chose to make use of Evans' chiral 
auxiliary (Figure 5.13)69,70 to prepare an enantiomerically pure sample of 5.25. This 
methodology relied upon two key observations: 1) that chiral sodium and lithium imide 
enolates undergo highly diastereoselective alkylation reactions and 2) hydrolysis, and full 
recovery, of the chiral auxiliary can be achieved under relatively mild conditions. 
o 
base hydrol. II R2 
.. HO~ 
chiral 
auxiliary 
Figure 5.13. Evans' chiral auxiliary methodology for stereoselective alkylations. 
The utility of this method lies in its general application towards a variety of acyl imides and 
the consistently high diastereoselectivities observed during the alkylation reaction. Recently 
this methodology has received increased attention with it being used extensively in the 
enantiomeric synthesis of a range of peptidomimetics and natural products. Exanlples of these 
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include butyrolactone containing compounds such as (-)-enterolactone/ 1 which have been 
shown to possess protective properties against certain types of cancer; apoptolidin a highly 
selective and very potent anticancer agent; the mycalamides (see Scheme 5.16),72-74 
compounds isolated from a New Zealand sponge of the genus Mycale that exhibit potent 
antitumor, antiviral and immunosuppressive action via inhibition of T-cell activation; the 
pectenotoxins (PTXS)/5 a highly selective class of cytotoxic compounds and the agents 
chiefly responsible for the onset of severe diarrhea and liver damage following the ingestion 
of bivalves (clams, muscles, scallops etc); as well as a range of carbocyclic nucleosides76 
including carbovir77 and abacavir (Ziagen),78,79 compounds that have been shown to be potent 
inhibitors of HIV replication. 
o 0 0 0 OH MeO QCOPh 
__ _. ". 2 e OAN~ OAN~ ._- :x;r~ :CO M 
'--\. '--\.. ~ 
I-Pr I~Pr ~OH 
: OH 
(+)-methy17-benzoylpederate 
.. X!1~e? 9H ~ ~t YY"'OMe o 0'-.,../0 
Mycalamide A 
Scheme 5.16. Enantioselective synthesis of Mycalamide A using Evans' chiral auxiliary 
methodology, Here an asymmetric aldol reaction leads. to the desired stereochemistry 
exhibited by the two adjacent lactone methyl groups. 
With this methodology seeing diverse application towards the enantioselective synthesis of a 
wide range of biologically important compounds, including 13-amino acids, we felt confident 
in using this method for the synthesis of 5.25 as a single enantiomer. With an 
enantiomerically pure sample of 5.25 in hand it was envisaged that its subjection to our (X-
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allylation, RCM strategy would give the corresponding enantiomerically pure cyclic ~-amino 
acids. The synthesis of (R)-5.25 is outlined in Scheme 5.17. 
oj H o~yBn . 0 l. 
CI 
5.38 
oj 
o~yBn 
0 
(+)-5.39 
) 
(+)-5.42a R=tBu 
(+)-5.25 R=Me 
11. 
iv . 
.. 
) 
O~C02R 
o~yBn 
o 
(+)-5.40a R=tBu 
5.40b R=Me 
! iii. 
) 
O~C02R 
OH 
(+)-5.4la R=tBu 
(-)-5.41b R=Me 
Scheme 5.17. Reagents and Conditions: i. nBuLi, THF, _78° C, 97%; ii. NaHMDS, 
BrCH2C02R, THF, -78° C, 5.40a 83%, 5.40b 82%; iii. LiOH-H20 2, THF-H20, 0° C, 5.41a 
95%, 5.41b 51 %; iv. DPPA, EhN, toluene reflux, BnOH 5.42a 79%, tBuOH 5.25 71 %. 
Thus, the chiral reagent (4S)-4-Benzyl-l ,3-oxazolidin-2-one was deprotonated in the presence 
of nBuLi, in THF at -780 C. Alkylation, with 4-pentenoyl chloride 5.38, gave, after 
purification by silica chromatography, the N-acyl oxazolidinone 5.39 in 97% yield (Scheme 
5.18). Measurement of the optical rotation for 5.39 gave an [a]D +63.4°, c=0.83 CHCh, a 
value that corresponded to that reported in the literature (+64.2, c=0.83, CHCh).76 
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(+ )-5.40a R=tBu 
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Scheme 5.18. Reagents and Conditions: i. nBuLi, -78 0 C, THF, 97%; ii. NaHMDS, 
BrCH2COzR, THF, _780 C, 5.40a 83%, 5.40b 82%. 
Acyl oxazolidinone (+)-5.39 was deprotonated, with NaHMDS, and the resulting anion 
alkylated with tert-butyl bromoacetate to give, after recrystallisation, the alkylated imide 
5.40a, as a single diastereoisomer by IH NMR, in 83% yield. Measurement of the optical 
rotation for 5.40a gave an [a]D +51.2 (c=1.0 CHzCb). 
The asymmetric outcome of this alkylation can be rationalised by considering the enolate 
intermediate for this reaction. Enolization of chiral imides under these conditions gives rise to 
a planar, metal chelated (Z)-enolate intermediate.so This is a result of rotation about the 
exocyclic amide bond, from the more stable trans geometry, to give an intermediate where 
both carbonyl oxygens are complexed by the metal. The bulky benzyl group on the chiral 
auxiliary has the effect of blocking the approach of the incoming electrophile from one face of 
the enolate intermediate.69 This leads to exceptionally high diastereoselectivities being 
obtained during alkylation. Figure 5.14 illustrates this concept where e represents the angle of 
approach of the incoming electrophile. 
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.. 
Figure 5.14. 
It has been observed that the imide alkylation diastereoselectivities exhibit a modest increase 
with the increasing size of the alkyl groups adjacent to the enolate carbon. A suggested 
explanation for this is that the approaching electrophile must alter its path, due to steric 
interactions with a large R group, thereby amplifying the influence of the benzyl group on the 
chiral auxiliary, and resulting in increased diastereoselectivities.69 This selectivity was 
observed during the synthesis of 5.40a with the added strength of this method being in the 
ease of separation of the isomers by recrystallisation. 
The relative configuration of 5.40a was established via x-ray crystallographic analysis, with 
5.40a crystallising in the space group P2 12121 with 4 superimposable molecules in the unit 
celL A perspective drawing of the solid-state structure of 5.40a, with atom labelling, is shown 
in Figure 5.15. 
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C17 
C23 
Figure 5.15. Perspective drawing of 5.40a with atom labelling 
The absolute stereochemistry at C4 of 5.40a, determined by the use of (4S)-4-benzyl-l ,3-
oxazo lidin-2-one as the starting chiral auxiliary, allowed the absolute stereochemistry at C 14 
to be assigned as R. Note that the amide-like 'backbone', represented by C4-N-C13-C14, is 
shown to adopt the more stable trans geometry about the N-C13 bond. This contrasts the cis-
configuration adopted by the metal-chelated enolate intermediate, prior to alkylation (Figure 
5.14). 
Alkylation of 5.39, with methyl bromo acetate was also carried out in a similar manner to that 
described for the preparation of (+)-5.40a (Scheme 5.18). The resulting imide 5.40b was 
isolated, after purification by silica chromatography, as a single diastereoisomer by IH NMR, 
in 82% yield. 
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Next, cleavage of the chiral auxiliary of (+)-5.40a was carried out using lithium 
hydroperoxide. Addition of lithium hydroxide and hydrogen peroxide to a solution of (+)-
5.40a, in THF, at 0° C, gave the differentially protected diacid 5.41a in 95% yield. The chiral 
auxiliary was also recovered from this reaction in 98% yield. 
) 
O~C02R __ i_._ ..... 
o~yBn 
o 
(+)-5.40a R=tBu 
5.40b R=Me iii. 
) 
O~C02R ___ ii_. __ 
OH 
(+)-5.41a R=tBu 
(-) -5.41b R=Me 
) 
(-)-5.43 
) 
~C02R CbzHN 
(+)-5.42 R=tBu 
(+)-5.25 R=Me 
Scheme 5.19. Reagents and Conditions: i. LiOH-H20 2, THF-H20, 0° C, 5.41a 95%, 5.42h 
51 %; ii. DPPA, Et3N, toluene reflux, BnOH, 5.42 79%, 5.25 71 %; iii. DPPA, Et3N, toluene 
reflux, tBuOH, 5.43 68%. 
A Curtius rearrangement procedure was then utilised for the conversion of 5.41a to the 
optically active Cbz-protected 13-allyl glycine tert-butyl ester 5.42.81 Thus, treatment of 5.41a 
with diphenylphosphoryl azide andtriethylamine,69 at room temperature for 30 minutes, 
followed by gentle heating to reflux, resulted in the formation of an intermediate isocyanate. 
Subsequent trapping of the isocyanate, with benzyl alcohol, gave after purification by radial 
chromatography, 5.42 in 79% yield. Measurement of the optical rotation for 5.42 gave an 
[a]D = + 1.8° (c=1.0, CH2Cb) signifying the compound to be optically active. The mechanism 
for this reaction is shown in Figure 5.16. 
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Figure 5.16. Mechanism of the Curtius realTangement, used in the conversion of (+)-5.41a to 
(+)-5.42. 
Here, pyrolysis of the acyl azide, followed by a realTangement, results in a stable, but seldom 
isolated, isocyanate intermediate. Hydrolysis of the isocyanate in the presence of water, or 
alcohol, yields the cOlTesponding amine or carbamate. 
Diphenylphosphoryl azide was used to generate the azide from (+)-5.41a. The azide 
realTanges to give an isocyanate which is trapped by benzyl alcohol to give carbamate (+)-
5.42. As an alternate method for the preparation of (+)-5.42 using a two-step procedure 
reported by Yakushijin et aI, was also carried out whereby the mixed anhydride of (+)-5.41a 
was generated, and treated with sodium azide in the presence of triethylamine. Hydrolysis of 
the isocyanate, with benzyl alcohol, yielded (+)-5.42 in comparable yield to the procedure 
utilizing DPPA. However, despite comparable yields being obtained on a small scale, in our 
hands this latter method was not amenable to application on a large scale. Therefore DPPA 
was used as the reagent of choice for the generation of the isocyanate in this reaction. 
Curtius rearrangement was also carried out on (+)-5.41a using tert-butyl alcohol as the 
trapping agent, to give the known Boc-protected derivative 5.43, as a single isomer by 'H 
NMR, in 68% yield (Scheme 5.19). Measurement of the optical rotation for 5.43 gave an [a]D 
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-9.8° (c=1.1 MeOH), a value that closely agreed with that reported in the literature (-10.09°, 
c=l.l MeOH)?O This was an important result as the agreement in optical rotation with this 
known compound established the enantioselective integrity of the synthesis. For the 
preparation of (-)-5.43, the moderate yield of the reaction can be attributed to the tendency of 
the more sterically hindered tertiary alcohol to give lower yields during hydrolysis of the 
isocyanate. 
Next, (+)-5.42 was converted to 5.25 such that the sequence outlined in Scheme 5.6 could be 
repeated using optically active material. This was achieved by hydrolysis of the tert-butyl 
ester of (+)-5.42, with trifluoroacetic in dichloromethane, to give the free acid 5.44, which was 
re-esterified with diazomethane, to form the Cbz-protected ~-allyl glycine methyl ester 5.25. 
Measurement of the optical rotation for 5.25 gave an [a]D = +4.2° (c=2.0 CHCb), a value in 
close agreement with that reported in the literature (+4.7°, c=2.0 CHCb).82 
) ) 
ii 
) 
-
: 
ZHN~C02tBU .. ~C02H • ZHN~C02Me ZHN 
(+)-5.42 5.44 (+)-5.25 
Scheme 5.20. Reagents and Conditions: i. TF A, CH2Clz,Me2S, 00 C to rt, 90%; ii. CH2N2, 
Et20, 0° C, 100%. 
Methyl ester (+)-5.25 was also prepared from (+)-5.39, by alkylation with methyl 
bromo acetate (Schemes 5.18 and 5.19), to give 5.40b, as a single diastereoisomer by 1 H NMR, 
in 82% yield. Hydrolysis of the chiral auxiliary from this compound gave (-)-5.41 b, in a 
moderate yield of 51 %, which was subjected to Curtius rearrangement conditions, quenching 
with benzyl alcohol, to give (+)-5.25 directly in 71% yield (Scheme 5.21). 
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-O~C02Me i. O~C02Me ii, 
.. 
o~yBn OR 
0 
5.40b (-)-5.41b (+)-5.42 
Scheme 5.21. Reagents and Conditions: i. LiOH-H20 2, THF-H20, 0° C, 51 %; ii. DPPA, Et3N, 
toluene reflux, BnOH, 71 %, 
Finally, synthesis of the optically active cyclic ~-amino acid was carried out as described for 
the racemic series (see Scheme 5.6), In particular, (+)-5.25 was allylated with allyl bromide, 
via a doubly lithiated intermediate, to give the diallylated derivative (+)-5.26, as a single 
diastereoisomer by IH NMR, in 49% yield (Scheme 5.22), Measurement of the optical 
rotation for (+)-5.26 gave an [a]D +8,2°, (c= 1.0 CH2Ch), 
) it ii, Y : ZHN~C02Me .. ZHN -ZHN 
C02Me C02Me 
(+)-5.25 (+)-5.26 (-)-5.27 
Scheme 5.22. Reagents and Conditions: 2LDA, LiCl, allyl bromide, THF, _78° C, 49%; ii. 
1.40 or 1.42, benzene reflux, 91 %, 
Diene (+)-5.26 was then SUbjected to ring-closing metathesis conditions to give, after 
purification by silica chromatography, (-)-5.27 in 91 % yield, as a single diastereoisomer by IH 
NMR. Measurement of the optical rotation for (-)-5.27 gave an [a]D =-31.2°, (c=l ,0, CHCb), 
a value in close agreement with that reported in the literature (-33.2°, c=1.0 CHCb).83 
To further confirm the validity of this methodology for the synthesis of ACHC's, (-)-5.27 was 
hydrogenated, and reprotected with benzylchloroformate, in the presence of DIEA and 
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DMAP, to give, after purification by silica chromatography, saturated (-)-5.28, in 75% yield 
(Scheme 5.23). 
ZHNiI .. ZHNiI 
C02Me C02Me 
(-)-5.27 (-)-5.28 
Scheme 5.23. Reagents and Conditions: H2, Pd-C, MeOH then DIEA, PhCH20COCl, DMAP, 
75%. 
Measurement of the optical rotation of (-)-5.28 gave an [a]D = -18.4° (c=O.9, CHCh), a value 
that is in agreement with that reported in the literature (-18°, c=O.9 CHCh).59 
5.5 Enantioselective Synthesis of Allyl Glycine 
An alternate strategy for the enantioselective synthesis of cyclic ~-amino acids of type 5.53 
(see introduction) involves a different optically active precursor to that used in Section 5.4. 
For preparations of cyclic ~-amino acids 5.27 (Scheme 5.6), 5.34 and 5.36 (Scheme 5.11), 
racemic allyl glycine was employed in the preparation of the key precursor 5.25. (see Scheme 
5.7). Optically active (+)-5.25 was subsequently prepared through the used of Evans' chiral 
auxiliary chemistry (Scheme 5.17). It was envisaged that the use of optically active allyl 
glycine as a precursor to 5.25 would also result in an efficient synthesis of enantiomerically 
pure compounds of this type. Hence, efforts were directed towards the enantioselective 
synthesis of allyl glycine. 
The importance of naturally occurring proteinogenic amino acids is well known, with the 
preparation of this class of compound, usually by microbiological means,84 well established in 
industry. However, the search for cheap and convenient methods for the synthesis of non-
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natural, or isotopically labelled amino acids still goes on. At present, there are several 
excellent general methods for the synthesis of non-natural amino acids,85 with the most 
important commercial examples being Seebach's and Oppolzer's derivatives 5.4586 and 5.4687 
respectively, and O'Donnell's stereospecific alkylation of glycine-derived benzimidines88, for 
which an efficient chiral phase-transfer catalyst 5.47 has recently been developed (Figure 
5.17).89 
5.45 X=O, NMe 
~ H SMe 
1:;?N,rAsMe 
02 ° 
5.46 
R 
5.47 R=~-Naph, 3,4,5-F3-Ph 
Figure 5.17. Agents for the enantioselective synthesis of both natural and non-natural amino 
acids 
Another method, developed by Belokon et ai, makes use of Ni(II) complexes of Schiff bases 
of (S)-2-[N-(N'-benzylprolyl)-amino]benzophenone (BPB) and glycine, to achieve high 
asymmetric induction for the synthesis of a-amino acids (Scheme 5.24). 
iL, iii. 
BPB 
Scheme 5.24. Reagents and Conditions: i. Ni(N03)2.6H20, glycine, MeOH, 50° C then 
MeONa; ii. NaOH, RX, CH3CN, rt; iii.. MeOH, 2N HCI, reflux, ion-exchange Dowex 50X8 
It. 
Originally developed as an artificial analogue of pyridoxal 5' -phosphate (PLP)-dependent 
enzymes,90 this system offers several advantages over other existing methods. These include 
the simplicity of operation, ambient temperatures of the reaction media, very high 
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concentrations of reagents, the use of cheap bases (NaOH, KOH, MeONa, NaH), and the 
convenient and facile recovery of the amino acids and the chiral auxiliary. The simple nature 
of this methodology and the use of cost-effective and recoverable reagents, makes this method 
particularly attractive in an environmental context.91 
Therefore, the preparation of (S)-allyl glycine hydrochloride 5.52 was carried out using the 
method reported by Belokon et al (Scheme 5.25).92 
~;)Ph N CO I I 
Bn HN "': 
Ih-
5.49 (BPB) 
t i. 
~C02H 
I 
Bn 
5.48 
ii. 
(+)-5.50 
5.49 (BPB) + 
(-)-5.52 
Scheme 5.25. Reagents and Conditions: i. SOCh, CH2Ch, -300 C then 2-aminobenzophenone, 
58%; ii. Ni(N03)z.6HzO, glycine, MeOH, 500 C then NaOMe, 90%; iii. NaOH, allyl bromide, 
CH3CN, rt, 94%; iv. MeOH, 2N HCI, reflux, ion-exchange Dowex 50X8 H+, 87%. 
Thus, thionyl chloride was added to benzyl-(S)-proline 5.48, in CH2Ch at -300 C, followed by 
2-aminobenzophenone, and the solution stirred at -300 C for 10h. Workup, followed by 
extraction and recrystallisation, gave BPB 5.49 in 58% yield. Subsequent availability of BPB 
from commercial sources negated this step in future preparations. Analysis of the IH NMR 
spectrum, and melting point, of 5.49 prepared by the method described in Scheme 5.25, gave 
data consistent with that observed for the commercial sample. 
Chapter Five 175 
Next, a suspension of BPB 5.49/ Ni(N03)2.6H20, and glycine was warmed to 50° C under 
argon. A solution of l.2N MeONa was quickly added, inducing a colour change from pale 
green to dark red/orange, and the mixture was stirred rigorously for 2h at 50° C. Addition of 
water, followed by extraction with CHCh, gave a red oil that, after purification by silica 
chromatography, gave 5.50, as a red solid in 90% overall yield. Measurement of the optical 
rotation of 5.50 gave an [a]D = + 1880° (c=0.125, MeOH),g a value that approximated that 
reported in the literature (+2006, c=1.0, MeOH).93 
With the key Ni(II)-BPB-glycine complex (+)-5.50.in hand, we proceeded with its alkylation 
using allyl bromide. To a stirred mixture of (+)-5.50, in dry CH3CN, was added finely 
powdered NaOH, followed by allyl bromide, and the reaction stirred at rt for 3h. Treatment of 
the solution with O.lM HCI, followed by extraction with CH2Ch gave, after purification by 
silica chromatography, 5.51 as a single isomer by IH NMR, in 94% yield. Subsequent 
hydrolysis of the complex was carried out by refluxing a solution of 5.51 in MeOHl2N HCI, 
followed by the addition of concentrated ammonia at room temperature. BPB 5.49, was 
recovered in 97% yield by extraction with CH2Ch. The aqueous layer was concentrated and 
chromatographed with a cation exchange resin (Dowex 50X8 H+) to give allyl glycine 5.52, as 
a hydrochloride salt, in 82% yield. Measurement of the optical rotation for 5.52 gave an [a]D 
-6.2° (c=2.1, 6N HCI), a value in close agreement with that reported in the literature (-6.4°, 
c=2.l, 6N HCI).94 
It is envisaged that the use of (-)-5.52 in the preparation of optically active 5.25 will make the 
stereoselective alkylation sequence described in Schemes 5.6 and 5.11 a more efficient method 
for the synthesis of enentiomerically pure aminocyclohexenylcarboxylic acids such as 5.27, 
5.34 and 5.36. 
f A commercial sample ofBPB was utilized for this reaction .. 
g Problems were encountered during the measurement of the optical rotation of 5.50 due to its 
large [a] value. Large dilutions were needed to obtained values suitable for comparison with 
those reported in the literature. 
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5.6 Conclusion and Future Work 
In summary, we have demonstrated a new and simple procedure for the synthesis of 
cyclohexenyl ~-amino acids based on RCM chemistry. This methodology was used to prepare 
the unsubstituted trans cyclic ~-amino acids 5.27 and 5.28 from the simple diene precursor 
5.26. 
) 
... 
(+1-) 
CbZHNY 
C02Me 
(+1-) 
CbZHNY 
C02Me 
(+1-) 
We have also demonstrated that an a-substituent, as in 5.34 and 5.36, can be introduced 
stereoselectively, by employing an allylationlalkylation sequence, the order of which defines 
the absolute stereochemistry of the product. This second class of cyclic ~-amino acids 
represents a new and important addition to the family of compounds. 
) CIcllNY. C02Me 
(+/-) 
~ CbZHN~ 
C02Me (+/-) 
Finally, we have shown that optically active (-)-5.27 and (-)-5.28 can be prepared using 
optically active (+)-5.25. This was obtained through the use of Evans' chiral auxiliary 
chemistry to carry out a stereoselective alkylation of a chiral imide 5.39, with tert-butyl 
bromoacetate, to give the key alkylated imide (+)-5.40a, as a single diastereoisomer by IH 
NMR. The solid-state structure of (+)-5.40a, and its associated space group (P212121), were 
subsequently determined by x-ray crystallography, allowing the absolute stereochemistry of 
(+)-5.40a to be assigned as (S,R). Hydrolysis of the chiral auxiliary from (+)-5.40 gave the 
differentially protected diacid 5.41a that was converted, via a Curtius rearrangement, to the 
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Cbz-protected f)-amino acid tert-butyl ester 5.42. Hydrolysis of 5.42, followed by re-
esterification with diazomethane gave optically active (+)-5.25 is good yield. Diacid 5.41a 
was also converted to the lmown Boc-protected f)-amino acid (-)-5.43, the optical rotation of 
which closely agreed with the literature value. 
) 
~C02Me CbzHN 
(+)-5.25 
Compound (+)-5.25 was also prepared by alkylation of the chiral imide 5.39, with methyl 
bromo acetate , to give the alkylated imide 5.41b. Hydrolysis of the chiral auxiliary from 5.41b 
followed by a Curtius rearrangement, in the presence of benzyl alcohol, gave (+)-5.25 directly 
in moderate yield. Use of (+)-5.25 in the preparation of optically active (-)-5.27 and (-)-5.28 
provided compounds with optical rotations that corresponded to those reported in the 
literature. 
) 
(+)-5.25 
Cb~~ 
C02Me 
(-)-5.28 
An alternate source of optically active 5.25 was also explored with the preparation of optically 
active allyl glycine.HCI (-)-5.52 via the stereospecific alkylation of the Ni(II)-BPB-glycine 
complex 5.50, with allyl bromide. Measurement of the optical rotation of5.52 gave a value in 
close agreement with that reported in the literature. 
r 
ClH3N C02H 
(-)-5.52 
Future work in this area lies in the incorporation of cyclohexyl-based f)-amino acid derivatives 
into novel f)-peptides to explore new and interesting forms of secondary structure. 
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SYNTHESIS OF a-SUBSTITUTED 
CYCLOPENTENYL-BASED 
~-AMINO ACIDS BY 
RING-CLOSING METATHESIS 
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6.1 Introduction 
2-Aminocyclopentanecarboxylic acids (ACPCs), and derivatives thereof, have shown a variety 
of interesting biological activities. A decade ago, (lR,2S)-ACPC, an antifungal antibiotic also 
known as cispentacin (Figure 6.1), was isolated independently by two Japanese groups from 
Basicillus cereus,l,2 and Streptomyces setonii.3,4 
H2N~ C(-yM NH 0 2 HO 
C02H N~ (~l 
N N NH2 
C02H HO 
cispentacin Amipurimycin 
Figure 6.1. 2-Aminocyclopentane carboxylic acids, and their derivatives show a variety of 
biological activities. 
cis-2-ACPC was also found to be a component of amipurimycin, an antibiotic isolated from 
Streptomyces novoguineensis that is strongly active, both in vitro and in vivo, against 
Pyricularia oryzae, the organism responsible for rice blast disease. The L-aspartyl dipeptides 
of all four stereoisomers of 2~ACPC have been used to probe a molecular model of taste 
(Figure 6.2).5 Here, Asp-trans-(1R,2R)~2-ACPC methyl ester and Asp-cis-(lS,2S)-2-APAC 
methyl ester were found to assume an L-shaped conformation required for sweetness, with 
Asp-trans-(lS,2S)-2-ACPC methyl ester tasting bitter, and Asp-cis-(lR,2S)-APAC methyl 
ester proving tasteless, as it fitted neither of the models for bitter or sweet. 
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a) b) c) d) e) 
Figure 6.2. a) Model of the sweet taste with L-Asp-L-PheOMe superimposed, b) Asp-trans-
(lR,2R)-2-ACPC.OMe, c) Aps-cis-(1S,2R)-2-ACPC.OMe, d) Asp-trans-(lS,2S)-2-
ACPC.OMe, e) Aps-cis-(1R,2S)-2-ACPC.OMe. 
Recently, increasing work has been devoted to the study of homogenous, sequence-specific 
oligomers that mimic various aspects of the folding and organization of polypeptides. Groups 
led by Seebach and Gellman have independently shown that polyamide sequences composed 
of C2 - and/or C3 -substituted ~-amino acids, adopt stable helical structures, both in solution and 
the solid-state (Figure 6.3). 
(l.·Peptide 
(t~Hc{jx 
poly·Ala 
14·Halix 
poIY'il~ ,hAla 
1\·Peptides 
12·Heli>; 10112·HoJi. 
poly.p3·hAla PoIY·(1l3·hAl;HI<.hAla) 
Figure 6.3. Structure of the a-helix compared with the helical structures adopted by ~­
peptides, namely, the 14-helix, 12-helix, and 1O/12-helix.6 
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Gellman further demonstrated that '~) -per-tides containing the conformationally strained cyclic 
amino acid s trans-2-aminocyclohexanecarboxylic acid (ACHC), or lrans-2-
aminopentanccarboxylic acid (ACPC) , adopted stable helical conformations much more 
readily than their acyclic counterparts . Systematic studies of ACt-IC-containing oligomers 
versus ACPC-containing oligomers, has revealed inherent preferences for different 
conformations. The cyclohexyl ring of I\CHC stabilises the 0 torsion angle to a value ncar 
±60°. which spccificarJy stabilises the 14-helical conformation (Figure 6.4. sec also Chaptcr 
5). The smaller ring size of ACPC tend; e towards larger values, thereby favouring a novel 
hcfical form, the 12-helix. 
Figure 6.4. Helical conformations adopted by ~-peptides composed of trans-ACHC (left), 
and trans-ACrC (right), compared with that of the a-helix (centre). 
The structure of the 12-helix is stabilised by a series of hydrogen bonds bet ween the amide 
carbonyl groups at position i, and the amide proton at position i+ 3, with the helix repeating 
approximately every 2.5 residues. The 12-helix also shows the same polarity as the a-helix, 
with the amide protons exposed from the tV-terminal end of the helix . This is in contrast to the 
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14-helix adopted by ACHC-containing ~-peptides, which show an opposite polarity to that of 
the a-helix. This ability to switch between two completely different ~-peptide helices, by 
means of a relatively small modification in residue structure, calls attention to a significant 
difference between a-amino acid and ~-amino acids as building blocks. Greater control can 
therefore be maintained over the intrinsic secondary structure propensity of ~-amino acid 
residues than is possible with a-amino acids residues. This has been illustrated in the 
preparation of a number of water-soluble derivatives. Oligomers of ACPC, while forming 
extremely stable helical structures in organic solvents, are not soluble in water. To address 
this limitation, derivatives incorporating such residues as trans-aminopyrrolidine-4-carboxylic 
acid (APC) (6.1 and 6.2), and 3-substituted ACPCs (6.2 and 6.3), have been prepared and 
found to adopt stable helical conformations in water. 7 
-011p;1yll-JNH2 gl H2 0 ~ ~ 
® 3 
6.1 
. -0l!p;1yll-JNH2 
gl H2 ° r ~ ® /0 3 
6.2 
i}411~~H2 
H3N 
e 6.3 
Figure 6.5. ~-Peptides incorporating derivatised ACPCs are water-soluble. 
Compounds of this type are of interest for their potential to mimic the a-helical confOlmations 
adopted by docking substrates in a number of receptor-mediated processes. Seebach et al 
have recently reported examples of helical ~-peptides that exhibit a variety of biological 
properties ranging from the inhibition of fat and cholesterol absorption, to potent antimicrobial 
activity. DeGrado et al subsequently reported derivatives that possessed highly potent cell-
lytic activity, 8 with compounds of this type designed to kill bacteria by disrupting the cellular 
membranes of their targets (Figure 6.6). The activity of these compounds has been directly 
related to their ability to adopt a helical conformation in solution. 
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Figure 6.6. Helical ~-peptides have been shown to exhibit potent antimicrobial activity.6 
On this basis, the synthesis of aminocyclopentanecarboxylic acids has become the subject of 
several recent investigations that has included traditional resolution, enzymatic resolution, and 
asymmetric synthesis. It has been known for some time that the selective reduction of 
anthranilic acid over Adams catalyst in acetic acid, or over a Rh-AI catalyst, gives racemic cis-
ACPC as the main prodUCt.9-12 However, resolution of racemic cis-ACPC was only reported 
after the isolation of natural cispentacin, with crystallisation of 6.4, in the presence of 
ephedrine, allowing separation of the diastereoisomers for use in synthesis (Scheme 6.1).5 
H2N-Y 
C02H 
__ i._ ..... B"'HN-Y 
C02H 
cis-(+I-)-ACPC cis-( +/-)-6.4 
ii., iv. 
-{ 
iii., iv. 
BOCHNJ:( 
C02H 
(-)-6.4 25% 
-
C02H 
(+)-6.4 26%) 
Scheme 6.1. Reagents and Conditions: LBoC20, HaHC03, THF/H20 (3:1), rt; ii. (+)-
ephedrine, EtOAc, crystallisation; iii. (-)-ephedrine, EtOAc, crystallisation; iv. NaHS04 
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Notesberg et al devised a simple four step synthesis of both enantiomers of trans-2-ACPC,13 
with the key starting components, either enantiomer of 6.5, readily available in high 
enantiomeric purity by enzymatic resolution. 14 Hydrolysis and Curtius rearrangement, 
followed by removal of the thioacetal, gave trans-2-ACPC enantiomers in good yield. 
s~ ;:)8 iv D 
BocHN: 880/: BocHN : 
C02Me C02Me 
(+)-6.6 
Scheme 6.2. Reagents and Conditions: i. HSCH2CH2SH, SnCI4, CH2Ch, rt; ii. NaOH, 
H20/dioxane (1: 1), rt; iii. DPP A, Et3N, tert-butanol, 80° C; iv. Raney-Ni, MeOH, reflux. 
Homologues of (lS,2S)-trans-ACACs have been prepared in a relatively short pathway by 
Enders et al. Addition of the chiral ammonia equivalent lithiated (S)-(-)-2-methoxymethyl-l-
trimethylsilylaminopyrrolidine (TMS-SAMP) to ro-halo-substituted enoate 6.7, followed by 
reduction, gave an N-silyl intermediate with 96-98% diastereoselectivity (Scheme 6.3).15-17 
Desilylation, reductive N-N bond cleavage, followed by hydrolysis and ion-exchange 
chromatography gave 6.8 in high ee. 
nn \< 
C~R 
6.7 n=1,2,3 
i. 
de~95% de~96% 6.8 ee~ 95% 
Scheme 6.3. Reagents and Conditions: i. a) TMS-SAMP, n-BuLi, THF, -780 C, b) HMPA, -
780 C, (n=2,3), c) NaHC03, H20; ii. Si02, EtOAc, (HCI); iii. a) Raney-Ni/H2, MeOH, b) 6N 
HCI, c) Dowex 50WX8-200. 
Gellman used a-methylbenzylamine in the reductive amination of 6.9, to obtain either isomer 
of 6.10, for use in the preparation of helical foldamers (Scheme 6.4.).18 
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i. iL n 
.. FmocHN~ 
29% 85% 
6.10 
Scheme 6.4. Reagents and Conditions: i. a) (S)-(- )-a-methylbenzylamine, AcOH, b) 
NaBH3CN, c) HCI, d) recrystallisation; ii. a) LiOH, H20, b) H2, 10% Pd/C, c) Fmoc-Osu. 
Altematively, enzymatic methods, using Balcer's yeast, were employed to obtain (lR,2R)-6.11 
for similar use (Scheme 6.5), although this method suffered from the need for large volumes 
of water, and tedious filtrations and extraction.19 
oJ:{ i. HO~ ii. Ni"'Y iii., iv. FmOdlN'''Y .. .. ------60% 45% 85% 
C02Et C02Et C02Et C02H 
6.9 6.11 
Scheme 6.5. Reagents and Conditions: i. Baker's Yeast; ii. HN3, PPh3, DEAD; iii. H2, 10% 
Pd/C then Boc20; iv. a) LiOH, b) 4N HCl, c) Fmoc-Osu, NaHC03• 
Gellman also extended these methods to the preparation of 3-substituted 2-ACPC's 6.12 and 
6.13, for incorporation into short, water-soluble, helical ~-peptides (Scheme 6.6).7 
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NC 
~OBn i. °'C(OBn ii. O"C( iii. CbzHN .. t( " , .. 85% 71% 73% OBn OBn 
NHBoc NHBoc 
v [84% iV.[82% 
FmOOHN')Y 
. NCt( RO 
vii. ~ VI. BOOHN"Y .. .. 27% CbzHN'" 75% CbzHN'" 
C02H OBn OBn C02H 
6.12 6.13 
Scheme 6.6. Reagents and Conditions: i. a) TiCl4/TBHP, CH2Ch, b) KOtBu, benzene, rt; ii. 
NaNiNH4CI, MeOH/H20, reflux, b) MsCI, pyridine, 0° C, c) LAH, THF, 0° C to rt; iii. a) 
Boc20INEt3, MeOH, rt, b) BF3.0EtvROH, CH2Ch, ~78° C; iv. a) 10% Pd/CINH4HC02, 
MeOH, reflux, b) Jones reagent, acetone, 0° C; v. a) CBz~ClINEt3, CH2Ch, 0° C, b) KCN/18-
crown-6, DMSO, 80° C; vi. a) BH3.THF, THF, rt, b) Boc20INEt3, MeOH, rt; vii. a) NalNH3, -
78° C, b) Fmoc-Osu/NaHC03, acetone/H20, rt, c) TEMPOINACLO, CH2CbIH20, 0° C. 
Given the prominent role of ACPCs in synthesis, a need exists for the simple asymmetric 
synthesis of a range of functionaHsed ACPCs available from a common low cost precursor. 
As part of a wider study towards the synthesis of a general class of cyclic ~-amino acids via 
ring-closing metathesis (RCM), we describe here the preparation of a range of cyclopentenyl-
based ~-arnino acids of type 6.14, that are either unsubstituted, or substituted at the a-position. 
As for the a-substituted cyclohexenyl-based analogues described in Chapter 5, this second 
class of compound represents an important addition to the family of cyclic ~-amino acids. The 
constituent olefin of these units is able to be hydrogenated, to give the corresponding saturated 
analogue, or functionalised to give new and important derivatives. 
Chapter Six 192 
6.2 Synthesis of a-Free Cyclopentenyl-Based Cyclic (3-Amino Acids 
The synthesis of compounds of type 6.14, utilised chemistry developed by Podlech and 
Seebach for the stereoselective alkylation of N-Cbz-protected ~-amino acids (Scheme 6.7).20 
Ph Jl f- -- 1. 2LDAI Li;L 
BnO if ~;l 2. electrophile I 
o OMe 
Ph 
1. 2LDAI LiCL )~ 5 
---..... ~ '- E2 
2. electrophile 2 BnO ~ "'El 
o OMe 
Scheme 6.7. Stereoselective alkylation of~-amino acids developed by Podlech and Seebach 
It was anticipated that ~-methionine derivatives would undergo oxidative elimination to give 
dienes suitable for ring-closing metathesis. The proposed synthesis of the a.-free 
aminocyclopentenylcarboxylic aCid 6.19, along with its saturated analogue 6.20, is described 
in Scheme 6.8. 
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SMe SMe SMe 
ZHN~02H i., ii. ZHN{C02Me iii. • C02Me ZHN 
6.15 6.16 
j iv. 
BOclINJ:{ vi. ZHNf{ v. .. ZHN C02Me 
COzMe COzMe 
6.20 6.19 
Scheme 6.8. Reagents and Conditions: i. CICOzEt, Et3N, THF, -lYC to 00 C, then CHzNz; ii. 
AgOBz, Et3N, MeOH, -250 C to.rt, 93% 2 steps; iii. 2LDA, LiCI, allyl bromide, THF, -780 C 
to rt, 16h, 53%; iv. a) HzOz-LiOH, AcOH, rt, 4h, quant., b) 2000 C, xylene, sealed tube, 76%; 
v. catalyst 1.42, benzene, rt, 92%; vi. a) Hz, Pd-C, MeOH, b) BoczO, NaHC03, THF/HzO 
(3:1), 75%. 
The synthesis began with the preparation of the leey precursor N-Cbz-~-methionine methyl 
ester 6.16. As with the ~-amino acid derivatives described in Chapter 5, Arndt-Eistert 
methodology was adopted for the preparation of 6.16 from (S)-N-Cbz-methionine. Thus, (S)-
N-Cbz-methionine 6.15 was treated with ethylchloroformate, in the presence of triethylamine, 
to give the corresponding mixed anhydride, which upon exposure to an ethereal solution of 
diazomethane gave the diazoketone intermediate 6.21 (Scheme 6.9). 
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SMe 
ZHN~02H 
6.15 
! i. 
SMe 
~I ::s + ZHN (,..N"N'-
o 
6.21 
ii. 
.. 
SMe 
~ .. CH ZHN F-
o 
Scheme 6.9. Reagents and Conditions: i. a) Et3N, CIC02Et, THF, -150 C, 15min, then 
diazomethane, 00 C; ii) AgOBn, Et3N, MeOH, -25 0 C to rt, 93%. 
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A characteristic singlet at OJ-] 5.50ppm, corresponding to the CHN2 proton, signified the 
successful preparation of this intermediate which was isolated, after purification by silica 
chromatography, as a yellow oil in quantitative yield. Treatment of diazoketone 6.21 with 
silver benzoate, at low temperature, in the presence of methanol, with the exclusion of light, 
resulted in a Wolff rearrangement to form the desired N-Cbz-~-methionine methyl ester 6.16 
:in 93% after purification by silica chromatography. 
With the key precursor 6.16 in hand, we set about introducing a substituent at the a-position in 
an analogous manner to that described by Podlech and Seebach, and previously used in the 
preparation of equivalent ~-allyl glycine derivatives (Chapter 5, Scheme 5 6 and 5.11). Here 
we were faced with two strategies for the preparation of the key diene 6.18 from 6.16. These 
were 1) oxidative elimination of the thiomethyl group of 6.16 first, followed by allylation with 
allyl bromide to give 6.18 (Strategy A, Figure 6.7), or 2) alkylation of 6.16 with allyl bromide 
first, followed by oxidative elimination to form 6.18 (Strategy B, Figure 6.7). 
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Strategy A 
Oxidative ~C02Me 
Elimination ZHN Allylation 
SMe / ~ 
·ZHN{C02Me 
~ 
ZHN 
C02Me 
SMe 
6.16 ~ / C02Me 
ZHN Oxidative 
Allylation Elimination 
Strategy B 
Figure 6.7. Two possible strategies for the preparation of diene 6.18 from 6.16. 
Strategy A was carried out first, with an elimination-ally lation sequence being employed for 
the preparation of 6.18. Thus, hydrogen peroxide was added to a solution of 6.16, in acetic 
acid, to form the corresponding sulphone (Scheme 6.10), which was subsequently dissolved in 
degassed xylene,a and sealed in a glass tube under vacuum. The tube was then heated at 2000 
C for 16 h to give a dark brown solution, which upon purification by chromatography, gave 
the a-substituted vinyl derivative 6.22, as a yellow oil in 62% yield over two steps. 
i. ii. 
.. 
ZHN 
6.16 6.22 
Scheme 6.10. Reagents and Conditions: i. a) AcOH, H20 2, rt, 3h, 99%, b) 2000 C, xylene, 
sealed tube, 62%; ii .. LDA, LiCI, THF, _78 0 C, allyl bromide, 27%. 
a A large volume of solvent and gentle heating was required for the sulphoxide to completely 
dissolve. 
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Next, 6.22 was deprotonated with LDA, in THF, at _780 C, in the presence of LiCI, and the 
corresponding enolate alkylated with allyl bromide. It is well documented that these 
conditions proceed via a doubly lithiated intermediate, with the electrophile adding to the Re 
face of the enolate to give the stereochemistry shown (Scheme 6.11, see also Chapter 5, 
Scheme 5.8) 
2LDA OLiSc A H 
BnO N I ¢:::::J Re 
LiO OMe 
6.22 
-' 
Scheme 6.11. Stereoselective alkylation of 6.22 to give 6.18 
allyl 
bromide 
lk-l,2 
6.18 
Purification by silica chromatography gave 6.18, as a single diastereoisomer by IH NMR, in 
27% yield. The poor yield of this reaction may, in part, be due to destabilisation of the vinyl 
moiety during allylation rather than a lack of specificity, as the minor diasteroisomer of 6.18 
was not detected. Measurement of the optical rotation for 6.18 gave an [a]D = -370 (c=1.0 
CHCh). 
Next, strategy B was carried out (Figure 6.7), which involved an allylation-elimination 
sequence, in an attempt to increase the overall yield of 6.18. Thus, 6.16 was deprotonated 
with LDA, in THF at -780 C, in the presence of LiCI, and the corresponding enolate alkylated 
with allyl bromide (Scheme 6.12). Purification by silica chromatography gave 6.17, with the 
stereochemistry shown, as a single diastereoisomer by IH NMR, in 53% yield. Significantly, 
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this allylation proceeded in higher yield than in strategy A, indicating that 6.16 was more 
conducive to alkylation than 6.22. 
SMe 
ii. 
.. 
ZHN ZHN 
·6.16 I 6.18 
Scheme 6.12. Reagents and Conditions: i. LDA, LiCI, THF, _78 0 C, ally bromide, 53%: ii. a) 
AcOH, Fh02, quant., b) 2000 C, xylene, sealed tube, 76%. 
Oxidative elimination of the thiomethyl group of 6.17 was then carried out. Hydrogen 
peroxide was added to a solution of 6.17, in acetic acid, to form the corresponding sulphone, 
which was subsequently dissolved in degassed xylene,b and sealed in a glass tube under 
vacuum. The tube was then heated at 2000 C for 16 h to give a dark brown solution, which 
upon purification via chromatography, gave the a-substituted vinyl derivative 6.18, as a 
yellow oil in 76% yield over two steps. Measurement of the optical rotation for this sample 
gave a [a]D 7°, a value which is in agreement with that observed for 6.18 obtained by 
strategy A. This led us to consider strategy B as the preferred method of preparation of 6.18 
from 6.16, as the allylation-elimination sequence had a 41 % yield over 3 steps, compared with 
the elimination-allylation sequence of strategy A which had a 17% yield over 3 steps. The 
difference in yield between the two strategies was reflected in the key allylation step where 
6.16 was more conducive to allylation than 6.22. 
With the key diene 6.18 in hand, we demonstrated the basic methodology for the preparation 
of cyclic ~-amino acids, by SUbjecting diene 6.18 to RCM conditions?l To this end, diene 
6.18 was treated with catalyst 1.42, in dry degassed benzene, and stirred at reflux overnight 
(Scheme 6.13). Purification by silica chromatography gave a fraction containing a 1.5: 1 ratio 
b Minimum solvent was required as the sulfoxide was readily soluble. 
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of regioisomers 6.19 and 6.23, in 89% yield. Attempts to separate the two regioisomers 
proved unsuccessfuL Assignment of the structures was based upon mass spectrometry, where 
a single mass of275.1158 (M+) was detected, and key 2D COSY correlations between HI and 
the olefinic protons of 6.19 and H2 and the olefinic protons of 6.23. 
ZHN ZHNJ;) ZHNJ;) 
C02Me + C02Me 
I 6.18 6.19 6.23 
Scheme 6.13. Reagents and Conditions: catalyst 1.42, benzene, reflux, 89%. 
Formation of the minor isomer 6.23 was thought to have been due to isomerism of the double 
bond of 6.19 brought about by the elevated temperature of the reaction conditions. The 
reaction was subsequently carried out at room temperature in an attempt to suppress formation 
of the minor isomer and maximise 6.19. Thus, diene 6.18 was treated with catalyst 1.42, in 
dry degassed benzene, and stirred at room temperature overnight. Purification by silica 
chromatography gave 6.19 exclusively, in 92% yield (Scheme 6.14). 
ZHN 
Scheme 6.14. Reagents and Conditions: i. catalyst 1.42, benzene, rt, 93%; 
Measurement of the optical rotation for 6.19 gave an [O:]D = +102.3 .0, CHCb). The 
structure of 6.19 was assigned based on key 2D COSY correlations observed for HI, H2, the 
ring-bound methylene, and the olefinic protons. The IH chemical shift data for 6.19, along 
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with the molecular connectivity information obtained from a 2D COSY experiment, are shown 
in Figure 6.8. Exclusive formation of 6.19, as a result ofRCM at room temperature, indicated 
that isomerization of the double bond of 6.19, and subsequent formation of 6.23, had been 
suppressed. 
o ~~sr=\63 5.12 )-l5.~ 2.62/2.87 ~o ~ 2:2.75 V 4.86 H o~o/ 3.72 
Figure 6.8. Key IH NMR and 2D COSY data for 6.19. 
The trans relative stereochemistry of 6.19 was confirmed by its conversion to the lmown 
aminocyclopentanecarboxylic acid 6.20. Thus, olefin 6.19 was hydrogenated in the presence 
of 10% palladium-on-carbon, followed by reprotection with BoczO, to give the literature 
compound 6.20 in 75% yield. 
-----_. BOCHNJ:) 
C02Me 
6.20 
Scheme 6.15. Reagents and Conditions: a) Hz, Pd-C, MeOH, b) BoczO, NaHC03, THF/I-hO 
(3:1), 75%. 
Comparison of the IH NMR data for 6.20, with that reported in the literature, confirmed the 
assigned relative stereochemistry of both the cyclic ~-amino acids 6.20 and 6.19, as well as 
that of their dienic precursor 6.18. Measurement of the optical rotation of 6.20 gave an [aJo 
+41.6° (c=O.65, CHCh), a value in close agreement with that reported in the literature (+44.6°, 
c=1.3, CHCb)Y Significantly, this same conversion was also carried out on the mixture of 
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6.19 and 6.23 obtained in Scheme 6.13, resulting in the exclusive isolation of 6.20 (Scheme 
6.16). This result further confirmed the relationship of 6.19 and 6.23 as regioisomers. 
ZHN;::) ZHN):) BOCHNJ:) 
C02Me + C02Me C02Me 
6.19 6.23 6.20 
Scheme 6.16. Reagents and Conditions: a) H2, Pd-C, MeOH, b) Boc20, NaHC03, THF/H20 
(3:1), 75%. 
6.3 Synthesis of ex-Substituted Cyclopentenyl-Based (3-Amino Acids 
With this methodology in place we turned our attention to the introduction of a substituent at 
the a-position. This strategy involved the preparation of suitable dienes, from the common 
precursor 6.16 (Schemes 6.8 and 6.9), via an alkylation-allylation sequence, similar to that 
described in Chapter 5 for equivalent cyclohexenyl-based compounds. The proposed 
synthesis of the trans a-substituted cyclopentenyl ~-amino acid 6.27 is shown in Scheme 6.17. 
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SMe SMe SMe 
ZHN{Co,M' 
l. ZIIN~C02M' ii. ". C02Me .. ZHN 
" 
'" 
6.16 6.24 
~ I iii. , 
-q,N"N-P- I ZHNf2 iv. C02Me ClY ZHN " cr~u=-'Ph .. '" 
pey} C02Me 
1.42 6.27 6.26 
Scheme 6.17. Reagents and Conditions: i. LDA, LiCl, THF, -780 C, Mel, 92%; ii. LDA, LiCI, 
THF, _780 C, allyl bromide, 43%; iii. AcOH, H202, quant., b) 2000 C, xylene, sealed tube, 
88%; iv. catalyst 1.42, benzene, ct, 92%. 
Here, N-Cbz-!)-methionine methyl ester 6.16 was used as the common precursor in the 
preparation of 6.27, having previously been obtained during the synthesis of the a-free 
derivative 6.19. Subsequent alkylation of 6.16, with methyl iodide in the presence of LDA 
and LiCI, at -78 0 C in THF, gave, after purification by silica chromatography, the a-
substituted methyl ester 6.24, as a single diastereoisomer by IH NMR, in 92% yield (Scheme 
6.18). Assignment of the stereochemistry of 6.24 as syn was based upon results observed for 
the preparation of 6.18 and 6.17 (see Schemes 6.11 and 6.12) and upon literature precedent?O 
Measurement of the optical rotation for 6.24 gave an [a]D = -14.40 (c=l.O, CHCb). 
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SMe SMe SMe 
{C02M' 1. ii. ~C02M' C02Me ZHN ZHN 2 ZHN 2 " 
'" 
6.16 6.24 I 6.25 
Scheme 6.18. Reagents and Conditions: i. LDA, LiCl, THF, _78° C, Mel, 92%; ii. LDA, LiCl, 
THF, _78° C, allyl bromide, 43%. 
An additional alkylation of 6.24, with allyl bromide, gave the a,a-disubstituted methyl ester 
6.25, as a single diastereoisomer by 1H NMR with the stereochemistry shown, in 43%.yield 
after purification by silica chromatography. Assignment of stereochemistry for 6.25 was 
based upon results obtained during the synthesis of equivalent a-substituted cyclohexenyl 
compounds described in Chapter 5, and upon literature precedent.2o Measurement of the 
optical rotation for 6.25 gave an [aJD = _30.6° (c=1., CHCh). Note that this second alkylation 
leads to an inversion of the methyl group at C2, and is the result of the electrophile 
approaching the planar enolate from the face opposite the benzyloxycarbonylamino group, in a 
manner similar to that for the preparation of 6.18 (Scheme 6.11, see also Scheme 5.12). It was 
anticipated that this stereochemistry would lend itself to the formation of the trans cyclic ~­
amino acid upon RCM of the subsequent vinyl diene. 
Next, oxidative elimination was carried out on the thiomethyl group of 6.25, to form the key 
vinyl diene 6.26 (Scheme 6.19). Hydrogen peroxide was added to a solution of 6.25, in acetic 
acid, to form the corresponding sulphone, which was subsequently dissolved in degassed 
xylene,C and sealed in a glass tube under vacuum. The tube was then heated at 2000 C for 16 
h to give a dark brown solution, which upon purification via chromatography, gave the a,a-
disubstituted vinyl derivative 6.26, as a yellow oil in 88% yield over two steps. Measurement 
of the optical rotation of 6.26 gave an [aJD = -30.2° (c=1.0, CHCh). 
C Minimum solvent was required as the sulfoxide was readily soluble. 
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SMe 
ZHN 
6.25 
ii. C02Me 
" ----'" 
6.26 
ZHN~ 
C02Me 
6.27 
Scheme 6.19. Reagents and Conditions: i. AcOH, H202, quant., b) 2000 C, xylene, sealed 
tube, 88%; ii .. catalyst 1.42, benzene, rt, 92%. 
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Subsequent exposure of diene 6.26 to catalyst 1.42, in benzene at room temperature, gave, 
after purification by silica chromatography, the a-methyl cyclic ~-amino acid 6.27, as a single 
ruastereoisomer by IH NMR, in 92% yield. The assigned trans stereochemistry is based on 
the results of the previous sequence (Schemes 6.8 and 6.15) and literature precedent.2o,22-24 
6.4 Conclusion and Future Work 
In summary, we have demonstrated a new and simple procedure for the synthesis of 
cyclopentenyl ~-amino acids, from methionine, based on RCM chemistry. This methodology 
utilizes an allylaticin-elimination sequence to prepare the optically active unsubstituted trans 
cyclic ~-amino acid (+)-6.19, via the simple diene precursor 6.18. Hydrogenation and 
reprotection of (+)-6.19, gave the known, but important, saturated analogue (+)-6.20, the 
optical rotation of which was in close agreement with that reported in the literature. 
We have also demonstrated that an a-substituent, as in 6.27, can be introduced 
stereos electively, by employing an alkylation-allylation sequence, the order of which defines 
the absolute stereochemistry. This second class of cyclic ~-amino acids represents a new and 
important addition to the family of compounds. 
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Future work in this area would include the olefinic derivatisation of compounds of this type, 
with subsequent monomers finding incorporation into oligomers for use in the development of 
novel foldamers. In addition, the corresponding cis isomer of 6.27 could easily be prepared by 
performing an allylation-alkylation sequence in the preparation of the key dienic precursor. 
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CHAPTER SEVEN 
SYNTHESIS OF AMINO ACID-BASED 
6-AND 7-MEMBERED RING LACTAMS 
By RING-CLOSING METATHESIS 
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7.1 Introduction 
There is increasing interest in the generation of cyclic peptides for use in peptidomimetic 
research and pharmaceutical development. Medium-sized ring lactams represent suitable 
fragments in this regard. We describe here the use ofRCM methodology for the synthesis of a 
range of7-membered ring lactams derived from a-amino acids and B-amino acids. 
Medium sized lactams have found widespread use in organic synthesis as key intermediates in 
the preparation of more complex structures, and as core components of natural products or 
pharmaceutically important compounds. However, the generation of such nitrogen-containing 
heterocycles remains a challenge. Compounds incorporating one or more lactam unit have 
been found to possess a range of interesting structural, biological and pharmaceutical 
properties. Over the past decade, a substantial number of monolactam-containing natural 
product examples have been described. J These include the cytotoxic bengazoles (Figure 7.1 ),2 
and related bengamides; the insecticides cripowellin A and B;3 tuberostemonone;4 and the 
fluvirucins BJ and B2, isolated in 1990 as a new class of antifungal agents with activity against 
the influenza A virus.5 
QR QH OMeH 0 
o~N"r1'!·Me(H) 
RO;=N OH 0 "-( 
H"~ OR 
00 N bengazoles 
fluvirucin B 
o O~OR <O~NY"ORI 
o 
tuberostemonone 
o 
cripowellin 
A,R= 
~H2 
HO):), - "OH 
,<-, " 7 " 
B2 
OMe 
M~9~Me 
OH 
B,R= 
Figure 7.1. Lactam-containing natural products isolated in the 1990's 
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In addition, lactams have been used in peptidomimetic design to construct such structural 
motifs as artificial turns or hairpins, or used to stabilise a bioactive conformation through the 
introduction of a rigid ring. Among the latter, Freidinger lactams have proved the most 
generally useful in drug design. 1,6 A Freidinger lactam is derived from a peptide in which the 
a-position of a chosen amino acid residue has been connected to a downstream amide nitrogen 
through the addition of a carbon bridge (Figure 7.2). 
H 0 R-:> 
XI(NYNX(NHY 
o H RJ H 0 
extended conformation 
trans amide bond 
side-chain to N 
a-Hto N 
cyc1isation 
c > 
H H 0 R~H XI(N/"D~NHY 
o 0 
Figure 7.2. Cyclisations between the in and in+! residues, resulting in Freidinger lactams 
A pivotal paper in this field published by Freidinger concerned the synthesis of a potent 
analogue of the hypothalamic hormone luteinizing-hormone-releasing hormone (LHRH, also 
known as gonadotropin-releasing hormone or GRH).7 The lactam-containing analogue 7.1 
was designed to mimic the Tyr-Gly-Leu-Arg type II t}-turn in the bioactive conformation of 
the molecule, and was found to be 2.4 times as potent as LHRH in in vivo studies (Figure 7.3). 
Lactams of this type were subsequently used to target other biological processes, with 7.2 
found to inhibit the formation of methane in sheep stomach fluid. 8,9a 
a This compound may prove useful in NZ's CUlTent political climate i.e. animal gas tax. 
Chapter Seven 210 
pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 
J \ 
J \ 
LHRH (GRR) / \, 
J \ 
. / f\N'-./C~-Arg-prO-GlY-NH2 
Pyro-Glu-Hls-Trp-Ser-Tyr-HN' If' ~ 
7.1 0y 7.2 
Figure 7.3. Examples of lactam-containing peptidomimetics 
Other recent examples include amnesia':reversal compounds of type 7.3 and 7.4,10 serine 
protease inhibitors of type 7.5,11 and hepatitis C virus NS3 protease inhibitors of type 7.6. 12 
J:/1 R(Q"NH '~A;YRJ /~~~x Rs •• ' N Rs N R2 ( ~ ° R4 n ° R2 Rl 
° 
o ~ Ph X 
° . R2 Et02C 
7.3 7.4 7.5 7.6 
Figure 7.4. Recent examples oflactam peptidomimetics 
Various bicyclic lactam scaffolds have been developed. These include the potent ACE 
inhibitors 7.7 (cilazaprilat) and 7.8, cyclophilin inhibitors of type 7.9,13 and f3-strand templates 
of type 7.10 that have recently been incorporated into potent inhibitors of a range of serine 
proteases, including thrombin (see Chapter 4).14 
7.7 7.8 7.9 7.10 X=C,N 
Figure 7.5. Bicyclic lactam peptidomimetics 
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The synthesis of lactam-based peptidomimetics has thus become the subject of much interest. 
The original route to Freidinger lactams remains one of the simplest and most useful methods 
for the preparation of y-Iactam peptidomimetics. The sulfide moiety of a methionine-
containing dipeptide is converted to an appropriate leaving group (i.e +SMez), and 
subsequently cyclized under basic conditions (Figure 7.6).7 Allyl groups and alkyl halides 
have also proven successful in this regard 
SMe 
~H Mel N'-../COzMe ---BocHN : ~SM~2 N'-../COzMe BocHN : NaH f\N COMe ---- BocHN'" 'IT' Y z 
o R o it o R 
X 
~Il RJ H PHN NyCOzMe ____ .. 
o Rz 
X CHO, OH, Br, I 
Figure 7.6 
An alternative method for the generation of lactams is through activation of the carboxylic 
acid, and subsequent intramolecular cyclisation, of amino esters. An example is the 
lactamisation of N-Boc-Iysine methyl ester using PyBop (Scheme 7.1).15 This can: also be 
achieved using the equivalent free acid under standard peptide coupling conditions. 
CNH2 
BocHN C02Me 
rJH BOCHNAyN 
o 
Scheme 7.1. Reagents and Conditions: PyBop, NaHC03, DMF, 85-90%. 
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A combination ofN and C activation has been used to generate 7-membered E-caprolactams of 
type 7.12 from a range of D-galactono-l,4-lactone-derived terminal azides 7.11 (Scheme 
7.2).]6-18 
.. 
7.11 
R2 R]",~OH 
O'~,,~"'OH 
HN 
7.12 
Scheme 7.2. Reagents and Conditions: H2/Pd (black), 65-98% 
Research from this laboratory has described the preparation of substituted enamino ester of 
type 7.15 from either enollactones 7.13,1l or ~-keto esters 7.14 (Scheme 7.3).]9 
ZHN R] ZHN R] ZHN R] . O~C02Et L O~C02Et ii. ~C02Me ~ .... MeO 0 N o 0 1 
7.13 R2 7.15 7.14 
Scheme 7.3. Reagents and Conditions: i. a) R2NH2.HCl, Et3N, CH2Ch, rt, b) PTSA, 1,2-
DCE, reflux; ii. a) R2NH2, 1,2-DCE, reflux, b) 1500 C, Imm, R=H 70%, R=Bn 43%. 
Bicyclic compounds of type 7.17 have been prepared through acid-mediated cyclisation of 
acyclic dipeptides 7.16 (Scheme 7.4).20 Various other methods for lactam formation have 
been reviewed. ] 
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7.16 7.17 
Scheme 7.4. Reagents and Conditions: i. TF AICH2Ch, reflux, 98%; iLa) TfOH, Tf20, 
CH2Ch, rt, 21h, b) NaI, MeC(O)Et, c) (TMS)3SiH, PhMe, reflux, 71 %, n=2 68%. 
Recently, RCM methodology has been used to prepare medium-sized ring lactams. The 
ability of this technique to access a range of ring sizes has made RCM of particular interest in 
this regard. Grubbs et aI, among others, have demonstrated the application of RCM 
methodology towards the synthesis of a range of cyclic amino acids including the 7-membered 
example 7.18 (Scheme 7.5).21 
Scheme 7.5. Reagents and Conditions: 5 mol%, CHCh, rt, 52%. 
Moeller et al used RCM in the preparation ofbicyclic lactams of type 7.19,22 while Brimble et 
al used similar methodology to access compounds of type 7.20 (Scheme 7.6).23 
t;~ ( 11 BocHN N Q?n • N BocHN 
o C02Me o C02Me 
n =0,1 7.19 
Scheme 7.6. Reagents and Conditions: 1.40, CH2Ch, reflux, 90%. 
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RCM methodology has been applied in the synthesis of a number of lactam-containing natural 
products. An example is the use, by Hoveyda et at, of Schrock's catalyst 1.39 in the 
enantiolective synthesis offluvirucin BI (Scheme 7.7)?4 
~ 
.? 0 EtY ii. .. Et'" 
HN 
fluvirucinB 
Scheme 7.7. Reagents and Conditions: i. 20 mol% 1.39, 90%; ii. H2/Pd-C, 84%. 
Another impressive example is the generation of advanced intermediates en route to 
manzamine A. Here, an 8-membered lactam and a 13-membered lactam are introduced under 
mild conditions at two different stages of the synthesis (Scheme 7.8).25,26 
manzamineA 
OMEM 
clI;';!3 _ Ph C?},~Ph 
Scheme 7.8. Use ofRCM in the synthesis ofmanzamine 
~: OMEM - ~ N H. -r-b o N~ 
TPSOJ ° ~ ~ OMEM 
~. -~ N H ",OH ~o 
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RCM has increasingly found use in the synthesis of a range of novellactams and as a result we 
desired to extend its application in the area of peptidomimetics to the preparation of 
compounds of type 7.21 and 7.22. The synthesis of a-un substituted examples of type 7.21 has 
previously been described by Grubbs et al (refer Scheme 7.5), however a need still exists for 
the development of a methodology for the incorporation, with stereo control, of a substituent at 
the a-position. Compounds of this type were unreported in the literature at the 
commencement of this work. Consequently, analogues of type 7.22 represent an extension of 
this methodology towards the synthesis of lactams incorporating functionalised ~-amino acids. 
R1.n PHN~N"'R2 
a 
7.21 
7.2 Lactams from a-Amino Acids 
PHN R2.\,) ... ~NR3 
RJ a 
7.22 
In order to develop a methodology for the synthesis of a-substituted lactams of type 7.21, we 
began by preparing the allyl glycine derivative 7.25, an analogue that is unsubstituted at the a-
position (Scheme 7.9). In a manner similar to that described by Grubbs in Scheme 7.5, (+1-)-
N-Boc-allyl glycine 7.23 was condensed with allylamine under standard EDCI/HOBtlDIEA 
coupling conditions, to give, after purification by silica chromatography, diene 7.24 in 92% 
yield. Exposure of diene 7.24 to RCM conditions, in the presence of catalyst 1.42, at 100° C, 
gave a crude mixture of the 7-membered lactam 7.25, and the 6-membered lactam 7.26, in a 
ratio of approximately 1:1 by IH NMR. Purification by silica chromatography allowed 
separation of the lactams, with 7.25 and 7.26 isolated in 45% and 46% respectively. This is 
the first report of a ring-contraction being observed during a reaction of this type, with the 
formation of 7.26 sugge~ting that a thennally induced migration of the terminal olefin had 
taken place prior to RCM. Subsequently, diene 7.24 was subjected to a second RCM reaction, 
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this time at a lower temperature of 85° C. The result was the exclusive formation, by IH 
NMR, of 7.25, which was isolated, after purification by silica chromatography, in 89% overall 
yield. 
BO'IIN~02H _i._ BO'HN~' 
7.23 
o 
7.24 
~ ii. ), 
BOclIN~ 
o 
iii. Q NH BocHN ( 
BocHN 
o 
7.25 
y NH 
o 
7.26 
+ 7.25 
Scheme 7.9. Reagents and Conditions: i. EDCI, HOBt, DIEA, allylamine, CH2Cb, 92%; ii. 
catalyst 1.42, benzene, 100° C, 7.25 45%, 7.26 46%; iii. catalyst 1.40 or 1.42, benzene, 85° C, 
7.2589%. 
The IH chemical shift and mass spectrometry data for 7.25 and 7.26, along with the molecular 
connectivity information obtained from respective 2D COSY experiments, are shown in 
Figure 7.7. 
1.44 
HRMS (ES) (~+Na) 249.1220 
5.68-5.74 
2.25/2.65 ~ 
P , I 0 ~ 7. ~.43/4.15 ~ )l,r~ NH 6.08 o N~f HI 0 
4.82 
7.25 
HRMS (ES) (~+Na) 235.1051 
2.19/2.82 6.06 
144)l 0 ~DU~6 ~.16 
. )1 t 
, , h NH 7.67 
o N'/I 5~9 \ 0 
4.27 
7.26 
Figure 7.7. Key IH NMR and mass spectrometry data for 7.25 and 7.26. 
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Key IH NMR results for 7.25 included correlations between the C-7 methylene protons and 
the adjacent C-6 olefinic proton and lactam NH. Key results for 7.26 included a correlation 
between the lactam NH and the adjacent olefinic proton at C-6. Subsequent analysis of 7.25 
and 7.26 by mass spectrometry confirmed these assignments. 
Having successfully prepared a-free lactams of type 7.21, we next turned our attention to the 
preparation of compounds of type 7.21 where a substituent is introduced at the a-position. The 
proposed synthesis of 7.28, is shown in Scheme 7.10, with oxazolidinone chemistry pioneered 
by Seebach used to prepare the a,a-disubstituted oxazolidinone 2.5, and amine hydrolysis, 
followed by RCM, used to effect formation of the lactam. The a,a-disubstituted 
oxazolidinone 2.5 provided a convenient, and optically active starting material for this 
synthesis, having found previous use in the syntheses of the tetrahydropiperidine 2.9 (see 
Schemes 2.2 and 2.4 in Chapter 2) and the bicyclic template 4.14 (see Schemes 4.2 and 4.3 in 
Chapter 4) This compound was previously demonstrated as having an enantiomeric excess 
>95% (refer Chapter 2.6), with the absolute stereochemistry, defined by the amino acid from 
which it is derived, having been confirmed by X-ray crystallography (Figure 2.10). Thus, n-
BuLi was stirred for 5min with allylamine in THF at -780 C, following which a solution of 2.5 
in THF was slowly added. The solution was then stirred at rt overnight following which 
purification by silica chromatography gave diene 7.27 in 91 %. 
P~ L f.~, )(. Ph y PhCO~'" 0 \, • PhCOHN" (NH PhCOHN 
)--0 0 0 
Ph H-2.5 7.27 7.28 
Scheme 7.10. Reagents and Conditions: i. n-BuLi, allylamine, THF, _78 0 C to rt, 91%; ii. 
catalyst 1.42. 
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Crystals of 7.27 were obtained and the solid-state structure was subsequently determined at 
5660 K and suitably refined A perspective drawing of 7.27, with atom labelling, is shown in 
Figure 7.8. 
C5 
Figure 7.8. Solid-state structure of diene 7.27. 
Analysis of the solid-state structure of 7.27 shows the diene in an extended conformation, with 
the terminal olefm adopting a trans relationship across the CI-Nl amide bond with respect to 
the rest of the molecule. The stereochemistry at the a-carbon (C2) of 7.27 was assigned as R, 
based on the previous assignment of 2.5 (refer Chapter 2), with the P212121 space group 
assigned to the crystal indicating the molecule to be chiral. 
Next, we subjected diene 7.27 to RCM in an attempt to prepare the a-substituted lactam 7.28. 
However, RCM did not occur under a range of conditions (CH2Ch or benzene, rt or reflux), or 
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with a variety of catalysts (1.40, 1.41, or 1.42), and in all cases diene 7.27 was recovered in 
quantitative yield. This contrasts the a-unsubstituted example 7.24 (Scheme 7.9) that readily 
underwent RCM, a result that led us to consider that substitution of the allyl amide nitrogen 
may be necessary to invoke RCM in the a-substituted case. While this was being 
contemplated, Priestley and Decicco at Bristol-Myers Squibb duly patented a similar 
methodology for the racemic synthesis of novellactams of type 7.33 as inhibitors of hepatitis 
C virus NS3 protease (Scheme 7.11).12 
i. 
Q R 0 R2 R) 4 N )( CbzHN ~N X 
o R3 H 
7.33 
ii. ~) 
CbZN'>yO 
'-0 
7.29 
~ ~ICbz~9rC02Me f 
l 7.32 . 
iii. 
.. 
v. Cb~~~C~Me 
o R3 
7.31 
Scheme 7.11. Priestley and Decicco's synthesis of a-substituted cyclic lactams. Reagents and 
Conditions: i. paraformaldehyde, TsOH, benzene; ii. KHMDS, allyl bromide; iii. NaOH, 
MeOH/flzO; iv. PyAOP, DIEA, DMF; v. catalyst 1.40; vi. a) LiOH, b) H2NCRIR2X. 
Here the racemic oxazolidinone 7.29 is hydrolysed to the acid 7.30, which is coupled to a 
substituted-N-allyl amino acid methyl ester using activating reagents suitable for hindered 
peptide coupling reactions, to afford dipeptide 7.31. RCM with Grubbs ruthenium catalyst 
1.40, results in the formation of lactam 7.32. This result is consistent with our suggestion that 
a-substituted dienes of this type require a substituent on the allyl amide nitrogen before RCM 
can occur. 
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7.3 Lactams from ~-Amino Acids 
Increasing interest has recently focused on the incorporation of ~-amino acids into 
peptidomimetics due to their enhanced biological properties and increased biostability. 
However, the incorporation of ~-amino acids into cyclic lactams has remained largely 
unexplored in this regard, and as such we set out to develop a methodology whereby lactams 
of type 7.22, that were either unsubstituted or substituted at the a-position, could be prepared 
from a common precursor. 
PHNR2'~'" n NR3 
Rl 0 
7.22 
The proposed synthesis of the a-unsubstituted ~-phenylalanine-derived lactam 7.38 is shown 
in Scheme 7.12. It was envisaged that stereoselective ally lation of Cbz-protected methyl 4-
phenyl-3-aminobutanoate 7.34, to give 7.35, followed by hydrolysis and coupling of allyl 
amine would give diene 7.37, that would subsequently undergo RCM to form the 7-membered 
cyclic lactam 7.38. 
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i. 
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.. 
ZHN . NH .,.. .. _-
Yf( I 
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ZHN~ 
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Ph/ 
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~~ 
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--_ .. 
iv. 
---
) 
ZHN~ 
: C02Me 
p~ 
7.35 
iii. 
, 
) 
ZHN~ 
: C02H 
Ph/ 
7.36 
221 
Scheme 7.12. Reagents and Conditions: i. a) Et3N, ClC02Et,THF, -150 C, 15min, b) CH2N2, 
EtzO, 0° C to rt, c) AgOBz, Et3N, MeOH, -25° C to rt" 96% 3 steps; ii. LDA, LiCl, allyl 
bromide, THF, _78° C, 64%; iii. NaOH, MeOH, 99%; iv. EDCI, HOBt, DIEA, allylamine, 
CHzCh, 74%; v. catalyst 1.42, benzene, 50° C, 89%. 
The synthesis follows a similar strategy to that used in the preparation of cyclic ~-amino acids 
described in Chapters 5 and 6 (Schemes 5.6 and 6.8), with Cbz-protected methyl 4-phenyl-3-
aminobutanoate 7.34 being prepared, using Amdt-Eistert methodology, in a manner similar to 
that of 5.25 (Scheme 5.7) and 6.16 (Scheme 6.9).Z7 Thus, N-Cbz-L-phenylalanine was reacted 
with triethylamine and ethylchloroformate, to give the corresponding mixed anhydride, which, 
upon treatment with diazomethane, gave a diazoketone intemlediate that exhibited a 
characteristic singlet at (5H 5.23ppm, corresponding to the CHN2 proton. Exposure of the 
diazoketone to silver benzoate, at low temperature, in the presence of methanol, with the 
exclusion of light, resulted in a Wolff rearrangement to form the desired Cbz-protected methyl 
4-phenyl-3-aminobutanoate 7.34, which was isolated after silica chromatography in 96% yield 
over 3 steps. With this key ~-amino acid in hand we set about introducing a substituent at the 
a-position, using a general method previously described by Podlech and Seebach?7 Thus, 
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7.34 was deprotonated with LDA, in THF at _78° C, in the presence of LiCI, and the 
corresponding enolate was alkylated with allyl bromide. Purification by silica chromatography 
gave 7.35, as a single diastereoisomer by IH NMR, in 64% overall yield. Hydrolysis of 7.35 
with NaOH gave 7.36, which upon coupling with allylamine under standard 
EDCIIHOBtJDIEA conditions gave, after purification by silica chromatography, diene 7.37 in 
74% yield. Subsequent treatment of diene 7.37 with catalyst 1.42, in dry degassed benzene at 
50° C for 2h, gave, after purification by silica chromatography, 7.38 in 93% yield. This is 
consistent with results obtained for the equivalent a-amino acid derived compound 7.25 
(Scheme 7.9). To illustrate that it was possible to incorporate compounds of this type into a 
peptide sequence, 7.38 was subsequently alkylated on the lactam nitrogen, with ethyl 
bromoactetate in the presence of NaH, to give, after purification by silica chromatography 
7.39 in 92% yield (Scheme 7.13). This result represents a new and novel application of 
functionalised ~-amino acids in the synthesis of cyclic lactams, with RCM methodology used 
as the key step in the formation of the heterocycle. 
() 
ZHN~NH 
. 0 PI! 
7.38 
() 
ZHN~N"-./C02Et 
. 0 PI! 
7.39 
Scheme 7.13. Reagents and Conditions: NaH, BrCH2C02Et, CH3CN, rt, 24h, 92%. 
Key IH NMR data, and 2D COSY connectivity correlations, confirming the structural 
assignment of 7.39, are shown in Figure 7.9. Correlations observed between the C-7 
methylene protons and the adjacent H-6 olefinic proton established connectivity within the 
lactam ring, with correlations between the H-3 a-proton and the adjacent ~-proton allowing 
assignment of the exocyclic resonances. 
Chapter Seven 223 
2.15/2.47 5.7~ __ ,,5.61 
~7 ~;?/ 3.07/4.21 
3.22 1': 7 0 
6.59 H ",,~'::. 3 II 3.78 
Ph'-../O~N~N~ /' 
5.09 II 3.96~)./ II 3.85/4.56 0 
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Figure 7.9. Key IH NMR data for 7.39. 
We next set about incorporating a substituent at the a-position of7.38 via the method shown 
in Scheme 7.14. It was envisaged that an alkylation allylation sequence would be carried out 
on the common precursor 7.34, to give 7.41 in a manner similar to that used in the preparation 
of the a-substituted cyclic ~-amino acids 5.34 (Scheme 5.11) and 6.27 (Scheme 6.17) 
described in Chapters 5 and 6. Hydrolysis of 7.41, followed by coupling of allylamine would 
give diene 7.43, which would then undergo RCM to give the a-substituted 7-membered ring 
lactam 7.44. 
) 
ZHN~ 
: C02Me i. ZHN~C02Me ii. ZHN~ : C02Me 
--".-~ ...... -~~ .... - ...... 
Ph/ Ph/ Ph/ 
7.34 7.40 7.41 
il 1m 
() v. ~~ iv. ) 
ZHNnNH ZHNyYNH 
.... ZHN~ 
: C02H 
pIf 0 p~ 0 Ph/ 
7.43 7.42 
Scheme 7.14. Reagents and Conditions: i. LDA, LiCl, Mel, THF, -780 C, 84%; ii. LDA, LiCI, 
allyl bromide, THF, -780 C, 39%; iii. NaOH, MeOH, 99%; iv. EDCI, HOBt, DIEA, 
allylamine, CH2Cb, 74%; v. catalyst 1.42, benzene. 
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Thus, alkylation of the common precursor 7.34 with methyl iodide, in the presence of LDA 
and LiCl, gave, after purification by silica chromatography the a-methyl substituted methyl 
ester 7.40, in 84% yield as a single diastereoisomer by IH NMR. The stereochemistry of 7.40 
was assigned as syn based upon literature precedent and analogous compounds prepared in 
Chapters 5 and 6 (refer Schemes 5.6 of Chapter 5 and Schemes 6.8 in Chapter 6).27 
Compound 7.40 was subsequently alkylated a second time, with allyl bromide, to give, after 
purification by silica chromatography, the a,a-disubstituted alkene 7.41, in 39% yield as a 
single isomer by IH NMR. The stereochemistry depicted is based upon both literature 
precedent,27 and analogous compounds prepared in Chapters 5 and 6 (refer Scheme 5.11 in 
Chapter 5 and Scheme 6.16 in Chapter 6). X-ray crystal analysis of 7.43, a derivative of 7.41, 
subsequently confirmed this assignment. Hydrolysis of 7.41 with NaOH gave 7.42, which 
upon coupling with allylamine under standard EDCI/HOBtlDIEA conditions gave, after 
purification by silica chromatography, diene 7.43 in 74% yield. 
The solid-state conformation of 7.43 was subsequently determined to allow confirmation of 
the relative stereochemistry. X-ray crystallographic analysis revealed 7.43 to have crystallised 
in the space group P21212\, with 3 independent molecules in the asymmetric unit. The 
absolute stereochemistry at C3 of 7.43 was assigned as S based upon the stereochemistry of 
(S)-phenylalanine from which it was derived. This allowed the relative stereochemistry of 
7.43 to be confirmed as that shown in Scheme 7.14. A perspective drawing of one of the 
molecules of 7.43, with atom labelling, is shown in Figure 7.10. 
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C8 
C23 
Cll cn 
Figure 7.10. Solid-state structure of 7.43. 
Subsequent treatment of diene 7.43 with catalyst 1.42, in dry degassed benzene at 80° C for 
4h, gave, after purification by silica chromatography, a single compound in 88% yield. 
Analysis by IH NMR and mass spectrometry revealed that RCM of diene 7.43 under these 
conditions had resulted in a ring-contraction to form the 6-membered ring lactam 7.45, rather 
than the anticipated 7-membered lactam 7.44 (Scheme 7.15). 
)~ ZHNYyNH _~ __ .. 
pi 0 
!( 
ZHNYyNH 
- 0 PI! 
ReM ~ 
ZHND(NH 
- 0 PI! 
7.43 7.45 
Scheme 7.15. Reagents and Conditions: catalyst 1.42, benzene, 80° C, 4h, 88%. 
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Formation of 7.45 had presumably occurred via migration of the amide olefin, as a result of 
the elevated reaction temperature, in a manner similar to that observed in the formation of the 
a-amino acid derived lactam 7.26 (Scheme 7.9). However, this ring contraction was not 
observed during the preparation of the a-unsubstituted ~-amino acid derived lactam 7.38 
carried out under similar conditions, suggesting that the a-methyl group may promote 
migration of the amide olefin prior to RCM. 
Note also that RCM of 7.43, to form 7.45, occurred readily, and in good yield, despite the lack 
of a substituent on the allyl amide nitrogen, an apparent requirement for ring-closure of 
equivalent a,a-disubstituted a-amino acid derived compounds (Scheme 7.11). This was also 
observed during the preparation of the a-free lactam 7.38, and suggests that dienes derived 
from ~-amino acids are more amenable to RCM than those derived from a-amino acids. This 
is of particular interest in the synthesis of the a-substituted examples where, in the case of the 
~-amino acid derived compounds, derivatisation of the lactam nitrogen is not constrained to 
occur prior to RCM (see Schemes 7.10 and 7.11). This lends itself to a greater degree of 
flexibility during the synthesis of cyclic lactams of this type. 
Key IH NMR chemical shifts for 7.45, and associated connectivity correlations from 2D 
COSY, HSQC and HMBC experiments are shown in Figure 7.11. 
2.03/2.62 
\ 5.07 
1.31 ~~5.98 
Ph"-../O~~ '-~ /NH 6.99 
4.80/4.94 II IT IT 
0 4.10 t" 0 Ph 
3.02/3.14 
Figure 7.11. Key IH NMR chemical shifts and connectivity data for 7.45. 
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Key observations include correlations between the lactam NH and the adjacent olefm, thereby 
establishing the connectivity of the ring, and correlations between the 
benzyloxycarbonylamino NH and the ~-amino acid side-chain confirming connectivity 
exocyclic to the ring. The structure of 7.45 was further supported by mass spectrometry (TOF 
MS ES+ 365.1866), with the IH chemical shifts observed for the olefinic protons in 7.45 (~= 
5.07 and 5.98ppm) also consistent with those observed for the equivalent protons in the 6-
membered a-amino acid derived lactam 7.26 (refer Figure 7.7). In addition, the difference in 
chemical shift between adjacent olefinic protons in the 6-membered lactams 7.26 and 7.45 
corresponds to ~0.9ppm, while the difference between equivalent protons in the 7-membered 
lactams 7.25 and 7.38 is ~O.lppm. This difference in chemical shift between equivalent 
olefinic protons of the 6- and 7-membered lactams provides a key diagnostic tool for 
distinguishing between the two ring systems. This information is summarised in Figure 7.12 
along side associated lactam NH chemical shifts. 
H-5 
H-6 
N-H 
BocHN Q n NH ZHNY'!(NH 
0 - 0 Ph/ 
7.25 7.38 
7-membered lactams 
5.74 
5.68 
6.08 
5.71 
5.61 
6.48 
BocHN 
(~ y NH ZHNnNH 
0 pI(" 0 
7.26 7.45 
6-membered lactams 
5.16 
6.06 
7.67 
5.07 
5.98 
6.99 
Figure 7.12. Comparison of the chemical shifts of the olefinic and lactam amide protons for 
the 7-membered lactams 7.25 and 7.38 and the 6-membered cyclic lactams 7.26 and 7.45. 
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It is envisaged that formation of the 7-membered ring lactam 7.44 (refer Scheme 7.14) could 
be achieved by lowering the temperature of reaction during ReM of diene 7.43, however this 
was not carried out here. Nevertheless, the preparation of 7.45 represents the first example of 
a-substituted lactams of this type incorporating a functionalised ~-amino acid. 
7.4 Conclusion and Future Work 
In summary, we have demonstrated the ability to prepare either 6- or 7-membered lactams 
from an allyl glycine-derived diene 7.24, using ReM chemistry. ReM of diene 7.24 at 85° e 
resulted in exclusive formation of the 7-membered lactam 7.25, while ReM at 100° e gave a 
1:1 mixture by IH NMR of 7.25 and the 6-membered lactam analogue 7.26. This is the first 
observed isomerization of this type during ReM. 
Suitable methodology was also developed for the synthesis of dienes of type 7.27, substituted 
at the a-position, that were envisaged to undergo ReM to form 7-membered lactams of type 
7.28. Priestley and Decicco subsequently demonstrated that a substituent was required on the 
allyl amide nitrogen before ReM will occur. 
Methodology has also been developed for the preparation of equivalent 6- and 7 -membered 
lactams derived from a common ~-amino acid precursor, with these being an important 
addition to this class of compound. Dienes of type 7.37 and 7.43, that are either unsubstituted, 
or substituted at the a-position, have been shown to undergo ReM to form the 7-membered 
lactam 7.38, and the 6-membered lactam 7.45, respectively. Initial efforts focussed on lactams 
derived from ebz-protected methyl 4-phenyl-3-aminobutanoate 7.34. Alkylation on the 
lactam nitrogen of 7.38, to give the dipeptide 7.39, further illustrated the ability of these 
compounds to be incorporated into peptide sequences. Formation of the 6-membered lactam 
7.45 is consistent with olefinic migration of the terminal alleene of 7.43, brought about by the 
elevated temperature of the reaction conditions (85° e). It is envisaged that preparation of the 
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equivalent 7-membered lactam 7.44 can be achieved by lowering the temperature at which this 
reaction is carried out, in a manner similar to that seen for the allylglycine derived 7.25. Future 
work in this area is envisaged to involve the olefmic derivatisation of compounds of this type, 
with subsequent monomers finding incorporation into larger structures for use in the 
development of novel peptidomimetics. This methodology is amenable to the use of a variety 
of starting amino acids with hydroxylated derivatives of this type also offering potential as 
HIV-l protease inhibitor scaffolds similar in structure to the potent cyclic urea SD-146. 
7.21 7.22 
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8.1 General Methods and Experimental Procedures 
Melting Points 
All melting points were obtained on an Electrothermal apparatus and are uncorrected. 
Nuclear Magnetic Resonance 
Proton NMR and nOe spectra were obtained on a Varian Inova spectrometer, operating at 
SOO MHz. Carbon NMR spectra were obtained on a Varian Unity 300 spectrometer, 
operating at 7S MHz, with a delay (D I) of 1 s. All spectra were obtained at 23°C unless 
specified otherwise. Chemical shifts are reported in parts per million (ppm) on the b scale. 
Solvents used for NMR analysis (reference peak listed) included: CDCb (CHCh at bH 
7.2Sppm, CDCb at be 77.0ppm); CD30D (CHD20D at bH 3.30ppm, CD30D at be 
49.3ppm). Two~dimensional NMR experiments included COSY, HSQC, HMBC, and 
CIGAR, and were obtained on the Varian Inova spectrometer operating at SOO MHz. The 
HSQC, HMBC and CIGAR experiments were all obtained with a delay (D I) of Is. 
Infrared Spectroscopy 
Infrared spectra were obtained using a Shimadzu 8201PC series FTIR interfaced with an 
Intel 486 PC operating Shimadzu's HyperIR software. Spectra were obtained in either 
CHCh (solution phase) or solid KBr (diffuse reflectance). 
Small Molecule Mass Spectrometry 
Electron impact (EI) mass spectra were detected on a Kratos MS80 RFA mass 
spectrometer operating at 4000 V (accelerating potential) and 70 eV (ionization energy). 
The source temperature was 200~2S0 °C Electrospray ionization (ESI) mass spectra were 
detected on a Micromass LCT TOF mass spectrometer, with a probe voltage of 3200 V, 
temperature of ISO °C and a source temperature of 80°C. Direct ionization used IOIlL of a 
IOllg mL-I solution, using a carrier solvent of SO% acetonitrile/H20 at a flow rate of20llL 
min-I. Ionization was assisted by the addition ofO.S% formic acid. 
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Microanalysis 
Microanalysis was performed at the University of Otago Microanalytical Laboratory. All 
reported values are within ±OA% of the calculated value. 
Optical Rotations 
Optical rotations were measured on a Perkin Elmer polarimeter Model 341, with a 10mm 
path length. The [aJD values are given in units of deg cm2 g-!, with the concentrations 
given in 1O-lgcm-3. 
Reagents, Solvents and Laboratory Methodology 
Oven-dried glassware was used in all reactions carried out under an inert atmosphere 
(either dry nitrogen or argon). All starting materials and reagents were obtained 
commercially unless otherwise stated. Removal of solvents "under reduced pressure" 
refers to the process of bulk solvent removal by rotary evaporation (low vacuum pump) 
followed by application of high vacuum (oil pump) for a minimum of 30min. Analytical 
thin layer chromatography (TLC) was performed on plastic-backed Mt;!rck Kieselgel 
KG60F254 silica plates, and visualized using short wave ultraviolet light, KMn04 or 
phosphomolybdate dip. Flash chromatography was performed using 230-400 mesh Merck 
Silica Gel 60 following established guidelines under positive pressure.! Radial 
chromatography was performed using a Harrison Chromatotron using Imm, 2mm and 
4mm silica gel plates tmder positive pressure. THF and diethyl ether were distilled fTOm 
sodium benzophenone kety} under an inert atmosphere immediately prior to use. 
Dichloromethane, 1,2-dichloroethane, benzene and toluene were distilled from calcium 
hydride under an inert atmosphere. Petroleum ether refers to the fraction collected 
between 60-70 °C. Ethyl acetate and petroleum ether were distilled from calcium hydride 
prior to their use in chromatography. DMF was dried by placing over 4A molecular 
sieves, applying a high vacuum for 15 min, then flushing briefly with an inert atmosphere. 
This process was repeated twice more over 24 h, after which the DMF was stored over 4A 
molecular sieves under an inert atmosphere. All other reagents and solvents were purified 
prior to use according to literature procedures? 
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General Procedure A: Preparation of Phenyl-5-0xazolidinones 
Amino acid (1 equiv) was dissolved in 1M aq. NaOH (1 equiv) with gentle wanning. The 
solution was evaporated under reduced pressme and the resulting white solid placed under 
high vacuum. The white solid was dissolved in 1,2-dichloroethane (~0.3 M) to give a 
suspension. Benzaldehyde (1.5 equiv) was then added and the mixtme refluxed with 
azeotropic removal of water using a Dean-Stark apparatus, for 24 h. The reaction mixture 
was cooled to -20 under nitrogen, and benzoyl chloride (1 equiv) added. The mixture 
was stirred at -20°C for 4 h, then at 0 °C for 3 days. Upon warming to rt the mixture was 
washed with 5% aq. NaHC03, 5% aq. KHS04, and H20, dried (MgS04, and the solvent 
removed under reduced pressure. Recrystallisation of the residue from MeOH gave the 
desired 5-oxazolidinone. 
Modified General Procedure A.3 
Amino acid (1 equiv) was dissolved in 1 M aq. NaOH (1 equiv) with gentle warming. The 
solvent was evaporated under reduced pressme and the resulting white solid placed under 
high vacuum. The white solid was then dissolved in dichloromethane (~0.3 M) to give a 
suspension. Benzaldehyde (1.5 equiv) was then added and the mixture refluxed, with 
azeotropic removal of water using a Dean-Stark apparatus, for 5-8 h. The reaction mixture 
was cooled to 0 °C under nitrogen, and benzoyl chloride (1 equiv) added. The mixture was 
stirred at 0 °C for 4 h, then at rt for 16 h. The solution was washed with 5% aq. NaHC03, 
5% aq. KHS04, and H20, dried (MgS04), and the solvent removed under reduced pressure. 
Recrystallisation of the residue from MeOH gave the desired 5-oxazolidinone. 
General Procedure B: Hydrolysis of Oxazolidinones to Carboxylic Acids 
Sodium hydroxide (2 equiv) was added to oxazolidinone (1 equiv) dissolved in MeOH 
(~O.l M) and the mixture refluxed for 1 h. The solution was cooled and concentrated 
under reduced pressure. The residue was talcen up in water, acidified to pH 1 with 10% 
HCI and extracted with ether (3x10mL)). The combined ether extracts were washed with 
NaCl(lOmL), dried (MgS04) and the solvent removed under reduced pressure to give the 
carboxylic acid. 
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General Procedure C: Esterification of Carboxylic Acids with CH2N2 
Ethereal diazomethane was added to a 0 °C solution of carboxylic acid in ether (~O.l M), 
until the bright yellow colour persisted over an extended period. The mixture was then 
stirred at rt for 2 h, whereupon the reaction was quenched with the addition of a few drops 
of acetic acid. The solvent was removed to give the methyl ester 
General Procedure D: Ailylation on Nitrogen 
A solution of methyl ester (1 equiv) dissolved in dry dimethylformamide (~0.1 M) was 
cooled to 0 °C under nitrogen. Allyl bromide (3 equiv) was added, followed by slow 
addition ofNaH (60% in oil, 3 equiv). Bubbling was observed as H2 was released. The 
solution was stirred at O°C for 1.5 h and at rt for 30 min. The mixture was quenched with 
sat. aq. NH4CI and extracted with ethyl acetate (3xlOmL»). The ethyl acetate extracts were 
combined and washed with water (2xl OmL), brine(10mL), dried (MgS04), and the solvent 
removed under reduced pressure. The residue was purified by silica chromatography to 
give the N-allylated product 
General Procedure E: Ring-Closing Metathesis 
CIt ~CY3 
Cl'l)u=--"'Ph 
PCY3 
1.40 
Bis(tricyclohexylphosphine) 
benzy lidene ruthenium(IV) 
dichloride 
Cl, ljCY3 crl)u~ 
PCY3 \ 
1.41 
Bis(tricyclohexylphosphine)-
3-methy 1-2-buteny Hdene 
ruthenium(IV) dichloride 
1\ 
MesNyNMes 
CL 
crl)u=--"'Ph 
PCY3 
1.42 
Tricycl ohexy lphosphine[ 1 ,3-bis(2,4,6-
trimethylphenyl)-4,5-dihydroimidazole-
2-y lidene benzylidene ]ruthenium(IV) 
dichloride 
The ruthenium catalyst (either 1.40, 1.41, or 1.42), dissolved in dry degasseJ1 benzene or 
CH2Ch, was added to a solution of diene (1 equiv) dissolved in dry degassed benzene or 
CH2Ch (~O.lmmol) under nitrogen. The solution was stirred at rt, or refluxed, for 2 h or a 
specified time (see experimental for details). Purification by radial chromatography gave 
the desired olefinic product. 
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General Procedure F: Hydrogenation of Olefins 
10% Palladium-on-carbon (20% w/w) was added to a solution of olefin (1 equiv) dissolved 
in dry MeOH (~0.05 M), and the solution stirred vigorously under hydrogen for 12 h. The 
mixture was then filtered through a small bed of Celite™, washing with MeOH, and the 
solvent removed under reduced pressure to give the product 
General Procedure G: Methyl Ester Hydrolysis 
Sodium hydroxide (2 equiv of 1M aq.) was added to a solution of methyl ester (1 equiv) 
dissolved in MeOH (~0.05 M), and the solution refluxed for 4 h. The MeOH was removed 
under reduced pressure and water added to malce up to a workable amount. The solution 
was acidified to pH 2 with 10% HCI and extracted with ethyl acetate (3xlOmL). The 
combined ethyl acetate extracts were dried over MgS04 and the solvent removed under 
reduced pressure to give the free acid. 
General Procedure H: Preparation of tert-Butyl-S-Oxazolidinones 
Amino acid (1 equiv) was dissolved in 1 M aq. NaOH (1 equiv) with gentle warming. The 
solvent was evaporated under reduced pressure and the resulting white solid placed under 
high vacuum. The white solid was dissolved in pentane (~0.3 M) to give a suspension, and 
trimethylacetaldehyde (pivaldehyde) (1.5 equiv) added. The mixture was then refluxed, 
with azeotropic removal of water using a Dean-Stark apparatus, for· 5-8 h. The solution 
was cooled to 0 °C under nitrogen, benzoyl chloride (1 equiv) added, and the mixture 
stirred at 0 °C for 48 h. The mixture was washed with 5% aq. NaHC03, 5% aq. KHS04, 
and H20, dried (MgS04), and the solvent removed under reduced pressure. 
Recrystallisation from MeOH gave the 5-oxazolidinone. 
a Degassed solvents were obtained using a "freeze-thaw" method in which the solvent was 
frozen solid under an inert atmosphere, and subsequently thawed under high vacuum. This 
process was repeated several times until the solvent was sufficiently free of oxygen. 
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General Procedure I: Conversion of Methionine Side Chain to a Vinyl Group via 
Oxidative Elimination 
a) Hydrogen peroxide (50% w/w solution, 1.4 equiv) was added a solution of the 
methionine derivative (lequiv) dissolved in acetic acid (~0.5 M), and the mixture stirred at 
rt for 4 h. CH2Ch (20mL) was added to the solution and the solution carefully neutralised 
with sat. aq. Na2C03 (vigorous bubbling was observed). The organic phase was then 
washed with water (lOmL), dried (MgS04), and the solvent removed under reduced 
pressure, to give the intermediate sulfoxide. 
b) The sulfoxide was then dissolved in degassed m-xylene and sealed, under vacuum, in a 
glass tube. The tube was then heated at 200°C in a Kugelrohr for 16 h. The solvent was 
then removed to give a brown solid, with purification by silica chromatography giving the 
desired vinyl derivative. 
General Procedure J: Synthesis of J3-Amino Acid Methyl Ester Derivatives from (l-
Amino Acids4 
a) Triethylamine (1 equiv) and ethyl chloroformate (1 equiv) were added under argon to a 
-15°C solution ofthe N-protected amino acid dissolved in THF (0.2 M). After 15 min the 
suspension was allowed to warm to 0 °C, whereupon ethereal diazomethane was added 
until the intensive yellow colour persisted over a longer period. (The colour of the 
diazo ketone is light yellow.) The mixture was allowed to warm to rt and then stirred for 
3h. Excess diazomethane was destroyed by vigorous stirring, or by the addition of a few 
drops of AcOH. After aqueous workup by extraction with satd. NaHC03 (10mL), NH4CI 
(10mL), and NaCI (lOmL) solutions, the organic solution was separated, dried (MgS04), 
and the solvents evaporated under reduced pressure. Chromatography of the residue on 
silica gel, or recrystallisatiol1, afforded the pure diazo ketone. 
b) The diazoketone was dissolved in dry MeOH (~0.25 M) under argon at -25°C with the 
exclusion of light. Silver benzoate (0.11 equiv), dissolved in Et3N (2.9 equiv), was added 
and the mixture was allowed to warm to rt within 3 h. The solvent was removed under 
reduced pressure and the residue was taken up in ethyl acetate. After workup by extraction 
with satd. NaHC03 (lOmL), NH4Cl (10mL), and NaCI (lOmL) solutions, drying (MgS04), 
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the solvents were removed under reduced pressure. Purification by silica chromatography, 
or recrystallisation, gave the homo amino acid methyl ester. 
General Procedure K: Synthesis of a-Substituted f3-Amino Acid Derivatives 
Anhydrous LiCI (3 equiv) was suspended in THF (Z-protected f3-amino acid methyl ester 
should be 0.2 M) and cooled to -78°C. LDA (2.2 equiv) was added and the solution 
stirred at -78°C for 10 min. The Z-protected f3-amino acid methyl ester (1 equiv) was then 
added and the mixture was stirred at -78°C for 1 h. The electrophile (4 equiv) was added 
slowly and the mixture was stirred at -78°C for 2 h and then allowed to warm to rt over 16 
h. Hydrolysis was carried out by addition ofNH4CI and after workup, by extraction with 
satd. NaHC03 (10mL), NH4CI (lOmL), and NaCI (10mL) solutions, and drying (MgS04), 
the solvents were removed under reduced pressure. Purification by silica gel 
chromatography gave the desired product. 
General Procedure L: Hydrogenation of N-Cbz-protected Olefins, Reprotection with 
Cbz 
10% Palladium-on-carbon (20% w/w) was added to a solution of olefin (1 equiv) 
dissolved in MeOH (~0.05 M) and the solution stirred vigorously under hydrogen for 12 h. 
The mixture was then filtered through Celite ™ and the solvent removed under reduced 
pressure. The residue was then taken up in CH2Ch (~0.1 M) and diisopropylethylamine 
(2.8 equiv) was added, followed by benzylchloroformate (1.6 equiv) and 
dimethylaminopyridine (0.3 equiv), and the solution stirred overnight at rt. The solvent 
was removed under reduced pressure and the residue taken up in' ethyl acetate and 
successively washed with sat. aq. NaHC03 (lOmL), NaCI (lOmL), water (lOmL), dried 
(MgS04) and the solvent removed to give the product. 
Modified General Procedure L: Hydrogenation of N-Cbz-protected Olefins, 
Reprotection with Boc 
10% Palladium-on-carbon (20% w/w) was added to a solution of olefin (lequiv) dissolved 
in dry MeOH (~0.05 M), and the solution stirred vigorously under hydrogen for 12 h. The 
mixture was then filtered through a small bed of Celite™, washing with MeOH, and the 
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solvent volume reduced to approximately 2mL. NaHC03 (1.5equiv) and di-tert-butyl-
dicarbonate (1.5 equiv) were then added and the solution stirred at rt for 3 h. The solvent 
was removed and the residue purified by silica chromatography to give the product. 
General Procedure M: Curtius Rearrangement - Acids to Amides 
Et3N (1.2 equiv) and CIC02Et (1.1 equiv) were added to a 0 °C solution of the acid (1 
equiv) dissolved in dry acetone (~0.1 M) under argon, and the mixture stirred at 0 °C for 1 
h. NaN3 (2.5 equiv) in H20, was then added and the mixture stirred at 0 °C for a further 
lh. The solvent was evaporated below rt and the residue extracted with toluene (3xl0mL). 
The combined organic extracts were dried over MgS04 and heated carefully using a 
distillation condenser. The volume was reduced to ~ 1 OmL over a 1 h period. Alcohol 
ctBuOH or BnOH, 3 equiv) was added and the distillation condenser replaced with a reflux 
condenser. The reaction was gently refluxed for 12 h. The solvent was removed under 
reduced pressure and the residue diluted with CH2Ch (20mL), washed with 3 M aqueous 
HC} (lOmL), water (10mL), brine (lOmL), dried (MgS04), and the solvent removed under 
reduced pressure to give the product. 
Modified General Procedure M: 
Et3N (1.2 equiv) and diphenylphosphorylazide (DPPA) (1 equiv) was added to a solution 
of the acid (1 equiv) dissolved in toluene (~0.1 M) under argon. The solution was stirred 
at rt for 30min before being slowly heated to reflux (N2 bubbling was observed at 70-80 
DC). Once bubbling has ceased (~3 h), the reaction was cooled to 50°C, alcohol (tBuOH or 
BnOH) (3 equiv) added, and the solution refluxed for a further 3 h. Upon cooling to rt, the 
reaction was quenched with sat. aq. NaHC03 (1OmL), and the mixture extracted with ether 
(3x10mL). The combined ether extracts were dried (MgS04) and the solvent removed 
under reduced pressure. Chromatography (EAIPE) gave the product. 
General Procedure N: Coupling of Carboxylic Acids with Allylamine 
EDCI (1.3 equiv), HOBt (1.5 equiv), allylamine (1.5 equiv) and diisopropylethylamine 
(1.1 equiv) were added to a solution of the acid (1 equiv) dissolved in CH2Ch (~0.1 M) 
under argon. The mixture was stirred at rt under argon for 16 h. The solution was diluted 
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with CH2Cb (lOmL), washed successively with 10% aqueous HCl (tOmL), water (lOmL), 
dried over Na2S04, and the solvent removed to give the product. 
8.2 Experimental Work Described in Chapter Two 
Preparation of (4S,2R)-3-Benzoyl-4-benzyl-2-phenyl-oxazolidin-5-one (+)-2.4, and 
(4S,2S)-3-Benzoyl-4-benzyl-2-phenyl-oxazolidin -5-one 2.10. 
Ph PhCON~O 
~o 
PI( 
(+)-2.4 
Ph PhCON~O 
~o 
Ph 
2.10 
Method A: (S)-Phenylalanine (lOg, 60.6mmol, 1 equiv) was reacted with 1M aq. NaOH 
(60.6mL, 60.6mmol, 1 equiv), and condensed with benzaldehyde (9.24mL, 90.9mmol, 1.5 
equiv) according to General Procedure A. Cyclisation with benzoyl chloride (7.035mL, 
60.6mmol, 1 equiv) gave a crude mixture containing a 4: 1 ratio, by NMR, of 2.4 and 
2.10. Recrystallisation from MeOH gave the trans-oxazolidinone (+)-2.4 (7.327g, 34%) as 
white needles 
Method B:3 (S)-Phenylalanine (8g, 48.5mmol, 1 equiv) was treated with 1M aq. NaOH 
(48.5mL, 48.5mmol, 1 equiv) and condensed with benzaldehyde (7.4mL, 72.7mmol, 1.5 
equiv) according to Modified General Procedure A. Cyclisation with benzoyl chloride 
(5.64mL, 48.5mmol, 1 equiv) gave a crude mixture containing a 4:1 ratio of 2.4 and 2.10. 
Recrystallisation of the residue from MeOH gave the trans-oxazolidinone (+)-2.4 
(10.206g, 59%) as white needles 
Data for (+)-2.4: 
mp 182-184° C (lit.3 184.3° C), 
IH NMR (CDCh) () 3.43 (brs, lH, CHaPh), 3.79 (brs, 1H, CHbPh, 5 (s, 1H, H4), 5.82 
(s, 1H, H2), 7.06-7.41 (m, 15H, PhH). 
13C NMR (CDCh) () 34.7, 57.6, 91.2, 126.6, 127.7, 128.5, 128.8, 129.8, 129.8, 130.7, 
135.2,136.1,169.2,171.2. 
FTIR (KBr) 1802, 1655cm·1 
Chapter Eight 243 
HMRS 357.1366 (M+). C23Hl9N03 requires 357.1365. 
[aJD +267°, c=1.0 CHCh (lit.3 +385.2°, .0, CHCh). 
Selected data for 2.10 (from crude): 
IHNMR (CDCh) 8 4.69 (m, IH, H4), 4.90 (brs, lH, H2). 
, 
Preparation of (4R,2R)~4~Allyl-benzoyl-4-benzyl-2-phenyl-oxazolidin-5-one (-)-2.5, 
(2R,4S,1' R)-3-Benzoyl~4-[benzoylam ino(phenyI)methy I] -4-benzyl-2-phenyl~ 1 ,3-
oxazolidin-5-one 2.11, and its C~I' epimer 2.18. 
\ rh PhCON,~O }-O 
PI)' 
(-)-2.5 
,Ph 
PhCOHN~'-Ph 
PhCO~r yo 
}-o 
Ph' 
2.11 
H Ph 
PhCOHN-X",'-Ph 
PhCO~~O ).-0 
PI-; 
2.18 
LiHMDS (6.501mL of 1M solution in THF/hexanes, 6.5mmol, 1.1 equiv) was added, 
under argon, to a solution of the oxazolidinone (+)-2.4 (2.11g, 5.91mmol, 1 equiv) in dry 
THF (15mL) at ~78°C. The solution was stirred at -78° C for 7min, whereupon allyl 
bromide (0.768mL, 8.87mmol, 1.5 equiv) was added and the mixture stirred at -78°C for 2 
h, before being allowed to warm to rtovernight. Sat. aq. NH4CI solution (20mL) was 
added and the solution extracted with ether (3x20mL). The ether extracts were combined, 
dried (Na2S04) and the solvent removed to give the product as a white solid. 
Recrystallisation from ether gave (-)-2.5 (2.342g, 93%) as white needles. Purification of 
the remaining residue by radial chromatography (EAIPE 1 :3) gave the self addition product 
2.11 (96mg, 6%),5 as a white solid. 
Treatment of (+)-2.4 with LiHMDS for extended periods (20-60min) before the addition of 
allyl bromide resulted in crude mixtures of (-)-2.5 and 2.11 being observed by IH NMR. : 
Treatment of (+)-2.4 (200mg, 0.56mmol, 1 equiv) with LiHMDS (0.72mL of 1M solution 
in THFlhexanes, 0.72mmol, 1.2 equiv) in the absence of allyl bromide gave a crude 
mixture containing 2.11 by 1 H NMR and <5% of a second diastereoisomer tentatively 
assigned as the C-1' epimer 2.18. Purification by radial chromatography (EAlPE 1 :3) gave 
2.11 (84mg, 55%) as a white solid. 
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Data for (-)-2.5: An analytical sample was obtained by the diffusion of petroleum ether 
into a solution of (-)-2.5 dissolved in ethyl acetate. Crystals suitable for X-ray 
crystallography were obtained (see Appendix for data). 
mp 141-143° C. 
'HNMR 500MHz (CDCb) (5 2.82 (dd J=13.7 and 5.4Hz, IH, CHaCH=CH2), 3.45 (d 
J=13.7Hz, IH, CHaPh), 3.59 (dd J=13.7 and 1O.1Hz, IH, CH bCH=CH2), 4.09 (d 
J=13.7Hz, IH, PhCHb), 5.50 (m, 4H, CH=CH2 and PhH), 5.98 (m, IH, CH=CH2), 6.03 (s, 
IH, H2), 6.66 (t J=7.8Hz, 2H, PhH), 6.77 (d J=7.3Hz, 2H, PhH), 6.95 (t J=7.3Hz, IH, 
PhH), 7.02 (tJ=7.5Hz, 2H, PhH), 7.14 (tJ=7.5Hz, IH, PhH), 7.38-7.45 (m, 5H, PhH). 
13C NMR (CDCh) (539.7,41.6,69.8,91.0, 122.2, 125.2, 127.4, 127.6, 127.8, 128.2, 129.0, 
129.1,129.1,130.8,131.3,135.0,136.2,136.6,169.9,173.3. 
FTIR (KBr) 3026, 1792, 1653cm-1 
HRMS (EI) 397.1672 (M+). C26H23N03 requires 397.1678. 
[ab -2.9° c=l.O CHCb 
Data for 2.11: 
'H NMR (CDCh) (53.61 (d 3.9 Hz, IH, CHaPh), 4.46 (d J=13.9 Hz, IH, CHbPh), 4.72 
(s, IH, H2), 5.25 (d J=7.3 Hz, 2H, PhH), 6.21 (dJ=8.8 Hz, lH, CHNH), 6.56 (tJ=7.8 Hz, 
2H, PhH), 6.67 (d J=6.8 Hz, 2H, PhH), 6.87 (t J=7.4 Hz, IH, PhH), 6.98 (t J=7.8 Hz, 2H, 
PhH), 7.10 (t J=7.8 Hz, IH, PhH), 7.41-7.62 (m, 13H, PhH), 8.08 (d J=6.8 Hz, 2H, PhH), 
9.52 (d J=8.8 Hz, IH, NH). 
l3C NMR (CDCh) (5 38.1, 60.8, 74.7, 90.8, 124.7, 127.3, 127.5, 127.6, 127.8, 127.96, 
128.3,128.7,129.0,129.2,129.3,129.4,131.1,131.8,133.6, 133.8, 135.2, 135.7, 137.6, 
166.2, 171.5, 172.7. 
FTIR (KBr) 3350, 1791, 1667cm-1• 
HRMS (ES) 567.2276 (M++H). C37H31N204 requires 567.2284. 
Selected data for C-l' epimer 2.18 (from crude mixture): IH NMR (CDCh) (5 3.90 (d, 
J=13.6Hz, IH, CHaPh), 4.41 (ddJ=13.6Hz, IH, CHbPh), 4.92 (s, IH, H-2), 5.31 (dd 
and 1.3Hz, 2H, PhH). 
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Preparation of (2R)-2-Benzoylamino-2-benzyl-pent-4-enoic acid 2.6. 
Oxazolidinone (-)-2.5 (2.9g, 7.3mmol) was dissolved in MeOH (60mL) and hydrolysed 
with NaOH (585mg, 14.61mmol, 2 equiv) according to General Procedure B, to give acid 
2.6 (2.254g, 100%) as a white solid. 
mp 178-180° C. 
IH NMR (300MHz CDCh) 8 81 (dd J=7.0 and 14.0Hz, 1H, CHuCH=CH2), 3.32 (d 
J=13.7Hz, 1H, CHaPh), 3.57 (dd J=7.8 and 13.7Hz, 1H, CHbCH=CH2), 3.93 (d J=13.2Hz, 
1H, CHbPh), 5.16 (m, 2H, CH=CHz), 5.72 (m, 1H, CH=CH2), 6.99 (s, 1H, NH), 7.18 (m, 
5H, PhH), 7.42 (t J=7.8Hz, 2H, PhH), 7.52 (t J=7.3Hz, 1H, PhH), 7.67 (d J=7.3Hz, 2H, 
PhH). 
13C NMR (CDCb) 8 39.4,40.1,66.2, 119.7, 126.9, 127.0, 128.3, 128.7, 129.8, 131.8, 
131.8, 134.7, 135.9, 168.0, 176.3. 
FTIR (KBr) 3385,1728, 1618cm-l . 
HRMS (El) 309.1360 (M1. CI9H19N03 requires 309.1365. 
Preparation of (2R)-2-Benzoylamino-2-benzyl-pent-4-enoic acid methyl ester (-)-2.7. 
Acid 2.6 (1.790g, 5.79mmol) was dissolved in ether (50mL) and esterified with ethereal 
diazomethane according to General Procedure C, to give methyl ester (-)-2.7 (1.864g, 
99%) as a colourless oil. 
IH NMR (500 MHz CDCh) 8 2.72 (dd J=7.3Hz, 1H, CHaCH=CH2), 3.21 (d J=13.7Hz, 
1H, PhCHa), 3.60 (dd J=7.3Hz, III, CHbCH=CH2), 3.83 (s, 3H, OMe), 3.95 (d J=13.7Hz, 
1H, PhCHb), 5.10 (m, 2H, CH=CHz), 5.65 (m, 1H, CH=CH2), 6.93 (br s, 1H, NH), 7.19 
(m, 2H, PhH), 7.41 (m, 3H, PhH), 7.41 (tJ=7.3Hz, 2H, PhH), 7.49 (tJ=7.3Hz, PhH), 7.68 
(m, 2H, PhH). 
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13C NMR (CDCh) <339.3,40.1,52.6,66.2,119.1,126.6,126.8,128.1,128.4, 129.5, 131.3, 
132.1,135.1,136.1,166.7,173.2. 
FTIR (KBr) 3414, 2953,1738, 1666, 1603, 1580, 1516, 1487, 1448cm-1 
HMRS (EI) 323.1525 (~). C2oH21N03 requires 323.1521. 
[a]D = -56.8°, c-1.0 CHCh. 
Preparation of (2R)-2-(Allyl-benzoyl-amino )-2-benzyl-pent-4-enoic acid methyl ester 
(+)-2.8. 
Methyl ester (-)-2.7 (4g, 12.4mmol, 1 equiv) was dissolved in DMF (120mL) and reacted 
with allyl bromide (3.215mL, 37.2mmol, 3 equiv) and NaH (l.486g of 60% in oil, 
37.2mmol, 3 equiv) according to General Procedure D. Purification by column 
chromatography (EAlPE 1 :3) gave 920mg (23%) of starting material (-)-2.7. Further 
elution gave.diene (+)-2.8 (1.343g, 30%) as a white solid. 
mp 92-93°C. 
IH NMR (CDCh) <32.73 (m, 2H, NCH2CH=), 3.09 (m, lH, CCHaCH=), 3.22 (d J=13.7Hz, 
IH, PhCHa), 3.63 (m, IH, CCHbCH=), 3.69 (d J=13.7Hz, IH, PhCHb), 3.75 (s, 3H, OMe), 
5.08-5.34 (m, 4H, 2xCH=CH 2), 5.54 (m, IH, NCH2CH=CH2), 5.87 (m, IH, 
CCH2CH=CH2), 7.21-7.43 (lOH, PhH). 
l3 C NMR (CDCh) <3 36.1, 36.6, 49.4,52.0,67.9, 116.6, 119.9, 126.2, 126.9, 128.2, 128.3, 
129.4, 130.7, 132.2, 136.4, 136.5, 136.8, 172.7, 172.7 
FTIR (KBr) 3423, 2924, 1732, 1628cm-1 
HRMS (EI) 362.1758 (M+-H). C23H24N03 requires 362.1756. 
[a]D= +64.3°, c=1.0 CHCh. 
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Preparation of (2R)-1-Benzoyl-2-benzyl-1,2,3,6-tetrahydro-piperidine-2-carboxylic 
acid methyl ester (+)-2.9. 
Catalyst 1.40 (ll4mg, 0.14mmol, 5mol%), dissolved in dry degassed CH2Ch (3mL), was 
added to a solution of diene (+)-2.8 (lg, 2.75mmol, 1 equiv) dissolved in dry degassed 
CH2Ch (25mL) under nitrogen, according to General Procedure E. The mixture was then 
stirred at rt for 2h. Purification by radial chromatography (EA/PE 1 :3) gave (+)-2.9 
(867mg, 94%) as a white solid. An analytical sample was obtained by the diffusion of 
petroleum ether into a solution of (+)-2.9 dissolved in ethyl acetate. Crystals suitable for 
X-ray crystallography were obtained (see Appendix for data). 
lH NMR 500MHz (CDCh) 82.43 (m, lH, CCHaCH=), 2.78 (m, lH, CCHbCH=), 3.18 (d 
13.2Hz, IH, PhCHa), 3.62 (d J=13.2Hz, 1H, PhCHb), 3.68 (s, 3H, OMe), 3.80 (m, 1H, 
NCHaCH=), 4.10 (m, lH, NCHbCH=), 5.67 (m, 1H, CCH2CH=), 5.88 (m, lH, 
NCH2CH=), 7.15-7.52 (m, 10H, PhH). 
13C NMR (CDCh) 828.5 (CCH2CH=), 38.9 (CH2Ph), 46.8 (NCH2CH=) , 51.9 (OCH3), 
62.7 (CC02Me), 124.6 (CCH2CH=), 125.3 (NCH2CH=), 127.0, 127.9, 128.1, 128.4, 
130.5, 130.5, 135.7, 135.8, 172.4, 172.6. 
FTlR (KBr) 2947, 1742, 1634cm-1• 
HRMS (El) 335.1520 (Ml. C21 H21N03 requires 335.1521. 
Micro. Calcd for C21H21N03, C, 75.19; H, 6.31; N, 4.18; Found: C, 74.94; H, 6.23; N, 
4.19. 
.0CHCb. 
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Preparation of (2R)-I-Benzoyl-2-benzyl-piperidine-2-carboxylic acid methyl ester (+)-
2.12. 
Olefin (+)-2.9 (23mg, 0.07mmol) was dissolved in dry MeOH (1.5mL) and reacted with 
10% palladium-on-carbon (4.5mg, 20% w/w), under a hydrogen atmosphere according to 
General Procedure F, to give (+)-2.12 (21mg, 92%) as a white solid. An analytical sample 
was obtained by the diffusion of petroleum ether into a solution of (+)-2.12 dissolved in 
ethyl acetate. Crystals suitable for X-ray crystallography were obtained (see Appendix for 
data). 
IH NMR (CDCh) 0 1.35 (m, IH, CH), 1.61 (m, 2H, CHz), 1.75 (m, 2H, CCHa and CH), 
2.15 (m, IH, CCHb), 2.34 (m, IH, NCHIl), 3.05 (d 3.7Hz, IH, PhCHa), 3.29 (m, IH, 
NCHb), 3.81, (s, 3H, OMe), 4.05 (dJ=13.7Hz, IH, PhCHb), 7.24-7.40 (m, 10H, PhH). 
l3C NMR (CDCh) 0 15.7, 21.3, 28.9, 39.0, 43.3, 52.2, 63.8, 126.6, 127.9, 128.3, 129.4, 
131.1,136.7,136.8,171.4,173.5. 
FTIR (KBr) 2949, 1736, 1630cm"1. 
HRMS (El) 337.1675 (M+). CZIH23N03 requires 337.1678. 
[a]D = +163.0°, .0 CHCh. 
Preparation of cis-(2S,4S,5R) and cis-(2S,4R,5S)-I-Benzoyl-2-benzyl-4,5-dihydroxy-
piperidine-2-carboxylic acid methyl esters, 2.13a and 2.13b respectively. 
2.13a 
QH 
HO"U· Ph , I 
" 
" 
N COzMe 
PhAO 
2.13b 
Olefm (+)-2.9 (45mg, O.13mmol, 1 equiv) in acetone (0.03mL) was added, under nitrogen, 
to a combined solution of K20S04 (2.5mg, 0.05 equiv) in tBuOH (0.02mL), and NMO 
(17mg, 0.15mmol, L06 equiv) in water (0.08mL) and acetone (O.03mL). The reaction 
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mixture was stirred at rt for 24h. A slurry of magnesium silicate (17mg), and sodium 
dithionate (2.5mg) in water (O.lmL), was added to the reaction mixture. The magnesium 
silicate was filtered off and the filtrate was adjusted to pH 7 with IN H2S04 • Acetone was 
removed under reduced pressure and the resulting aqueous phase acidified to pH 2. This 
was then saturated with NaCI and extracted with ethyl acetate (2x2mL). The organic 
extracts were combined, dried (MgS04) and the solvent removed under reduced pressure to 
give a crude mixture containing 2.13a and 2.13b in a ratio of 3: 1 by IH NMR The residue 
was purified by radial chromatography (EAlCH2Ch 1: 1) to give a fraction containing the 
major cis isomer 2.13a. 
Data for 2.13a: 
IH NMR (CDCb 300 MHz) 8 2.02 (ddJ=14.2 and 4.9Hz, 1H, CCHnCHOH), 2.27 (m, 2H, 
CCHbCHOH and NCHaCHOH), 3.04 (dJ=13.7Hz, INCHbCHOH 
12C NMR (CDCb) 8 35.0, 38.9,49.0,52.6,63.6,64.0,65.0,126.9,127.1, 128.3, 128.6, 
130.1, 131.0, 135.8, 136.0, 171.9, 173.0. 
Selected data for 2.13b (from crude): 
IH NMR (CDCb) 32.22 (m, 1H), 2.58 (dJ=12.7Hz, lH), 3.01 (d J=14.lHz, 1H, CHaPh), 
3.75 (dd J=13.7 and 3.4Hz, IH), 3.86 (s, 3H, OMe), 3.99 (dJ=14.1Hz, 1H, CHbPh). 
Preparation of (2S ,4S,SS) and (2S,4R,SR)-1-Benzoyl-2-benzyl-4,S-dibromo-
piperidine-2-carboxylic acid methyl esters and (2S,4S)-2-Benzoyl-1-benzyl-4-bromo-
6-oxa-2-aza-bicyclo[3,2,I]octan-7-one, 2.14a, 2.14b and 2.16 respectively. 
Br Br 0 
B'''QPh Brn? B' ... ~ • I 
" N "" 0 " N C02Me N C02Me I 
PhAO PhAO PhAO Ph 
2.14a 2.14b 2.16 
Bromine was added dropwise to a solution of olefin (+)-2.9 (15mg, 0.045mmol) dissolved 
in CH2Clz (5mL) under nitrogen, until a permanent brown colour remained. The solution 
was stirred under N2 for 3 h. Analysis of the crude IH NMR gave a mixture of 2.14a and 
2.14b in the ratio of 4:1 by IH NMR. Purification by radial chromatography (EAIPE 1:3) 
yielded the major isomer 2.14a (15mg, 52%).as a brown oil. 
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Data for 2.14a: 
IH NMR (CDCh) () 2.40 (dd .9 and 14.7Hz, lH, CCHaCHBr), 2.58 (d J=13.2Hz, lH, 
CCHbCHBr), 2.82 (dd J=5.1 and 15.9Hz, IH, NCHaCHBr), 3.04 (d J=13.7Hz, IH, 
CHaPh), 3.60 (dd J=2.2 and 15.9Hz, IH, NCHbCHBr), 3.88 (s, lH, OCH3), 4.00 (m, lH, 
NCH2CHBr), 4.08 (d J=14.2Hz, IH, CHbPh), 4.57 (m, IH, CCH2CHBr), 7.23-7.50 (m, 
10H, PhH). 
Selected data for 2.14b (from crude mixture): 
IH NMR (CDCh) () 3.18 (d 3.7Hz, IH, CHaPh), 3.76 (s, 3H, OMe), 4.24 (d 3.7Hz, 
lH, CHbPh), 4.82 (m, IH). 
Attempted crystallisation by the diffusion of petroleum ether into a solution of 2.14a 
dissolved in ethyl acetate, over a period of 6 months, gave 2.16, the structure of which was 
solely determined on the basis of X-ray crystal structure analysis. 
Preparation of (2R)-I-Benzoyl-2-benzyl-1,2,3,6-tetrahydro-piperidine-2-carboxylic 
acid 2.15. 
Olefin (+)-2.9 (50mg, 0.15 mmol, 1 equiv) was dissolved in MeOH (3mL) and hydrolysed 
with 1M aq. NaOH (0.3mL, 0.3mmol, 2 equiv) according to General Procedure G, to give 
acid 2.15 (44mg, 92%) as a white solid. 
IH NMR (CDCb 500 MHz) 8 2.48 (m, lH, CCHaCH=), 2.80 (bd J=16.6Hz, IH, 
CHbCH=), 3.18 (d J=13.7Hz, 1H, PhCHa), 3.61 (m, IH, NCHaCH=), 3.82 (d 3.7Hz, 
IH PhCHb), 3.98 (dd J=5.4 and 16.6Hz, IH, NCHbCH=), 5.70 (m, IH, CCH2CH=), 5.97 
(m, IH, NCfhCH=), 7.24-7.51 (m, 10H, PhH). 
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Preparation of (2S)-2-Benzoylamino-2-benzyl-4-oxo-butyric acid methyl ester (-)-2.21. 
Ozone was bubbled through a solution of (-)-2.7 (1.8g, 5.57mmol, 1 equiv), stirred with 
solid NaHC03 (500mg) at -78°C in a mixture of CH2Cb (30mL) and MeOH (9mL) until 
the solution was distinctly blue in colour. The mixture was stirred for an additional 15min 
until the blue colour no longer remained, whereupon dimethyl sulfide (4 drops) was slowly 
added. The resulting colourless solution was strirred at -78°C for 10min, and then allowed 
to warm to rt and stirred for 6h. The mixture was filtered and the solvent removed to give 
a white residue. Purification by radial chromatography (EA/PE 4: 1) gave aldehyde (-)-
2.21 (1.741g, 96%) as a colourless oil 
IH NMR (CDCh) <5 3.06 Cd J:=13.7Hz, IH, CHaCHO), 3.23 (d J=18.1Hz, IH, PhCHa), 
3.79 (s, 3H, OMe), 3.91 (dJ=13.7Hz, IH, CHbCHO), 4.29 (dJ=18.1Hz, IH, PhCHb), 7.00 
(m, 2H, PhH), 7.16 (d J=6.8Hz, IH, NH), 7.21 (m, 3H, PhH), 7.40 (t J=7.3Hz, 2H, PhH), 
7.49 (t J=7.3Hz, IH, PhH), 7.65 (d J=7.3Hz, 2H, PhH), 9.67 (s, IH, CHO). 
13 . C NMR (CDCh) <5 40.6,48.4,52.7,61.4,126.7,127.1,128.1,128.4,129.5, 131.5, 134.4, 
134.5, 166.9, 172.1, 198.7. 
FTIR (KBr) 3406, 3032, 2955, 1744, 1659, 1601, 1582, 1516, 1489cm-1 
HRMS (ES) 348.1220 (M++Na). CI9HI9N04Na requires 348.1212. 
[a]D = -83.6°, c=1.0 CHCh. 
Preparation of (2S)-2-Benzoylamino-2-benzyl-4-hydroxy butyric acid methyl ester 
2.22 and (3S)-N-[3-Benzyl-2-oxo-tetrahydro-furan-3-yl]-benzamide 2.23. 
O~Ph 
PhCOHN "'~02Me 
2.22 
" 0 fh;q 
PhCOHN " 
o 
2.23 
LiBH4 (24mg, 1.07mmol, lequiv) was added to a solution of aldehyde (-)-2.21 (354mg, 
1.07mmol, 1 equiv), in THF (5mL), at -78° C. The mixture was stirred at _78° C for Ih then 
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at rt for 1h. The solvent was removed under reduced pressure and the residue purified by 
radial chromatography (EA/PE 1:1) to give an initial fraction containing lactone 2.23. 
Removal of the solvent gave 2.23 (189mg, 53%) as a white solid. Further elution gave a 
fraction containing alcohol 2.22. Removal of the solvent gave 2.22 (144mg, 41 %) as a 
colourless oil. 
Data for 2.22: 
'H NMR (CDCb) 8 2.76 (dt J=13.2 and 9.8Hz, 1H, CCHaCH20), 2.87 (ddd J=13.2, 6.5 
and 2.2Hz, 1H, CCHbCH20), 3.25 (d J=13.2Hz, 1H PhCHa), 3.33 (d J=13.2Hz, 1H, 
PhCHb), 3.61 (dt J=7.3 and 9.8Hz, 1H, CHaO), 4.35 (dt J=2.4 and 9.8Hz, 1H, CHbO), 6.62 
(s, 1H, NH), 7.27 (m, 2H, PhH), 7.33 (m, 3H, PhH), 7.44 (t J=7.5Hz, 2H, PhH), 7.53 (t 
J=7.3Hz, 1H, PhH), 7.73 (dJ=7.3Hz, 2H, PhH). 
'3C NMR (CDCb) 8 32.9, 41.6, 60.1,65.8, 127.0, 127.8, 128.5, 128.8, 130.0, 132.0, 133.2, 
133.7, 166.7, 177.0. 
HRMS (El) 295.1206 (M+). C'8H17N03 requires 295.1208. 
Data for 2.23: 
'H NMR (CDCh) 8 2.37 (m, 1H, CHaCH20H), 2.96 (m, 1H, CHbCH20H), 3.22 (d 
J=13.4Hz, 1H, PhCHa), 3.67 (m, 1H, CHaOH), 3.75 (m, 1H, CHbOH), 3.80 (s, 3H, OMe), 
3.86 (d J=13.4Hz, 1H, PhCHb), 7.02 (m, 2H, PhH), 7.18 (m, 3H, PhH), 7.24 (s, 1H, NH), 
7.41 (t J=7.5Hz, 2H, PhH), 7.50 (t J=7.3Hz, 1H, PhH), 7.70 (dd J=8.3 and 1.0Hz, 2H, 
PhH). 
l3C NMR (CDCb) 8 37.8, 40.7, 52.7, 58.7, 64.1,126.8,126.9,128.2,128.6,129.8,131.6, 
134.9, 135.9, 167.0, 174.2. 
HRMS (El) 327.1462 (M+). C'9H2,N04 requires 327.1470. 
Preparation of (2S,2S)-2-Benzoylamino-2-benzyl-4-(3,3,3-trifluoro-2-methoxy-2-
phenyl-propionyloxy)-butyric acid methyl ester 2.24. 
o 
Ph II 
MeO>( '~ 
CF3 .J<Ph 
PhCOHN \"~02Me 
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Et3N (l0IlL, .077rnmol, 5equiv) and a solution of (S)-MTPA-Cl (3 ilL, 0.02rnmol, 
1.3equiv) in CH2Ch (0. 15mL) was added, under argon, to a solution of alcohol 2.22 (5mg, 
0.015mmol, lequiv) and DMAP (2.05mg, 0.017rnmol, 1. 1 equiv) , in dry CH2Ch (0.5mL). 
The solution was stirred at rt for 10min, with the reaction followed by TLC to determine 
the reaction had gone to completion. The solvent was removed under reduced pressure to 
give 2.24 (8.3mg, quant.) which was analysed without further purification 
IH NMR (CDCb) IS 2.59 (m, IH, CCHaCH20), 3.12 (d J=13.7Hz, 1 PhCHa), 3.21 (dt 
J=4.9 and 1 1H, CCHbCH20), 3.50 (s, 3H, COMe), 3.67 (s, 3H, C02Me), 3.89 (d 
J=13.7Hz, 1H, CHaCO), 4.20 (m, 1H, CHaO), 4.43 (m, 1H, CHbO), 6.89 (s, IH, NH), 6.95 
(m, 2H, PhD), 7.16 (m, 3H, PhH), 7.31-7.63 (m, lOH, PhH). 
Preparation of (2S,2R)-2-Benzoylamino-2-benzyl-4-(3,3,3-trifluoro-2-methoxy-2-
phenyl-propionyloxy)-butyric acid methyl ester 2.25. 
Et3N (lOIlL, 0.077mmol, 5equiv) and a solution of (R)-MTPA-Cl (3.5IlL, 0.02mmol, 
1.3equiv) in CH2Cb (0. 15mL) was added, under argon, to a solution of alcohol 2.22 (5mg, 
0.015mmol, lequiv) and DMAP (2.05mg, 0.017mmol, 1.1equiv), in dry CH2Ch (0.5mL). 
The solution was stirred at rt for 10min, with the reaction followed by TLC to determine 
the reaction had gone to completion. The solvent was removed under reduced pressure to 
give 2.25 (8.3mg, quant.) which was analysed without further purification 
IH NMR (CDCb) IS 2.50 (m, 1H, CCHaCH20), 3.10 (d 3 IH, PhCHa), 3.24 (dt 
J=4.9 and 15.1Hz, 1H, CCHbCH20), 3.46 (s, 3H, COMe), 3.60 (s, 3H, C02Me), 3.89 (d 
J=13.7Hz, IH, CHaCO), 4.23 (m, 1H, CHaO), 4.40 (m, IH, CHbO), 6.96 (m, 2H, PhH), 
7.03 (s, NH), 7.18 (m, 3H, PhH), 7.35-7.67 (m, 10H, PhH). 
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8.4 Experimental Described for Chapter Three 
Preparation of (2R,4S) and (2S,4S)-3-Benzoyl-4-(2-methylsulfanyl-ethyl)-2-phenyl-
oxazolidino-S-one, (+)-3.11 and 3.23 respectively. 
SMe 
PhCON~O 
,\Lo 
Ph" 
(+)-3.11 
SMe 
Phco>ro /-0 
Ph 
3.23 
254 
(S)-Methionine (5g, 33.55mmol) was reacted with 1M aq. NaOH (33.6mL, 33.55mmol, 1 
equiv), and condensed with benzaldehyde (5.116mL, 50.33mmol, 1.5 equiv) according to 
Modified General Procedure A. Cyclisation with benzoyl chloride (3.895mL, 33.55mmol, 
1 equiv) gave a crude mixture containing a 4:1 ratio, by IH NMR, of (+)-3.11 and 3.23. 
Recrystallisation from MeOH gave the trans-oxazolidinone (+)-3.11 (7.21g ,63%) as a 
white solid. 
Data for (+)-3.11: 
mp 157-159° C (lit.3 157° C) 
IH NMR (CDCb) 82.06 (br s, 3H, SCH3), 2.20-2.83 (m, 4H, CH2CH2SCH3), 5.00 (br s, 
IH, H4), 6.71 (br s, 1H, H2), 6.80-7.61 (m, 10H, PhH). 
13 C NMR (CDCb) 814.9,28.7,55.2,91.1,126.7,126.9,128.7,129.9,131.2, 134.9, 136.7, 
170.6, 172.1. 
HMRS (ES) 342.1160 (M++H). Cl9H20N03S requires 342.1164. 
[a]D = +222° c=1.0 CHCb (lit.3 +280.4°). 
Selected data for 3.23 (from crude): 
IH NMR (CDCb) 8 4.91 (m, 1H, H4), 6.92 (s, 1H, H2). 
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Pre par a t ion 0 f ( 4R,2R)-3-Benzoyl~4-benzyl-4-(2-m cthylsulfanyl-ethyl)-2-phenyl-
oxazolidin-5-one, (+)-3.12, N-{[3-Benzoyl-4-(2-methylsulfanyl-ethyl)-5-oxo-2-phenyl-
oxazolidin-4-yl]-phenyl-methyl}-benzamide 3.30, and (3S)-N-[3-Methylsulfanyl-1-
(pyrrolidine-1-carbonyl)-propyl]-benzamide 3.26. 
SMe 
~ Ph PhCON~O 
}-o 
Pn' 
3.12 
Ph SMe 
PhCOHN~ 
PhCO~~O 
,~O 
Pn' 
3.30 
~' 0 
PhCOHN~( 
o 
3.26 
Method A: Oxazolidinone (+)-3.11 (5g, 14.7mmol, I equiv) was dissolved in dry THF 
(lOOmL) and cooled to -78°C under argon. LDA (9.S3mL of a 2M solution in hexane, 
19.1mmol, 1.3 equiv) was added dropwise and the resulting red solution was stirred at-
78°C for 15min. Benzyl bromide (2.6ISmL, 22mmol, 1.5 equiv) was then added and the 
reaction mixture stirred at -78°C for 2 h then at rt overnight. The solution was quenched 
with sat. aq. NH4Cl (20mL) and extracted with ether (3x20mL). The combined ether 
extracts were washed with water (20mL), dried (MgS04) and the solvent removed under 
reduced pressure. Purification by radial chromatography gave (+1-)-3.12 (3.28Ig, S2%) as 
a white solid. Further elution gave the self-addition product 3.30 (76mg, 2%) as a white 
solid. An analytical sample was obtained by the diffusion of petroleum ether into a 
solution of (+1-)-3.12 dissolved in ethyl acetate. Crystals suitable for X-ray 
crystallography were obtained (see Appendix for data). 
Method B: Pyrrolidine (0.614mL, 7.33mmol, lequiv) was dissolved in dry THF (SmL) 
and cooled to -SO° C under argon. n-Butyllithium (4.045mL of a 2M solution in THF, 
8.07mmol, 1.lequiv) was added and the solution stirred at -20°C for 30min. The mixture 
was recooled to -Soo C and a solution of oxazolidinone (+)-3.11 (2.Sg, 7.33mmol, I equiv), 
dissolved in dry THF (15 mL), added slowly. The solution was stirred at -SO° C for 20min 
whereupon benzyl bromide (1.311mL, 11.02mmol, l.Sequiv) was added slowly. The 
reaction mixture was stirred at -50° C for lh then allowed to warm to rt overnight. The 
dark yellow solution was quenched with saturated aqueous NH4CI solution (IOmL) and the 
aqueous layer extracted with ether (3x20mL). The combined ether extracts were washed 
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with water (20mL) dried (MgS04), and the solvent removed under reduced pressure. 
Purification by radial chromatography (EAIPE 1 :9) gave (+)-3.12 (1.925 g, 61 %) as a white 
solid. Further elution (EAlPE 1:1) gave 3.26 (511mg, 29%) as a white solid. 
Data for (+)-3.12: 
IH NMR (CDCb) 8 2.22 (s, 3H, SMe), 2.69-2.75 (m, IH, CHaCHzSMe), 2.84-2.98 (m, 
3H, CHbCH2SMe), 3.37 and 3.88 (dd J=13.4 Hz, 2H, CHzPh), 5.36 (s, IH, C2H), 6.66 (d 
J=5.9 2H, PhH), 6.74 (d J=5.9 Hz, 2H, PhH), 7.03 (m, 4H, PhH), 7.13 (m, 2H, PhH), 
7.39 (m, 2H, PhH), 7.44 (m, 3H, PhH). 
13C NMR (CDCb) 8 15.4,29.2,36.9,40.1,68.7,90.4,125.6,127.2,127.9, 128.1, 128.2, 
129.0, 130.1, 135.0, 136.1, 169.3, 173.5. 
FTIR (KBr) 1787.9, 1654.8 cm-l 
HMRS (ES) 432.1637 (M++H). CZ6Hz6N03S requires 432.1633. 
Micro. Calcd for CZ6Hz5N03S: C, 72.36; H, 5.84; N, 3.25; S, 7.43. Found: C, 72.39; 
6.04; N, 3.47; S, 7.24. 
[a]D +14.3°, c=1.0 CHCb. 
Data for 3.30: 
lH NMR (CDCb) 8 2.06 (s,3H, SMe), 2.75 (m, 2H, CH2), 3.05 (m, 1H, CHa), 3.30 (m, 
lH, CHb), 5.32 (s, 1H, H2), 6.15 (dJ=9.2Hz, 1H, NHCH), 6.65-8.03 (m, 20H, PhH), 9.56 
(dJ=8.8Hz, IH, NH). 
Data for 3.26: 
IH NMR (CDCb) 8 1.85 (m, 2H, 2xNCHzCHa), 1.98 (m, 3H, 2xNCHzCHb and 
CHaCHzSMe), 2.08 (m, 4H, SMe and CHbCHzSMe), 2.56 (m, 2H, CHzSMe), 3.41 (m, 
lH, NCHa), 3.48 (m, 1H, NCHb), 3.53 (ddd J=6.l, 10.1 and 16.9Hz, IH, NCHa,), 3.73 
(ddd J=6.6, 10.0 and 16.8Hz, IH, NHCHb'), 5.07 (m, 3H, NH and PhH), 7.45 (m, 1H, 
PhH), 7.80 (tJ=7.3Hz, 2H, PhH). 
l3C NMR (CDCb) 8 15.6,24.0, 25.9, 30.2, 32.3, 46.0, 46.5, 50.3, 127.1, 128.3, 131.5, 
133.7, 166.8, 169.8. 
HRMS (ES) 307.1484 (M++H). Cl6H23Nz02S requires 307.1480. 
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Preparation of (4R,2R)-3-Benzoyl-4-benzyl-2-phenyl-4-vinyl-oxazolidin-5-one (+)-
3.13. 
Oxazolidinone (+)-3.12 (1.312g, 3.04mmol, 1 equiv) was dissolved in acetic acid (6mL) 
and treated with HzOz (0.289mL of a 50% w/w solution, 4.25mmol, 1.4 equiv) according 
to General Procedure Ia to give the .intermediate sulfoxide 3.27 (1.26g, 94%), as a tan 
solid. The sulfoxide was then dissolved in degassed m-xylene and underwent oxidative 
elimination according to General Procedure lb. Purification by radial chromatography 
(EA/PE 1 :3) gave the vinyl oxazolidinone (+)-3.13 (998mg, 93%) as a white solid. An 
analytical sample was obtained by the diffusion of petroleum ether into a solution of (+)-
3.13 dissolved in ethyl acetate. Crystals suitable for X-ray crystallography were obtained 
(see Appendix for data). 
Data for 3.27: 
1 . H NMR (CDCh) 0 2.70 (s, 3H, SOMe), 2.84-3.32 (m, 4H, CH2CH2SMe), 3.41 (d 
J=13.6Hz, IH, CHaPh), 3.91 (br d J=13.6Hz, IE CHbPh), 5.50 (m, IH, H2), 6.63 (m, 2H, 
PhH), 6.73 (m, 2H, PhH), 7.05 (m, 4H, PhH), 7.16 (m, 2H, PhH), 7.36 (m, 2H, PhH), 7.44 
(m, 3H, PhH). 
Data for (+)-3.13: 
mp 148-149° C 
IH NMR (CDCh) 0 3.51 (d J=13.7Hz, IH, CHaPh), 4.06 (d J=13.7Hz, IH, CHbPh), 5.58 
(d J=13.7Hz, =CHa), 5.64 (m, 2H, =CHb and CH=CHz), 6.61 (d J=7.3Hz, 2H, PhH), 6.73 
(m, 3H, PhH), 7.06 (m, 4H, PhH), 7.16 (t J=7.3Hz, IH, PhH), 7.21 (t J=7.3Hz, IH, PhH), 
7.41 (m, 4H, PhH). 
l3C NMR (CDCh) 0 40.6, 69.1, 90.4, 117.9, 125.8, 127.0, 127.8, 128.3, 128.9, 129.6, 
129.8,130.1,135.1,135.8,135.9,168.8,171.5. 
FTIR (KBr) 3034,2939, 1801, 1649cm-1. 
HRMS (El) 383.1521 (~). C2sH21N03 requires 383.1521. 
[aJD = +139.0°, c=1.0 CHCh. 
Chapter Eight 258 
Micro. Calcd for CZ5HzIN03. C, 78.2; H, 5.5; N, 3.7. Found: C, 77.8; H, 5.6; N, 3.7. 
Preparation of (2R)-2-Benzoylamino-2-benzyl-but-3-enoic acid 3.14. 
Oxazolidinone (+)-3.13 (998mg, 2.61mmol, 1 equiv) was dissolved in MeOH (20mL) and 
hydrolysed with NaOH (209mg, 5.22mmol, 2 equiv) according to General Procedure B, to 
give acid 3.14 (760mg, 99%) as a white solid. 
IH NMR (CDCb) <3 3.54 (d J=13.7Hz, 1H, CHaPh), 3.74 (d 3.7Hz, 1H, CHbPh), 5.38 
(m, 2H, CH=CH2), 6.18 (m, 1H, CH=CH2), 6.87 (s, 1H, NH), 7.20-7.27 (m, 5H, PhH), 
7.42 (tJ=7.3Hz, 2H, PhH), 7.52 (tJ=7.3Hz, 1H, PhH), 7.67 (m, 2H, PhH). 
HRMS (ES) 296.1286 (M++H). ClsHlSN03 requires 296.1287. 
Preparation of (2R)-2-Benzoylamino-2-benzyl-but-3-enoic acid methyl ester (+)-3.15. 
Acid 3.14 (760mg, 2.58mmol) was dissolved in ether (20mL), and esterified with ethereal 
diazomethane according to General Procedure C, to give methyl ester (+)-3.15 (797mg, 
100%) as a colourless oiL 
IH NMR 500MHz (CDCh) <3 3.43 (d J=13.7Hz, IH, CHaPh), 3.83 (s, 1H, OMe), 3.92 (d 
J=13.7Hz, 1 CHbPh), 5.33 (m, 2H, CH=CH2), 6.20 (m, lH, CH=CHz), 7.00 (br s, lH, 
NH), 7.09 (m, 2H, PhH), 7.21 (m, 3H, PhH), 7.42 (t J=7.8Hz, 2H, PhH), 7.51 (t J=7.3Hz, 
IH, PhH), 7.71 (dd J=7.3 and 102Hz, 2H, PhH). 
l3C NMR (CDCb) <3 40.0, 53.0, 65.8, 116.3, 126.9, 127.1, 128 128.6, 129.9, 130.0, 
131.6,134.7,135.6,136.2,166.4,172.2. 
FTlR (KBr) 3464, 1749, 1645, 1543cm-1. 
HRMS (El) 309.1365 (M+). C19H19N03 requires 309.1359. 
[a]D= +54.1 0, .0 CHCh. 
Micro. Calcd for C19H19N03. C, 73.7; H, 6.2; N, 4.5. Found: C, 73.3; H, 6.2; N, 4.4. 
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Preparation of (2R)-2-(Allyl-benzoyl-amino )-2-benzyl-but-3-enoic acid methyl ester (-
)-3.16. 
Methyl ester (+)-3.15 (612mg, 1.98mmol, 1 equiv) was dissolved in DMF (20mL) and 
reacted with allyl bromide (0.514mL, 5.94mmol, 3 equiv) and NaH (238mg of 60% in oil, 
5.94mmol, 3 equiv) according to General Procedure D. Purification by radial 
chromatography (EA/PE 15/85) gave of 311mg (51 %) of starting material (+)-3.15. 
Further elution gave.diene (-)-3.16 (214mg, 31 %) as a clear yellow oil. 
lH NMR (CDCh at 500MHz) 8 3.33 (d J=13.4Hz, 1H, CHaPh), 3.38 (m, 1H, NCHa), 3.64 
(m, 1H, NCHb), 3.81 (s, 3H, OMe), 4.03 (d J=13.4Hz, 1H, CHbPh), 4.99 (m, 2H, 
NCH2CH=CH2), 5.34 (m, 1H, NCH2CH=CH2), 5.36 (d J=3.4Hz, 1H, CCH=CHa), 5.39 (d 
J=3.4Hz, lH, CCH=CHb), 6.22 (m, 1H, CCH=CH2), 7.24-7.42 (m, 10H, PhH). 
l3C NMR (CDCh) 8 39.6,50.7,52.3, 70.1, 116.6, 117.3, 126.4, 126.9, 128.1, 128.1, 129.7, 
131.0, 134.9, 135.8, 136.2, 136.5, 171.8, 173.0. 
FTIR (KBr) 3395, 1736, 1624cm-1. 
HRMS (ES) 350.1763 (M++H). C22H24N03 requires 350.1756. 
Micro. Calcd for C22H23N03. C, 75.6; H, 6.6; N, 4.0. Found: C, 75.6; H, 6.5; N, 4.0, 
[a]D = -62.8°, c=1.0 CHCh. 
Prepara tion of (2R)-1-Benzoyl-2-benzyl-2,5-dihydro-1H-pyrrole-2-carboxylic acid 
methyl ester (-)-3.17. 
A Ph \~ ~t C02Me 
Ph~ 
° 
Catalyst 1.41 (18mg, 0.02mmol, 5mol%), dissolved in dry degassed benzene (0.5mL), was 
added to a solution of diene (-)-3.16 (156mg, 0.45mmol), in dry degassed benzene (5mL) 
under argon, according to General Procedure E. The mixture was then stirred at reflux for 
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16h. Purification by radial chromatography (EAIPE 1:3 gave (-)-3.17 (133mg, 94%) as a 
white solid. An analytical sample was obtained by the diffusion of petroleum ether into a 
solution of (-)-3.17 dissolved in ethyl acetate. Crystals suitable for X-ray crystallography 
were obtained (see Appendix for data). 
lH NMR (CDCh) 8 3.29 (d J=13.7Hz, 1H, PhCHa), 3.47 (d J=15.2Hz, 1H, NCHa), 3.83 (s, 
3H, OMe), 3.93 (d J=15.2Hz, 1H, NCHb), 3.99 (d J=13.7Hz, 1H, PhCHb), 5.71 (s, 2H, 
CH2CH=CH and CH2CH=CH), 7.19-7.40 (m, 10H, PhH), 
l3C NMR (CDCh) 8 38.0, 52.7, 56.9, 76.6, 126.4, 126.5, 127.6, 128.3, 129.3, 129.8, 130.7, 
136.4, 136.5, 169.1, 171.6. 
FTIR (KBr) 2951, 1738, 1645cm"l. 
HRMS (ES) 322.1444 (M++H). C2oH20N03 requires 322.1443. 
[aJo = -116.6°, c=1.0 CHCh 
Preparation of (2R)-I-Benzoyl-2-benzyl-pyrrolidine-2-carboxylic acid methyl ester (-
)-3.21. 
Olefin (-)-3.17 (18mg, 0.06mmol) was dissolved in dry MeOH (1.5mL) and reacted with 
10% palladium-on-carbon (3.6ing, 20% w/w), under a hydrogen atmosphere according to 
General Procedure F, to give (-)-3.21 (17mg, 95%)as a white solid. 
lH NMR (CDCb) 8 1.32 (m, 1H, CH2CHaCH2), 1.81 (m, 1H, CH2CHbCH2), 2.07 (m, IH, 
CCHa), 2.22 (m, 1H, CCHb), 2.82 (m, 1H, NCHb), 3.13 (dJ=13.7Hz, 1H, PhCHa), 3.82 (s, 
3H, OMe), 4.01 (dJ=13.7Hz, 1H, PhCHb), 7.24-7.46 (m, 10H, PhH), 
L3C NMR (CDCh) 823.6,34.5,37.4,51.7,52.5,68.7,126.7,127.1,128.1, 128.2, 130.1, 
131.2, 136.7, 136.8, 169.3, 174.3. 
FTlR (KBr) 2930, 1736, 1634, 1408cm-1• 
HRMS (El) 323.1523 (IVIl. C2oH2lN03 requires 323.1521. 
[aJo= -106.5°, c=1.0 CHCh. 
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Preparation of (2S,4S) and (2R,4S)-3-Benzoyl-4-(2-methylsulfanyl-ethyl)-2-tert-butyl-
oxazolidino-5-one, (+)-3.24 and 3.25 respectively. 
SMe 
PhCOJ.rO 
-10 
(+)-3.24 3.25 
(S)-Methionine (6g, 40.2mol) was treated with 1M aq. NaOH (40.2mL, 40.2mmol, 1 
equiv), and condensed with pivaldehyde (6.56mL, 60.3mmol, 1.5 equiv) according to 
Modified General Procedure A. Cyclisation with benzoyl chloride (4.68mL, 40.2mmol, I 
equiv) gave a crude mixture containing a 5:1 ratio, by IH NMR, of. (+)-3.24 and 3.25. 
Recrystallisation of the residue from MeOH gave the cis-5-oxazolidinone (+)-3.24 (9.175g, 
71%) as white. needles. Crystals suitable for X-ray crystallography were obtained (see 
Appendix for data). 
mp 123-125° C, (lit.6 126.2-126.6°). 
IH NMR (CDCh) 8 1.03 (s, 9H, C(CHl)J), 1.87 (s, 3H, SCHl), 2.03 (m, lH, CHaCH2S), 
2.19 (m, 1H, CHbCH2S), 2.37 (m, 1H, CHaS), 2.56 (m, IH, CHbS), 4.18 (dd J=3.4 and 
10.7Hz, 1H, H4), 6.09 (s, 1H, H2), 7.40 (m, 2H, PhH), 7.45-7.53 (m, 3H, PhH). 
8.5 Experimental Described for Chapter Four 
Preparation of (4S)-N-(4-Benzyl-3-oxo-2,3,4,5-tetrahydro-pyridazin-4-yl)-benzamide 
(-)-4.12. 
Ph~ I N 
" I 
" NH 
PhCOHN 
o 
Hydrazine monohydrate (0.362mL, 7.24mmol ,1.3equiv) was added to a solution of 
aldehyde (-)-2.19 (1.7g, 5,23mmol, 1 equiv) in THF (30mL), and the resulting solution was 
stirred at rt for 10min and then refluxed for 2 days. The mixture was cooled to rt and the 
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solvent removed to give a white solid. The solid was dissolved in ethyl acetate (lOmL), 
filtered through a silica plug, and the solvent removed to yield (-)-4.12 (1.378g, 85%) as a 
white solid. 
mp 189-192° C 
IHNMR (CDCb) 8 2.90 (d J=1802Hz, IH, CHaCH), 3.04 (d J=13.7Hz, 1H, PhCHa), 3.58 
(d 3.7Hz, lH, PhCHb), 3.90 (dd J=4.6 and 1802Hz, IH, CHbCH), 7.07 (m, 2H, PhH), 
7.19 (s, 1H, CH=N), 7.21-7.26 (m, 4H, PhCONH and PhH), 7.42 (t J=7.6Hz, 2H, PhH), 
7.51 (tJ=7.3Hz, IH, PhH), 7.70 (dJ=7.8Hz, 2H, PhH), 8.79 (brs, 1H, N=NH). 
l3C NMR (CDCb) 8 34.1,39.0,56.3, 126.9, 127.3, 128.2, 128.5, 130.0, 131.8, 134.1, 
134.4, 145.6, 167.1, 167.2. 
FTIR (KBr) 3387, 3229, 3125, 2878,1686,1647,1601,1582,1516, 1489cm-1 
HRMS (ES) 308.1395 (~+H). ClsH22N30 2 requires 308.1399. 
[a]D 28.4°, .0 CHCb. 
Preparation of (4S)-N-( 4-Benzyl-3-oxo-hexahydro-pyridazin-4-yl)-benzamide (-)-4.13. 
PJ:; I NH 
" I 
" NH 
PhCOHN 
o 
A small crystal of methyl orange was added to a solution of hydrazone (-)-4.12 (1.55g, 
5.05mmol) dissolved in MeOH (40mL) at O°C, causing the solution to turn yellow. Drops 
of 2N aqueous HCI in MeOH were added until the solution turned red. NaBH3CN 
(330mg, 5.3mmol, 1.05 equiv), was added slowly. Whenever the colour of the reaction 
mixture started to turn yellow during addition, drops of 2N aqueous HCI in MeOH were 
added immediately to restore to red colour. The reaction was stirred at O°C for 3h then 
allowed to warm to rt overnight. The solvent was removed under reduced pressure, the red 
residue taken up in ethyl acetate and washed with saturated aqueous NaHC03 (2x20mL), 
water (2x20mL) and dried over MgS04. The solvent was removed to give the product as a 
white foam. Purification by radial chromatography (EAlPE 1:3) yielded (-)-4.13 (1.135g, 
73%).as a sticky white solid. 
Chapter Eight 263 
IH NMR (CDCh) () 2.51 (m, 2H, CHzN) , 2.83 (m, 1H, CHaCH2N), 3.15 (m, 1H, 1H, 
CHbCH2N), 3.19 (d J=13.2Hz, lH, PhCHa), 3.53 (d J=13.2Hz, IH, PhCHb), 6.99 (brs, lH, 
NH), 7.23 (s, lH, NH), 7.26 (m, 2H, PhH), 7.31-7.35 (m, 3H, PhH), 7.42 (t J=7.5Hz, 2H, 
PhH), 7.50 (m, 1H, PhH), 7.20 (dJ=8.3Hz, 2H, PhH). 
BC NMR (CDCh) () 34.4, 43.6, 44.5,57.7, 127.0, 127.3, 128.3, 128.5, 130.3, 131.6, 133.8, 
134.8, 166.8, 173.2. 
FTIR (KBr)J248, 3063, 2936, 1649, 1638, 1580, 1508, 1483cm-1 
HRMS (ES+) 310.1549 (M++H). C1sH2oN30 2 requires 310.1556. 
[a]D -25.7°, .0 CHCh. 
P reparation of (7S,1S)-7-Benzoylamino-7-benzyl-8-oxo-hexahydro-pyrrazo10[1,2-
a]pyridazine-1-carboxylic acid ethyl ester 4.14. 
Formaldehyde (29M-L of 37% aqueous solution, 0.33mmol, 1.1 equiv) was added to a 
stirred solution of cyclic hydrazide (-)-4.13 (100mg, O.3mmol, 1 equiv), dissolved in ethyl 
acrylate (5mL) at 90°C, and the mixture then refluxed at 100-110° C for 4h. The mixture 
was then cooled to rt and the solvent removed under reduced pressure. Purification by 
radial chromatography (acetone/CHCh 1 :20) yielded 4.14 (26mg, 21 %) as a colourless oil. 
IH NMR (CDCh) () 1.28 (t J=7.3Hz, 3H, C02CH2CH3), 2.25 (m, IH, CHaCHC02Et), 2.55 
(m, 2H, CHbCHC02Et and CCHlICH2N), 3.00 (ddd J=6.3, 9.3 and 18.6Hz, IH, 
CHIICH2CHC02Et), 3.04 (m, 3H, CCH bCH2N and CCH2CHzN), 3.21 (m, lH, 
CHbCH2CHC02Et), 3.57 (d J=13.2Hz, IH, PhCHa), 3.68 (d J=13.2Hz, IH, PhCHb), 4.22 
(q J=7.3Hz, 2H, C02CH2CH3), 4.60 (dd J=2.6 and 9.0Hz, IH, CHC02CH2CH3), 7.05 (m, 
2H, PhH and NH), 7.20 (m, 3H, PhH), 7.38 (m, 3H, PhH), 7.47 (t J=7.3Hz, IH, PhH), 
7.72 (dJ=7.3Hz, 2H, PhH). 
13C NMR (CDCh) () 14.1,28.9,34.0,41.2, 52.1, 54.3, 57.5,59.5,61.8, 126.9, 127.0, 
128.1, 128.4, 130.0, 131.4, 134.8, 136.5, 165.5, 166.7, 170.2. 
FTIR (KBr) 2939, 1736, 1649cm"1 
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Preparation of 4.16. 
o 
P~./""-.. yNHCOPh INN "" 
", I I I 
' N N 
PhCOHN '-../" Ph 
o 
Formaldehyde (27J.LL of 37% aqueous solution, 0.31mmol, 1.1 equiv) was added to a 
stirred solution of cyclic hydrazide (-)-4.13 (94mg, 0.28mmol, 1 equiv), dissolved in ethyl 
acrylate (5mL) at 80a C, and the mixture then refluxed at 80-90° C for 4h. The mixture 
was then cooled to rt and the solvent removed under reduced pressure. Purification by 
radial chromatography (acetone/CHCb 1 :20) yielded 4.16 (41mg, 45%) as a white solid. 
IH NMR (CDCb) d 2.62 (m, 1H, CH2CHaN), 2.74 (m, 1H, CH2CHbN), 3.36 (m, 3H, 
CH2CH2N and CHaPh), 3.60(d J=13.7Hz, 1H, CHbPh), 4.42 (m, 1H, NCHIIN), 5.09 (d 
J=10.2Hz, 1H, NCHbN), 6.94 (s, 1H, NH), 7.20-7.67 (m, 10H, PhH). 
\3C NMR (CDCb) d 28.8, 42.3, 46.1, 58.6, 64.5, 126.9, 127.4, 128.4, 128.5, 130.2, 131.6, 
134.3, 135.1, 166.7, 170.0. 
HRMS (ES+) 643.3035 (M++H). C38H39N604 requires 643.3033. 
8.6 Experimental Described in Chapter Five 
Preparation of (3R)-3-Benzyloxycarbonylamino-hex-5-enoic acid methyl ester (+)-
5.25. 
) 
Method A: (+I-)-(3R)-5.25: Et3N (2.794mL, 20.4mmol, 1 equiv) and CIC02Et (1.920mL, 
20.4mmol, 1 equiv) were reacted with (+I-)-N-Cbz-Allyl glycine (5g, 20.1mmol, 1 equiv) 
according to General Procedure Ja. The resulting diazo ketone was dissolved in dry MeOH 
(80mL) and reacted with silver benzoate (506mg, 2.21mmol, 0.11 equiv) dissolved in Et3N 
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(8.103mL, 58.23mmol, 2.9 equiv), according to General Procedure Jb. Purification by 
column chromatography (EAlPE 1 :3) gave (+1-)-5.25 (5.254g, 94%) as a colourless oil. 
Method B: (+)-(3R)-5.25: Et3N (0.10mL, 0.72mmol, 1.2 equiv), DPPA (0.129mL, 
0.59mmol, 1 equiv) and benzyl alcohol (0.186mL, 1.80mmol, 3 equiv) were reacted with 
(+ )-5.41b (103mg, 0.59mmol) dissolved in toluene (6mL), according to Modified 
Procedure M, to give (+)-5.25 (11 7mg, 71 %) as a colourless oil. 
Method C: (+)-5.25: Ethereal diazomethane was added to a solution of 5.44 (80mg, 
0.38mmol, 1 equiv) dissolved in ether (3mL), according to General Procedure C, to give 
(+)-5.25 (83mg, 100%) as a colourless oil. 
lH NMR (CDCh) 8 2.34 (m, 2H, CH2CH=CH2), 2.56 (bd J=5.4Hz, 2H, CH2C02Me), 3.67 
(s, 3H, OMe), 4.06 (m, IH, aH), 5.08 (m, 4H, PhCH2 and =CH2), 5.22 (m, IH, NH), 5.74 
(m, IH, CH=CH2), 7.35 (m, 5H, PhH). 
l3C NMR (CDCh) 8 37.92, 38.55, 47.49, 51.61, 66.53, 118.35, 127.93, 127.97, 128.38, 
133.70, 136.39, 155.62, 171.77. 
FTIR (KBr) 3339, 1724, 1643, 1529cm-1• 
HRMS (El) 278.1391 (~+H). ClsH19N04 requires 278.1392. 
Micro. Calcd for ClsH19N04. C, 64.96; H, 6.91; N, 5.05. Found C, 64.67; H, 6.79; N, 5.33. 
[aJo = +4.2°, c=2.0 CHCh (lit.? +4.7°) .. 
Preparation of (2R,3R)-2-Allyl-3-benzyloxycarbonylamino-hex-5-enoic acid methyl 
ester (+)-5.26. 
Anhydrous LiCl (444mg, 10.83mmol, 3 equiv), LDA (3.971mL of a 2M solution in THF, 
7.94mmol, 2.2 equiv), and allyl bromide (1.258mL, 14.44mmol, 4 equiv) were reacted 
with a solution of (+1-)-5.25 (lg, 3.61mmol, 1 equiv), dissolved in THF (20mL) at _78° C 
under nitrogen, according to General Procedure K. Purification by radial chromatography 
(EAIPE 1:4) gave (+1-)-5.26 (674mg, 59%) as a colourless oil. 
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Anhydrous LiCI (294mg, 7.17mmol, 3 equiv), LDA (2.629mL of a 2M solution in THF, 
5.25mmol, 2.2 equiv), and allyl bromide (0.S33mL, 9.56mmol, 4 equiv) were reacted with 
(+)-5.25 (662mg, 2.39mmol, 1 equiv), dissolved in THF (12mL) at _78° C, according to 
General Procedure K. Purification by radial chromatography (EAlPE 1 :4) gave (+)-5.26 
(370mg, 49%) as a colourless oil. 
IH NMR (CDCb) 3 2.1S-2.44 (m, 4H, 2xCH2CH=CH2), 2.69 (m, IH, CHC02Me), 3.67 (s, 
3H, OCH3), 3.93 (m, 1 NHCH), 5.02-5.13 (m, 6H, PhCH2 and 2xCH=CH2), 5.63 (d 
J=9.SHz, IH, NH), 5.73 (m, 2H, 2xCH=CH2), 7.35 (s, 5H, PhH). 
13C NMR (CDCh) 3 34.2, 39.0,47.5,51.2,51.6,66.6, 117.5, 118.1, 127.9, 128.0, 128.4, 
133.S, 134.4,136.6,156.1,174.7. 
FTIR(KBr) 3344, 2953,1717,1643, 1506cm-'. 
HRMS (ES) 340.1536 (M++Na). C18H23N04Na requires 340.1525. 
Micro. Calcdfor C1sH23N04. C, 68.12; H, 7.3; N, 4.41. Found: C, 68.37; 7.47; N, 4.53. 
[aJD = +S.3°, 1.0 CH2Cb. 
Preparation of (6R,lR)-6-Benzyloxycarbonylamino-cyclohex-3-enecarboxylic acid 
methyl ester (-)-5.27. 
Catalyst 1.40 (46mg, 0.06mmol, 5mol%), dissolved in dry degassed benzene (0.5mL), was 
added to a solution of diene (+1-)-5.26 (355mg, 1.12mmol), dissolved in dry degassed 
benzene (1 OmL) under argon, according to General Procedure E. The mixture was then 
stirred at reflux for 4h. Purification by radial chromatography (EAIPE 1 :3) gave (+1-)-5.27 
(311 mg, 96%) as a colourless oiL 
Catalyst 1.42 (Smg, O.Olmmol, 5mol%), dissolved in dry degassed benzene (0.5mL), was 
added to a solution of diene (+)-5.26 (59mg, 0.19mmol), dissolved in dry degassed 
benzene (1 OmL) under argon, according to General Procedure E. The mixture was then 
stirred at reflux for 4h. Purification by radial chromatography (EAlPE 1 :3) gave (-)~5.27 
(49mg, 91 %) as a colourless oil. 
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IH NMR (CDCb) 8 1.99 (brd J=9.8Hz, IH, NHCHCHaCH=), 2.30 (dd and 5.9Hz, 
IH, CH(CHaCH=)C02Me), 2.49 (m, 2H, NHCHCHbCH= and CH(CHbCH=)C02Me), 
2.72 (m, IH, CHC02Me), 3.64 (s, 3H, OMe), 4.11 (m, IH, NHCH), 4.90 (brs, IH, NH), 
5.08 (s, 2H, PhCH2), 5.59 (m, IH, NHCHCH2CH=), 5.66 (m, IH, CH(CH2CH=)C02Me), 
7.33 (m, 5H, PhH). 
BC NMR (CDCb) 826.6,31.0,44.3,47.8, 51.8, 66.6, 124.1, 124.9, 128.0, 128.1, 128.4, 
136.4, 155.5, 173.9. 
FTIR (KBr) 3339, 3032,2930,2853, 1732, 1520cm-1. 
HRMS (ES) 290.1402 (M++H). C16I-hoN04 requires 290.1392. 
Micro. Calcdfor C16H19N04. C, 66.48; H, 6.62; N, 4.84. Found: C, 66.38; H, 6.83; N, 4.94. 
[a]D = -31.2°, CHCb (lit.8 33.5°). 
Preparation of (2R,lR)-2-Benzyloxycarbonylamino-cyclohexanecarboxylic acid 
methyl ester 5.28. 
(+1-)-5.28: 10%-Palladium-on-carbon (5mg, 20% w/w), DIEA (0.072mL, 0.42mmol, 2.4 
equiv), DMAP (6.2mg, 0.05mmol, 0.28 equiv) and benzylchloroformate (0.04mL, 
0.27mmol, 1.6 equiv) were reacted, with (+1-)-5.27 (50mg, 0.17mmol), dissolved in dry 
MeOH (3mL), according to General Procedure L, to give (+1-)-5.28 (43mg, 86%) as a 
colourless oiL 
(-)-5.28: 10%-Palladium-on-carbon (5mg, 20% w/w) , DIEA (0.029mL, 0.17mmol, 2.4 
equiv), DMAP (2.5mg, 0.02mmol, 0.28 equiv) and benzylchloroformate (0.016mL, 
0.112mmol, 1.6 equiv) were reacted, with (-)-5.27 (20mg, 0.07mmol), dissolved in dry 
MeOH (1.5mL), according to General Procedure L, to give (-)-5.28 (15mg, 75%) as a 
colourless oil. 
IH NMR (CDC b) 81.13-1.44 (m, 3H), 1.56-1.81 (m, 3H), 1.90 (m, IH), 2.06 (m, IH), 
2.27 (m, IH), 3.61 (s, 3H, OMe), 3.73 (ddd J=20.5,11.3 and 4.2Hz, IH), 4.08 (brs, IH), 
5.06 (s, 2H, PhCHz), 7.27-7.37 (m, 5H, PhH). 
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BC NMR (CDC13) (5 24.3, 24.6, 28.6, 32.8,49.7, 51.7, 66.5, 128.0, 128.4, 136.6, 155.4, 
174.3. 
FTIR (KBr) 3331, 1733cm-l. 
HRMS (El) 291.1474 (~). Cl6H21N04 requires 291.1471. 
[a]D -18.4°, c=0.9 CHCb (lit.9 _18°). 
Preparation of (6R,lR)-6-Benyloxycarbonylamino-cyclohex-5-enoic acid 5.29. 
1M Aq. NaOH (0.34mL, 0.35mmol, 2 equiv) was added to a solution of (+1-)-5.25 (50mg, 
0.17mmol) dissolved in MeOH (3mL), and refluxed for 4h according to General Procedure 
G, to give (+1-)-5.29 (47mg, 99%) as a yellow oil. 
IH NMR (CDCb) (5 2.00 (dd J=4.9 and 17.6Hz, IH, NHCHCHaCH=), 2.34 (bd 6.1Hz, 
1H, CH(CHaCH=)C02H), 2.52 (m, 2H, NHCHCHbCH= and CH(CHbCH=)C02H), 2.78 
(m, IH, CHC02Me), 4.13 (m, lH, NHCH), 5.07 (bs, lH, PhCHa), 5.11 (d J=12.3Hz, IH, 
PhCHb), 5.61 (m, IH, NHCHCH2CH=), 5.66 (m, lH, CH(CI-hCH=)C02Me), 7.33 (m, 5H, 
PhH). 
HRMS (ES) 257.1052 (M+-OH). C15H15N03 requires 257.1052. 
Preparation of 2-[(6-Benzyloxycarbonylamino-cyclohex-3-enecarbonyl)-amino]-3-
phenyl-propionic acid methyl esters 5.30a and'5.30b. 
(S)-Phenylalanine methyl ester hydrochloride (35mg, 0.l65mmol, 1.1 equiv), EDCl 
(39mg, 0.195mmol, 1.3 equiv), HOBt (32mg, O.225mmol, 1.5 equiv) and DlEA (0.035mL, 
O.165mmol, 1.1 equiv), were added to a solution of (+1-)-5.28 (40mg, O.15mmol, 1 equiv) 
dissolved in CH2Clz (5mL) and the solution stirred at rt for 2h. The mixture was washed 
with NaHC03 (lOmL), NaCl (lOmL), dried (MgS04), and the solvent removed under 
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reduced pressure. Attempted purification by radial chromatography (EA/PE 1: I) gave a 
fraction containing 5.30a and 5.30b (58mg, 91 %), in a ratio of 1: I by IH NMR, that could 
not be separated further. 
IH NMR (CDCh) B 2.20-2.37, (m, 2H, =CHCH2CHCO), 2.68, 2.78 (m, IH, CHCHCO) 
2.99-3.13 (m, 2H, CH2Ph), 3.64, 3.66 (s, 3H, OMe), 3.78, 3.87 (m, IH, NHCHCH), 4.81, 
4.85 (m, IH, CHC02Me), 5.01-5.22 (m, 3H, PhCH2 and NH), 5.57-5.64 (m, 2H, 
CH=CH), 6.37, 6.48 (m, IH, NH), 7.07-7.35 (m, lOH, PhH). 
13C NMR (CDCh) B 28.3, 31.1 (CH2CH=CHCH2), 37.6, 37.9 (CH2Ph), 45.6, 46.0 
(CHCHCO),48. 49.0 (NHCHCH), 52.2, 52.2 (OCH3), 53.0, 53.3 (CHC02Me), 66.6, 
66.8 (PhCH20), 124.4,124.6 (CH=CH), 125.0,125.2 (CH=CH), 127.0, 127.0, 127.1, 
127.9,128.0,128.1,128.4,128.5,128.5,128.6,129.1, 129.1 (Aromatic CH), 135.9,136.1, 
136.3, 136.4 (Aromatic C), 156.0 (CHCONH), 172.0 (CO), 173.2 (CO). 
Micro. Calcd for C16H19N04. C, 68.79; H, 6.47; N, 6.42; Found: C, 68.84; H, 6.20, N, 6.39. 
Preparation of (2R,3R)-2-Methyl-3-benzyloxycarbonylamino-hex-5-enoic acid methyl 
ester (+I-)-5.32a. 
) 
ZHNy 
C02Me 
Anhydrous LiCI (266mg, 6.5mmol, 3 equiv), LDA (2.383mL of a 2M solution in 
4.76mmol, 2.2 equiv), and Mel (0.543mL, 8.66mmol, 4 equiv) were reacted with a -780 C 
solution of (+1-)~5.25 (600mg, 2.17mmol) dissolved in THF (lOmL) under nitrogen, 
according to General Procedure K. Purification by radial chromatography (EA/PE 1:4) 
gave (+I-)-5.32a (543mg, 86%) as a colourless oil. 
IHNMR(CDCh) 0 1.22 (dJ=6.Hz, 3H, CCH3), 2.26 (m, 2H, CH2CH=CH2), 2.73 (m, IH, 
CHCH3), 3.67 (s, OCH3), 3.86 (m, 1H, NCH), 5.08 (m, 4H, OCH2 and CH=CH2), 
5.50 (dJ=9.3Hz, 1 NH), 5.75 (m, 1H, CH=CH2), 7.35 (m, 5H, PhH). 
l3C NMR (CDC b) B 14.7,38.2,51.5, 52.8, 66.4, 117.8, 127.8, 127.9, 128.3, 133.9, 136.5, 
156.2, 175.4. 
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FTIR (KBr) 3317, 2952, 1717, 1642, 1506, l206cm-1. 
Micro. Calcd for C16H21N04. C, 65.96; H, 7.26; N, 4.81. Found: C, 66.05; H, 7.33; N, 4.99. 
Preparation of (3 R,2R)-3-Benzyloxycarbonylamino-2-ethyl-hex-5-enoic acid methyl 
ester (+1-)-5.32b. 
) 
ZHN~Et 
C02Me 
Anhydrous LiCl (193mg, 4.7mmol, 3 equiv), LDA (1.727mL of a 2M solution in THF, 
3.45mmol, 2.2 equiv), and Etl (0.503mL, 6.28mmol, 4 equiv) were reacted with a -780 C 
solution of (+1-)-5.25 (435mg, 1.57mmol) dissolved in THF (lOmL) under nitrogen, 
according to General Procedure K. Purification by radial chromatography (EA/PE 15185) 
gave (+1-)-5.32b (302mg, 63 %) as a colourless oiL 
IH NMR (CDC b) 8 0.93 (t J=7.2Hz, 3H, CH2CH3), 1.58 (m, lH, CHaCH3), 1.71 (m, lH, 
CHbCH3), 2.17-2.27 (m, 2H, CH2CH=CH2), 2.51 (m, IH, CHC02Me), 3.68 (s, 3H, OMe), 
3.93 (m, IH, NHCH), 5.05-5.13 (m, 4H, CH=CH2 and PhCH20), 5.62 (d J=9.8Hz, IH, 
NH), 5.75 (m, IH, CH=CH2), 7.35 (m, 5H, PhH). 
I3C NMR (CDCh) 8 11.7, 23.0, 38.7, 49.2, 51.0, 51.3, 66.3, 117.8, 127.7, 127.8, 128.2, 
133.8, 136.5,156.1,175.2. 
FTIR(KBr) 3342,2930, 1720, 1643, 1502, 1227cm- l . 
HRMS (ES) 306.1711 (M++H). C17H24N04 requires 306.1705. 
Micro. Calcd for C17H23N04. C, 66.86; H, 7.59; N, 4.59: Found: C, 66.14; H, 7.31; N, 
4.59. 
Preparation of (2R,3R)-2-Allyl-3-benzyloxycarbonylamino-2-methyl-hex-5-enoic acid 
methyl ester (+I-)-5.33a. 
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Anhydrous LiCI (25mg, 0.62mmol, 3 equiv), LDA (0.226mL of a 2M solution in THF, 
0.45mmol, 2.2 equiv), and allyl bromide (0.072mL, 0.84mmol, 4 equiv) were reacted with 
a -780 C solution of (+I-)-5.32a (60mg, 0.21mmol) dissolved in THF (ImL) under 
nitrogen, according to General Procedure K. Purification by radial chromatography 
(EAIPE 1:9) gave (+I-)-5.33a (32mg, 47%) as a colourless oil. 
IH NMR (CDCb) 0 1.19 (s, 3H, CCH3), 1.93 (m, 1 H, C3CHaCH=CH2), 
2.24 (ddJ=7.3 and 13.7Hz, IH, C2CHaCH=CH2), 2.43 (m, 1H, C3CHbCH=CH2), 2.51 (dd 
J=7.3 and 13.7Hz, 1H, C2CHbCH=CH2), 3.65 (s, 3H, OCH3), 3.80 (td J=3.4 and 10.8Hz, 
IH, NCH), 5.07 (m, 6H, OCH2 and 2 x CH=CH2), 5.44 (d 0.7Hz, IH, NH), 5.79 (m, 
2H, 2 x CH=CH2), 7.30 (m, 5H, PhH). 
I3C NMR (CDCh) 0 19.4,36.0,41.3,49.6,51.7,56.3,66.5, 117.5, 118.8, 127.9, 127.9, 
128.4, 133.0,134.4, 136.6, 156.2, 175.9. 
FTIR (KBr) 3348, 3076, 2980, 1724, 1641 cm-I. 
HRMS (ES) 332.1863 (M+H). C19H25N04 requires 332.1862. 
Micro. Calcd for C19H25N04. C, 68.86; H, 7.60; N, 4.23. Found: C, 68.80; H, 7.60; N, 4.23. 
Preparation of (2R,3R)~2-Allyl-3-benzyloxycarbonylamino-2-ethyl-hex-5-enoic acid 
methyl ester (+I-)-5.33b. 
) ~ ZHNq. 
C02Me 
Anhydrous LiCl (36mg, 0.89mmol, 3 equiv), LDA (0.324mL of a 2M solution in THF, 
0.65mmol, 2.2 equiv), and allyl bromide (O.l03mL, 1.2mmol, 4 equiv) were reacted with a 
_780 C solution of (+I-)-5.32b (90mg, 0.3mmol) dissolved in THF (1.5mL) under nitrogen, 
according to General Procedure K. Purification by radial chromatography (EAlPE 1 :9) 
gave (+I-)-5.33b (41mg, 42%) as a colourless oil. 
IH NMR (CDCh) 00.89 (t J=7.5Hz, 3H, CH2CH3), 1.64 (m, lH, CHaCH3), 1.78-1.96 (m, 
2H, CHbCH3 and CHCHaCH=CH2), 2.35 (m, 2H, CHCHbCH=CH2 and CCHaCH=CH2), 
2.52 (ddd J=6.8, 16.1 and 30.7Hz , 1H, CCHbCH=CH2), 3.68 (s, 3H, OMe), 3.97 (ddd 
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J=3.2, 11.3 and 21.2Hz, 1H, NHCH), 4.97-5.14 (m, 6H, 2xCH=CHz and PhCHzO), 5.32 
(dJ=10.3Hz, 1H, NH), 5.55-5.77 (m, 2H, 2xCH=CH2), 7.35 (m, 5H, PbH). 
BC NMR (CDCh) 8 7.7, 24.3, 36.2, 36.3, 51.8, 52.9, 54.1, 66.6, 117.4, 118.3, 127.9, 
128.0, 128.4, 133.7, 134.5, 136.7, 156.5, 175.8. 
FTIR (KBr) 3350,2930, 1720, 1643, 1502, 1223cm-1• 
Pre par at io n 0 f (6R,lR)-6~ Benzyloxycarbonylamino-l-methyl-cyclohex-3-ene-
carboxylic acid methyl ester (+I-)-5.34a 
Catalyst 1.40 (3mg, 5mol%), dissolved in d,y degassed benzene (0.5mL), was added to a 
solution ofdiene (+I-)-5.33a (25mg, 0.08mmol), dissolved in d,y degassed benzene (lmL) 
under argon, according to General Procedure E. The mixture was then stirred at reflux for 
4h. Purification by radial chromatography (EAIPE 1:3) gave (+I-)-5.34a 24mg, 96%) as a 
colourless oil. 
IH NMR (CDCb) 8 1.17 (s, 3H, C2CH3), 1.89 (dd J=17.1 and 1H, C2CHa), 1.95 (dd 
J=17.6 and 2Hz, 1H, NCHa), 2.42 (d J=17.6Hz, 1H, NCHb), 2.72 (d J=17.l, 1H, C2CHb), 
3.65 (s, 3R, OCH3), 4.31 (m, IH, C3H), 4.79 (d J=9.3Hz, IH, NH), 5.09 (s, 2H, OCHz), 
5.56 (m, IH, NCH2CH=CH), 5.65 (m, IH, NCH2CH=CH), 7.35 (m, 5H, PhH). 
FTIR (KBr) 3346, 3032, 2932, 2851, 1728, 1526cm-1• 
Preparation of (6R,lR)-6-Benzyloxycarbonylamino-l-ethyl-cyclohex-5-enoic acid 
methyl ester (+I-)--5.34b. 
Catalyst 1.40 (2.5mg, 5mol%), dissolved in dry degassed benzene (0.5mL), was added to a 
solution of diene (+I-)-5.34b (21mg, 0.06mmol) dissolved in d,y degassed benzene (lmL) 
under argon, according to General Procedure E. The mixture was then stirred at reflux for 
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4h. Purification by radial chromatography (EAlPE 1:9) gave (+/-)-5.34b (18mg, 94%) as a 
colourless oil. 
'H NMR (CDCh) 0 0.81 (t J=7.8Hz, 3H, CHzCH3), 1.51 (ddd J=28.8, 14.2 and 7.3_Hz, 
IH, CHaCH3), 1.77 (m, 2H, CHbCH3 and CHaCC02Me), 2.02 (d 8.6Hz, IH, 
CHCHaCH=), 2.38 (dJ=18.6Hz, IH, CHCHbCH=), 2.75 (dJ:=18.6Hz, lH, CHbCCOzMe), 
3.68 (s, 3H, C02Me), 4.37 (dJ=1O.2Hz, 1H, NHCH), 4.86 (d 0.2Hz, 1H, NH), 5.10 
(dd J=21.5. and 2.2Hz, 2H, PhCHz), 5.55 (m, IH, CHCH2CH=), 5.70 (m, 1H, 
=CHCH2CC02Me), 7.34 (m, 5H, PhH). 
l3C NMR (CDCh) 0 8.4, 28.6, 29.3, 30.5, 49.0, 49.8, 51.9, 66.9, 123.4, 125.9, 128.2, 
128.5, 136.3, 156.3, 175.0. 
FTlR(KBr) 3343, 3032, 2951,1732,1717,1504,1454, 1234cm-'. 
HRMS (ES) (M++H). C'SHZ4N04 requires 318.1705. 
Preparation of (2S,3R)-2-Allyl-3-benzyloxycarbonylamino-2-methyl-hex-5-enoic acid 
methyl ester (+/-)-5.35. 
Anhydrous LiCl (43mg, 1.0mmol, 3 equiv), LDA (0.381mL of a 2M solution in THF, 
0.76mmo1, 2.2 equiv), and Mel (0.086mL, l.4mmol, 4 equiv) were reacted with a-78° C 
solution of (+1-)-5.26 (11 Omg, 0.35mmol) dissolved in THF (1.8mL) under nitrogen, 
according to General Procedure K. Purification by radial chromatography (EAlPE 15:85) 
gave (+1-)-5.35 (71mg, 68%) as a colourless oil. 
'H NMR (CDCb) 01.14 (s, 3H, CH3), 1.99 (m, IH, C3CHaCH=CHz)' 2.19-2.33 (m,2H, 
C2CHaCH=CH2 and C3CHbCH=CHz), 2.56 (dd J=6.6 and 23.9Hz, IH, C2CHbCH=CHz), 
3.67 (s, 3H, COzMe), 4.00 (td and 10.7Hz, lH, NHCH), 4.93 (d J=lO.3Hz, 1H, 
NH), 4.97-5.13 (m, 6H, PhCH2 and 2 x CH=CH2), 5.73 (m, 2H, 2 x CH=CHz), 7.29-7.37 
(m, 5H, PhH). 
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Preparation of (6R,1S)-6-Benzyloxycarbonylamino-l-methyl-cyclohex-3-ene-
carboxylic acid methyl ester (+1-)-5.36. 
Catalyst 1.40 (1.7mg, 5mol%), dissolved in dry degassed benzene (0.5rnL), was added to a 
solution of diene (+1-)-5.35 (14mg, 0.04mrnol, 1 equiv), dissolved in dry degassed benzene 
(1 mL) under argon, according to General Procedure The mixture was then stirred at 
reflux for 4h. Purification by radial chromatography (EAlPE 1 :3) gave (+1-)-5.36 (12mg, 
91 %) as a colourless oiL 
IH NMR (CDCb) (5 1.27 (s, 3H, CCH3), 2.06 (dd J=2.4 and 21.0Hz, 1H, =CHCHaC), 2.12 
(m, IH, CHCHaCH=), 2.37 (m, IH, CHCHbCH=), 2.69 (dd J=4.4 and 17.1Hz, 1H, 
=CHCHaC), 3.66 (s, 3H, OMe), 3.94 (m, IH, NHCH), 5.10 (dd .0 and 12.7Hz, 2H, 
PhCH20), 5.56-5.65 (m, 3H, CH=CH and NH), 7.30.7.37 (m, 5H, PhH). 
l3C NMR (CDCb)(5 23.3, 30.8,35.1,45.2,51.9,52.6,66.6,125.1,125.3,128.0,128.5, 
136.6, 156.2, 176.6. 
FTIR (KBr) 3437, 2951,1724,1504 ern-I. 
HRMS (El) 303.1471 (M+). C17H21N04 requires 303.1475. 
Prepa ra tion of (6R , lR)-6-(Benzyloxycarbonyl-methyl-amino)-cyclohex-3-ene-
carboxylic acid methyl ester (+1-)-5.37. 
z,~iI 
Me C02Me 
Anhydrous LiCI (26mg, 0.6mmol, 3 equiv), LDA (0.381mL of a 2M solution in THF, 
0.47mrnol, 2.2 equiv), and Mel (0.053rnL, 0.9mrnol, 4 equiv) were reacted with a-78° C 
solution of (+1-)-5.27 (62mg, 0.21mmol) dissolved in THF (lmL) under nitrogen, 
according to General Procedure K. Purification by radial chromatography (EAlPE 1 :3) 
gave (+1-)-5.37 (51mg, 78%) as a colourless oil. Further elution also gave 7mg (11%) of 
starting material (+1-)-5.27. 
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Reported as a mixture of rotamers: lH NMR (CDCb) 0 2.13-2.46 (m, 4H, 
CH2CH=CHCH2), 2.83, 2.84 (s, 3H, NMe), 2.91 (m, 1H, CHC02Me), 3.56, 3.58 (s, 3H, 
OMe), 4.39 (m, 1H, NHCH), 5.12 (m, 3H, PhCH20 and NH), 5.63 (brs, 2H, CH=CH), 
7.28-7.39 (m, 5H, PhH). 
HRMS (ES) 303.1468 (M\ C17H21N04 requires 303.1471. 
Preparation of 4-Pentenoyl Chloride 5.38. 
4-Pentenoic acid (9.5mL, 0.094mol, 1 equiv) was dissolved in dry ether (40mL) and 
cooled to O°C. Oxalyl chloride (9.03mL , O.I03mol, 1.1 equiv) was slowly added and the 
solution stirred at O°C for 10 minutes. 4 Drops of dry dimethylforrnamide from a pPasteur 
pipette were then added and the solution allowed at warm to room temperature overnight. 
Purification by distillation gave 4-pentenoyl chloride 5.38 as a colourless liquid (l0.322g, 
93%). 
IH NMR (CDCh) 02.45 (q J=13.9 and 7.1Hz, 2H, CH2CH=CH2), 2.99 (t J=7.3Hz, 2H, 
CICOCHz), 5.10 (m, 2H, CH=CH2), 5.78 (m, 1H, CH=CH2). 
Preparation of (4S)-4-Benzyl-3-pent-4-enoyloxazolidin-2-one (+)-5.39. 
(S)-(-)-Benzyl-2-oxazolidinone (6g, 33.9mmol, 1 equiv) was dissolved in THF (lOOmL) 
and cooled to -78°C under argon. N-Butyllithium (24.18mL of 1.6M solution in THF, 
37.3mmol, 1.05 equiv) was added dropwise over 10min and the solution was stirred for an 
additional lOmin. 4-Pentenoyl chloride 5.38 (4.23mL, 37.3mmol, 1.05 equiv) was then 
added dropwise over 10min and the solution stirred at -78°C for 15min and then at rt for 
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30min. The solution was quenched with sat. aq. NH4CI at O°C, the solvent removed under 
reduced pressure, and the residue extracted with CH2Ch (3x50mL). The organic extracts 
were combined, washed with 1M aqueous NaOH (50mL), water (50mL), brine (50mL), 
dried (MgS04) and the solvent removed under reduced pressure to yield (+)-5.39 (8.593g, 
97%) as a colourless oil. 
IH NMR (CDCb) 8 2.45 (ddd J=21.5, 8.1 and 1.5Hz, 2H, CH2CH=CH2), 2.76 (dd J=9.5 
and 13.4Hz, 1H, CHaPh), 3 .. 05 (ddt J=43.2, 17.4 and 7.3Hz, 2H, NCOCH2), 3.29 (dd 
J=13.4 and 3.2Hz, 1H, CHbPh), 4.15 (dd J=9.3 and 2.9Hz, 1H, OCHa), 4.19 (t J=8.1Hz, 
IH, OCHb), 4.66 (m, lH, NCH), 5.07 (m, 2H, CH=CH2), 5.88 (m, 1H, CH=CH2), 7.20 (d 
J=7.3Hz, 2H, PhH), 7.27 (tJ=7.3Hz, 1H, PhH), 7.33 (tJ=7.3Hz, 2H, PhH). 
BC NMR (CDCb) 828.1,34.7,37.8,55.1,66.1,115.6, 127.3, 128.9,129.3,135.2,136.6, 
153.4,172.5. 
FTIR (KBr) 3368, 2924, 1782, 1732, 1643, 1389, 1211cm-1. 
HRMS (El) 259.1213 (M+). ClsH17N03 requires 259.1208. 
[aJD = +63.4°, c=0.83 CHCb (lit. 10 +64.2°). 
Preparation of (2R,4S)-3-«4-(tert-Butoxy)-2-allyl-4-oxobutanoyl)-4-phenylmethyl)-
1,3-oxazolidin-2-one (+)-5.40a. 
) 
NaHMDS (7.381mL of a 1M solution in THFlhexane, 7.38mmol, 1.1 equiv) was added, 
over 5min, to a-78° C solution of (+)-5.39a (1.738g, 6.71mmol, 1 equiv) dissolved in THF 
(50mL) under argon. and the solution stirred at -78° C for 1h. tert-Butyl-bromoacetate 
(2.971mL, 20.1mmol, 3 equiv) was added and the solution was stirred at -78° C for 3 h. 
Upon warming to rt, the reaction mixture was partitioned between sat. aq. NH4CI (20mL) 
and ethyl acetate (20mL), and the layers separated. The aqueous layer was back extracted 
with ethyl acetate (3x10mL) and the combined ethyl acetate extracts dried over MgS04. 
Removal of the solvent under reduced pressure, followed by purification by radial 
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chromatography (EA/PE 15185), gave (+)-5.40a (2.076g, 86%) as a white solid. An 
analytical sample was obtained by the diffusion of petroleum ether into a solution of (+)-
5.40 dissolved in ethyl acetate. Crystals suitable for X-ray crystallography were obtained 
(see Appendix for data). 
IHNMR (CDCh) 8 1.42 (s, 9H, C(CH3)3), 2.20 (m, 1H, CH aCH=CH2), 2.29 (m, IH, 
CHbCH=CH2), 2.46 (dd J=4.1 and 6.8Hz, 1H, CHaC02tBu), 2.72-2.83 (m, 2H, CHaPh and 
CHbC02tBu), 3.31 (dd J=3.2 and 13.5Hz, 1H, CHbPh), 4.13 (dd J=3.5 and 8.4Hz, 2H, 
OCH2), 4.26 (m, 1H, NCOCH), 4.63 (m, 1H, CHCH2Ph), 5.06 (m, 2H, CH=CH2), 5.77 
(m, 1H, CH=CH2), 7.25 (m, 3H, PhH), 7.32 (m, 2H, PhH). 
l3C NMR 8 28.0,36.1,36.6,37.5,38.9,55.4,65.8,80.6,117.7, 127.1, 128.8, 129.4, 134.4, 
135.6, 153.0, 171.1,175.0. 
FTIR (KBr) 2978, 1773, 1732, 1699cm-1• 
HRMS (ES) 396.1791 (~+Na). C21H27NOsNa requires 396.1787. 
[a]D = +51.20 , c=1.0 CH2Ch. 
Preparation of (2R)-2-Allyl-succinic acid 4-tert-butyl ester (+)-5.41a. 
) 
O~C02tBU 
OR 
H20 2 (1.276mL of 50% wlw in water, 18.8mmol, 4 equiv) and aq. LiOH (225mg, 
9.4mmol, 2 equiv, in 20mL of water) were added to a O°C solution of (+)-5.40a (1.75g, 
4.7mmol, 1 equiv) in THF (50mL). The reaction was stirred at O°C for 1 h, whereupon 
satd. aq. NaHS03 (lOmL), and satd. aq. NaHC03 (lOmL) were added and the mixture 
stirred for an additional 20min. THF was removed under reduced pressure and the residue 
diluted with CH2Ch (lOmL) and water (lOmL). The organic layer was separated, the 
solvents removed under reduced pressure, and the resulting white solid recrystallised from 
EA/PE to yield (S)-(-)-benzyl-2-oxazolidinone (821mg, 99%) as white needles. The 
aqueous layer was then acidified with 3M aqueous HCI and extracted with CH2 Ch 
(3x10mL). The combined organic extracts were washed with water (lOmL), brine (lOmL), 
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and dried over MgS04. The solvent was removed under reduced pressure to yield (+)-
5.41a (953mg, 95%) as a white solid. 
IH NMR (CDCh) 8 1.43 (s, 9H, C(CH3)3), 2.30 (m, 1H, CHaCH=CH2), 2.39-2,48 (m, 2H, 
CHbCH=CH2 and CHaC02tBu), 2.59 (dd J=16.8 and 8.9Hz, 1H, CHbC02tBu), 2.90 (m, 
1H, H02CCH), 5.09 (m, 2H, CH=CH2), 5.74 (m, 1H, CH=CH2). 
13C NMR 8 28.0,35.6,36.2,40.9,81.0, 118.0, 134.2, 171.0, 180.3. 
[a]D = +3.4°, c=1.4 CH2Ch. Oit. ll +3.4°) 
Preparation of (2R)-2-Allyl-succinic acid 4-methyl ester (-)-5.41b. 
) 
HO~C02Me 
o 
H20 2 (0.168mL of 50% w/w in water, 2,48mmol, 4 equiv) and aq. LiOH (29mg, 
1.24mmol, 2 equiv, in 3mL of water) were added to a O°C solution of 5.40b (205mg, 
0.62mrnol, 1 equiv) in THF (10mL). The reaction was stirred at O°C for 1 h, whereupon 
satd. aq. NaHS03 (10mL), and satd. aq. NaHC03 (lOrnL) were added and the mixture 
stirred for an additional 20min. THF was removed under reduced pressure and the residue 
diluted with CH2Ch (10mL) and water (lOmL). The organic layer was separated, the 
solvents removed under reduced pressure, and the resulting white solid recrystallised from 
EA/PE to yield (S)-( -)-benzyl-2-oxazolidinone (106mg, 97%) as white needles. The 
aqueous layer was then acidified with 3M aqueous HCI and extracted with CH2Ch 
(3x10mL). The combined organic extracts were washed with water (lOrnL), brine (lOmL), 
and dried over MgS04• The solvent was removed under reduced pressure to yield (-)-
5.41b (54mg, 51%) as a white solid. 
IH NMR (CDCh) 8 2.34 (m, 1 CHaCH=CH2), 2.47 (m, 2R, CH bCH=CH2 and 
CHaC02Me), 2.69 (dd J=8.9 and 16.8Hz, 1H, CHbC02Me), 2.97 (m, 1H, H02CCH), 3.68 
(s, 3H, OMe), 5.10 (m, 2H, CH=CH2), 5.73 (m, 1R, CH=CH2). 
[a]D (0.5 CH2Ch) 
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Preparation of tert-Butyl (3R)-N-(Benzyloxycarbonyl)-3-amino-4-allylbutanoate (+)-
5.42a. 
) 
Et3N (1.073mL, 7.71mmol, 1.1 equiv), DPPA (1.508mL, 7.01mmol, 1 equiv), and benzyl 
alcohol (2.175mL, 21.03mmol, 3 equiv) were reacted with a solution of (+)-5.41a (1.5g, 
7.01mmol, 1 equiv) in toluene (60mL), according to Modified General Procedure M. 
Purification by column chromatography (EAlPE 1:9) gave (+)-5.42a (1.752g, 79%) as a 
colourless oil. 
IH NMR (CDCh) 8 1.43 (s, 9H, C(CH3)3), 2.32 (m, 2H, CH2CH=CH2), 2.42 (d J=5.4Hz, 
2H, CH2C02tBu), 4.03 (m, 1H, NCH), 5.08 (m, 4H, CH=CH2 and PhCH2), 5.27 (d 
J=8.3Hz, 1H, NH), 5.76 (m, 1H, CH=CH2), 7.28 (m, 5H, PhH) .. Compare series 6 of 
Evans ref 
l3C NMR 8 27.9, 38.7, 39.3, 47.7, 66.5, 81.0, 115.3, 118.2, 127.9, 1128.4, 133.9, 136.5, 
155.6, 170.7. 
HRMS (ES) 342.1680 (M++Na). CISH25N04Na requires 342.1681. 
[aJD = +1.8°, c=1.0 CH2Ch. 
Preparation of (3R)-3-tert-Butoxycarbonylamino-hex-5-enoic acid tert-butyl ester (-)-
5.43. 
) 
Et3N (O.078mL, 0.56mmol, 1.2 equiv), CIC02Et (0.050mL, 0.52mmol, 1.1 equiv), NaN3 
(76mg in 1mL of water, 1.17mmol, 2.5 equiv), and tert-butyl alcohol (0. 134mL, 1.4mmol, 
3 equiv) were reacted with a solution of (+ )-5.41a (100mg, 0.4 7mmol), dissolved in dry 
acetone (5mL), according to General Procedure M. Purification by column 
chromatography (EAlPE 1 :9) gave (-)-5.43 (90mg, 68%) as a colourless oil. 
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IH NMR (CDCh) 8 1.42 (s, 9H, C(CH3)3), 1.44 (s, 9H, C(CH3)3), 2.28 (m, 2H, 
CH2CH=CH2), 2.41 (d J=5.4Hz, 2H, CH2C02tBu), 3.95 (m, IH, NCH), 4.99 (s, IH, NH), 
5.08 (m, 2H, CH=CH2), 5.76 (m, IH, CH=CH2). 
[a]D = -9.8°, .1 MeOH, (lit.lI -10.09°). 
Preparation of (3R)-3-Benzyloxycarbonylamino-hex-5-enoic acid 5.44. 
) 
Me2S (0.346mL, 4.7mmol, 10 equiv) was added to a 0° C solution of (+)-5.42 (150mg, 
0.47mmol, 1 equiv), dissolved in CH2Ch/TFA (7:3, 4mL), and the mixture stirred at rt for 
3.5h. Upon removal of the solvents under reduced pressure, the residue was taken up in 
CH2Ch (5mL) and extracted with 1M NaOH (15mL). The aqueous layer was then washed 
with CH2Ch (2xI5mL), acidified to pH 1 with 1M HCI, and extracted with CH2Ch 
(3xl0mL). The combined organic extracts were dried (MgS04), and the solvent removed 
under reduced pressure to give 5.44 (107mg, 87%) as a colourless oil. 
IH NMR (CDCh) 8 2.36 (m, 2H, CH2CH=CH2), 2.61 (d J=4.9Hz, 2H, CH2C02H), 4.08 
(m, IH, NCH), 5.l1 (m, 4H, CH=CH2 and PhCH2), 5.21 (d J=7.8Hz, IH, NH), 5.74 (m, 
1H, CH=CH2), 7.34 (m, 5H, PhH). 
Preparation of (S)-2-[N-(N'-benzylprolyl)-amino]benzophenone (BPB) 5.47. 
Q~o Ph N CO 
I I 
Bn HN ~ 
1// 
Freshly distilled SOCh (0.074mL, 1.02mmol, 2 equiv) was slowly added to a solution of 
(S)-N-benzyl proline (166mg, 0.81mmol, 1.6 equiv) suspended in CH2Ch (5mL) at -30° C, 
and the mixture stirred at -30° C until it became semi-transparent. A solution of 2-
aminobenzophenone (100mg, 0.51mmol, 1 equiv) in CH2Ch (2mL) was then added and 
the solution stirred at -30° C for 10h. After warming to 0° C, a solution of Na2C03 
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(l61mg, 1.52mmol, 3 equiv, in 3mL of water) was added and the organic layer separated. 
The aqueous layer was extracted with CHzCh (3x10mL) and the combined organic extracts 
dried over MgS04. The solvent was removed under reduced pressure and the residue 
purified by radial chromatography (acetone/CHCb 1 :9, streaky) to give 5.47 (l13mg, 58%) 
as a white solid. 
mp 99-101 ° C, (lit. 1Z 101-102°). 
IH NMR (CDOD 500MHz) 8 1.80 (m, 2H), 1.96 (m, 1H), 2.25 (ddd J=22.7, 13.2 and 
9.8Hz, 1H), 2A1 (ddJ=9.6 and l6AHz, 1H), 3.22 (tJ=6.8Hz, lH, a-Hpro), 3.32 (ddJ=4.8 
and 14.8Hz, 1H), 3.59 (d 13.2Hz, lH, CHaPh), 3.92 (d .2Hz, 1H, CHbPh), 7.07-
8.56 (m, 14H, PhH), 11.53 (brs (lH, NH). 
Note: Connnercial samples ofBPB were used in all subsequent reactions. 
Preparation of Gly-Ni-BPB Complex (+)-5.48.12 
A solution of 1.2N MeONa (l5mL, 18mmol, 5 equiv) was quickly added to a 50° C 
suspension of BPB 5.47 (lg, 2.6mmol, 1 equiv, commercial sample), Ni(N03)z.6Hz) 
(1.49g, 5.1mmol, 2 equiv), and glycine (0.97g, 13mmol, 4 equiv) dissolved in MeOH 
(50mL) under argon, and the resulting red mixture was stirred vigorously at 50° C for 2h. 
Water (50mL) was then added and the complex extracted with CHCh (4x20mL). The 
combined organic extracts were dried (NazS04) and the solvent removed under reduced 
pressure. Purification by column chromatography (CHCb/acetone 5:1) gave (+)-5.48 
(1.158g, 90%) as a red solid. 
IH NMR (CD30D) 81.75 (m, 3H, prolyl-H), 2.23 (m, IH, prolyl-H), 2.52 (m, IH, prolyl-
H), 3.19 (m, IH, prolyl-H), 2.29 (m, 1H, prolyl-H), 3.30 (t J=1AHz, 2H, gly-CHz), 3.73 
(dd J=12.7 and 32.2Hz, 2H, PhCHz), 7.09-8.18 (14H, PhH). 
LRMS (ES) 498.0 (~-H). C27H26N303Ni requires 499.2. 
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[aJD +1880 (c=O.l25*, MeOH), (lit.13 +2006°, c=1.0 MeOH). 
*Unable to obtain a reading at c=1.0, MeOH. 
Preparation Alkylation of Gly-Ni-BPB Complex with Allyl Bromide of 5.49. 14 
282 
Finely powdered NaOH (200mg, 5mmol, 2.5 equiv) and allyl bromide (0.26mL, 3mmol, 
1.5 equiv) were added to a stirred mixture of the red Ni-BPB-glycine complex (+)-5.48 
(1 2mmol, 1 equiv), in dry CH3CN (lOmL) under N2, and the mixture was stirred at rt for 
3h. O.lM HCI (30mL) was then added and the solution extracted with CH2Clz (4x20mL). 
The organic extracts were combined, dried over MgS04 and the solvent removed under 
reduced pressure. Purification by column chromatography (2:1 CH2Clz/Me2CO) gave 5.49 
(1.02g, 93%) as a red solid. 
IH NMR (CDCDCh 500MHz) 02.0-2.17 (m, 2H), 2.38-2.59 (m, 3H), 2.77 (m, 1H), 3.41-
3.54 (m, 3H), 3.59 (d J=12.5Hz, 1H, CHaPh), 4.02 (m, 1H, gly-aH), 4.42 (d 2.5Hz, 
1H, CHbPh), 5.15-5.41 (m, 2H, CH=CH2), 6.43 (m, 1H, CH=CH2), 6.61-8.17 (m, 14H, 
PhH). 
l3C NMR (CDCh) 023.3 (y-Cpro), 30.7 (~-Cpro), 38.4 (CH2CH=CHz), 56.8 (o-Cpro), 
63.1 (CHzPh), 70.2, 70.3 (a-Cpro and CHCH2CH=CH2), 119.7 (CH=CI-Iz), 120.65 (ArC), 
123.6 (CH=CH2), 126.4, 127.0, 127.7, 128.5,128.8, 129.0, 129.7, 130.0, 131.5, 132.1, 
132.2, 133.1, 133.3, 133.9, 142.4 (ArC), 170.8 (C=N), 178.8 (NCO), 180.3 (CHC02). 
Preparation of Allylglycine.HCI (-)-5.50. 
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A solution of (+)-5.49 (1.02g, 1.9mmol) in MeOH (33mL) was added to a warm 2N HCI 
solution (23mL) and the mixture stirred at reflux for Ih. The resulting pale orange solution 
was then cooled to rt and conc. NH4 added until the pH was between 9-10. The pale green 
aqueous layer was extracted with CH2Ch (3x20mL), the organic extracts combined, and 
the solvent removed under reduced pressure to give BPB (+)-5.47 (681mg, 97%) as a white 
solid. The remaining blue aqueous layer was purifed by ion exchange chromatography 
(IN HCI) to give (-)-5.50 (234mg, 82%), as a white solid. 
IH NMR (D20) 8 2.53-2.68 (m, 2H, CH2CH=CH2), 3.92 (m, IH, aH), 5.31 (m, 2H, 
CH=CH1), 5.69 (m, IH, CH=CH2). 
1, 6N HCI, (lit. 14 6.4°). 
8.7 Experimental Described in Chapter Six 
Preparation of (3R)-3-Benzyloxycarbonylamino-5-methylsulfanyl-pentanoic acid 
methyl ester (-)-6.16. 
Et3N (2.548mL, 17.67mmol, 1 equiv), CIC02Et (l.663mL, 17.67mmol, 1 equiv) and 
ethereal diazomethane, were reacted with a-15° C solution of (S)-N-Cbz-methionine 6.15 
(Sg, 17.67mmol), in (90mL) under nitrogen, according to General Procedure Ja. The 
resulting diazoketone was dissolved in dry MeOH (70mL) and reacted with silver benzoate 
(44Smg, 1. 94mmol, 0.11 equiv) dissolved in Et3N (7.l28mL, 51.24mmol, 2.9 equiv), 
according to General Procedure Th. Purification by column chromatography (EAlPE 1 :3) 
gave (-)-6.16 (S.12g, 93%) as a colourless oil. 
IH NMR (CDCb) 8 1.80 (m, IH, CHaCH2SMe), 1.88 (m, IH, CHhCH2SMe), 2.09 (s, 3H, 
SMe), 2.52 (m, 2H, CH1SMe), 2.S8 (m, 2H, CH1C02Me), 3.66 (s, 3H, OMe), 4.09 (m, lB, 
NBCH), 5.08 (s, 2B, PhCH1), 5.35 (d J=8.8Hz, IH, NH), 7.32 (m, 5H, PhH). 
I3C NMR (CDCb) 8 15.4,30.6,33.6,38.5,47.3,51.7,66.6, 128.0, 128.0, 128.4, 136.4, 
155.7, 171.7. 
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FTIR(KBr) 3321,1736,1690, 1541cm-1. 
HRMS (ES) 312.1272 (~+H). C15H22N04S requires 312.1270. 
Micro. Cald for C15H21N04S. C, 57.81; H, 6.80; N, 4.50; S, 10.50. Found: C, 57.61; H, 
7.04; N, 4.52; S, 10.54. 
[a]D=-18.8° c=1.0 CHCb 
Pre para ti 0 n 0 f (2S,1S)-2-(1-Benzyloxycarbonylamino-3-methylsulfanyl-propyl)-
pentanoic acid methyl ester (-)-6.17. 
Anhydrous LiCI (l98mg, 4.8mmol, 3 equiv), LDA (1.768mL of a 2M solution in THF, 
3.54mmol, 2.2 equiv), and allyl bromide (0.557mL, 6.43mmol, 4 equiv) were reacted with 
a -780 C solution of (-)-6.16 (500mg, 1.61mmol, 1 equiv) dissolved in THF (lOmL) under 
nitrogen, according to General Procedure K. Purification by radial chromatography 
(EAIPE 1:4) gave (-)-6.17 (301mg, 53%) as a colourless oil. 
1H NMR (CDCb) 8 1.72 (m, 2H, CH2CH2SMe), 2.08 (s, 3H, SMe), 2.31 (m, 1H, 
CHaCH=CH2), 2.41 (m, 1H, CHbCH=CH2), 2.52 (m, 2H, CH2SMe), 2.66 (m, 1H, 
CHC02Me), 3.67 (s, 3H, OMe), 3.99 (m, 1H, NHCH), 5.03-5.14 (m, 4H, CH=CH2 and 
PhCH2), 5.57 (d J=9.8Hz, 1H, NH), 5.74 (m, 1H, CH=CH2)' 7.32-7.37 (m, 5H, PhH). 
l3C NMR (CDCb) 8 15.3, 30.4, 33.8, 33.8, 48.2, 50.7, 51.4, 66.4, 117.3, 127.8, 127.8, 
128.2, 134.2, 136.3, 156.1, 174.3. 
FTIR (KBr) 3342,2953, 1717, 1701, 1653, 1506cm-1. 
HRMS (EI) 351.1516 (M+). C1sH25N04S requires 351.1504. 
[a]D = -20.9°, c=1.0 CHCb 
Chapter Eight 285 
Preparation of (2S,3S)-2-Allyl-3-benzyloxycarbonylamino-2-methyl-pent-4-enoic acid 
methyl ester (-)-6.18. 
A: Alkene (-)-6.17 (295mg, 0.84mmol, 1 equiv) was dissolved in acetic acid (2mL) and 
treated with H202 (0.086mL of a 50% w/w solution, 1.26mmol, 1.4 equiv) according to 
General Procedure la. The resulting sulfoxide was then dissolved in degassed m-xylene 
(lOmL) and underwent oxidative elimination according to General Procedure lb. 
Purification by radial chromatography (EAlFE 1:3) gave diene (-)-6.18 (211mg, 76%) as a 
yellow oil. 
B: Anhydrous LiCI (94mg, 2.3mmol, 3 equiv), LDA (0.837mL of a 2M solution in THF, 
1.67mmol, 2.2 equiv), and allyl bromide (0.263mL, 3.0mmol, 4 equiv) were reacted with a 
-780 C solution of 6.22 (200mg, 0.76mmol, 1 equiv) dissolved in THF (4mL) under 
nitrogen, according to General Procedure K. Purification by radial chromatography 
(EAIPE 15:85) gave (-)-6.18 (62mg, 27%) as a yellow oil. 
IH NMR (CDCh) <52.35 (m, 1H, CHaCH=CH2), 2.43 (m, 1H, CHbCH=CH2), 2.72 (m, 1H, 
CHC02Me), 3.63 (s, 3H, OMe), 4.45 (m, 1H, NHCH), 5.05-5.23 (m, 6H, 2xCH=CH2 and 
PhCH2), 5.76 (m, 2H, 2xCH=CH2), 7.32-7.37 (m, 5H, PhH). 
13C NMR (CDCh) <5 33.8, 48.6, 51.5, 53.4,66.7, 115.8, 117.6, 127.9, 128.0, 128.4, 134.2, 
136.3, 136.4, 155.9, 174.1. 
FTIR(KBr) 3342, 2953,1724,1643, 1504cm-1• 
HRMS (El) 303.1465 (Ml. C17H21N04 requires 303.1471. 
[aJD = -37.1 0, .0 CHCh. 
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Preparation of (3S,2S)-3-Benzyloxycarbonylamino-cyclopent-3-ene carboxylic acid 
methyl ester (-)-6.19, and (5S,1S)-5-Benzyloxycarbonylamino-cyclopenten-2-
enecarboxylic acid methyl ester 6.23. 
ZHNJ:) 
C02Me 
(+)-6.19 
Catalyst 1.42 (4.2mg" 5mol%), dissolved in dry degassed benzene (0.5mL), was added to 
a solution of diene (-)-6.18 (30mg, O.lmmol, 1 equiv), dissolved in dry degassed benzene 
(lmL) under argon, according to General Procedure E. The mixture was then stirred at 
reflux for 16h. Attempted purification by radial chromatography (EA/PE 1:3) gave a 
fraction containing 6.19 and 6.23 (24mg, 89%), in a ratio of 1.5:1 by IH NMR, that could 
not be separated further. 
In a second reaction, catalyst 1.42 (l8mg" 5mol%), dissolved in dry degassed benzene 
(0.5mL), was added to a solution of diene (-)-6.18 (l26mg, 0.42mmol, 1 equiv), dissolved 
in dry degassed benzene (4mL) under argon, according to General Procedure E. The 
mixture was then stirred at rt for 2h. Purification by radial chromatography (EA/PE 1 :3) 
gave (+)-6.19 (l05mg, 92%) as a white solid. An analytical sample was obtained by the 
diffusion of petroleum ether into a solution of 6.19 dissolved in ethyl acetate . 
. mp 92-93° C 
IH NMR (CDCh) 8 2.62 (m, 1H, CH=CHCHn), 2.75 (m, 1H, CHC02Me), 2.87 (m, 1H, 
CH=CHCHb), 3.72 (s, 3H, OMe), 4.86 (brs, 1H, NH), 5.06 (m, 1H, NHCH), 5.12 (m, 2H, 
PhCH2), 5.63 (brs, 1H, CH=CHCH2), 5.86 (m, 1H, CH=CHCH2), 7.30-7.38 (m, 5H, PhH). 
BC NMR (CDCh) 835.5,50.7,52.1,61.1,66.7,128.1,128.5,130.0, 132.4, 136.3,155.5, 
174.8. 
FTIR (KBr) 2953, 1734, 1684, 1537cm-J• 
HRMS (EI) Found 275.1158 (M+). C1sH17N04 requires 275.1158. 
Micro. Calcd for C1sH17N04. C, 65.44; H, 6.23; N, 5.09. Found: C, 65.13; H, 6.31; N, 5.25. 
[aJD = +102.3°, c=1.0 CHCh. 
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Preparation of (3S,2S)-3-tert-Butyloxycarbonylamino-cyclopentane carboxylic acid 
methyl ester (+)-6.20. 
lO%~Palladium-on-carbon (6mg, 20% w/w), NaHC03 (14mg, 0.17mmol, 1.5 equiv), and 
di-tert-butyl-dicarbonate (37mg, 0.17mmol, 1.5 equiv) were reacted with (+)-6.19 (30mg, 
O.11mmol), dissolved in dry MeOH (3mL) under a hydrogen atmosphere, according to 
Modified General Procedure L. Purification by radial chromatography (EAIPE 1 :7) gave 
(+)-6.20 (20mg, 75%) as a white solid. 
lH NMR (CDCb) is 1.43 (s, 9H, C(CH3)3), 1.47 (m, lH, NHCHCH a) 1.72 (m, 2H, 
CHaCHC02Me and CHaCH2CHC02Me), 1.89 (m, IH, CHbCH2CHC02Me), 1.97 (m, IH, 
CHbCHC02Me), 2.11 (m, IH, NHCHCHb), 2.57 (dd 6.1 and 8.3Hz, IH, CHC02Me), 
3.68 (s, 3H, OMe), 4.11 (m, lH, NHCH), 4.57 (brs, IH, NH). 
[a]D = +41.6°, c=0.65 CHCh. (lit. 15 +44.6°, c=1.3). 
Preparation of (3S)-3-Benzyloxycarbonylamino-penteuoic acid methyl ester 6.22. 
Methyl ester (-)-6.16 (720mg, 2.32mmol» was dissolved in acetic acid (5mL) and treated 
with H20 2 (0.230mL of a 50% w/w solution, 3.25mmol, 1.4 equiv) according to General 
Procedure la. The resulting sulfoxide was then dissolved in degassed m-xylene (10mL) 
and underwent oxidative elimination according to General Procedure lb. Purification by 
radial chromatography (EAlPE 15:85) gave 6.22 (430mg, 63%) as a yellow oil. 
lH NMR (CDCb) is 2.65 (m, 2H, CH2C02Me), 3.67 (s, 3H, OMe), 4.58 (m, 1H, NHCH), 
5.11 (s, 2H, PhCH 20), 5.18 (m, 2H, CH=CH2), 5.45 (brs, IH, NH), 5.85 (m, 1H, 
CH=CH2), 7.31-7.45 (m, 5H, PbH). 
DC NMR (CDC b) is 38.5, 49.5,51.3,66.2,67.4, 115.15, 127.6, 127.9, 128.0, 136.4, 136.5, 
155.4, 171.0. . 
FTIR (KBr) 3339, 2953, 1720.4, 1514cm-l . 
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Pre par a t ion 0 f (3S,28)-3-Benzyloxycarbonylamino-2-methyl-5-methylsulfanyl-
pentanoic acid methyl ester (-)-6.24. 
Anhydrous LiCl (396mg, 9.65mrnol, 3 equiv), LDA (3.537mL of a 2M solution in THF, 
7.07mmol, 2.2 equiv), and Mel (0.801mL, 12.86mmol, 4 equiv) were reacted with a -780 C 
solution of (-)-6.16. (lg, 3.22mrnol), dissolved in THF (15mL) under nitrogen, according 
to General Procedure K. Purification by radial chromatography (EAJPE 1:4) gave (-)-6.24 
(0.962g (92%) as a colourless oil. 
IH NMR (CDCb) 0 1.22 (d J=6.8Hz, 3H, CHCH3), 1.73 (m, 2H, CH2CH2SMe), 2.08 (s, 
3H, SMe), 2.52 (m, 2H, CHzSMe), 2.70 (m, 1H, CHC02Me), 3.67 (s, 3H, OMe), 3.91 (m, 
1H, NHCH), 5.10 (dd J=12.4 and 14.4Hz, 2H, PhCH2), 5.49 (d J=9.8Hz, 1H, NH), 7.29-
7.37 (m, PhH). 
I3C NMR (CDCb) 0 14.8, 15.5, 30.7, 33.6, 42.6, 51.7, 52.6, 66.6, 127.9, 128.0, 128.4, 
136.5, 156.5, 175.4. 
FTlR(KBr) 3337,2953,1717,1699,1510, 1454cm"1. 
HRMS (ES) 326.1429 (M++H). C16H24N04S requires 326.1426. 
[a]D -14.3°, c=l.O CHCh. 
Micro. Calcd for C:59.05, H:7.12, N:4.30, S:9.85; Found C:59.l H:7.30, N:4.40, S:9.95. 
Preparation of (2S,IS)-2-(1-Benzyloxycarbonyl-3-methylsulfanyl-propyl)-2-methyl-
pent-3-enoic acid methyl ester (-)-6.25. 
Anhydrous LiCI (326mg, 7.95mrnol, 3 equiv), LDA (2.918mL of a 2M solution in THF, 
5.83mmol, 2.2 equiv), and allyl bromide (0.918mL, 10.6mrno1, 4 equiv) were reacted with 
a -780 C solution of (-)-6.24 (862mg, 2.65mmol), dissolved in THF (15mL) under nitrogen, 
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according to General Procedure K. Purification by radial chromatography (EA/PE 1 :9) 
gave (-)-6.25 (411mg, 43%) as a colourless oil. 
IH NMR (CDCb) 8 1.19 (s, 3H, CHCH3), 1.42 (m, lH, CHaCHzSMe), 1.91 (m, IH, 
CHbCH2SMe), 2.07 (s, 3H, SMe), 2.23 (dd J=7.4 and 13.7Hz, 1H, CHaCH=CH2) 2.43-
2.58 (m, 3H, CHbCH=CHz and CH2SMe), 3.66 (s, 3H, OMe), 3.79 (dt J=1O.7 and 2.4Hz, 
1H, NHCH), 5.02-5.16 (m, 4H, CH=CH2 and PhCH20), 5.42 (d J=1O.7Hz, IH, NH), 5.67 
(m, IH, CH=CHz), 7.31-7.37 (m, 5H, PhH). 
I3C NMR (CDCb) 8 15.7, 19.5,31.2,31.4,41.2,49.8,51.8,56.3,66.7, 118.9, 128.0, 
128.1, 128.4, 132.9, 136.5, 156.4, 175.8. 
FTIR (KBr) 3343, 2951, 1720, 1641, 1510cm- l . 
[a]D -30.6°, c=l.O CHCh. 
Preparation of (2S,3S)-2-Allyl-3-benzyloxycarbonylamino-2-methyl-pent-4-enoic acid 
methyl ester (-)-6.26. 
Alkene (-)-6.25 (352mg, O.97mmol) was dissolved in acetic acid (2mL) and treated with 
H20 2 (0.092mL of a 50% w/w solution, 1.35mmol, 1.4 equiv) according to General 
Procedure la. The resulting sulfoxide was then dissolved in degassed m-xylene (lOmL) 
and underwent oxidative elimination "according to General Procedure lb. Purification by 
radial chromatography (EAlPE 1:3) gave diene (-)-6.26 (267mg, 88%) as a colourless oil 
IH NMR (CDCb) 8 1.17 (s, 3H, CCH3), 2.26 (dd J=7.3 and 13.7Hz, IH, CHaCH=CH2), 
2.51 (dd J=7.3 and 13.7Hz, IH, CHbCH=CH2), 3.65 (s, 3H, OMe), 4.22 (t 8.3Hz, IH, 
NHCH), 5.04-5.26 (m, 6H, PhCHzO and 2xCH=CH2), 5.71 (m, 2H, 2xCH=CH2), 7.26-
7.36 (m, 5H, PhH). 
I3C NMR (CDCb) 8 19.1,41.0,49.3, 51.8, 59.2, 66.7, 117.83, 119.0, 128.1, 128.4, 132.7, 
134.3, 136.4, 155.7, 175.6. 
FTIR (KBr) 3342, 2951, 1707, 1641, 1501cm-1• 
HRMS (ES) 340.1526 ~+Na). ClsH23N04Na requires 340.1525. 
[a]D= -30.2, c=1.0 CHCb 
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Pre par at ion 0 f (lS,2S)-2-Benzyloxycarbonylamino-1-methyl-cyclopen-3-ene-
carboxylic acid methyl ester (+)-6.27. 
Catalyst 1.42 (24mg" 5mol%), dissolved in dry degassed benzene (0.5mL), was added to a 
solution of diene (-)-6.26 (180mg, 0.57mmol), dissolved in dry degassed benzene (5mL) 
under argon, according to General Procedure E. The mixture was then stirred at rt for 16h. 
Purification by radial chromatography (EAIPE 1:3) gave (+)-6.27 (151mg, 92%) as a white 
solid. 
IH NMR (CDCh) 8 2.24 (d J=17.1Hz, IH, CH=CHCHa), 2.95 (d J=17.1Hz, lH, 
CH=CHCHb), 3.73 (s, 3H, OMe), 4.74 (brdJ=7.3Hz, IH, NH), 5.10 (ddAB J=12.5Hz, 2H, 
PhCH2), 5.21 (brd J=9.3Hz, IH, NHCH), 5.53 (brs, IH, CH=CHCH2), 5.83 (brs, lH, 
CH=CHCH2), 7.25-7.36 (m, 5R, PhH). 
l3C NMR (CDCh) 8 18.8,44.2,51.4,52.1,62.8,66.5,127.9,128.3,129.5, 131.6, 131.8, 
136.4, 155.7, 177.2. 
FTIR (KBr) 3350, 2951,1697,1634, 1502cm"l. 
HRMS (ES) 290.1396 (M++H). C16H19N04 requires 290.1392. 
[o.]D +50.5°, c=1.0 CHCh. 
8.8 Experimental Described in Chapter Seven 
Preparation of (1-Allylcarbamoyl-but-3-enyl)-carbamic acid tert-butyl ester (+1-)-
7.24. 
~( NH BodIN 
o 
EDCI (459mg, 2.24mmol, 1.3 equiv), HOBt (378mg, 2.58mmol, 1.5 equiv), allylamine 
(0.145mL, 2.58mmol, 1.5 equiv) arid diisopropylethylamine (0.415mL, 1.9mmol, 1.1 
equiv) were added to a solution of N-Boc (+I-)-allyl glycine 7.23 (370mg, 1.72mmol, 1 
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equiv) dissolved in CH2Clz (l5mL) under argon. The mixture was stirred at rt under argon 
for 16h. The solvent was removed under reduced pressure and the residue purified by 
radial chromatography (EAIPE 1:3) to give (+1-)-7.24 (404mg, 92%) as a white solid. 
IH NMR (CDCL3) 0 1.42 (s, 9H, CCH3), 2.48 (m, 2H, CHCHzCH=CH2), 3.85 (m, 2H, 
NHCHzCH=CH2), 4.18 (bs, 1H, aH), 5.14 (m, 5H, 2xCH=CHz and NHCH), 5.76 (m, 2H, 
2xCH=CH2), 6.53 (bs, IH, NHCH2). 
DC l\TMR 028.2,36.9,41.7,53.8,80.1, 116.2, 118.8, 133.1, 133.8, 155.6, 171.3. 
FTIR (KBr) 3261,2980, 1697, 1661, 1547cm-1 
HRMS (ES) 277.1517 (M++Na). C13H22N203Na requires 277.l528. 
Preparation of (2-0xo-2,3,4,7 -tetrahydro-lH-azepin-3-yl)-carbamic acid tert-butyl 
ester (+1-)-7.25 and (2-0xo-l,2,3,4-tetrahydro-pyridin-3-yl)-carbamic acid tert-butyl 
ester (+1-)-7.26. 
Q NH BocHN ~ NH BocHN 
o o 
7.25 7.26 
Catalyst 1.42 (9mg, 5mol%), dissolved in d,y degassed benzene (O.SmL), was added to a 
solution of diene (+1-)-7.24 (60mg, 0.24mmol), dissolved in dry degassed benzene (5mL) 
under argon, according to General Procedure E. The solution was then refluxed vigorously 
for 4h. IH NMR analysis of the crude revealed it to contain a 1: 1 mixture of (+1-)-7.25 and 
(+1-)-7.26. Purification by radial chromatography (EA/PE 1 :3) gave (+1-)-7.25 (23mg, 
46%) as a white solid. Further elution gave (+1-)-7.26 (24mg, 45%) as a white solid. 
In a second reaction, catalyst 1.42 (8mg, Smol%), dissolved in dry degassed benzene 
(0.5mL), was added to a solution of diene (-)-6.26 (SOmg, 0.2mmol), dissolved in dry 
degassed benzene (4mL) under argon, according to General Procedure E. The mixture was 
then refluxed at 8So C for 2h. IH NMR analysis of the crude showed the exclusive 
formation of (+1-)-7.25. Purification by radial chromatography (EA/PE 1: 1) gave (+1-)-
7.25 (40mg, 90%) as a white solid. 
Data for (+1-)-7.25: 1 H NMR (CDC h) 0 1.44 (s, 9H, C(CH3)3), 2.2S (m, 1H, 
CHCHaCH=CH), 2.65 (bd 8Hz, 1H, CHCHbCH=CH), 3.43 (m, 1H, NHCHa), 4.15 (bd 
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J=7.1Hz, IH, NHCHb), 4.82 (m, 1H, NHCH), 5.68 (m, IH, =CHCH2NH), 5.74 (m, 2H, 
CH=CHCH2NH, and NHCH), 6.08 (bs, 1H, NHCH2). 
l3C NMR (CDCb) 828.3,32.6,39.5,49.8, 79.6, 124.6, 129.0, 142.5, 155.1, 174.7. 
HRMS (ES) 249.1220 (M++Na). CllHlSN203Na requires 249.1215. 
Data for (+/-)-7.26: 
IH NMR (CDCb) 8 1.44 (s, 9H, C(CH3)3), 2.19 (m, 1H, CHaCH=), 2.82 (m, IH, 
CHbCH=), 4.27 (m, 1H, NHCHCH2), 5.16 (t J=7.1Hz, 1H, CH=CHNH), 5.49 (bs, 1H, 
NHCHCH2), 6.06 (m, 1H, CH=CHNH), 7.67 (bs, 1H, CH=CHNH). 
J3C NMR 827.2,28.3,50.0, 79.8, 105.5, 124.7, 155.6, 170.I. 
HRMS (ES) 235.1051 (M++Na). ClOH161\h03Na requires 235.1059. 
Preparation of (lR)-N-(l-Allylcarbamoyl-l-benzyl-but-3-enyl)-benzamide 7.27. 
I, ( Ph~ ~ 
PhCOHN'" (NH 
o 
Allylamine (l1.5f1.L, 0.15mmol, 3 equiv) was dissolved in dry THF (2mL) and cooled to -
78°C under argon. n-Butyllithium (95f1.L, 0.15mmol, 3 equiv) was added and the mixture 
stirred at -78°C for 5 min. A solution of oxazolidinone (-)-2.5 (20mg, 0.05mmol, 1 equiv) 
dissolved in dry THF (lmL) was then added and the solution allowed to warm to room 
temperature overnight. The reaction mixture was quenched with saturated aqueous NH4CI 
and successively washed with saturated aqueous NaHC03 (5mL), NaCI (5mL) and dried 
over MgS04. Purification by radial chromatography eluting with 1:3 ethyl 
acetate/petroleum ether yielded 7.27 (l6mg, 91 %) as a white solid. An analytical sample 
was obtained by the diffusion of petroleum ether into a solution of 7.27 dissolved in ethyl 
acetate. Crystals suitable for X-ray crystallography were obtained (see Appendix for data). 
IH NMR (CDCb) 8 2.77 (m, 1H, CCHaCH=CH2), 3.25 (m, CCHbCH=CH2), 3.37 (d 
. J=13.9Hz, 1H, PhCHa), 3.67 (d J=13.9Hz, 1H, PhCHb), 3.88-4.01 (m, 2H, NHCH2), 5.12-
5.26 (m, 4H, 2 x CH=CH2), 5.74 (m, 1H, CCH2CH=), 5.84 (m, 1H, NHCH2CH=), 6.51 (t 
J=4.5Hz, 1H, NH), 7.13 (m, 3H, PhH and PhCONH), (NH couples long range to PhCH2) 
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7.22 (m, 3H, PhH), 7.40 (t J=7.8Hz, 2H, PhH), 7.49 (m, 1H, PhH), 7.67 (dd J=1.2 and 
8.5Hz, 2H, PhH). 
I3C NMR (CDCb) 0 40.0, 40.9, 42.5,64.4,117.1,119.8, 126.8, 127.1, 128.3, 128.6,130.1, 
131.6, 132.3, 133.6, 135.0, 135.7, 167.3, 171.9. 
HMRS (EI) 348.1829 (~). C22H24N202 requires 348.1838. 
Preparation of (3S)-3-Benzyloxycarbonylamino-4-phenyl-butyric acid methyl ester (-
)-7.34. 
Et3N (2.326mL, 16.72mmol, 1 equiv) and ClC02Et (1.574mL, 16.72mmol, 1 equiv) were 
reacted with (S)-N-Cbz-phenylalanine (5g, 16.72mmol, 1 equiv) according to General 
Procedure Ja. The resulting diazoketone was dissolved in dry MeOH (80mL) and reacted 
with silver benzoate (421mg, 1. 84mmol, 0.11 equiv) dissolved in Et3N (6.746mL, 
48.49mmol, 2.9 equiv), according to General Procedure Jb. Purification by column 
chromatography (EAlPE 1:3) gave (-)-7.34 (5.294g, 97%) as a white solid 
mp 50-52°, (lit. .453-55°). 
lH NMR (CDCh) 0 2.48 (dd J=16.1 and 5.8Hz, IH, CHa), 2.54 (ddJ=16.1 and 5.4Hz, 1H, 
CHb), 2.84 (dd J=13.8 and 7.8Hz, lH, CHa), 2.96 (dd .4 and 6.2Hz, IH, CHb), 3.67 
(s, 3H, OMe), 4.23 (m, lH, NHCH), 5.07 (s, 2H, PhCHzO), 5.29 (d J=8.8Hz, 1H, NH), 
7.16-7.37 (m, 5H, PhH). 
FTIR (KBr) 3313, 2949, 1687cm-1• 
LRMS (ES) 328.1 (M++H). C19H21N04 requires 328.1. 
Preparation of (2S,1S)-2-(1-Benzyloxycarbonylamino-2-phenyl-ethyl)-pent-4-enoic 
acid methyl ester 7.35. 
) 
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Anhydrous LiCl (565mg, 13.76mmol, 3 equiv), LDA (5.05mL of a 2M solution in THF, 
10.09mmol, 2.2 equiv), and allyl bromide (l.589mL, 18.36mmol, 4 equiv) were reacted 
with a -780 C solution of (-)-7.34 (1.5g, 4.59mmol) dissolved in THF (20mL) under 
nitrogen, according to General Procedure K. Purification by radial chromatography 
(EAIPE 1 :4) gave 7.35 (l.068g, 64%) as a colourless oil that solidified on standing. 
mp 46-48° C. 
IH NMR (CDCh) (3 2.29 (m, 1H, CHaCH=CH2), 2.41 (m, IH, CHbCH=CH2), 2.61 (m, IH, 
CHC02Me), 2.67 (dd 3.7 and 8.3Hz, IH, CHCHaPh), 2.91 (dd 3.5 and 6.5Hz, 1H, 
CHCH~h), 3.71 (s, OMe), 4.09 (m, 1H, NHCH), 4.99-5.14 (m, 2H, CH=CHz), 5.08 
(dd J=21.0 and 12.2Hz, 2H, PhCHz), 5.65 (m, IH, CH=CH2), 5.81 (d J=9.3Hz, IH, NH), 
7.18-7.38 (m, 10H, PhH). 
l3C NMR (CDCh) (3 34.3,40.6,46.4,51.6,53.1,66.5,117.4,126.5,127.9, 127.9, 128.4, 
129.2, 134.3, 136.6, 137.5, 155.9, 174.7. 
FTIR (KBr) 3333, 2957, 1728, 1699, 1539cm-1• 
HRMS (ES) 368.1874 (~+H) C22H2sN04 requires 368.1862. 
Preparation of (2S,1S)-2-(1-Benzyloxycarbonylamino-2-phenyl-ethyl)-pent-4-enoic 
acid 7.36. 
) 
1M aq. NaOH (1.74mL, 1.74mmol, 2 equiv) was reacted with methyl ester 7.35 (320mg, 
0.87mmol, 1 equiv) dissolved in MeOH (15mL) according to General Procedure G, to give 
7.36 (305mg, 99%) as a yellow oil. 
IH NMR (CDCb) (3 2.34 (m, lH, CHaCH=CH2), 2.46 (m, lH, CHbCH=CH2), 2.64 (m, lH, 
CHC02H), 2.77 (dd J=13.7 and 8.8Hz, lH, CHaPh), 2.95 (dd J=13.9 and 6.6Hz, lH, 
CHbPh), 4.24 (m, lH, NHCH), 5.00-5.15 (m, 4H, PhCHz and CH=CHz), 5.68 (m, IH, 
CH=CH2), 5.71 (d J=9.8Hz, 1H, NH), 7.14-7.37 (m, lOH, PhH). 
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Preparation of (2S,1S)-(2-Allylcarbamoyl-l-benzyl-pent-4-enyl)-carbamic acid benzyl 
ester 7.37. 
!( 
ZHN~(NH 
p~ 0 
EDCI (232mg, 1. 12mmol, 1.3 equiv), HOBt (190mg, 1.3mmol, 1.5 equiv), allylamine 
(0.073mL, 1.3mmol, 1.5 equiv) and diisopropylethylamine (0.205mL, 0.95mmol, 1.1 
equiv) were added to a solution of 7.36 (305mg, 0.86mmol, 1 equiv) dissolved in CH2Ch 
(1 OmL) under argon. The mixture was stirred at rt under argon for 16h. Purification by 
radial chromatography (EAIPE 1 :4) gave 7.37 (261mg, 74%) as a white solid. 
mp l68-169°C. 
IH NMR (CDCL3) 8 13 (m, IH, CHCH2CH=CH2), 2.27 (m, lH, CHCHaCH=CH2), 2.42 
(m, 2H, CHCHbCH=CH2), 2.62 (dd J=13.7 and 9.2Hz, IH, CHCHaPh), 3.05 (dd J=l3.9 
and 6. 1Hz, IH, CHCHbPh), 3.89 (m, 2H, NHCHzCH=CH2), 4.06 (m, IH, NHCH), 4.99 
(m, 2H, NHCHzCH=CH2), 5.09 (dd J=15.6 and 12.7Hz, 2H, CHCH2CH=CHz), 5.20 (m, 
2H, PhCHzO), 5.47 (br s, lH, NHCH2), 5.64 (m, IH, CHCH2CH=CH2), 5.84 (m, IH, 
NHCH2CH=CH2), 6.50 (dJ=8.8Hz, IH, NHCH), 7.11-7.36 (m, lOH, PhH). 
I3C NMR 8 34.9, 40.4, 41.8, 47.2, 53.8, 66.3, 117.1, 117.7, 126.6, 127.8, 127.9, 128.4, 
128.6, 129.0, 133.7, 134.7, 136.8, 138.1, 156.2, 173.6. 
FTIR (KBr) 3433, 1693, 1643, 1551, 1265cm-1. 
HRMS (ES) 393.2176 (~+H). C2.M29N203 requires 393.2178. 
Prepa ration of (3S,IS)-[1-(2-0xo-2,3,4, 7 -tetrahydro-IH -azepin-3-yl)-2-phenyl-ethyl]-
carbamic acid benzyl ester 7.38. 
n 
ZHNyYNH 
- 0 
Ph/ 
Catalyst 1.42 (9mg" 5mol%), dissolved in dry degassed benzene (0.5mL), was added to a 
solution of diene 7.37 (70mg, 0.18mmol, 1 equiv) dissolved in dry degassed benzene 
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(3mL) under argon, according to General Procedure E. The mixture was then stirred at 50° 
C for 2h. Purification by radial chromatography (EAlPE I :1) gave 7.38 (58mg, 89%) as a 
white solid. 
IH NMR (CDCb) d 2.15 (bd J=9.0Hz, 1H, CHCHaCH=), 2.47 (m, 1H, CHCHbCH=), 2.95 
(m, 2H, CHCH2CH= and PhCHa), 3.06 (dd J=6.3 and 13.2Hz, 1H, PhCHb), 3.28 (m, 1H, 
NHCHIICH=), 3.81 (bd J=7.6Hz, JH, NHCHbCH=), 3.99 (m, IH, NHCH), 5.08 (dd 
J=12.2 and 24.4Hz, 2H, PhCH20), 5.59 (m, IH, NHCH2CH=), 5.68 (m, lH, CHCH2CH=), 
6.16 (bs, IH, NHCH2), 6.58 (dJ=9.8Hz, lH, NHCH), 7.20-7.37 (m, lOH, PhH). 
l3C NMR (CDCb) d 29.5, 39.2, 39.9, 40.6, 55.5, 66.4, 124.3, 126.4, 127.8, 127.9, 128.4, 
128.6, 129.1, 130.5, 136.7, 138.6, 156.5, 177.5. 
FTIR (KEr) 3275,2924, 1699, 1651cm·1. 
HRMS (ES) 365.1862 (~+H). C22H25N203 requires 365.1865. 
Preparation of (3S,1S)-[3-(1-Benzyloxycarbonylamino-2-phenyl-ethyl)-2-oxo-2,3,4,7-
tetrahydro-azepin-l-yl]-acetic acid methyl ester 7.39. 
() 
ZHNyY N",,-/C02Me 
. 0 
Ph./" 
NaH (13mg of 60% in oil, 0.33mmol, 2 equiv) was slowly added to a solution of 7.38 
(60mg, 0.165mmol) dissolved in dry CH3CN (5mL), and the mixture was stirred at rt for 
l6h. After filtering, the solvent was removed under reduced pressure and the residue 
purified by radial chromatography (EAlPE 1: 1) to yield 7.39 (66mg, 92%) as a white solid. 
IH NMR (CDCb) 8 2.15 (m, 1H, CHCHIICH=), 2.47 (m, 1H, CHCHbCH=), 2.92(dd 
J=10.3 and 13.2Hz, 1H, PhCHa), 3.03 (dd J=5.8 and 13.2Hz, 1H, PhCHb), 3.07 (dt J=2.9 
and 13.2Hz, 1H, NCHaCH=), 3.22 (dd J=7.8 and 17.6Hz, IH, CHCHCO), 3.78 (s, 3H, 
OMe), 3.85 (d J=17.6Hz, 1H, CHaC02Me), 3.96 (m, 1H, NHCH) , 4.21 (dt J=2.9 and 
17.6Hz, 1 NHCHbCH=), 4.56 (d 7.1Hz, IH, CHbC02Me), 5.09 (dd J=12.5 and 
20.8Hz, 2H, PhCH20), '5.61 (m, IH, NHCH2CH=), 5.71 (m, 1H, CHCH2CH=), 6.59 (d 
J=10.3Hz, 1H, NHCH), 7.20-7.37 (m, lOH, PhH). 
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BC NMR 830.0,39.9,40.6,47.3,49.6,52.2,55.9,66.3, 123.3, 126.4, 127.7, 127.8, 128.4, 
128.6, 129.2, 131.2, 136.7, 138.6, 156.5, 169.6, 175.4. 
HRMS (ES) 437.2083 (M++H). CZSHZ9NzOs requires 437.2076. 
Preparation of (3S,2S)-3-Benzyloxycarbonylamino-2-methyl-4-phenyl-butyric acid 
methyl ester 7.40. 
Anhydrous LiCl (753mg, 18.35mmol, 3 equiv), LDA (6.73mL of a 2M solution in THF, 
13.5mmol, 2.2 equiv), and Mel (1.524mL, 24.5mmol, 4 equiv) were reacted with a _780 C 
solution of (-)-7.34 (2g, 6.l2mmol) dissolved in THF (30mL) under nitrogen, according to 
General Procedure K. Purification by radial chromatography (EA/PE 1 :4) gave 7.40 
(1.998g,96%) as a colourless oi1.4 
IH NMR (CDCI3) 8 1.21 (d J=7.3Hz, 3H, CH3), 2.65 (m, 1H, CHCH3), 2.72 (dd J=13.7 
and 8.1Hz, 1H, PhCHa), 2.90 (dd J=13.7 and 6.9Hz, 1H, PhCHb), 3.71 (s, 1H, OCH3), 
4.02 (m, 1H, NHCH), 5.07 (dd J=16.3 and 12.5Hz, 2H, OCH2), 5.68 (d J=10.3Hz, 1H, 
NH), 7.17-7.39 (m, 10H, PhH). 
LRMS (ES) 342.3 (M++H). CzoH2iN04 requires 342.3. 
Preparation of (2S,1S)-2-(1-Benzyloxycarbonylamino-2-phenyl-ethyl)-2-methyl-pent-
4-enoic acid methyl ester 7.41. 
) 
ZHN~ 
: COzMe 
pj(" 
Anhydrous LiCl (685mg, 16.7mmol, 3 equiv), LDA (6.13mL of a 2M solution in THF, 
12.25mmol, 2.2 equiv), and allyl bromide (l.928mL, 22.28mmol, 4 equiv) were reacted 
with a -780 C solution of 7.40 (1.9g, 5.57mmol) dissolved in THF (25mL) under nitrogen, 
according to General Procedure K. Purification by radial chromatography (EAlPE 1 :4) 
gave 7.41 (819mg, 39%) as a colourless oi1.4 
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IH NMR (CDCb) 8 1.29 (s, 3H, CCH3), 2.29 (dd J=13.9 and 7.5Hz, lH, CHaCH=CHz), 
2.41 (dd J=13.6 and 10.7Hz, lH, PhCHaCH), 2.55 (dd J=13.7 and 7.4Hz, IH, 
CHbCH=CHz), 3.03 (dd J=13.7 and 3.4Hz, lH, PhCHbCH), 3.66 (s, 3H, OMe), 4.01 (td 
J=10.7 and 3.4Hz, lH, NHCH), 4.92 (ddAB J=53.5 and l2.5Hz, 2H, PhCHzO), 5.06 (m, 
2H, CH=CHz), 5.38 (d J=10.7Hz, lH, NH), 5.71 (m, lH, CH=CHz), 7.17-7.39 (m, 10H, 
PhH). 
Preparation of (2S,1S)-2-(1-Benzyloxycarbony lamino-2-phenyl-ethyl)-2-methyl-pent-
4-enoic acid 7.42. 
) 
ZHN~ 
: COzH 
Ph/ 
1M aq. NaOH (2.36mL, 2.36nimol, 2 equiv) was reacted with methyl ester 7.41 (450mg, 
1.18mmol) dissolved in MeOH (20mL) according to General Procedure G, to give 7.42 
(420mg, 97%) as a yellow oil. 
IH NMR (CDCb) d 1.44 (s, 3H, CCH3), 2.36 (ddJ=13.7 and 7.8Hz, IH, CHaCH=CHz, 
2.51 (ddJ=13.9 and 115Hz, IH, CHCHaPh), 2.62 (dd 3.7 and 7.3Hz, IH, 
CHbCH=CHz), 3.07 (ddJ=13.9 and 3.4Hz, IH, CHCHbPh), 4.11 (td 1.1 and 3.4Hz, 
IH, NHCH), 4.87 (ddJ=74.9 and 12.2Hz, 2H, PhCHzO), 5.12 (m, 2H, CH=CHz), 5.78 (m, 
IH, CH=CHz), 7.17-7.39 (m, 10H, PhH). 
HRMS (ES) 368.1864 (~+H). Cz2Hz6N04 requires 368.1862. 
Preparation of (2S,1S)-(2-Allylcarbamoyl-1-benzyl-2-methyl-pent-4-enyl)-carbamic 
acid benzyl ester 7.43. 
~~ 
ZHNnNH 
- 0 
Ph/ 
EDCI (118mg, 0.57mmol, 1.3 equiv), HOBt (97mg, 0.66mmol, 1.5 equiv), allylamine 
(0.037mL, 0.66mmol, 1.5 equiv) and diisopropylethylamine (0.1 04mL, 0.48mmol, 1.1 
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equiv) were added to a solution of 7.42 (160mg, 0.44mmol) dissolved in CH2Ch (5mL) 
under argon. The mixture was stirred at rt under argon for 16h. Purification by radial 
chromatography (EA/PE 1 :3) gave 7.43 (128mg, 71%) as a white solid. An analytical 
sample was obtained by the diffusion of petroleum ether into a solution of (+1-)-3.12 
dissolved in ethyl acetate. Crystals suitable for X-ray crystallography were obtained (see 
Appendix for data). 
mp 99-101°C 
IH NMR (CDCb) 0 1.28 (s, 3H, CCH3), 2.27 (dd J=13.6 and 7.8Hz, 1H, CHaCH=CH2), 
2.48 (dd J=13.6 and 10.7Hz, 1H, PhCHaCH), 2.58 (dd J=13.5 and 6.5Hz, 1H, 
CHbCH=CH2), 2.98 (dd .7 and 3.4Hz, 1H, PhCHbCH), 3.88 (m, 3H, NHCH and 
NHCHz), 4.86 (d J=12.7, 2H, PhCHaO), 4.94 (d 2.7Hz, 1H, PhCHbO), 5.06-5.22 (m, 
4H, 2xCH=CH2), 5.71 (m, 1H, CCH2CH=CH2), 5.84 (m, 2H, NH CH2 and 
NHCH2CH=CH2), 6.09 (d 0.3Hz, 1H, NH), 7.16-7.37 (m, 10H, PhD). 
I3C NMR (CDCb) 0 19.9, 37.8,41.9,42.0, 48.8, 59.0, 66.1, 116.8, 119.1, 126.3, 127.6, 
127.7,128.2,128.3,129.3,133.3,136.9,138.2,156.2,175.4. 
FTlR(KBr) 3279,1709,1634, 1547cm-J. 
HRMS (ES) 407.2334 (M++ 1). C2sH3JN203 requires Calcd 407.2335. 
Micro. Calcd for C2sH30N203, C, 73.86; H, 7.44; N, 6.89. Found: C, 73.56; H, 7.54; N, 
6.98. 
Preparation of (1S,3S)-[1-(3-Methyl-2-oxo-1,2,3,4,-tetrahydro-pyridin-3-yl)-2-phenyl-
ethyl]-carbamic acid benzyl ester 7.45. 
Catalyst 1.42 (8mg" 5mol%), dissolved in dry degassed benzene (0.5mL), was added to a 
solution of diene 7.43 (75mg, 0.185mmol» dissolved in dry degassed benzene (3mL) 
under argon, according to General Procedure The mixture was then refluxed at 800 C 
for 4h. Purification by radial chromatography (EA/PE 1 :3) 7.45 (59mg, 88%) as a white 
solid. 
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lH NMR (CDCh) b 1.31 (s, 3H, CCH3), 2.03 (dd 7.1 and 5.6Hz, lH, CHaCH=CH), 
2.62 (bd 7.lHz, lH, CHbCH=CH), 3.02 (m, lH, PhCHaCH), 3.14 (m, lH, PhCHbCH), 
4.10 (m, lH, NHCH), 4.80 (d J=12.7, 1H, PhCHaO), 4.94 (d J=12.7Hz, lH, PhCHbO), 
5.07 (m, 2H, CCH2CH=CH and NH), 5.98 (m, 1H, NHCH=), 6.99 (m, lH, Nil), 7.11-7.32 
(rn, lOH, PhH). 
13C NMR (CDCh) b 20.3 (CCH3), 31.1 (CH2CH=CH), 37.7 (CH2Ph), 45.1 (CCH3), 57.5 
(NHCH), 66.3 (PhCH20), 103.9 (CH=CHNH), 123.7 (=CHNH), 126.2, 127.7, 127.8, 
128.2, 128.4, 129.2, 136.6, 138.9, 156.6 (OCONH), 174.7 (CONH). 
HRMS (ES) 365.1866 (M++ 1). C22H25]'Jz03 requires 365.1865. 
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Crystallography 
Tables 1 3 list crystal data for the eleven crystal structures discussed in this thesis. Selected 
bond angles and torsion angles are listed in the discussion of the structures, and the remaining 
distances and angles, as well as atom coordinates, anisotropic displacement parameters and 
hydrogen atom coordinates are available from the Chemistry Department of the University of 
Canterbury . 
All measurements were made with a Seimens CCD area detector using graphite 
monochromised Mo Ka (A 0.71073 A) radiation at the temperature indicated in the 
following tables. The data reduction was performed using SAINT.l Intensities were corrected 
for Lorentz and polarization effects and for absorption using SADABS. Space groups were 
determined from systematic absences and checked for higher symmetry. The structures were 
solved by direct methods using SHELXS, and refined on using all data using full-matrix 
least squares procedures with SHELXL-97. All non-hydrogen atoms were refined with 
anisotropic displacement parameters. All hydrogen atoms were fixed in idealized positions. 
Absolute structure determinations were based on the Flack parameter. In all cases, final 
Fourier syntheses showed no significant residual electron density in chemical sensible 
positions. 
References 
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Table 1. Crystal data and X-ray experimental details for (-)-2.5, (+)-2.9, (+)-2.12,2.16,3.12. 
Compound (-)-2.5 (+)-2.9 (+)-2.12 2.16 3.12 
Data Collection Device CCD CCD CCD CCD CCD 
Emperical Formula C27H23N03 C21H21N03 C21H23N03 C2oH1sBrN03 C2Ji2SN03S 
Formula Weight 409.46 335.39 337.40 400.26 431.53 
Temperature (K) 158(2) 293(2) 168(2) 168(2) 168(2) 
Crystal System Orthorhombic Orthorhombic Orthorhombic Orthorhombic Monoclinic 
Space Group P212121 P212121 P212121 P212121 P2dc 
Unit Cell Dimensions: a (A) 7.091(14) 11.000(4) 7.582(7) 6.271(11) 8.762(2) 
b (A) 16.52(3) 13.360(4) 13.621(16) 15.83(3) 19.013(5) 
c (A) 17.85(3) 24.060(4) 17.52(2) 17.57(3) 13.712(4) 
0: (0) 90 90 90 90 90 
~ (0) 90 90 90 90 99.836(4) 
Y (0) 90 90 90 90 90 
Volume (A3) 2091(7) 3535.9(18) 1809(3) 1745(5) 2250.7(11) 
Z 4 8 4 4 4 
Density (calculated) (Mg/m3) 1.301 1.260 1.239 1.523 1.273 
Absorption coefficient (mm-1) 0.085 0.084 0.082 2.374 0.171 
F(OOO) 864 1424 720 816 912 
Crystal Size (mm3) 0.75xO.65xO.3 0.75xO.12xO.10 0.75xO.55xO.25 
Theta range for data collection CO) 1.68 to 26.41 2.94 to 26.40 1.89 to 26.40 2.32 to 26.79 1.85 to 26.40 
Reflections collected 7583 13962 7931 6974 29292 
Independent reflections [R(int)] 3639 6730 3582 3395 4577 
Data / restraints / parameters 3639/0/271 6730/0/453 3582/0/227 3395/0/226 4577/0/289 
Goodness-to-fit on F2 1.071 1.054 0.790 1.025 1.033 
Rl [I>2cr(I)] 0.0712 0.0398 0.0432 0.0315 0.0396 
0.1648 0.0779 0.0867 0.0745 0.1122 
Table 2 •. Crystal data and X-ray experimental details for (-)-3.24, (+)-3.13, (-)-3.17, (+)-5.40a, 7.27. 
Compound (-)-3.24 (+)-3.13 (-)-3.17 (+)-5.40 a 7.27 
Structure 
Data Collection Device CCD CCD CCD CCD CCD 
Emperical Formula C17H23N03S C25H21N03 C2oH19N03 C21H27N05 C22H24N204 
Formula Weight 321.42 383.43 321.36 373.44 348.43 
Temperature (K) 168(2) 293(2) 168(2) 168(2) 566(2) 
Crystal System Monoclinic Orthorhombic Monoclinic?? Orthorhombic Orthorhombic 
Space Group P21 P212121 P212121 P212121 
Unit Cell Dimensions: a (A) 9.847(4) 8.612(4) 19.516(4) 5.773(6) 9.806(4) 
b (A) 9.356(4) 9.467(6) 7.2111(15) 10.373(13) 10.895(5) 
c (A) 10.168(4) 24.782(15) 24.682(5) 33.36(4) 18.899(9) 
a (0) 90 90 90 90 90 
~ (0) 112.216(5) 90 103.468 90 90 
Y (0) 90 90 90 90 90 
Volume (A3) 867.2(6) 2020(2) 3378.1(12) 1998(4) 2019.2(16) 
Z 2 4 8 4 2 
Density (calculated) (Mg/m3) 1.231 1.261 1.264 1.242 1.146 
Absorption coefficient (mm-1) 0.198 0.083 0.085 0.088 0.074 
F(OOO) 344 800 1360 800 744 
Crystal Size (mm3) 0.12xO.44xO.5 0.54xO.43xO.25 0.77xO.55xO.48 0.55xO.38xO.33 
Theta range for data collection CO) 2.16 to 26.41 2.30 to 25.40 2.15 to 26.43 2.31 to 26.41 2.16 to 26.36 
Reflections collected 11239 8763 20377 8924 4899 
Independent reflections [R(int)] 3504 4006 3414 3563 3645 
Data 1 restraints 1 parameters 3504/0/199 4006/0/257 3414/0/219 3563/0/244 364510/235 
Goodness-to-fit on F2 0.918 1.022 1,097 0.905 0.983 
Rl [I>2cr(I)] 0.0279 0.0442 0.0436 0.0322 0.0681 
0.0559 0.1104 0.1071 0.0685 0.1621 
Table 3 . . Crystal data and X-ray experimental details for 7.43. 
Compound 
Structure 
Data Collection Device 
Emperical Formula 
Formula Weight 
Temperature (K) 
Crystal System 
Space Group 
Unit Cell Dimensions: a (A) 
b (A) 
c (A) 
a (0) 
Volume (A3) 
Z 
B C) 
y (0) 
Density (calculated) (Mglm3) 
Absorption coefficient (mm- I ) 
F(OOO) 
Crystal Size (mm3) 
Theta range for data collection CO) 
Reflections collected 
Independent reflections [R(int)] 
Data / restraints / parameters 
Goodness-to-fit on F2 
RI [1>20'(1)] 
WR2 (all data) 
7.43 
CCD 
C25H30N203 
406.51 
163(2) 
Orthorhombic 
P21212I 
13.460(2) 
18.666(3) 
27.632(4) 
90 
90 
90 
6942(2) 
12 
1.167 
0.077 
2616 
0.50x0.20xO.08 
1.68 to 26.47 
53219 
14198 
14198/546/838 
0.941 
0.0755 
0.2411 
